<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2510211232
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2021
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Vitram Film-Coated Tablet 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        LEVETIRACETAM
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        500
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        83.95
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="AJA PHARMACEUTICAL INDUSTRIES" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            AJA PHARMACEUTICAL INDUSTRIES
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 1916]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            AJA PHARMACEUTICAL INDUSTRIES
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            AJA PHARMACEUTICAL INDUSTRIES
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        N03AX14
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Levetiracetam is an antiepileptic medicine (a medicine used to treat seizures in epilepsy).</p><p>VITRAM is used:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; on its own in adults and adolescents from 16 years of age with newly diagnosed epilepsy , to treat a certain form of epilepsy . Epilepsy is a condition where the patients have repeated fits ( seizures ) . Levetiracetam is used for the epilepsy form in which the fits initially affect only one side of the brain but could thereafter extend to larger areas on both sides of the brain ( partial onset seizure with or without secondary generalization ) . Levetiracetam has been given to you by your doctor to reduce the number of fits .</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; as an add - on to other antiepileptic medicines to treat :</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; partial onset seizures with or without generalization in adults , adolescents , children and infants from one month of age ;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; myoclonic seizures ( short , shock - like jerks of a muscle or group of muscles ) in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy ;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; primary generalized tonic - clonic seizures ( major fits , including loss of consciousness ) in adults and adolescents from 12 years of age with idiopathic generalized epilepsy ( the type of epilepsy that is thought to have a genetic cause )</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not take VITRAM If you are allergic to levetiracetam,<br />pyrrolidone derivatives or any of the other ingredients of this<br />medicine (listed in Section 6).<br /><strong>Warnings and precautions</strong><br />Talk to your doctor before taking VITRAM</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you suffer from kidney problems, follow your doctor&#39;s instructions. He/s he may decide if your dose should be adjusted.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you notice any slowdown in the growth or unexpected puberty development of your child, please contact your doctor .</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A small number of people being treated with anti-epileptics such as VITRAM have had thoughts of harming or killingthemselves. If you have any symptoms of depression and/or suicidal ideation, please contact your doctor.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have a family or medical history of irregular heart rhythm (visible on an electrocardiogram), or if you have a disease and/or take a treatment that make(s) you prone to heartbeat irregularities or salt imbalances.</p><p>Tell your doctor or pharmacist if any of the following side effects gets serious or last longer than a few days:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abnormal thoughts, feeling irritable or reacting more aggressively than usually, or if you or your family and friends notice important changes in mood or behavior.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Aggravation of epilepsy</u></p><p>Your seizures may rarely become worse or happen more often , mainly during the first month after the start of the treatment or increase of the dose . If you experience any of these new symptoms while taking VITRAM, see a doctor as soon as possible .</p><p><strong>Children and adolescents</strong></p><p>VITRAM is not indicated in children and adolescents below 16 years on its own ( monotherapy ) .</p><p><strong>Other medicines and VITRAM</strong></p><p>Tell your doctor or pharmacist if you are taking , have recently taken or might take any other medicines .</p><p>Do not take macrogol ( a drug used as laxative ) for one hour before and one hour after taking levetiracetam as this may results in a loss of its effect .</p><p>&nbsp;</p><p><strong>Pregnancy and breast - feeding</strong></p><p>If you are pregnant or breastfeeding , think you may be pregnant or are planning to have a baby , ask your doctor for advice before taking this medicine . Levetiracetam can be used during pregnancy, only if after careful assessment it is considered necessary by your doctor .</p><p>&nbsp;</p><p>You should not stop your treatment without discussing this with your doctor . A risk of birth defects for your unborn child cannot be completely excluded</p><p>&nbsp;</p><p>Breast - feeding is not recommended during treatment .</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>VITRAM may impair your ability to drive or operate any tools or machinery , as it may make you feel sleepy . This is more likely at the beginning of treatment or after an increase in the dose . You should not drive or use machines until it is established that your ability to perform such activities is not affected .</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor or pharmacist<br />has told you. Check with your doctor or pharmacist if you are not sure.<br />Take the number of tablets following your doctor&#39;s instructions,<br />VITRAM must be taken twice a day, once in the morning and once in the evening, at about the same time each day.<br />&nbsp;</p><p><strong>Monotherapy</strong></p><p><strong>Dose in adults and adolescents ( from 16 years of age ) :</strong> General dose : between 1000 mg and 3000 mg each day . When you will first start taking VITRAM , your doctor will prescribe you a lower dose during 2 weeks before giving you the lowest general dose .</p><p>Example : if your daily dose is 1000 mg , your reduced starting dose is 2 tablets of 250 mg in the morning and 2 tablets of 250 mg in the evening .</p><p><strong>Add - on therapy</strong></p><p><strong>Dose in adults and adolescents ( 12 to 17 years ) weighing 50 kg or more</strong></p><p>General dose : between 1000 mg and 3000 mg each day . Example : if your daily dose is 1000 mg , you might take 2 tablets of 250 mg in the morning and 2 tablets of 250 mg in the evening .</p><p><strong>Dose in infants ( 1 month to 23 months ) , children ( 2 to 11 years ) and adolescents ( 12 to 17 years ) weighing less than 50 kg :</strong></p><p>Your doctor will prescribe the most appropriate pharmaceutical form of VITRAM according to the age , weight and dose . VITRAM 100 mg / ml oral solution is a formulation more appropriate to infants and children under the age of 6 years and to children and adolescent ( from 6 to 17 years ) weighing less than 50kg and when tablets don&#39;t allow accurate dosage .</p><p>&nbsp;</p><p><u>Method of administration</u></p><p>Swallow VITRAM tablets with a sufficient quantity of liquid ( e.g. a glass of water ) . You may take VITRAM with or without food . After oral administration the bitter taste of levetiracetam may be experienced .</p><p><u>Duration of treatment</u></p><p>VITRAM is used as a chronic treatment . You should continue VITRAM treatment for as long as your doctor has told you .</p><p><u>Do not stop your treatment without your doctor&#39;s advice as this could increase your seizures</u> .</p><p><strong>If you take more VITRAM than you should</strong></p><p>The possible side effects of an overdose of VITRAM are sleepiness , agitation , aggression , decrease of alertness , inhibition of breathing and coma .</p><p>Contact your doctor if you took more tablets than you should .</p><p>Your doctor will establish the best possible treatment of overdose .</p><p><strong>If you forget to take VITRAM</strong></p><p>Contact your doctor if you have missed one or more doses Do not take a double dose to make up fo a forgotten tablet&nbsp; <strong>If you stop taking VITRAM</strong></p><p>If stopping treatment , VITRAM should be discontinued gradually to avoid an increase of seizures . Should your doctor decide to stop your VITRAM treatment , he / she will instruct you about the gradual withdrawal of VITRAM .</p><p>If you have any further questions on the use of this medicine , ask your doctor or pharmacist .</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines , this medicine can cause side effects , although not everybody gets them .</p><p><strong>Tell your doctor immediately , or go to your nearest emergency department , if you experience</strong> :</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; weakness , feel light - headed or dizzy or have difficulty breathing , as these may be signs of a serious allergic</p><p>anaphylactic ) reaction</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling of the face , lips , tongue and throat ( Quincke&#39;s edema)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; flu - like symptoms and a rash on the face followed by an extended rash with a high temperature , increased levels of liver enzymes seen in blood tests and an increase in a type of white blood cell ( eosinophilia ) and enlarged lymph nodes ( Drug Reaction with Eosinophilia and Systemic Symptoms [ DRESS ] )</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; symptoms such as low urine volume , tiredness , nausea , vomiting , confusion and swelling in the legs , ankles or feet , as this may be a sign of sudden decrease of kidney function</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;a skin rash which may form blisters and look like small targets ( central dark spots surrounded by a paler area , with a dark ring around the edge ) ( erythema multiforme )</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a widespread rash with blisters and peeling skin , particularly around the mouth , nose , eyes and genitals ( Stevens - Johnson syndrome )</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;a more severe form of rash causing skin peeling in more than 30 % of the body surface ( toxic epidermal necrolysis )</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; signs of serious mental changes or if someone around you notices signs of confusion , somnolence ( sleepiness ) , amnesia ( loss of memory ) , memory impairment ( forgetfulness ) , abnormal behavior or other neurological signs including involuntary or uncontrolled movements . These could be symptoms of an encephalopathy .</p><p>The most frequently reported side effects are nasopharyngitis , somnolence ( sleepiness ) , headache , fatigue and dizziness . At the beginning of the treatment or at dose increase side effects like sleepiness , tiredness and dizziness may be more common . These effects should however decrease over time .</p><p><strong>Very common :</strong> may affect more than 1 user in 10 people</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nasopharyngitis ;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; somnolence ( sleepiness ) , headache</p><p>&nbsp;</p><p><strong>Common :</strong> may affect 1 to 10 users in 100 people</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; anorexia ( loss of appetite ) ;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; depression , hostility or aggression , anxiety , insomnia , nervousness or irritability ;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; convulsion , balance disorder ( equilibrium disorder ) , dizziness ( sensation of unsteadiness ) , lethargy ( lack of energy and enthusiasm ) , tremor ( involuntary trembling ) ;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; vertigo ( sensation of rotation ) ;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cough ;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;abdominal pain , diarrhea , dyspepsia ( indigestion ) , vomiting , nausea ;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rash ;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sthenia / fatigue ( tiredness ) .</p><p>&nbsp;<strong>Uncommon</strong> : may affect 1 to 10 users in 1000 people</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decreased number of blood platelets , decreased number of white blood cells ;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;weight decrease , weight increase ;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;suicide attempt and suicidal ideation , mental disorder , abnormal behavior , hallucination , anger , confusion , panic attack , emotional instability / mood swings , agitation ;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; amnesia ( loss of memory ) , memory impairment ( forgetfulness ) , abnormal coordination / ataxia ( impaired coordinated movements ) , paranesthesia ( tingling ) , disturbance in attention ( loss of concentration ) ;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diplopia ( double vision ) , vision blurred ; elevated / abnormal values in a liver function test ; hair loss , eczema , pruritus ;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; muscle weakness , myalgia ( muscle pain ) ;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; injury .</p><p><strong>Rare</strong> : may affect 1 to 10 users in 10,000 people</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; infection ;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decreased number of all blood cell types ;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; severe allergic reactions ( DRESS , anaphylactic reaction [ severe and important allergic reaction ] , Quincke&#39;s edema [ swelling of the face , lips , tongue and throat ] ) ;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decreased blood sodium concentration ;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; suicide , personality disorders ( behavioral problems ) , thinking abnormal ( slow thinking , unable to concentrate ) ;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; delirium ;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; encephalopathy ( see sub - section &quot; Tell your doctor immediately &quot; for a detailed description of symptoms ) ;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; seizures may become worse or happen more often ;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; uncontrollable muscle spasms affecting the head , torso and: limbs , difficulty in controlling movements , hyperkinesia ( hyperactivity )</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; change of the heart rhythm ( Electrocardiogram ) :</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pancreatitis</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; liver failure , hepatitis ;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sudden decrease in kidney function</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; skin rash , which may form blisters and looks like small targets ( central dark spots surrounded by a paler area , with a dark ring around the edge ) ( erythema multiforme ) , a widespread rash with blisters and peeling skin , particularly around the mouth , nose , eyes and genitals ( Stevens - Johnson syndrome ) , and a more severe form causing skin peeling in more than 30 % of the body surface ( toxic epidermal necrolysis ) .</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rhabdomyolysis ( breakdown of muscle tissue ) and associated blood creatine phosphokinase increase . Prevalence is significantly higher in Japanese patients when compared to non- Japanese patients</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; limp or difficulty walking .</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Reporting of side effects</strong></p><p>If you get any side effects , talk to your doctor or pharmacist . This includes any possible side effects not listed in this leaflet</p><p><strong>To report any side effect ( s ) :</strong></p><p><strong>Saudi Arabia </strong></p><p>The National Pharmacovigilance Centre ( NPC )</p><p>Fax : + 966-11-205-7662</p><p>SFDA Call Center : 19999</p><p>E - mail :&nbsp;npc.drug@sfda.gov.sa&nbsp;</p><p>Website :&nbsp;https://ade.sfda.gov.sa</p><p><strong>Other GCC States :</strong></p><p>Please contact the relevant competent authority .</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children .</p><p>Do not use this medicine after the expiry date stated on the carton box and blister after EXP . The expiry date refers to the last day of the month .</p><p>Do not store above 30 &deg; C .</p><p>Do not throw away any medicines via wastewater or household waste .</p><p>Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is called levetiracetam .</p><p>One tablet of VITRAM 500 mg contains 500 mg of levetiracetam.</p><p>The other ingredients are:</p><p>Maize Starch , Povidone , Talc , Colloidal Silicon Dioxide , Magnesium Stearate .</p><p>Film - coating 500 mg : Opadry II 85F32004 Yellow .</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                VITRAM 500 mg film coated tablets are yellow , oblong tablets with one central score on both faces , one side marked " L 5 " .
The score line is only to facilitate breaking for ease of swallowing and not to divide into equal doses . 
VITRAM tablets are packaged in blister packs supplied in cardboard boxes containing : 
•	500 mg : ( 30 ) film - coated tablets .
 Packs is available in aluminum / PVC blisters .

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&nbsp;AJA Pharmaceutical Industries Company , Ltd.</p><p>Hail Industrial City MODON , Street No 32</p><p>PO Box 6979 , Hail 55414</p><p>Kingdom of Saudi Arabia</p><p>Tel : +966 11 268 7900</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                01/2021 
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>ليفيتيراسيتام هو دواء مضاد للصرع (دواء يستخدم لعلاج التشنجات المصاحبة للصرع)</p><p>ويستخدم <strong>فيترام</strong> لما يلي :</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يستخدم <strong>فيترام</strong> لوحده للأشخاص البالغين ابتداء من عمر 16 سنة الذين يتم تشخيصهم حديثا بمرض الصرع. وذلك لعلاج انواع معينة من الصرع. الصرع هو مرض او حالة بتعرض فيها المصاب لنوبات متكررة من التشنجات.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ويستخدم ليفيتيراسيتام لعلاج تلك الأنواع من الصرع التي تؤثر فيها التشنجات ابتداء على جانب واحد فقط من الدماغ، ولكنه يمكن ان ينتشر في مراحل لاحقة الى مناطق اوسع في جانبي الدماغ (الصرع الجزئي عند البداية مع او بدون انتشار عام).&nbsp;وقد وصف لك الطبيب ليفيتيراسيتام لتقليل عدد نوبات التشنج.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ويستخدم كدواء اضافي بجانب أدوية التشنج الأخرى وذلك لعلاج مايلي:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الصرع الجزئي مع او بدون انتشار عام لدى البالغين والمرا هقين والأطفال والرضع من عمر شهر واحد.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التشنجات العضلية الإرتعاشية (تقلصات قصيرة حادة متتابعة تحدث في عضلة واحدة أو مجموعة من العضلات) لدى البالغين والمراهقين اعتبارا من عمر 12 عاما المصابين بالصرع التشنجي الارتعاشي العضلي.<br />التشنجات الارتجاجيه العامة (Generalized toinc-clonic ) (نوبات تشمل فقدان الوعي) لدى البالغين والمراهقين من عمر 12 عاما المصابين بالصرع التشنجي العام ذاتي العلة (الصرع الذي يعتقد ان له اسباب وراثية)</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>لا تتناول فيترام إذا كنت تعاني من حساسية ضد ليفيتيراسيتام أو أي من مكونات فيترام الأخرى (المدرجة في الفقرة رقم - 6)<br />تحذيرات واحتياطات</p><p>&nbsp;يرجى ابلاغ الطبيب قبل ان تبدأ في تناول <strong>فيترام</strong> في الحالات التالية:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اذا كنت تعاني من مشاكل في الكلى ،يجب عليك اتباع تعليمات الطبيب الذي قد يقرر تعديل جرعاتك من هذا الدواء.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اذا لا حظت أي تباطؤ أو تأخر في نمو طفلك او أي تطورات غير متوقعة تتعلق بمرحلة البلوغ فيجب عليك ان تبلغ الطبيب.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هناك عدد قليل من الأشخاص الذين تناولوا أدوية مضادة للصرع مثل <strong>فيترام</strong> راودتهم افكار انتحارية. فإذا لاحظت أي اعراض اكتئاب و/أو أي افكار انتحارية يجب عليك إبلاغ الطبيب.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك تاريخ عائلي أو طبي لعدم انتظام نبضات القلب (يمكن ملاحظتها عبر تخطيط القلب ) ، أو اذا كانت تعاني من مرض أوتتناول أدوية تؤثر على انتطام القلب أو مستوى الأملاح بالدم .</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تواصل مع الطبيب أو الصيدلي إذا أي من الأعراض التالية تضاعفت أو استمرت لتفرة أطول من ثلاث أيام :</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أفكار غير طبيعية، الشعور بالتوتر والعدوانية أكثر من المعتاد، أو في حال لاحظ أحد أفراد العائلة أو الاصدقاء تغيرات في السلوك أو المزاج .</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاقم التشنجات</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نادرا ما تحدث التشنجات أو تزداد سوءاً خاصة خلال الشهر الأول من تناول الدواء أو زيادة الجرعة. إذا عانيت من أي من هذه الأعراض خلال تناول فيترام يرجى التواصل مع الطبيب أو الصيدلي فوراً</p><p><strong>الأطفال والمراهقون</strong><br />&nbsp;لا ينصح بإعطاء <strong>فيترام</strong> للأطفال والمراهقين الذين تقل أعمارهم عن 16 عاماً لوحده(علاج وحيد ) .</p><p><strong>الأدوية&nbsp;الأخرى&nbsp;وفيترام</strong><br />ابلغ الطبيب أو الصيدلي إذا كنت تتناول أو تناولت مخرا أو من الممكن أن تتناول أي أدوية أخرى .</p><p>لا تناول ماكروجول (دواء يستعمل كملين) قبل ساعة من تناول ليفيتيراسيتام او بعد ساعة من تناوله حيث ان ذلك قد يؤدي إلى فقدان مفعوله.</p><p>ا<strong>لحمل والإرضاع</strong><br />بالنسبة للمرأ ة الحامل أو المرضعة أو التي متوقع حملها أو تخطط للحمل يجب أن تستشير<br />الطبيب قبل ان تأخذ هذا الدواء. من الممكن تناوله خلال فترة الحمل إذا قام الطبيب بتقييم لحالة بشكل دقيق.</p><p>ينبغي أن لا تتوقف عن تناول <strong>فيترام</strong> قبل الرجوع للطبيب .</p><p>من الغير ممكن استبعاد نسبة إصابة الجنين بتشوهات.</p><p>لاينصح باستخدام <strong>فيترام</strong> اثناء الإرضاع</p><p><strong>قيادة المركبات وتشغيل الالات </strong><br /><strong>فيترام</strong> يمكن ان يعيق قدرتك على قيادة المركبات او تشغيل الالات<strong> </strong>، حيث انه يؤدي إلى الشعور<br />بالنعاس، ويحدث ذلك على الأرجح في بداية تناول الدواء او عند زيادة الجرعة.<br />يجب عليك عدم قيادة المركبات أو تشغيل الالات<strong> </strong>حتى يتم التأكد من أن قدراتك على القيام بمثل هذه<br />الأعمال لم تتأثر.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>من المهم تناول الأقراص كما يصفها لك الطبيب. وإذا كنت غير متأكد عليك استشارة الطبيب أو<br />الصيدلي.</p><p>عليك تناول نفس عدد الأقراص حسب تعليمات الطبيب.<br />ويجب تناول <strong>فيترام</strong> مرتين يومياً مرة في الصباح وأخرى في المساء وأن يكون في نفس التوقيت<br />تقريبا من كل يوم .</p><p>تناول فيترام لوحدة<br /><strong>الجرعة لد البالغين والمراهقين (ابتداء من عمر 16 عاماً)</strong><br />الجرعة العامة: تتراوح ما بين 1000 ملجم و 3000 ملجم يوميا وعندما تبدأ في تناول <strong>فيترام</strong> للمرة الأولى فإن الطبيب سوف يصف لك جرعة أقل من 1000 ملجم لمدة اسبوعين.</p><p><br />مثال : إذا كانت جرعتك اليومية 1000 ملجم فإن جرعة البداية لديك ستكون قرصين كل منهما 250 ملجم صباحاً وقرصين كل منهما 250 ملجم مساءً.</p><p><strong>تناول كعلاج اضافي مع نوع اخر </strong><br /><strong>الجرعة لدى البالغين والمراهقين (في عمر 12 - 17 عاماً)</strong><br />الجرعة العامة: تتراوح ما بين 1000 ملجم &nbsp;و 3000 ملجم &nbsp;يوميا<br />مثال : إذا كانت جرعتك اليومية 1000 ملجم &nbsp;فإن جرعة البداية لديك ستكون قرصين كل منهما 250 ملجم &nbsp;صباحاً وقرصين كل منهما 250 ملجم &nbsp;مساءً</p><p><strong>الجرعة لدى كل من الأطفال الرضع (في عمر 1 - 23 شهرًا)، والأطفال (في عمر سنتين إلى 11 سنة) والمراهقين (في عمر 12 - 17 عاماً) الذين تقل أوزانهم عن 50 كغم </strong><br />سوف يصف الطبيب الشكل الصيدلاني المناسب من <strong>فيترام</strong> بناء على العمر ووزن الجسم ومقدار<br />الجرعة</p><p><strong>فيترام</strong> شراب بالفم 100 ملجم &nbsp;/ مل هو تركيبة مناسبة بصورة أفضل للأطفال الرضع والذين تقل<br />اعمارهم عن 6 سنوات وهو مناسب أيضا للأطفال والمراهقين (في عمر 6 - 17 عاماً) الذين تقل<br />اوزانهم عن 50 كغم حينما لا تتيح الأقراص اعطاء الجرعة الدقيقة .</p><p><u>طريقة تناول الدواء</u><br />يجب ابتلاع القرص كاملا مع بعض السوائل (كوب من الماء مثلاً). ويمكن تناول <strong>فيترام</strong> مع الطعام أو بدونه. قد يتغير الطعم بعد تناوله ويصبح أكثر مرارة.</p><p><u>مدة العلاج</u></p><p>&nbsp;يستخدم <strong>فيترام</strong> لمدة طويلة ، ويجب مواصلة تناوله طالما نصح الطبيب بذلك. &nbsp;</p><p>&nbsp;<u>لا تتوقف عن تناول العلاج بدون الرجوع للطبيب حيث ان ذلك قد يؤدي إلى زيادة نوبات&nbsp;</u><u>التشنج.</u></p><p>إ<strong>ذا تناولت جرعة من فيترام أكثر من الموصى بها </strong><br />تتمثل الأعراض الجانبية لزيادة جرعة <strong>فيترام</strong> في الشعور بالنعاس والتكدر والسلوك العدواني ونقص الانتباه، وتعطل التنفس والغيبوبة.<br />يجب عليك الاتصال بالطبيب إذا تناولت عددا من تلك الأقراص اكثر مما ينبغي، فإن الطبيب هو الذي يقرر افضل طريقة لعلاج مشكلة زيادة الجرعة.</p><p><strong>إذا نسيت تناول فيترام</strong><br />يجب عليك الاتصال بالطبيب إذا نسيت تناول جرعة واحدة أو أكثر.</p><p>لا تأخذ جرعة مضاعفة لتعويض الجرعة التي نسيتها.</p><p><strong>إذا توقفت عن تناول فيترام</strong><br />إذا لزم التوقف عن تناول <strong>فيترام</strong> فيجب ان يتم ذلك بصورة تدريجية حيث يتم خفض جرعات <strong>فيترام</strong> تدريجيا وذلك لتفادي زيادة نوبات التشنج.<br />وإذا قرر الطبيب ان تتوقف عن العلاج فإنه سيرشدك بخصوص السحب التدريجي لفيترام حتى التوقف.</p><p>إذا كان لديك مزيد من الأسئلة حول استعمال هذا المنتج عليك ان تسأل الطبيب أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p><strong>فيترام</strong> كغيره من الأدوية يمكن أن يسبب آثارا جانبية مع انها لا تظهر عند كل شخص يتناوله .</p><p>يجب عليك إبلاغ الطبيب أو مراجعة أقرب مركز للطوارئ فوراً إذا حدثت لك أي من الأعراض الجانبية التالية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف، شعور بعدم الاستقرار او الدوخة، او صعوبة في التنفس، حيث ان تلك قد تكون اعراض ردة فعل حساسية خطيرة (الصدمة الاستهدافية).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;انتفاخ الوجه، والشفتين، واللسان، والحلق (وذمة كوينكي(.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اعراض مشابهة لأعراض الأنفلونزا (الزكام والرشح)وظهور طفح على الوجه يلها انتشار<br />الطفح في الجسم مع ارتفاع درجة الحرارة، ارتفاع مستويات انزيمات الكبد في الدم (تظهر في نتائج تحليل الدم)، وزيادة في أعداد نوع من كريات الدم البيضاء (زيادة الكريات حمضية الصبغة) في الدم، وتضخم الغدد اللمفاوية (ردة فعل على الدواء تتمثل في زيادة تعداد الكريات البيضاء الحمضية مع اعراض عامة في الجسم [DRESS])</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد تمثل بعض الاعراض مثل نقص كمية البول، الإرهاق، الغثيان، التقيؤ، الارتباك والتشوش، تورم الرجلين أو الكاحلين أو القدمين حدوث نقص مفاجئ في وظائف الكلى.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الطفح الجلدي الذي يتحول بعضه الى نفط والذي يبدو بمظهر هدف الرماية )نقط داكنة صغيرة في المركز محاطة بمنطقة باهتة وحلقة سوداء حول الحافة) )الحماوية عديدة التشكل(</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;طفح جلدي منتشر في انحاء الجسم ويسبب النفط وتقشر الجلد خاصة حول الفم والأنف والعينين والأعضاء التناسلية )متلازمة ستيفن جونسون(.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي اكثر شدة منتشر في انحاء الجسم ويسبب النفط وتقشر الجلد في منطقة تزيد عن 30 % من مساحة سطح الجسم (تنخر البشرة التحللي التسممي(.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أعراض حادة لتغيرات مزاجية أو إذا لاحظ شخص قريب منك انك تعاني من تشوش او ارتباك، أو نعاس، أو فقدان الذاكرة، أو ضعف الذاكرة ( كثرة النسيان ) ، أو سلوكيات غير طبيعية ، أو أعراض عصبية أخرى بما فيها الحركات اللاإرادية او الخارجة عن السيطرة. فهذه كلها يمكن ان تكون اعراض اعتلال دماغي.</p><p dir="RTL">الأعراض الأكثر تبليغاً هي التهاب البلعوم الأنفي، نعاس، صداع، خمول ، دوخة، بداية العلاج أو عند زيادة الجرعة تكون الأعراض مثل النعاس ، التعب ، الدوخةأكثر شيوعا ولكنها تقل مع مرور الوقت.<br /><br /><strong>تأثيرات جانبية شائعة جداً</strong> (قد يصاب بها ما يزيد عن 1 من بين كل 10 أشخاص(</p><p dir="RTL">_ &nbsp;التهاب بالأنف والبلعوم<br />&nbsp;_ نعاس ، صداع<br /><strong>تأثيرات جانبية شائعة</strong> (قد يصاب بها 1 إلى 10 أشخاص من بين كل 100 شخص(<br />- نقص أو فقد الشهية.<br />-اكتئاب، سلوك اندفاعي او عدواني، قلق، أرق، نرفزة او تكدر المزاج .<br />- تقلصات عضلية، خلل التوازن، دوخة، وسن او شعور بالضعف، ارتجاف.<br />&nbsp;-دوار.<br />&nbsp;-سعال/ كحة.<br />&nbsp;-آلام في البطن، اسهال، عسر الهضم، تقيؤ، غثيان.<br />-طفح جلدي<br />&nbsp;-وهن / خمول<br /><strong>تأثيرات جانبية غير شائعة</strong> (قد يصاب بها 1 إلى 10 أشخاص من بين كل 1000 شخص(<br />&middot; انخفاض في اعداد الصفائح الدموية، وانخفاض في اعداد كريات الدم البيضاء.<br />&middot; نقص أو زيادة وزن الجسم.<br />&middot; افكار انتحارية ومحاولات انتحار، خلل عقلي، سلوك غير طبيعي، هلوسة، نوبات غضب، ارتباك وتشوش، نوبات هلع، عدم استقرار&nbsp;&nbsp;عاطفي / تقلبات في المزاج، تكدر وتهيج.<br />&middot; فقدان الذاكرة، ضعف الذاكرة (كثرة النسيان)، خلل في التوافق الحركي/خلل التوازن، تنميل، خلل في الانتباه (فقدان التركيز(.<br />&middot; تشوش الرؤية، نتائج غير طبيعية لوظائف الكبد، تساقط في الشعر، اكزيما،هراش.</p><p dir="RTL">&middot; &nbsp;ضعف بالعضلات، ألم بالعضلات</p><p dir="RTL">&middot; &nbsp;إصابات (جروح)</p><p dir="RTL"><br />تأثيرات جانبية نادرة (قد يصاب بها 1 إلى 10 أشخاص من بين كل 10000 شخص(<br />&middot; اصابات (عدوى(.<br />&middot; انخفاض في مستوى الخلايا الدموية.<br />&middot; ردة فعل حساسية شديدة&nbsp; )DRESSزيادة مستوى الكريات البيضاء الحمضية مع اعراض عامة في الجسم(، وذمة كوينكي )(تورم في الوجه، والشفتين واللسان والحلق(<br />&middot; انخفاض تركيز الصوديوم في الدم<br />&middot; سلوك انتحاري، اضطرابات في الشخصية، تفكير غير طبيعي (بطء في التفكير وعدم القدرة على التركيز(.<br />&middot; هذيان</p><p dir="RTL">&middot;اعتلال عقلي</p><p dir="RTL">&middot; تشنجات عضلية لا يمكن السيطرة عليها في الرأس و الجذع و الأطراف ، صعوبة في التحكم بالحركات ، فرط النشاط</p><p dir="RTL">&middot; عدم انتظام نبضات الثلب<br />&middot; التهاب البنكرياس.<br />&middot; فشل الكبد، التهاب الكبد.<br />&middot; انخفاض مفاجئ في وظائف الكلى.<br />&middot; طفح جلدي بعضه يتحول الى نفط والذي يبدو بمظهر هدف الرماية (نقط داكنة صغيرة في المركز محاطة بمنطقة باهتة وحلقة سوداء حول الحافة) (الحماوية عديدة التشكل)، طفح جلدي منتشر في انحاء الجسم ويسبب النفط وتقشر الجلد خاصة حول الفم والأنف والعينين والأعضاء التناسلية (متلازمة ستيفن جونسون)، طفح جلدي اكثر شدة منتشر في انحاء - الجسم ويسبب النفط وتقشر الجلد في منطقة تزيد عن 30 % من مساحة سطح الجسم (تنخر البشرة التحللي التسممي(.<br />&middot; تحلل النسيج العضلي يصاحبه ارتفاع في انزيم فوسفوكاينيز الكرياتنين بالدم. ينتشر ذلك بنسبة اعلى بين المرضى اليابانيين مقارنة بغير اليابانيين</p><p><strong>الإبلاغ عن التأثيرات الجانبية: </strong></p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>المملكة العربية السعوية </strong></p><p>&nbsp;</p><p><!--[if gte vml 1]><v:rect
 id="Rectangle_x0020_1" o:spid="_x0000_s1026" style='position:absolute;left:0;
 text-align:left;margin-left:68.25pt;margin-top:17.75pt;width:410.25pt;
 height:129.75pt;z-index:251659264;visibility:visible;mso-wrap-style:square;
 mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;mso-wrap-distance-right:9pt;
 mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:margin;mso-position-vertical:absolute;
 mso-position-vertical-relative:text;v-text-anchor:middle' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" filled="f" strokecolor="black [3213]" strokeweight="1pt">
 <w:wrap anchorx="margin"/>
</v:rect><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p dir="RTL">المركز الوطني للتيقظ الدوائي</p><p dir="RTL">الهاتف الموحد : 19999</p><p dir="RTL">فاكس :+966112057662</p><p dir="RTL">البريد الالكتروني : npc.drug@sfda.gov.sa</p><p dir="RTL">الموقع الإلكتروني : https://ade.sfda.gov.sa</p><p>&nbsp;</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;دول مجلس التعاون الخليجي الأخرى: &nbsp;</p><p>يرجى الاتصال بالسلطات المختصة في كل بلد</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>احتفظ بالدواء دائما بعيدا عن متناول الأطفال<br />لا تتناول الدواء بعد تاريخ انتهاء الصلاحية المطبوع على العلبة او على الشريط. ويشير التاريخ<br />الموضح بالشهر والسنة إلى آخر يوم من ذلك الشهر.<br />يخزن في درجة حرارة لاتزيد عن 30 درجة مئوية<br />يخزن في عبوته الأصلية لحمايته من الضوء.<br />يجب عدم التخلص من الدواء بالقائه في مياه الصرف الصحي أو في النفايات المنزلية. اسأل<br />الصيدلي عن كيفية التخلص من الأدوية التي لا تحتاجها، فإن ذلك يساهم في حماية البيئة</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>المادة الفعالة في <strong>فيترام</strong> هي ليفيتيراسيتام<br />كل قرص فيترام مغلف 500 ملجم &nbsp;يحتوي على 500 ملجم &nbsp;ليفيتيراسيتام<br /><br />المكونات الأخرى هي:<br />نشا الذرة البيضاء، بوفيدون، تالك، ثاني اكسيد السيليكون الغروي، ستياريت المغنيسيوم.</p><p>غلاف القرص 500 ملجم:اوبادي-2 ،85اف43004 أصفر.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>كيف يبدو فيترام ومتحويات العبوة : </strong><br />ليفيتيراسيتام أقراص مغلفة 500 ملجم &nbsp;: أقراص مستطيلة مغلفة بلون أصفر. وهي مقسومة بخط<br />غائر من المنتصف من الناحيتين ومكتوب على وجه واحد &ldquo;L5&rdquo;</p><p>الخط الغائر في المنتصف هو فقط لتسهيل عملية تقسيم القرص من اجل سهولة ابتلاعه وليس من<br />اجل قسمته إلى جرعتين متساويتين<br />يتوفر <strong>فيترام</strong> في شرائح بثورية داخل علبة كرتون تحتوي علآ:</p><p>500 ملجم :30 قرص مغلف</p><p>العبوة متوفرة في شرائح ألومنيوم/ بي في سي</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>&nbsp;</p><p>شركة أجا للصناعات الدوائية المحدودة</p><p>المدينة الصناعية، مدن بحائل، شارع رقم 32</p><p>ص.ب 6979، حائل 55414</p><p>المملكة العربية السعودية</p><p>هاتف: +966112687900</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            01/2021
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                VITRAM 500mg film-coated tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each film-coated tablet contains 500mg levetiracetam. For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablet.
VITRAM 500 mg are yellow, oblong tablets with one central score on both faces, one side marked “L 5”.
The score line is only to facilitate breaking for ease of swallowing and not to divide into equal doses.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>VITRAM</strong> is indicated as monotherapy in the treatment of partial onset seizures with or without secondary generalization in adults and adolescents from 16 years of age with newly diagnosed epilepsy.</p><p><strong>VITRAM</strong> is indicated as adjunctive therapy</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp; in the treatment of partial onset seizures with or without secondary generalization in adults, adolescents, children and infants from 1 month of age with epilepsy.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp; in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with Juvenile Myoclonic Epilepsy.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp; in the treatment of primary generalized tonic-clonic seizures in adults and adolescents from 12 years of age with Idiopathic Generalized Epilepsy.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p><em>Monotherapy for adults and adolescents from 16 years of age</em></p><p>The recommended starting dose is 250 mg, 500mg, 1000mg twice daily which should be increased to an initial therapeutic dose of 500 mg twice daily after two weeks. The dose can be further increased by 250 mg, 500mg, 1000mg twice daily every two weeks depending upon the clinical</p><p>response. The maximum dose is 1500 mg twice daily.</p><p><em>Add-on therapy for adults (&ge;18 years) and adolescents (12 to 17 years) weighing 50 kg or more</em></p><p>The initial therapeutic dose is 500 mg twice daily. This dose can be started on the first day of treatment.</p><p>Depending upon the clinical response and tolerability, the daily dose can be increased up to 1,500 mg twice daily. Dose changes can be made in 500 mg twice daily increases or decreases every two to four weeks.</p><p><u>Discontinuation</u></p><p>If levetiracetam has to be discontinued it is recommended to withdraw it gradually ( <em>e.g</em>. in adults and adolescents weighing more than 50 kg: 500 mg decreases twice daily every two to four weeks; in infants older than 6 months, children and adolescents weighting less than 50 kg: dose decrease should not exceed 10 mg/kg twice daily every two weeks; in infants (less than 6 months): dose decrease should not exceed 7 mg/kg twice daily every two weeks).</p><p><u>Special populations</u></p><p><em>Elderly (65 years and older)</em></p><p>Adjustment of the dose is recommended in elderly patients with compromised renal function (see &ldquo;Renal impairment&rdquo; below).</p><p><em>Renal impairment</em></p><p>The daily dose must be individualized according to renal function.</p><p><br />For adult patients, refer to the following table and adjust the dose as indicated. To use this dosing table, an estimate of the patient&#39;s creatinine clearance (Clcr) in ml/min is needed. The Clcr in ml/min may be estimated from serum creatinine (mg/dl) determination, for adults and adolescents weighting 50 kg or more, the following formula:</p><p><img src="data:image/jpeg;base64,/9j/4AAQSkZJRgABAQEAYABgAAD/2wBDAAMCAgMCAgMDAwMEAwMEBQgFBQQEBQoHBwYIDAoMDAsKCwsNDhIQDQ4RDgsLEBYQERMUFRUVDA8XGBYUGBIUFRT/2wBDAQMEBAUEBQkFBQkUDQsNFBQUFBQUFBQUFBQUFBQUFBQUFBQUFBQUFBQUFBQUFBQUFBQUFBQUFBQUFBQUFBQUFBT/wAARCAKoBCgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD9U6KKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAENc/4r8X6N4I0S51jxBrOn6FpVvt86/wBTuUtrePc21d0rnavzHFdDXz1+3d/ybdq3/YW0b/052tHWwHrXgv4j+FPiNYTX/hPxLo/iiygfy5LjRb+K8ijk/uM0TN81dVmqs0Kz27RHdtZdrFW2tXyl+zTpsei/tcftJ6fayXT2sD6D5SXFzLPs32ksrrud2/jdv++qIrmbXlcT0jc+tvvUdq5Pxt4nk8M6K1xawfbdTndbawsw237RcN9xc/3erM38KK7dq+b/ANi1tS0/xx+0N/b2ry61qNv4wIub6VNm/baxcKv8KL91V/ugVN9/JXG9Pw/E+u+wor42/Zx8O6X+1p8NdY+KHjC2/tLU9e1W/TQLqX/X6BZxStb2/wBjf/lhL+63NLFhmavT/wBi/wCK2q/F/wCBGk6p4gmS78R6bc3Gi6ncJ/y3ntpWjMv/AANdj/8AAq0ta4me+UcVx3xI+Imh/Cnwff8AinxLefYNH08IZZTGztud9iKqL95mdlUY/vVx3h39oCy1b4iWHgnXPDHiHwX4i1Gzlv8ATbbXltXW+hiI81ontbiddyblOx9rfWoT5tgeiuex0V5R4k+OVhpHie+8NaJ4e1vxrr+nQR3Wpaf4fW232EMhcRvK1xPCu5tjYjRmlPXZVbwL+0p4B+I3hnWNf0rUdQTQ9Jid7691PRryyt4thKyJ5s8SJI6MrKyozUX0uU9HY9fpa8al/aM0bSfHGi+HvEPh3xD4U/t6fyNF1TWYIFtdRnKbhEvlSu8Um0H5LhImr2Fqb0VyU7uxTvL+DT40kuZI4ImZYw0jbcszbVX9av188fBvxMvx4+Ifjjxhc7rrw/4Z1iXw94csnX5Elt1H2u9/66vK7RK38KRfL99q2/hR+0da/Fj4jeKvBkXgjxV4b1XwyIv7UbXls0iiaX5olXyrqVn3ruZWVdvyH5qOgdbHttFeUaJ8crHUNQ8brqvh3XPCmleEZfLvtb1j7KLSf5PM/cNFPK7/ACOjcqv3gv3vlqlJ+0Zo+k+ONE8O+IfDviDwmdem8jRtT1mCBbXUZym/yl8qV3ik2g/JcJE1AHsdLXjXin9obT9B8Sa9oWj+GPEHjfUfD0EU+uR+HktSNN81N8Qf7RcRb2ZMtti8xqz/ABh+1l4D8H/BPT/iu7azq/hHUbfz7e50nSprhtv/AE1+XbB83yZlZF3Uulx9bHueKgmnjtoXklZY4lXczt91a8z/AOF4aXatrVzqOka5pGgaXpUetf8ACQ3dl/oF3btn5YGRmZpflH7plV/nXaGq/oHxUTV9cstH1Dwtr/hrVL5J5bS31WCJ1lii27pfNt5ZYk++vyO6y/7FV1sTfS53VrcRX0Ec8EqywyLuV0bcrLXEw/HD4c3Piw+FIfH3hibxQszWv9ix6zbNfeav3ovI379/H3dvavNo/EUXwV/aU0DwPEVt/Cfj20vLrT7VvuWmqW+x5Ui/upLE+/b/AH0b+9Uv7Un/ACP3wC/7HlP/AE33tTH3kiu/km/wufQ1FV5PurWF4w1678N6Dd6laaLqHiGW2Tcum6T5X2qf/c82WJPzam9BX1sdLRXzv4T/AGvNE8c/BvUPiJpXgnxdc2tjqf8AZL6N5VmuqtPvSJtkBuuod9uxmWTIOEr23RNVm1bSbO+uNOutJlnjWVrK+8szwbv4H8p2Td/us1HS7H1sbdFeON+0Baw/Ha0+FVx4Q8S22qXNpLqVtrEi2Y06W2j273V/tHm/fdE2eVv+b7u35qj8A/H628efFvxP8PT4O8TaBrPh2CK7u7jVls1tmilb900TxXDswfa38PGz5trcUK4PQ9noryvRfjbp+oeHdc1zV9C1jwrpukX76cZdS8iX7VKsvlfuFtZ5fM/ejytv39/y7aq6b8fdL/4WNp/gjxDoGueC9a1dZZdHGuRW3k6ssf8ArPIlgnlXeF+bypNku3nbR1sC1Vzvo/EekXXiO60WDVLGXWbWBLi505Z0a4iifhGaP7yq237x/u1u14v4D+LHgTxx8bvGGgaPol5ZeOdHs4F1bUL3RXsppbfzXWJPNkVJJY/vMvVMNuWrWu/H7TtN8RazpWjeHtf8ZP4fZU1ybQYoHj0tmXdtk82aJpX2fN5UCyvyPlyy5T/QFqej6/4g0zwvpc2pazqVrpOnQLuku76dYIY1/wBp2O2tRZFljDK25W+6y18QftlfEfwB+0J+xL448T+HbeTW7XT47a403VNS0G6tURnuIkL2r3UKbsqXUtFXv118fNJ8I674L0HWdG1mysPEUsWn6b4ilhiOnz3rIxS3/wBb56M+xtrPFtb+9VdPnb8gekVLvf8AA9l4pT6V8z/Ef4++LfDf7R/hnwRYfDzW9X0i6sLy/E2n3enrNqDRqi/ulluogscfm/P5rKxbZtXjJ+kVk3KrFWT/AGWpapJvr/nYOrXb/K5XvL+DT41kuZI4ImZYw0jbcszbVX9az9O8UaRq2rajpdlqlld6jp4Rry1guEeW2L7tnmqvKbtj9f7rV4x8GPEy/Hr4i+NfF91vufD/AIZ1iTw74etJR+6WW3Ufa73b/wA9Wld4lb+FIvl++9eZfszWGjfD39qD9qeLTNLttJ0qyuNFnWzso44IkzZSyPt+6i7mL9dv3qaV0/JX/IVz7T460CvL/CfxeOteF9V8Q694P8QfDzRrC1+2tdeKmsYwYgGZ2KwXUrJt25bzdn865HUv2uvDHh3T9F1bX/Dni3QPDmvSxQ6JrU+lfaodUllXdEkUFq0tyjP/AArLFHuqerQ3ornuFnqFteSzxwTxzSwNslVH3NG391qvdK+a/wBorxInw/8ABdj8btAtLuC70Y2s+qRTW0trNf6S8qrNFPBIqvuiR/NTeu6JkP8AeevoPTNSt9Wsbe9tpVltbmNZY5U/iVvu/wA6fS4trX6mlRTKfSWowooopgFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFMoAfRTKKAH0UyigB9FMp9ABRRRQAUUUUAFFFFABXzx+3d/ybfq//YW0b/052tfQxrxH9rfwT4h+IHwN1fRfC+lS63rUl7ptxFYwzxRPKsV7byvteV0T7kT/AHmo63A9q/hr5V/Z7uIpP20P2nFWVXfd4f8Al3f9OT19A+DfEl/4t0uaXWfB+s+EnWTyvsetyWcryrj73+i3E6bf95qwPDv7Pfwv8H61Bq3h74beEtB1m1ZjDqGmaHa29xEWXaxWVE3L8rURfK2/KwnqrGH4u0f4kr8TP7Z0Xw34W1/R7O0EOmpq3iW606W3lfm4doo7C4Vmb5VDb+FDf32rw39kGbxdqXxZ/aEtdS0HQ4NOvPFcqarLBrUszWsv2VPkgRrNfPT/AG3aL/cr7Z6c1g6P4U0bw5eapeaZo1jpl1qlx9qvZrS1SJ7uXH35WX77f7TVNt/NWG+h8vfsYX1r8Av2cvEnhHxXcxaVd/DnU9Sh1E3bJEfs/mvcRXH+5LFKm1qzv2a/gf8AEex/ZL0q20DxfL8J/GuvatP4ju7ttEg1Joo52dlt2gm/2PK77l219Ta18OfCniXXtO1rVvC2japrOm/8eWo3unRS3Fr/ANcpWXcn/Aa6mr0u2Jq/3nyJ8T7jx/8As/8AwF8QXfxJ8b6V8Zby/wBU06xsZte8N2um6fpzS3CRrLPFFnzUR2WT1+TisfxnpsXh39t74EnUvF114h1ZtH16S9uL66jRYk+zqybIItkcS/f/AIdzqnzO+yvr7XND0/xJpV3pur2Ftqmn3UflT2d7AssMqn+F0b5WrBs/hP4K0+HQo7bwfoMCaCzNpSxaZAi6czfe+zjb+6/4BUq0dUD1Vj5i174ieHPgv+058TdU0Lxt4FtdW1i207+3NB8d+JV0VFuVifyZbaXypWb90U3p5X8SfNWD4y8C29n+xH49bwH4ksfiVcXXiL/hJ9Ym8Iajvilb+0Irq6ggeJ2ZNsS/3t1eg61pHhLUPH3iq4+M/wAHj4h1SbUHh0XWofBcviO3l05VTyVVoIJ3gb5n3JKqfNuxuWvWPhf8IPCnw/1rU9Y8JeErHwXa6lBFBNZ6bZRWSzFGf960SY2/e/3qF8JT1dzwjwyf2ZfjVbeFL7TPFt/421lbyDU9H8P6h8QNWvb6C8X7j/Y5bxnRkydzMnyruz8tfZcn3RXK6D8MPCPhPXNR1vRPCmhaRq9//wAfeoafpkNvcXP/AF1lRdz/AI111U3dWJSs7nyn/wAE87Kbw/8AB/xL4cvi39qaH4w1iwvFk+8JftG//wAeVkb/AIFR+0Tqv/DPfxu8IfGVbeVvD2pQ/wDCKeKUtl3Ntc77C42/7Mu+L/ttXqg+Hd94L+Kl74o8MRQy2HiV408QaW7eU3mquxL2Bv7+0Ikq/wASojD5l+flo/G2ofHjxBL4Vf4ceKvDvh3R9bSTUtW8VWMdrBe/ZZfNi+xqXZpVeVIm37VXZupLdA1ucf8AtMeC/EVp+x1r0Vpptzf6+txb69q1lpk7JLcH7bHdXaRSr8/3Q6rt+b5UrC8M/wDDM3xot/Ct5pfiu/8AG2sLeW+p6P4f1D4gateX0F4v3H+xS3rOjxZO52T5V3fw19l1yeg/DDwl4T1y/wBb0Pwroekaxf8A/H3qGn6ZDb3Fz/11lVNz/jRfVh0SPAtP8XJ8SviX8b9Om1C18EaH4ZmgstR/svyrXU9XZrXd591dffWLY6rF5Wx/k/1v8NfPs1/bf8Ob1i+0R+amkp8u/wCf/kK//YN/3zX6C3Hw88LXPiyPxRceHNJn8TRReRHrD2MTXqx/3BLt37fbNYV98CPhtq2hW+j3Xw+8K3ei28zXUGm3GiWsttHK33pVi2bQzf3qI6JruP7Sl2KHxTtvCmtfAnWLbxpdCHwhfaYlvqF0s/leVBLtUy7/AOHbu3bvavFPhufiR8D/AI1eBfAur+NIvi14C8RwXX9k6nfQr/bGlLBBv3yyp/r4n4TzT/E619MeHvAvhzwj4fh0LQfD+l6Lokb+ZHpunWcVvbo2/duSJF2/e+aodB8A+GfA9xqmoeHPC+laReX7+fePpNjFby3cvrIy7d7f71NPVg0meBftLWkmuftTfs06bZx+be22p6tqkrKP9VbR2qI7f99uldJ+1F/yP3wA/wCx5X/033tdl4N+Hd5J48v/AIg+JUjTxNc2i6bY2UEvmRaVZB9/lBv45ZX+aV+nyoq/c3Pw3xcsvGHxG+Knwvgsfh9rlno/hbxX/ad5rl7d6d9llgW1uIt8SrdNOfmlX70S0J2SQu/mmvvVj6Gk+6tVry+g0+0lurqZbeCBGeSWV9qqq/xNV1ayfEHh3S/FWj3mk6zptrq+m3kXlXNjfQLNBOh/hdG+VqTswR8X+MmtvgP8SrT9o3SrSOX4U+JbmJPEFjEzZtvN/dW+uxJu2b337X43eU/952r7W03VLPWtNtr+wuYryyuY1lhnhbekitgqysO1cnf/AAT+HereFdO8MX3gTw1deGrCTzbPRLjR7Z7K2lO7544SmxG+Z/u/3j61veFPBujeB9Dg0bw7o9h4f0yFm8mx0u1jtYI9zbm2xp8o/KjdWY+tzxD9ryFvBh+H/wAXbZf+RG1pH1R1/wCgTdf6Pd/98bopf+2VeffE6/1D4Q/EzwV8dEtbu5fxZ5/hrUdP2M7ol18+jps/g2yxIj/7Vw9fX2r6RZ67ps+najaW9/Y3CmKa2uollilX+66t96m6lpdpq0awXlpFdxJLFOqXEasquj7lYf7Ssu6hX0B63Plj9rrw7eeBf2d/Bkjwalqmk+E9d0zU/EL6VPLBdzWsTn7VcI8DJKr7mMu5GXFS+DLX9nb4j+KvBuseGPFdz8Q/FWn3KXukW0vjzU9UuLAtgSzvaz3UhiVUPzeYn+ye1fWEkSXEZRlDo3ysrVzPhH4Y+E/h/cahP4Y8MaN4fnv5PNu5NL0+K1a5b+9IUUbqOtxdjwXwLd27f8FAPipCs0bSr4S0jdFu+b/Wz/8Axaf991xGkfFTw78Gvi18X7Xwz4++H8Eeq64s+oaZ468SJpNzY6j9nXz5YBskNxB/qvkYR/Oso82vpnSPgX8NtA8TDxHpvw+8L6d4jWZ7j+2LTRLWK78xvvt5qrv3NubnPO6vCtL0TwTq+vao3xl+Ci6l41vdVnX+138FPr9rc23mlLXy7mC3n8qPyhENs3l872x1pfa+VvyBKzbPPvjR4R8MfDv/AIJf+IdC8NeK7DxnpNnbKW1zTLhJbe5nk1JJZdm1nXb5rv8ALurv/wBtTUrdfA/wMmN3CqyfEPw+6yiT5GTc5r0/Qf2YfhdJb6kj/DXw3DoV9PFcx6DdaNbSWkMyIyfaFgKbY5WVtmV/hRK3L79nP4U6pYWFne/DLwfe2enRvFY29xoFq8dsrNuZIkMXyLu+b5aq+rv3v+RV7xUfX8Tzr4hXMVn+3B8JXlkWNZfDGuorN/vWrV9GLItxEJImV0ddyujfermdS+G3hXV7fRoNQ8NaPe2+iusumRXFjFKlgyrtR4N64j2r/drsDU6tJPp/ncXVvv8A5I+U/wDgnrZzaD8H/E3hy+Lf2pofi/VrC8WT7wl8/f8A+PKyP/wKvEF0fxdqP7Un7SHiPwNcjVdV8Max4e1STwtKyvb63FHZP5sDf9NU+9F/clRa+xF+Hl54L+Kl94o8MJFLYeJWjXxBpUreUfNVdiXsDdN+0Ikq/wASojffX59DQ/gF8MvCupzalonw48J6PqUkbRteafotrbysrfeXeiBsNVRdr+aa/ITWjXc4nx148+H3xs/ZT8VeIbrVpYfAupaFdG/uoEH2qzUI3mrs/hnRv4T/ABLXg9v4u0H4seD/AIceBPFXxf8AhPDo+iXml3zajpPiyKXU9VltdjRQfZW2LbMzhQzpLL0+RF3fJ734++DukfDr4deIZfhL8MfDdlrl5HFb3lnommWlhcXtn5qfaIkfaqNJ5Xm7N7bd1cz4d+FvwC8aLNpth8A9OttQERR7fVvh02nKn8P/AB9S2qRN3+aKVv8AY3VK0k33E1eKT6HR/tyXlvZ/sk/FEzYdZdFmt41H8UsuEi/8fZa9H+EOiXfhv4W+D9Jv8fbbDR7K1n/66JCqvXD33wcu/FEPhXwrrKlfA3hMWUqI8vmza1dQIvleb/cgifa/953T+BE/e+3Ud/MbV7eQ3PNPoopjCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAopKbS62Ace1eV3H7RXgdbx7ey1DUtfWOVoJrrw7od/qttBKrbXWWe1glijK+jsO/pXkH/BRbx/q/hP4L6L4c0G+k0q78a+ILPw2+oW77Xggl3+aV/4Cm3/AIHX0j4I8G6V8P8AwrpXhzQ7SOw0fTbZLW2toh8iItEXzK4PSxzEfx18D33h3Utc0jXP+Em07TZ1gvX8N2dxq0tvKcfI8Vqksm5c/Mu35f4ttZvwh/aW+H/x3Zn8Dajqmt2oDf8AEw/4R/Ubeyyv3l+0SwJFv+b7m7dXU6L4H0zwv4k8T61p0CW03iB4ri8iRdoluI0MXm/7zJ5S/wDABXgP/BNM/wDGK+j/APYW1T/0tloi+a5TjaHN5pfefV+BTq4n4pfETTPhP8P9e8Yazv8A7N0e1a5lSL7744VFH95mIX8a8217xx8YfCOreD9UuPDml+JfDutajBZajomgWc/9oaCko/4+Hunn23MaNnf+4ipk6nv2aQivmt/jV8SNU/aU8S/Cq00Xw7p0cPhttd0zVZJ57xctceVEbhP3X91t0UW773+t4+b3Lwf/AG+fC+mf8JV/Zy+ITbr/AGguktI1oJv4vK8z59n+9R0uJs0NV1Wz0TTrm+vrmO0sbeNpZridtiRov3mZqpeGdet/FGkQ6jbw3MdrN/qvtUDRPIv8L7WG7aw/vV4H+0h4im8Q/HH4LfCtPm0rXtQuta1hA2PNt7GLzYonH8SvL5X/AHxW3+018aPF3wTs/B974e0PR9W0zVtcstGu5b+7lSaDz5VRfKiVNrfLv+Yyrt+X5XqU7xT7uwN6tdlc9/aoZpPKjZvm+X+6u4188/EP4v8Aj34afG7wB4aubDQNZ8NeN5bmytlt0mtrvTrqKIS/vZWd1uI2w/3YojWloXxW8YaV+0g/wy8TjRdSttR0OXX9J1LSrWW1aJIrhYmt50kll3t86/vF2/7lPd2Xn+GodL+n4nVfB/48eHfjTc+JrbQLbV4H8O3y2F8ms6fLYzJLt3f6qX97/wB9qtdkviK2bxb/AGFGJHulszeSso+WJC+xN3+/8+3/AK5NXgX7K/8AyWb9pD/scIv/AEiirptY8TeIdF+Hfjv4keHtKsdY1Wcy3Fna6hetaxNYWqsqfOqP9/ZLKv8A18feWolLlV/JP7wi+Y91pwr5G8UftJfEnSf2S/DnxvtNM8NyRJpdrq2saDLDPuuYpdm4QT+b+4Zd/wDGkvSus+LHxu8ZfC6TwL4lltNFufB+v6zYaLeaOYZf7QtftTFVuFuvN8p9uV3ReV6/va0s7287D6J97/gevX3jVtP8eaV4aGh61cfb7O4uv7Xgs92nwGIp+6ll3fJI247FxztauurwO++M3i/T/wBqrRvhrd6NpNt4b1PR7rVLPU47uWa6l8ry02um1Fi+Z/8App+FYvww+M3xJ+JnxE+LPgufTPDXhjUfCMtpb214rz6lB+/ieVWdf3DS/Ls+X91t+b79Gtr+Tf3OxLdvvS+89r8YeNLHwJpZ1TVFuI9KhdVuryOMvHbIf+Wsv92L+8/8H3m+XLDore4ivYUmikSWGRdyujblZa8e/Zt+Ll98a/AmpXOv6faWmv6NrF74e1SKy3fZZLi2lKO8W/5tjDDbWrk/2QfEM1lffFH4bTSNLF4F8SS2Wm723eXp06+fbxf8A3On+6qUlq0vK4nJJN9nY+mKK5jxtrB0PwjqmonW9K8OG1tml/tbWk3WVr/00lXzYvl6/wDLVP8Aer56/wCGjP8Aq6f4Af8Agr/+/wBQncs+rKK8g+CfxGPj6bWFHxS8A/Ef7KsRx4ItfK+x7t3+u/0+6+//AA/c+433q9fpgFMp9FABRTKKAH0UyigB9FMooAfTKKKTV0AU+mUUJWQD6KZRTAKKKKT7gFPpnmU+mAUUUygB9MoooAKKc3Sm0B0FPanUyigSH0UyigY+imUUAPooplAD6jXpS0UdQ6CN0qSmUUdQ6D6KZR5lABRRRQAUUUUAFPplFAD6KZR5lAD6KZRQA+imU+gBPWig189/trfEfVfh78CdQ/sGf7Fr+vXtr4esLrftaCW6l8rzU/2kUs34VEna3m7AeseHfGGn+Kr3U10p5ru0sZhBJeKn+jtKuQ6RP/HtwNxX5R93724V1leaat4V17wb8LbfQPhl/Y2lajpVmlvpsOsWc1xZssS4WJliliZd3Hz7uP7rV4d8Kv2hvib8ZPhrYWWl3PhXSvi/Za1Lp/iXQ9Q0W6EGkxRNh96i93/d2Okodll3bdq/MyUtZNCv7vMfXtJVGzjmFvEs7rJPs/eOq7VZv92rNKT5bjWpw3jn4veF/h3dW1lq99dPqd1E88GmaXp91qN68an5pPs9tFLJ5a/39u2ul8O+JdN8XaPa6ro19DqWmXK74Lu2k3o9fM37JurP46/aC/aO8U3odry18RQeG7YSD/UW1nFt2p/su7u9N/ZN1mTT/j9+0h4GgLR6LpXiG11WzjP3I2vIDJOq/wB3513f8Dqlr91xN2+8+nPEHiHTfCei3uratfQabpllE01zdXMmyKJP7zNXHeHfjl4Q8Vaxb6Vb3WoaffXe4WcOs6PeaYb3b8zfZmuYovP+X5v3W7jmsP8Aak+H958SPgzq+m6drdr4d1Gzmg1e11LUDi0iltZkuF8//pl+6+avCfhn8bB+0/8AEnwh4S+IOmD4beOPBl6niE6BL5qy6zKsUqJLas6L/ou19/8AEzfd+6u95Tu2vML6Jn078WPjL4P+BPhNvEvjjXI9D0VZUt/tDwSys0jfdVUiRmb/AICtZ3wX/aE8B/tCaReat8Ptbk17TLOf7PPcfYLm2RZNu7aPPiTd1/h9a4n48fDj4wa54x0bxX8MPG2haZNo9pNBF4c17SPOtryWT77vcK2+L7qL8i/3/m+bbW3+zX8cLv40eGdWTW9Bfwr4z8O6i2j69orvuWC5VFfdE38UTK+5f8mqBuyTPa6xPE3ibTPB+g3+t61fRadpNhA1xc3Vw21Io1+8zVsGvkr/AIKTL4jtv2WfFU+mapp1po+LWHULS406Se4n33tuqeVN56rFjPzbopd3+z1qb6pd3YpK565ofx3sNQ+JFl4L1Lw14i8Pahqds97pV1qdpEbTUYk+ZvLeKWXy2Uc7JvKb/Zr1uvC/F3xQ1/4J/D3TpfFN3o3inxRrOrWujaHaaRYy6VDPcXBVIom82e4b5fmdn/ur9ysbxx8ZvGnwN8TeGJPH66Hrng7xFqcekf2poFhPZy6NdS/6jz1lnl8+Jz8vmr5e0j7tV/nYlu1/I+je4or5ob4z/EjUv2lPEnwsttF8Oaalt4cbXNM1V557wHdP5URuE/dH+Ft0UW77w/e8fN7p4PXXx4X0v/hKRYL4hNuv9oLpLSNaCb+LyvM+bZ/vVP2UwTvJx7f8D/M6Skr598dfEvx94J/aQ8BeGp7zw6Ph34t+1RQTPpk/9oRXUEXm+R532ryv3vzsr+V/Bs2fx1neFfi/43T9rTWPhd4k1LwzPoaaI+uaXJp+l3EN3KDNs8iV2unTfErozfJ829W+ShdBn0nRmvnvUPjhrnw3+H/jTxv4yutJ1nRrfVW03w5ZaJp8tncXb+f9nRJWluJVZnn+Tcu1dq7/AOPamf8AFT4zfED4AaHZeNfGsHh3V/BD3kFvqsOh2k8F1oqSuE87zZJXW6VZGXd+6gqnoC1PpQ4pMivnrxJ8bPGmi/tOeFfh3DomiSeG/EWm3d/Zasb+R7h/IiUtvi2KsXzP/D5u4f3edtbwp8X/AIhXnx28afCrWIfD8+oadpkGs6Z4hsbWeK3+zSsybJrVp3ZpEZG+5Ku7/ZqXdW+f4EOVvw/Fn0dmkr5y8C/tGXllovxfb4iDT4rv4a3bx6jf6LC0UF5b/Z1nilSGWV2jcq23Z5rfMPvV5z4z/bqsfAMWgeJpfHfwz8S6Bf3UEGo+F/D+prLrGmJL8vmpMtw63XlfxJ5EX+9TV3su34lJ3/H8D7UqhqV49jY3FxHBLdvGhYQQj5pOvyr/ALVeCTfG3xsf2rk+FaaLoMWi3PhuXX7PVUvJZ52Tz4oVaVNqKn/Lb5F37vk+dfmrS+Cnxf8AEXin4lfEj4d+Lo9Nl1/wZNZONS0aCW3t761uofMifyZJJWjddrKw81qEnZNrfX8bFf8AA/E9R8I+MNK8c6HFqWi3QuoGZo33BkkilX5XilVhujkVvlZG+Za6evmaTxFL8Of24INAhLLo3xC8Nvevb4+X+0rN9vm/8Dt2VW/65JX0xmmtUn6k3V7D6KSloGFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFACU2n0UutwPCv2t/gG/wC0N8I7jQLO+XTvEdjdRapot833YLyL7m7/AGW+Zf8AgVL4I+PmoQWthpXj7wN4u8M+K1CxXMNj4evdV0+SX7u+K7s4pYvKb7371lZM/N617me1B70RXKrA9ThNY8eP4f8AD97ruraRrEWnqVWGysNNn1G+bJ6/Z7VJX/8Aif4tv8Py5+w78RI/hH8A7Dw54w8JePtF1m31G/ne3bwLrVx8ktw8iNuitXX7rivt7rSUR9242248vmn9x8vfFOx1f9rz4QfFDwppOl634XsDaxWWkS+JdIn01r68RkuPN8qdFkEG5YotxT/nrUnwc/aF+Ivja3tPCfiH4NeNfDHjG2iSDU9ZvLW3TRYn6NPFcNL+/wD7+yJH/u/7VfT9JR3E9T4+svEU1v8A8FBNW1qXwv4uHh648IQeHo9aHhjUWsmv1vXfZ5vkbfL2v/rf9V/t19e+gqWin0sTynyx+0Nocnh79p34CfEdv+QVb3l/4av2P/LNryHbbv8A9/V2f8CWqX7dmoahP4Z8CaXpXhjxL4kvIfFul6vcDQtDu75IbW3n3yu7xRMqn/Y3BvSvpHxZ4U07xpoV3o2sW32zTrqLypYnPH/AW+8rf7VL4V0e58P6Lb2N5qlzrUsQ2i8uwpnZeNvmFfvN/tUkrJLs7jtq33Vj5Y/aI8byap8cvgHq+m+FvGuqaRoWoXWp6neWXg/VJVtIJ7MxRb/9H3b8v8yfeX+JKn8XeKprP9unwzrg8J+MrrQbLwvdaJdava+FdRltYrmW4ilRfNWA71+T76/KtfX+KO9PZ39fxH0t6fgfEvwS8Ua0vjD9oE2PhLxhpF54m1xbvw/e6v4Yv7K3lR4YrXzd8kSbdrfPsfa20f72PffjGsXgX4BeINN0zTNV1BIdEk0uy0/RtOnv7iRvI8qJFiiV2/u/N90fxV69jmiplHmVvJL7hR0Pz98S6pqF7/wTTtvAcPg3xzJ4ubQLfQv7FXwpqP2lbqLyt/Hkf6rAP737n8P3vlrqv2pPFV14q+DHwuGi+D/HGrXsfiLSdVn0638Jaj9pgt7aX/SPNT7P+6b/AGG+9/DvXmvtf2pau/vX+Y+iXa/4nx14h8by6x+2t8OPEFp4V8bP4eg8P3umz6q/g7VI7eCe6eJ4Vdmtxs4Ubn+6n8e359rf2ffGEumftHftAazqXhPxppmk63c2F7pl7deE9RjivIrWy8qbZ/o/3ty/Kn3n/h3V9j032pdEvJr73cTSe/dfgfJ37CNxfR6b8SrPVPDHiXw3c3njTVNatV1/QrqwWe1nl3ROjyxKrdPufeWtX9knR21Lxv8AG74hqpWw8UeK3g05iv8ArbezT7L5o/2WlSX/AL5r3Xxp4du/FmmrpcGqXGi207Yu5rNf9Ikg6NEj/wDLLfn74+YDO3a2GXS8PeHdN8J6LZaRpFjDp2l2MS29ta267UiiX7qqKNmn5WJ5bpru7mqO9SUUUkrFhRRRTAKKKKAOO+JHw38PfFzwbqHhPxVp/wDanh7UlVL2zE8kPmqrbsbomVvvKvQ1wHwo/Y5+EXwOk1uTwR4QOiS6zZ/YL8/2leXHnQf3P3sr7f8AgNe4UgGKAPnr4Z/sKfBD4M+NLDxb4N8Ff2P4isS6215/a19Ps3oyONks7L91m/OoNN/YE+BWk+P4fG1p4E8jxPBqX9sRagNYvmK3Xm+bv2efs+9zt27a+jaKW4Hzl46/YH+A3xK8bah4s8SeBP7Q8Q6jN9ourz+176LzH/vbEnVf4f7ta3xi/Yv+Dvx88VQ+IPHvhD+3tXhtUs4rj+07y32xKzMqBYpUX+Nq93opgeC+PP2Kvg58SvDfhHQPEvg7+0tH8JWr2Wi2v9p3kX2aJtny7o5VZv8AVJ9/dRqf7FXwc1z4U6N8Nb3wZ53grSb19QtNM/tK8Ty5337n80S+Y3+tf7zV71RQB4b4c/Y5+EfhP4W+I/hvpPhH7F4K1+dbjUtN/tK8fz3XZz5rS+Yv+qT7rU74Ufsc/CL4HSa3J4I8IHRJdZs/sF+f7SvLjzoP7n72V9v/AAGvcKKAPnn4Z/sKfBD4M+NLDxb4N8Ff2P4isS6215/a19Ps3oyONks7L91m/OoNN/YE+BWk+P4fG1p4E8jxPBqX9sRagNYvmK3Xm+bv2efs+9zt27a+jaKAPnLxx+wP8BviV411Dxb4k8Cf2h4i1Gf7RdXn9r38XmP/AHtiTqv8P92tj4wfsZfB749eKofEXjvwh/b2rwWiWcVx/ad5b7IVZmVAsUqL1dvzr3Wih6geG+Ov2NfhD8SfBfhTwl4k8Jf2j4f8KwfZ9GtP7SvIvsqbVXG6OVXfhF++zVXk/Ys+Dc3wlg+GDeEM+CIdQOqx6b/ad58tz/f83zfN/iPy7696ooA8P8H/ALG/wi+H/wAOvFHgXQPCX2Hwv4mXbq1j/ad5J9q+Xb99pS6/8AZarfCv9i34OfBXVNUv/BXg86JdanYyabeONTvLjzbdj86fvZX/ALq17zRQB89fDH9hX4H/AAa8Zaf4t8HeCv7H8RWJcW95/a19Ps3IyP8ALLO6/dZvzqvpv7AvwK0bx/b+NbPwIYPE8Gpf2xFqA1i+Ypdeb5u/Z5+z73O3btr6NooA+fPil+w38EfjV4yvPFXjPwZ/bXiG8SNZrz+1r6DeqLtT5Yp0X7q1P8UP2Kfg58ZrjRZvGng461Jo2nppdi39p3lv5Vun3U/dSru/3mr3ymUAeF+Lf2L/AIN+PPAvhTwdr/g4X3hvwojpo9j/AGneRi1VvvfOsod/u/xs1Tr+xv8ACFPg+3wtHhHPgOS8+3tpR1K8z5+7du83zfN/8er22n0AeCeC/wBin4N/D3wd4u8K+H/Bv2DQPFUCW+sWf9p3kv2pF3bfmeVmT77fc2074V/sW/Bz4K6pql/4K8HnRLrU7GTTbxxqd5cebbsfnT97K/8AdWveaKAPnn4Z/sJ/A/4N+MtO8W+DfBP9j+IbHd9mvP7Wvp9m9GRvklnZfus351Xf9gT4EP8AENvG7eBM+J21L+2Gvv7Xv+brzfN83y/P2ff527dtfR1FAHz58Uv2G/gj8avGV54q8Z+DP7a8Q3iRrNef2tfQb1RdqfLFOi/dWp/ih+xT8HPjNcaLN408HHWpNG09NLsW/tO8t/Kt0+6n7qVd3+81e+UUAeEeLf2L/g3488C+FPB2v+DhfeG/CiOmj2P9p3kYtVb73zrKHf7v8bNU6/sb/CFPg+3wtHhHPgOS8+3tpR1K8z5+7du83zfN/wDHq9wooA8M8A/sa/CD4Y+E/Fvhrwx4R/svQ/FtsLLWrX+0ryX7VFtddm6WVmTiV/uFetQfCb9in4M/AvxRPr/gjwb/AGJq09nJZST/ANp3lxugfbvTbLK6/wAIr3qigD50+HP7BfwK+E3jjTPFvhPwN/ZOv6czy2t7/a19L5TMjIfklnZfuu3VaTXf2A/gR4n8dXfjPU/Av2rxLd339oz339r3y77jfv37FnCfe/2a+ilprdKAZ4V8XP2Kfg18dvGD+KPHXg7+3dbaBLY3R1W8t8ov3V2RSotHxD/Yr+DnxW0vwxpvirwh/atl4XsV03SYv7SvIvs1uoX5P3Uq7vup97d0r3UcUtAkeEa9+xb8GvE/wx8OfDzVPB/2nwh4fuJZ9N07+07xfIkk3F/3qyiRvvt95qk039jb4Q6P8I9V+F9p4R8nwNql6uoXmkjUbxhJOvlYfzfN81f9Un8X8Ne50+gZ4L4B/Yp+Dfwz8PeK9D8M+DV03S/FVmNP1iA6peS/aYPm+TdJKzL99vu7aPhN+xT8GfgX4on1/wAEeDf7E1aezkspJ/7TvLjdA+3em2WV1/hFe9UUAfOvw5/YK+BXwl8caZ4t8J+Bv7J1/TmeW1vf7WvpfKZkZD8ks7L9126rTdd/YD+BHifx1deM9T8C/avEt3ff2jPff2vfLvuN+/fsWcJ97/Zr6MooA8G+Ln7FPwa+O3jB/FHjrwd/buttAlsbo6reW+UX7q7IpUWj4hfsVfBv4raX4Y03xX4Q/tW08L2K6bpMX9pXkX2a3UL8n7qVd33V+9u6V7zRQB4Zr37HPwi8SfCvQfhlqXhI3PgrQrpr3T9L/tO8TyJW835vNWXzG/1sv3m/irpvgv8As++Av2edBvdG+H2gjw/pt5c/ap7YXk9xvl2Km7dK7t91fWvTaKAG9q+a/wBvbwbe+KfgBc6pp1s97feE9Ts/Esdun3pFtZd0v/kLza+lqheJZo2V13q38L1Dje3k7gcJ4y+JFt4Z+Gs/jCz03UvE1r9kW6tLHQrOW7urzeB5SxxxqzfNuX5v4a+XfiwmufCHxf4K+OPg7w/4s8S+JfE3lWvizw3pmgX7Nf2Wz7zxeV/o09v8ixebsZ8sP79fVngPwDD8PbW603S7qb+wmcS2WlyAsmnf3oom6iL+6n8HIX5dqp21UtJNit7vKYnh/Wo/E2i2eqW0N7bQXcSypHf2ctpcL/vxSqro3+yyitapqSlJc1xrQ+XvC+g3X7OPxu+JOtS6RrGqeC/HdxBq8Eug6XPqMtnqKrsuIpYoEZlWX5JFk2bfv7mXir/wB+H+p/DmH4pfEnxLpNzH4k8Y6rLrDaNaKst3DZwKUtLX5H2vPsB+VWxul29q+kqKrp8rCav99z50+OVp4k+NnwE0PVfDOg6xaX39oadrk/hTWY0sr66t4LhJpbKVGfYkjKuNrttrB+KejWX7RXjD4cX2geF/EGmeI/CviG01KfXtY0O70v8As61Q7riBJJ0i8/zdoi2xeavz7u1fU9LSSt99weqSPL9R+M0ej+PZPC1/4Q8Xxfuo5bPWrfQp7zTbot1TzoN/lMuOfP8ALqT4Z+BBoWv+MvFdxa/Y9T8VX0V3PaMFYwxRQJBErbf4tqb2/wB/b/DXpp7UHvTBq9hpr5T/AOCh0l/rX7N+veFdE8P+IvEniDWGtns7XQtDvL/iK7ilfdLFE6RfKv8AGylv4a+r6Tiptqn2dyk7Hyj+0F4d1n4+/CzwX4v8BaZq3/CTeC/EVn4hs9F1uwn0ie9a3P7238q6ReWR22t93/aq18XLef8Aal8O+GfC+neH/Emj2ia9Z3+tXHiDSJ9O+wRQN5rInnqqzuzIsS+R5q/MX34HzfUnpRT6/O5LV7+Z8f2PiKa3/wCCgmp6y/hjxcPD0/hGDw5HrX/CMaj9i+3reu+zzfI2+XtfPm/6rvvr69p+0UnWjol2/wCHFbVvv/keHftZeBdS8YfCdtU8O2sl34s8JX1v4k0WCCPfLPcWz7vKX/rrF5sX/A64H4yfDXxtD4f8D/Efwto4uvihpetfbbuzRvvW99st7i3f/Zii8j5/+nXdX1hkUZFUtCulj5z/AGlv2f8AVPHv7N0fg/wjcKmv6C9lf6QLhtqTXFqyOqu3+3tb5v7zVzXxi1HVf2pvgfe/Dmx8H+JvD+u63LZ2+sJrWkz2cGkxpcJJO/2iVfKuf9U4XyGk3blr6ypKlq7uC0Pjf4katNo/7aHwqntvC/jG90Dw9o1/pV5rFl4Zv57S3luFh8r96kW11+T5nTcq/wAWPmqXwr4qnuP28PFusnwt4wh8P3nhm10W11ibwrqEVnJdQXEryp5rQD5fm4f7jf3vu19hUnvTetvRr7yHG/4fg7nwP4Z8L3/xq1b9qPwonh/xR4bi8fGJ9E1XXfDd9ZWs3lWqxb2aWJNn7xR8r/NivTvhD+0D8S9ZtbLwH4m+DPi7RfHVrbi1uvEAtYv+EcDKu37QLppfmX+LykVm/hr6r4zS0tdPl+BSVvvb+8+PtT125j/4KEaXrP8AwjPiuXQofB7+HZNdj8NX7WRvJL1ZVXz1i2bNv/LX/V/7VHwL1y5uP2zfjRqc3hbxZpujeIbXSoNL1TVPDd/aWtw9nbyrP+9liVVGW+Xdt3fw+/2BWdqsN1Np1wthcizu2jZYp2j8xY2/vbP4qak7JPorfjcq/wCn4Hzn4g0eTxx+3l4VubZGNp4E8LXVzdzY+Rbi+fyoov8Ae8qKV6+nO1cd4F8B2fgXT7tYDLdajqMovNT1K62tcX1xsVDJJtAH3URQq/KqoqqMV2VC0SXr/mTbW/oLS0UUDCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK5Tx14usPh74S1bxBqYuXstPga4kitYvOmlx/BGn8bt91Vrq6pz28UyossasFZWXcv8AFSeg0fKWqf8ABQqw0WxmvNT+A3xx02yi/wBZdXng9IYk/wB52uNtev8AxX+PelfCXTbGS50HxJ4j1u+j8628PeF9MbUtSdB99vLj+VVXd95m21n/ABuH/CZeNPh34AjG6C+1P+3dTU/8+djtlX/vq6a0X/vqvVV0q0g1S41BbdBezxpFLP8AxMqbti/+Pt/31Q+jF1Z5t8D/ANozwf8AtAWOov4cbUrDVtLkWDVdB1qze11DTZWH3JYm/wDZSy/LXr1fP/wZ8D22rfG34l/FmCBbey8RpZaXpzr/AMvkFqrbrv8A4G7bV/2IVb+OvVfGWi6x4g8N3lhoviG78K6nIn7nVLKCC4khf/cnR42X229/4aJOyBanV0V8VfCPx78VPHWh618Kde8b61oPxr0DWPM1PXl0nTvs76Zv+S4ii8jy2ili+VPl8zzf4tiNX1/ptlNZ2dvbz3k1/LGiq1zdKivK395tiqu7/dVafS4r62Naivmb4g/HSz0n9oRfAOv/ABAk+GUK2Ftf6K09rbpBrkrPKs0Tz3MTrtX90vlxNFKd5w/pr/Eb4z6z8KPCPgWx1wmfxX4k1P8As2S70fR579I9iSyzTQ2kHmyt+7i+Vfm27l3cK1Ju0blJXdj6BFJXyV4J+Lnj5fjRD4W0ybxl4v8ACWuadcSx+JPF3gS603+wr9E3RLKwtbOOWB+fk+Vs/wDLX5qZ+z34n+LHxs8OeJptV8fW+kaj4c8dXWlC50vRYGhvrO2dVlheKTf5Yf5trJLuXd95vu1SRDla3m7H1zR718tfs/8Aizxr4o+KPx58C63441PVrbw1fWVnpOqy2dhFd2yzWrSs37q3SJ23f3om+7XIeC/jD8U779lH4o+LI/GFpf8AinwhrGtxw6hq+kRS/aLWxZ9kRjg8hFdgn+s2/wDAKnRK77J/eHMtvOx9pg0vpXxZ8Tvi98SvBf7Ifgn4zWXi4vrdvp2kX2o6PNp9t9h1RLk26y+afK82Nv3u/dE8S/7Fdz8cvHvjP4P+MvhRrcHiiTUNL8TeJrbw1qXh2azgWzRLhZdtxBJ5XnrKuz+OVlb+7VOLT+dhx1SfdXPpqk71Fu6/Svm/R/E/jn49eDPEnifwP4tuPCf2LUb+w0Gyt7O1livmtpni3XjTxStslljb/VeUVX+Imk9AvpfzsfSvpS18hfHD4rfGHwF4B+DmqtPo/hrxBruv6To3iLR/sf2rEtxL+9CXG9kRfkZfuN9/5X+Wu1+KPxC8RfAazabVPEt54nk8Wa/BpuhxJoDTzaUrxFpf3Vmnm3W1YpXVdm77is/8VT38m0Vb8rn0R60Zr5N8J/GHxpY/HvwzoFkfHvjvwFr8d0t9qfiTwPdaQ+gTqm6L9/8AYrWN4n+ZfmVmU/x1kfGr4n/Ef4f+D/iF4r1bx2vg3XdHlvbrw34LsLSz1GHUtOtz8lxdJ5UtziX+J0liWLem7bQ/0uJaux9capqFrpVr9pu5kt4FdELsf4mYKv8A481YPjTXtf0S102Tw94dbxNNPqVvbXcRv4rQ2tq7fvbjL/f8pfm8sfM3Svlj9qq61f4jfCP4H+KYPEmr+HDqviTw7LPp+kmD7PuuJon3t5sT72ib7qt8n99Grrf2kPGXxF+DVn8KBovjJdQ07VPFem6Bq82raZA2o3aTz/M/mxKkCfKvlbVtx9/du4q7PTzdvy/zFF8yTR9T0rYr5o+JPxA+Ifh/9q/4Z+DrHXdPi8J+JrLUrh7RdN/0iNraBfvSs7b/AJpA3yrF93HzVY8C+PPFukftQeL/AIY6r4ik8T6YPD8HiTStQ1C0t47mz8yV4Xt28hIlkj3JuX5N/q7dp1tf1/Anm38rfiew+GNe1/V9Z8S2ms+GToun2N6sWmXv26Of+04PKVvO2LzF8+5drf3a67jNfMXwF8efEzx1e/Grw/rvibSbnXvDet/2Xpepw6L5VrF/o6vva387c33/ALrS/wDAq4b4dfFP4pfEf9jHUPiZP43bS/Fempq2oRmx0y1+z3P2We42W9wkkT/utsSp+62S997UO9m7bJP7y43la3V2PtaivmDVv2oJm+G/wa1E213Z6v8AEG1ju5Tpuk3OqSWkS2onuGit4EeV2+4q/JtXfubhag+Dvxa8bn44nwhOnjHxn4EvtLa9h8U+JvB9zo0+nXqt89rK32O1ilVl+ZW8tWB4+aq1u0+guifc+p6q3V1BZW8k88qw28a7mkdtqqtT96+ZP28vFs+l/DHwx4Stpmt/+E78V6d4YnZP+faeX/SF/wCBIrL/AMDqFq0u7sNLmPafAvjyHx7p7apYW06aJKf9AvpBt+3R9fNVf4Yv7rN97/0LtR0rwv8Aao8TeLPhl8AvE3iXwLqemaNe+HbGW923mn/aklijRv3SDzU8tvu/Od3T7teb/GX4mfEf4d/BT4f/ABM0zxWst08+kxanoNxZQfYr9Lp4on+fyvNSTdLu3I6p/sUJ3v62Jbtv5/hY+u80V80/Ffxp4y+Enxb+FEi+KpdX0HxdrA8P6hoV1YQJbQO1u8iz28ip56tui+7LLL9+reqeNvE/xG/aC8V/DTS/EF94E0/w1pFlqb6hpltay32oS3LS/d+0xSxLAuz+5u3fxLVjWv3XPow81zFr4nGoeM9R0SG3Bi061gnmut/G+Vn2xbfXam7/AIEteMfswfFDx98RJPH/APwmmpaG9l4V1+88PJ/Z2kS2rztAU/0hrh7h0bcr/MixLtb+Ktq++JFj8JfgT4s+LWswMRdRy+IHtx8jyKyLFawf73lJbp/vUg3L/wC038cZv2dfhfqPjQeFb7xVa2f/AB8JaXUECQBvlRpWlbdt3sq/Ijn5/u1U+K37Q03wt8VfDvSZ/CGoX9p4w1W20qLWEuoEtbWeXd8jLv8ANZtis33Nn+3Xg/7b2ieP4v2OfGmua14sbVZL+0s21HQvsltFp9mrXEX/AB6sqef8rbf9bLLv+b5Vzx3H7W3/AB+fs1/9lE0v/wBJ7ijXS3cqVuRPyb+5Hu1z8QrbSfHVr4c1a0l09tQX/iU38jbre/ZU3PFv/hlQbm2N95fmTdtfZ3XSvnj9uS0nH7M/jHWrFzBrHh2OLXtOuF+9BcWsqSo4/wC+W/76r2H4f+Jh428DeH9fEfk/2tp1vfBf7vmxK/8A7NRum+xlzKNr9Tp6KjAxUlJamgUUUUwCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKjapKKTA8y8K+GdTk+KvjDxPqtt9miaK10jSFMitutY082WX5ful5ZWXH/AEwSuA/aJ8ZfFqw1TT9E8CfB248f+HJIy+qXh8S2OlrMf+fdfNZn2/3js/2V9a+iu1LT7B1PB/gr49+L/i/xBJZ+Nvg7b/CjQLK2zC6+JLXVmuZMhUiVIFXy1Vf/AGWvUPHWsav4f8J6jf6HoMviXWYIt1rpME8UDXEn8K75XVV/76rqaKTVwWh8ZfGT4Z/EG60P4efFDwL4I1Kb45afcq1/bvqNjCs9vKAbq1uma48toPl/deU0mzan+1X1T4R1rUdc8O2N7qmhXXhzUZot8+l3ssUstu/9zfEzxt/wFq6SimtrCtrc8F+Lnhe48crrOieLvhVb/EzwVPLF/Z8VvcWn2qByv712W4eJY1Vv+WiS+b975a8x1D9ln4g6P+z78NdO8NeIrZPiL8PtRfVNI/tGR5rRo2MqfYJZPvMiwS+Vv/2P4RX2RRSa92xSdnc8G+GfjT4yeMLeS/8AHXwzh8ADTUaT+zrHxDb6ld6rJ5X3E27Iol3Z+/L/AHfu43Vx/wCxr4b8eeBY/HumeMfh9qfhgaz4p1LxFZ3k9/YXMHlTyoyRN5Fw7+by38G35fvV9TntS4quvysQ4p/fc+aPBPgLxj8Lf2kPijrNt4afXPDnjprG9ttWtryCJLCe3t/KeK6SR/N2scbWiWX/AHK8t8NfC34v+D/2c/jV4NufAKavfeKdQ1h9Hj03WLXzm+3NN886StFHFEvyt8krt+8+51r7pxSYqd1Z9kvuHFKLv53Phj4seAfih4w/YV8P/C7TvhVrJ8YpYadps9vLqukrBbtaPbu8vm/avmR/LbZs+b+9srqf2nNL+JXxO034RN4c+FOuXVzoHiew8T6lDcarpMXkJA0qtb7/ALZ88vO75Pk/2+q19eniiq5m2Psuxk6feTXlnBNcWU9hLJGpa2uSm+E/3W2Oy7v91mr5M8D+Ffjh+zX438ReHfBngrS/iX8Ntc1efVtPu7rX00qXQ2nbfLFKGikaSPduK+UjH89tfZdFS9XqJaK3nc+Sv2qvBvxH8YeGfhdYaH4Ou/F2qaT4rsPE2qz6fe2cFvEsErO9vH9pniZvv7V+X7qfNtNdp+0V8L/FXxr+G3hzVPC7v4P8f+HNSt/EWjQauYnRbqNXT7PceU7rtZZXXKs3WvoDHSiktn5tv7/+GKvpbyseGfCPxd8ZfHFwkXxA+HNh8NrexbdLPZ+IItSl1F1/55RRL+6i/wB92b+Hb/FXj1n8G/iQvwe+PHgi78Irf+KPFM+rSWviuXVIPs2rR3CN9nX73mxPEuyLyniSL5Pv819qe1C0Am0fJ3j34U+O/En7NHww0yz8N7fE/hPUNB1KfQGvoPNnWy8rzYll3+UH+Vtv73b/ALdL+1x4f+InxB0v4bw+FvhxqOty6T4r0/xJfKmp6fCsEFrKzmL97cLunfI+7uQf36+saTgVV3dPs7/kTFcqsj5R+J2m/ELXP2pPhH4y0z4Ya5feHPDdlqEOoT/2jpiOrXkUa/IjXnzeUyfN/wCOb6XTNH8fR/tuaz43k+GusxeD5vDC+HI9UbUNOyZIrp5fP8oXW/yn/wC+/ubkWvq04pTS6W9fxFy7+dvwPkr4B2vxG8G+OvjXrWu/CfX7C18Sap/belQR6ppUks+2FIvIfZeYjlbbu/ufe+fpu5T4O+Bvil4K/Yp8T/DrVPhXq48XSW2pWlpaxatpbRXP2x52RvN+1fKkXmrv3/N/d319wUneh3180l9xcW4pJdHc+Jrb4I/FG++AvwT1PQdKTwj8WPhfFHawaTr1zBLa6pF9nS3uIvNtpXRElT7rn5/l/hzur3H4O+Jvix46WK8+IPgOy+GkdicLp9vr0eqXF423bl/LRY44+S23c7E7fu7fm9ozRVa3bfUnt5De9fO/7bngO98XfCWw1zSbOS+1fwTrth4strSJdzz/AGWXdKif7XlNLX0XQahaNPs7lLQ+fv2nota+KP7NPiPSvAGgXHjS68WaS1rYtY3drBEsc8R2zu88sS7en3dzfMPlry344eF/ih49/Za8G+DdH+E+tf8ACS28ultd20uq6UsVt9jliZ/3n2z5t/lfJs/4Ftr6n8J+CtK8EnUIdHheys7yczmzSX/R4ZG+95Sf8s933tq/L9K6zrQla/rchxvv5/ifJH7R2n/EXxx4o+DOreH/AIVa/fx+Gtei8QalDLqWkxPEvlSxPbruvPml+fd8vydPn/u4fx5/4WPrnxnup9D+DEnxFs7LSbW3tb7RvGy+G9R0h5d8txBLcxMrtv8A3R2JLtCov/PWvtKvFZvhF4v8K+LPEGs+AfHFvpSeJL3+0NR0vxNo7atapP5aRb4PLuLeWLckSfKzuvyfw1Q0kvusef8Awz1bxTrXgjUfhvqHwYl+EF9cp+5s7bWbbUreezluFS9uPtEX/LdfNZm3jezOrfPmvWf2gvg3Z/HD4K+J/h/LKljFqtn5NvcbNywSoyvE+3/ZZErs9F0e4tZDcX0631+VCNMsXlIq/wB1F52r/wACat+ga0dz44+MnhT4x/Gj9lXxB8N73wCNP8aSW9nZS6kdWtf7MvSksReW3Ky+av3N+yWKP/gVSftBeH/il4wHwT+yfDC41S98MeIrPxFq40fW7F7WJIlmjMET3MsDSS7XVv8AVKnP3q+w2pKV9geqt5NfefOX7YN9e+If2e9T8LadbyJ4j8cGDw9p1jKyiRZZ2Al37WbPlRCV225/1TV7f4O8O23g/wAK6Podr/x6aZZxWUR/2Y0CD/0GqEfgaxXxdJ4lm+03uqeWIIHuZdy2cX8SwJ91N/8AG33m7thVFddT2vbqRyp2v0GA5qSiiktCwooopgFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAJRS0UAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUU0cLQA6io91LQA+imUUAPoplFK9gH0UyimA+imU+gAooooAKKKZQA+imUUAPooooAKKKZQA+imUUAPoplFArj6KZRQMfRRUbY7UASUUnWm0rgPopn8VFMB9FMpF6VLdlcCSiox3qSqAKKaOlMHGKAJKWol5yKdQJaq4+imUeZQMfRTKKAH0UyigB9FMp9ABRRRQAUUUUAFFFFABRRRQAUUUygB9FMooQD6KZRSvrYB9FMozmmA+io/4jS0APoplPoAKKKKACiikPSgBaKZRQA+imUi0ASUUyn0AFFMooAfRTKfQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAeefEL4a/8ACyJNDgudd13SNMsLp7q5h0HWLnTZbw7Cqo8tu6SeXlyxXf8AwpXznofw3tr39sfxZ4Gm8U+Pn8K2HhOx1S308+Pdb+W5kuJUdvN+17/uqvy7sV9m9K+XfDX/ACkU8df9iDpv/pXPQtZWJl8LscN+2n8KV8Cfsc/EojxH4o1WK1u1v9NbUfEF5cSwJK1vE0ErvLuli+eX5Jd/36+iYPjX4P0zXPDvhO61aS21rVolTTmlsZ0tbyVU+aKK62fZ2l+X/VLLurzr/go1/wAmZ/Ej/r2tv/SuGsX9s4/Y/BvwKaD9y8PxE8PpFt/g+dloi7mnL7kfn+h774u+JWh+AfKi1SW8ku5VaaKw0zT7jUbuWJSqs6wWySSsq7ly22ubvv2l/hhpfw7j8eX3jjSbPwpJK9sl/cS7N067t8Hl/f8ANXY/7rbv+WvEPtl5qf7bXxH8L3fxH13wBqN5o+kS6HDp8enOupWqpL5uz7Za3H3JXl+VNv3qyPjR8HvD/wAI/wBmP9o+LTPEGteJ77WrZ9X1aXWWtdq3ki9VW3giRW+VGZdv9yk/dTfZXErNpd3Y+lbz49eBtN1rQNNudae3n1+RItMnlsrhbS7lb7kK3JTyvN/6Zb9/+zXoxb5TXyD+1dDHb/sw/DMxKqeVr3hvy9n8P+kRfdr68/hFD2fk7fgjOMrteaPmFvil4g+N/wC0d4k+G3hXV5vDfhDwRBby+JNVsBi9vryU5jsonZMRR7Ffc6fP/dK9a6b4hfBDXNB8FajL8M/G3i3RtfjxOItR1y61qK8VM7oP9Oa4aLcu5d0Wxt2015R+zdZj4P8A7Znx38G67/olx41u7fxPoNxM21b6H96Zkjz95o2lx/wGvsq/1CDTbaW5uZFit4l3M7VS+FFv4mfHv7cOi3mneJPg9e6R4s8ZeHJvEvjbTtC1NNH8TX9lDLZyq+9fKWXyom+X76IrV9XeFPDNr4R0W20yxlv7i2g3bX1LUJ7+4O5t3zTzu8jf8Cavmv8Abubdqn7Orf3vihpP3v8Adlr6jvLuDT7KW5uplht4U3ySSNtVVXktUp3jzB1sYnjDx3ovgazjm1e4mjMzssFva2st1dXDL822KCJWllb2RWrnLH9oX4d3ngvVfFbeKrKw0DSLj7JqFzqe+yewn4/dTxTqkkUnzL8jqG+avF/+FnWdn+3VoMetzNY6Z4i8AxDwy18vlK8/2vzbiJcn/WsnlfL/ALC16v4g8H+FPDMPxSvtF0yG18Qa7pj3mtXEA5mZYHjiZ/8Aa27/APx6k3ZJiejsaHhv9oDwF4rvvC1npWu/bJ/FEEtxpEiWc/k3SxJuf97s2K2z5trsG29q1vip4q8H+FvAmqXPjrVrLR/DM8X2W7udRufIjZZfk2b/APaz/DXm37CtvDD+yL8LVhjjhV9Fic+Uu3523bv+BV2v7SUay/s/fEtHVXVvDeo/K3/Xu9E3ypspakXhHxV4E8F/Bfwzqfh+7+z+BY9Ptk0XbHPK8tu6r9nWJG3Tysw27V++3vXReEfiH4f8cTTQaTeyNe28UU9xp93bS2t3brLv2edbzIssW7Y3yuq/dr5u8I+AL74kfsZ/AnTdE8WN4L8V2un6Rf6JqZg89ftkdkzeXJE330aLzf8APB6v4AfE7xve/FLxF4G+KnhbSdK+INhpVveprnh2V30/VrDzpURlV/niZHd/lb+833a0tq12BqyufS9cd46+I2gfDu1s7jXr9rY3k5t7O3hgluLq7l2F/KggiVpZX2qzbEVj8tda3Svn/wCPGv6Wnxg+FOg2Wh2uqfEG8n1C60HUdSklW10pIoNt1cOqOpl+R1Xyv4s/eT71QtXYErnpPw9+LvhX4pQ6h/wjeqNdXGmz/Z76yu7Oeyu7SX+7LbzoksX/AAJa8++OnxC8Da94R8WeE7/WtSjnjt5VuLzRTfQW9nOqlkimv7b91BLu2fupZVLbh8p3V5X8IY9d0T9qj9p5Ir5ta19NH0OeOVrdbdHn+y3GxVRf4f8Avpv9pq2/2bbvTPE/7A9o8rR3jz6BfrrP2j7z3n737V5v+15u/dSl1fYOtjG+Gvi74Y6V+wH8OoPjFrFrZ+GNU0a3jnW9uZYnvJV/e7V8o+a7fJu+SvfvFHxy8G+AfFXhjwxrN/eWN/4hljtdIzpd41vcyvu2RfaVi8pX+X7jNu9q+QvGTK3/AAR7siv/AELdh/6VxV6j+11Gf7e/Zkm/hi+IFgrN/wBu8taeXZ2/IVrwUu9/wPdf+F2eFf8AhaUHw8e+vLfxbPDLdQWlxpd1FDcRIqs7RTtF5Uu3cv3Xpdc+NXhDw7rF3p2oanLavp6GS+vPsVw1lY/Lv/0q7VPIgbayttldfvV5B8UbmOP9vb4IRM67m8Pa9tX/AIBF/wDE1z3xE8P/ABU+FOu+OfHXw4u9I+IngTVLye98Q+CdYU293byxxeVcGzuBn7yRL8knp8n36h9H/W5MXd2O9+L/AO1Npvwz+Jnw+8Kro+v3kfia4eSXUbHQ7y7hFutvLKFi8qJmlldlT5Ig2xdzPtr1LxF8TdD8L6XZ319Nf+Zfxefa6fb6ZdXGoSp8u7bZxRNcfLvTd+6+TPz4r548c+K7Dxz8Sv2Q/EemQyWml6vcXt7a286fOkUukO6I1VvEmpXU/wC29rPh2++IetfD661HwxYHQf7PjsGW/CzT/aIkN5a3Hz7mT5Ytuf8Aa21b6FrVX8j6T+H/AMSvDXxQ8OnW/DGrRapYeY8MjqrRvBKp+eKWJ9rxSL/Ejqre1fJ/7fnxK8F+Of2ZfGI0zW9VbULBIm069tft1lp94zypFMsVx8ltefuml+TfJ/FxTvjt8LpPgZ8Cf2h9Z8H+LvEXibxlr2nQX+tSanLap5C/6qWWJbW3iWKT7P5v/fCVuftvSaDqv/BPHxBc6Q1tNon9k6dLpzxf6rZ9ot/K2/8AAaXW/YqFrpPqfWmif8gXT/8Arin/AKDXyn8ePjppkn7Q3gT4c6rp3iC/8Jy22qT69psfhXUbyLU3SFEii8pLdvtUH712fyvMT7m+vqnQ/wDkC2X/AFwT/wBBr5z+KDf8Z7fBL/sXte/9BgqWvfMpSsmdX4R0PwD+zToN3Hpd7qmn6T4iu21LTvDkdvPdPbHyl3xWFhFEZ1Xo7RInyFm+7XZeH/jb4H8UeHdX1yy8R28em6Nu/tVr5Xs5dP2pvb7VFKEaD5R/y1Va8a0zWp7b/gobrWn62WjS68Dw/wDCPNI3y7FuN92qf7e7bu/2USm22i3Vr/wUY1C+0dNmn3Hw/ifXTG3yPP8AbWW13f7exH/4ClO99Sltbt+p6Zo37TPw117TdEv9O8VRalp+s6n/AGLY3trazywS3e4oqGVU2JuZW2M21Wx8pNX/ANoLQ7fxJ8GvF0NxcXtssOmXF1FLp99PZyrLEjOn72Jlb7yj5a8p/wCCftvDH8HPEbRRxrLL4x1tpmTqzfbH+9/wHZXtvxo/5JF41/7At7/6Jes56R+4IvWx4R+zT8fPBfgD9mH4Qp4k1mawS50Kyt31KSyuHsYp/KX5J71YvIhb/rrItfRPiTxlpPhHSDqms6nDp1izrGksj8O7fKiJ3dnY/Kq/M3GK+bPAY0Yf8Ez9JOuCF9H/AOFffv1uPuf8ev8A8VXA6fdeJPBfiT9ii18biaDTE0+e1vPtTf6nVm0/ZaJL/wBNdvmp/vbq13k/Kwl08z608E/Gnwh4/wBWutI0rUbiDWbSMTz6Pq+n3Wm6gkbHAl+y3UUUvl5/j27ar/ED4meEdFmn8O6xqF897cQf6TaaPa3lxcWsEm9RNK1qjPbRfK/799i/L96vJP2kdBnf9pT9nHVNEQnX4tYv4p5I/vNpv2X/AEjd/s/c/wCBPUn7HPiCfWtc+OC606r4sg8d3iX0L/61LfZEtl/2y8pV2f8AAqm9k35NhzNPbyOG/ZC+J3hf4TfBP4neI9d1bUX8Lad481eBNTSO81ZktVdEid3iWWV02qv71/8Avqvo7Sfjl4S1z4VyfEaxn1K58IiD7Ut4ujX3mtD/AM9lt/K811/i3Kn3fm6V4r+wlpunXPgP4tab5ED6a3xD163aD7yGLzF+X/d21hfB3UJ/D9j4i/ZnvJJZL7SdXWy08v8Afl8Mz7rjdu/2Illtd/8Ae8qhatJ9k/vM46J+TPrHwf4u03x54bsde0eS4k02+i862e6tJbV2U9G8qVFdf+BLWJrvxi8KeHNaOk319cC5iG65kh0+4ntbJQu7ddXEcTRW3y/89WSu4jRYUVVGFVa+T/iH4W+LHw78f+O/Hvwm1LQ/HGhajcJN4h8Ba4vlS+fFapE32W6X7rNEkXyS/LRezZqtVc9l1H9oPwRpPi7wt4au9Tu7fU/FAU6Lu0y8+z3u5d/yXPleVu2fNt3VdtPjd4RvfifN8PVv7yHxfHZvfCyuNKuoElgQqHlineLypV+dfuO1fM3xC8Vad8QNe/Y48V6Lp8ml6Hf6s8trazt89qjWDbIv/Hf/AByu78UTRr/wUQ8EIzLvbwDqO1f+3qKh6TS9fyuJPc7pv2sPhO2k+JdTt/Gdnqlh4c2/2rc6TDLfJbBv4z5CNuVdvzMudn8W2vKfjh8fNH1H9oL4f+ANRsde1PwXdWmqXmt6fF4V1G9h1TbCiW6oqW7faoP3rs3leZF9zfWp+zjawt+1t+09P5cf2kajoib9vzbf7Pq18TWx+3p8Egf4vD2vf+g29U1afL/WyZHNpexu+FU+G37MEd1pWlXutQ2/iKV9Zs/CNpp95qMtjDtRXNvYwQvLBBu+8GXYrv8Aw/dr1PwT8SvDnxC8Ip4k0LV7bUNHYOWuo5cJEV++su7/AFbL/ErcrXkOraxDrn7U+paJ4S02z07xlZeGbYa34r1BZZ/KsGuWaG1gtQ6qzs3mt5rcL8v+t+4PluG61fw3+xJ8fJLaS81hbH4j3/8AabpEvmz2aahb/at6rtT54vN37F2/fpatlN2dj7k0n9oTwHq/irT/AA7Dq88Opaju/s83unXVrb6jtXd/otxLEsVz8v8Azyd60vHXxc8M/D1Zl1e6vmuIojPJa6Tpl1qVxFFz+9eK1ildIvlb52ULWJqsHw4+LXhvwX4unisdf02xvLfVNAvIZOEum+WIxbW+9833a8H+GdxeeKv2mfjh4an+KPiLwT4nTWILq20awt9Mb7Xp32OJYpY/tlnO7Bfmzsbb833Ruo62GtVc+r/CXjDRvHnh6z13w/qNtrOi30fm219ZyebFKtUPHXxG0D4d2tnc6/fm1a8mNvZ28MEtxdXcuwv5UEEStLK+1WbYisflrjv2d/hDoHwV0DxB4f8AD+vax4ht21qe+urjWZbd3S6l2NKieRFEqru+bbt+871znx21/S4/i98J/D9noVrqvxCvbjULrQNS1J5UtdJSODbdXDojL5p2OirF/H/eT71D0dilqdt4f+PXgPxN4f1/WbbxHBZWegvs1gaxHLp0unf9fEFyqSRf8DVd1UdA/aW+G/ii28NXOk+JV1K18SX0um6ZdW9nO9vcXUW/enm+VsQ/un27tu/Z8u6vH/2fbXUNN/bJ/aIg1HU31W9+weHmkuPs6wK3+jzfdRf4f++m/wBqtP8A4Jvxxj9k/Q3jjVZJNT1Zpdv8Tfb7j+m2qto2NqyueueMv2gPAngC4li1vWZraC3k8q7vrfTrq4tLB/l+W6uIomitfvr/AK10rW8YfFjwx4HsNNutV1XK6o23T7fT7eW/ur75N3+jwQI8kvy/N8itXyV+y14Zf43fBnxD4c1T4teK9I1WPUNW0/xR4WtYdG/0aWS6l87d5tg8u19xO5m/iPSuvsdL8OeBfFHwU+HXgi0fxB4o03SNTTw/4s8Sz+Yml6dFsillaKLylut/7pFRdny/NuWojqKS5XY+h/h/8VPDPxRsby48NaoL02M/2S8tp4JbW6s5f7k8EqJLE/8Asuq1a+I3jjTPhf4G13xZq8nlaXo9pJeTsv8AcRfu185/sq2d5p37Sn7TFpe6nJqlyuq6M0t1LEsO5msv7qfL/s/8A/irX/4KSWuo3n7GvxDTTSfMWK1lnC9fIW6iaX/x0GnJJWuxR952Oy+G/g69+JHw8i13xtdajDrvia0jupo9J1C6sJNNgbZLFa28sEqyRhRs3srZkYHd/drxr9kH4WwfFD4TapqHibxj8Q9V1S38Q6ppsd7/AMJ3rMLrFBdPFF8kV0i/dX+7X1x4XuYrrw5ps8G3yHtYmj2/3dtfIX7GvwX8P+PPhb4i1DU77xRBNL4r1uJotL8W6rptvtF7KP8AUWtzFEPwWol7suVDWqudZ+yx8S/Fd/8AGP4x/C/XtcuPF+meCru1Gm+IruNftTrPFve3naJVR3i+7u+9XP8A7P8A8QtL/aI8deONP8X+Mdd0/wAe6H4ivLS28J2Ou3WkpYWcT7YmW3ieL7Vwm53lWX52/hXiqv7POtL8J/2wPiB8DvC9tb3HgaPTk8RrOqhrrTr2XZ5kVxP/AK2ffu3bp2aX7nzba6r4n/sufDD9rzTrbxpYvceGvGkEkkMHizw5P5V9bzwO0TpKV/1ux02/N8+PustW9GhLW57R8KdH8T+GdJ1Ow8U+I7jxVeR6nM1tqd5BFDJLbNtaJdkSIvyJ8mVX5mRm7157+2HrnjiH4Uaxo/w0vpbDxn9il1VLmD78dtalXdE/2pW2Rf8AA2rE/Yz8Y+PrrTfH3g/4jatF4n1bwRrv9jx+JoVK/b4vKSRd/wDtru+b6/N/ePRaLovxG8aa3q/jLw54q8K6bpGt7IbG31nwvcalL9ji3rE4li1CBdku+WXG3/lrSkrO4R1ujvPgb8ULP40/CPwn42sCvlaxYxXLp/zyl/5ap/wF9y/hXC/EDxIfgL8SvC+pefK3grxprC6NqNnNJuisL+Vf9Huov7iSuvlSr93c6P8AL8+/yn9i2O/+BfxU+JXwE16+tpXsp18TeHmtLf7Lby2V1/rkghd3ZVil4272611X/BRa3mu/gBZ21mu/U7jxNo0Viqff8/7bFs2/+PVXbzJva59T0jyKi7mPy01PlVa53x1rWneHPBev6rrQaTSLOxnuLxUXdugRGZ//AB3NZyly3ZUdTibX9pz4a3ms6fp0fiJ0bUZ/sdjqMmm3Uem3k/8Azygvmi+zSt1+VJW6e1dP4r+KHh7wZqFnp9/PeS310SVttO026v5Il3f62VYIn8qLP/LWXan+1XxV8WIb7VP2TPhXrOnRW/g/wQ2veHpdD8L2P794LV7pfK+0XUu5nfYyt8m3Y38cte3fGL4f/EyH4tXXj34O+JtHk8Rw6Va6frHhDxGjG0voElmlgdZV+aKT97P/ALNa2FfWx9AeG/EmmeLNHt9V0i9g1LT7jcYrqB98Um1tnyt/vLW3XkP7M/xIT4rfCuy1n/hHZfCd8l9eWmpaLJJv+y3kVxIlwqt/Evm769dHSofYE7ux8l/tGfHKw0n47fC34eXln4gutAvbvUJtfs7bw3qV0moxR2W+KFPLgb7VHvlVpEi81Rs/e4r0DwToPw5/Zz0e+1TRptR0HSPFNwl5Y+F1tLjEUvlb3istNWLzY3f5meJIt3+yuK5D4/Nt/bV/ZlH95PEf/pElM1TWrnT/APgopolnrbMmlXvgO4i8PO7YQ3f2tXu1X/pr5Sxf8BWnFXimM9t8GfFDwn8WLTVINB1WS6ltX+y6hZSRT2d7Zuy/dlglVJoG/wB9Vr54/Yw8K2d3pn7QXhmefUrjTU8ealpqmXVLprtYEt7eNF+1b/Pzt/j37q6DXtFmh/4KBeGNS0ePZ5/gm8TX2hb70S3CfZfN/wBrfu2/7jVD+xL/AMh/9ob2+Jupf+ibep5tG+yb/IOl/NIm/wCCf4aP4I6nA91PceR4p1mFJbqdpZtiXjqm52+dv+BV6XcftKfDmDUrezm12SO3uJ/ssOqyafdLpcsu/Z5S3/lfZWbf8u3za+XPh0+uw/sA/GWTwz539tLqniXyHg/1v/H3Lv2/7W3dXqviqTwt42/4J46hJbrbP4al8AvLCp27IvKtPk/4Gjp/30tO+l/JBb3ku9/wseseLvj94N8C/EPQfBGs3WpWviXXn26Zaw6Jf3EV3/e2TxQNF8v3n+f5F+Z9oqGP9oDwVJ8Wh8Nhf6kPGjQNdDTW0S/VDCv3pvP+z+V5X8O/ft3fL97ivA/HWg+KbP8AYx+FXjjUILmbxx8O7bSfEk8T/wDHw6xRIt7E3+00Dy1J8ZPFEWn+NPBH7RWn6iH8H6DqaaFczKf3Uuk3n7q4u/8AgF00X/Abena7sgeiPo63+MXhO41zxNpUl7d2dz4dj8/VJtQ026tLWCPH3hcSxJFKuM/cdqTw78YPDHi3Ubewsry6t9RuPNaCx1LTrmwuJ449oeWKK4iRni+dP3q/J833q4XVfBNp8QPgD4qt9b1OXRB4482eXUrdfntlnZYrT8Ui+zr/AMBrh/h/42+Kfw7+L3g3wF8ZLHRfFMWqLdQeHPHeho8DyyxW5lliurX+B2jRuV+X5KSvdoOlz37w38T/AA34z8TeKfDui6kbzWPDE0dvqtv5EqfZZZE3ou9l2tlf7u6u0plPpgFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFeJab+yb8OtL8eHxvbWniJPFjhVk1R/F+sPNIitvWJ91188ef+WTfJ/s4r22il1uB518Wvgv4U+OHh86B4xsLvU9FZvMks7fUruyjl/wCunkSp5n+61cn4q/ZN+GvjzRtA0bxBp+uapp/h6TfpcVx4q1YmBwzMr7/tW5pE3na7ZZV+VTtGK9xopJWHfSx5J8Uv2afht8bfD+maN468LQ+JbbS18uzmvLif7VEuVzi6V/N+bYu75/m/izUGsfsv/DPWfhhbfDqXwwbTwRb/ADDRtKvrqxhl/wCuvkSo0vPzfPuyw3fer2E0CnYR4h4k/ZH+Gfi/wfo3hbWtM1nU/D+jtvsLGbxPqpSJhjaf+PrLFMYXd9z+HbXqmi6PBoOmWWn2j3UlvaxLFG95dS3cpVf78srM8jcfeZmatsGhqYkrHFfED4W+FPilZW9l4q8P2mrw2spuLV5k2y20v/PWGVfnif8A20ZWqHwn8IfDXg2USWg1bUZI5PNibXtdvtXMD4+9F9rnl8r/AIBtrvKKWzuM8f8Ail+zH4A+M2tWOqeLtP1jVLuwmS5slXxHqVtDazL9yaKKK4SOKT/bVd1Vdc/ZN8AeJtMm07V38Y6vYyj97Z6h47124gl/3o3vdrV7VRQtFYDzf4s/AfwB8cvD8Oi+OPDNrr9hC++FZt8csLD/AJ5Sxssif8Bas7Sf2cvh74e+Gs/w+0bw62g+FbgYltNHvbizkl6ffnilWVt235vn+Yfe6mvWaKGrqwrHn3wr+Dfhf4MeHf7B8IW99p2kqP3VlcareXsVv/sxCeV/KX/ZTbVr4jfDfQ/ix4Vu/DniS3u7vRbxcXNva6hc2XnL02M0EiMy4zlfutXb0ntSkuZWGtDyrw/+zz4B8N+CtJ8IWmhyTeH9JuRdafZahf3V59jlVdiNE88jtHs3Hbtb5f4cVu+C/hn4f+H73EulwXUl9dIqXF/qWoXF/ezopcoj3Vy7ysqb22qX+XcfWu5pPWqvqD1VhjdK4L4gfB3wp8TptGn8Q6fLc3mjz/atMv7O8ns7uzkP3vKuIGWVdy8N83zV6DRS63A850P4JeCvDPjfUvFulaAllr+pQxQXl5DPKEn8ot5TvFv2NKN7fvdu/wCY/NWd/wAM5fD6HWtb1WLQHtZteDHVrW01C6gsb52HzSy2qS+Q8v8A01ZN/wDtV6vSVMk5Jq+4HxB8aPCnwu1D4I/EX9n/AOENto2j+M5Z7K3n8M2ULR3DO1xbf6QwYbpUSLYzTfMq7eWr6j8afC3w58SPCtv4f8UacNW06J4pUAlkimilj+5LFLG6yRyL/fRg1d32pap7P1v+Q27qx5RqH7OPw48Qa54e1nWPC1vrusaCmzTr3WZ5b2WL5kbezSu/my/u0/evuf5PvVNrHwH8Ea5eX95caROjahM1xqEdjqNzawakz/I32yGKRUuvk+XbMrjb8vSvUOmKU96aJSs7nAeNPhH4U8fR6EmsaaXGg3K3WlSWVzLZy2cqrsBikgdGUbfl2iqPxS/Z6+HPxs8N2mieNPCVjrWmWfNtG++KWD/rlLEyun/AWr0zvSnpR1BKyscJ4B+E/hP4WeDYPCfhTQbPRfD0Sug0+Bd0b7vv7y2WkZgfmZ9xrjl/ZP8AhYvhnUfDreFnfw1fSrK+hyanePp8TK+79xatL5UHzf8APJU3V7Zmik1ca0dznfCfhPRPAvh+00Tw9pVroujWg221jZQrFDGv3vlVa848W/sr/Dvxx48i8Z6xaa/P4pg3C21K38VatbPaq+dyweVdKsSn+7HtFe1UUdbitpY4Lxx8IPCnxMt9PTxFpJup9NfzbC+hupbe9s3/AL8VzEyyxN7q9Jo3wo8OaFoWpaRYW11awakgS+vU1C5GoXPy7d8l55vntJt/5a+Zv9672il0SG9Xc8p+Ff7Pvgr4Hrdw+CbHUdJt712kmtptcvruAyM253EU87qrt/fUbua9IureK8t2hmjWaGRdrI67lZav0h96r1BaO55J4f8A2a/hz4Ulzpvh1rWxS4W7j0YahdNpcEqsGWSKwaX7NE29d25Ilrr/ABp4B8PfErQJtF8UaTa61pUrJKbW8Tcm9fmR1/usv95a62igDg/B3wm8M+A5hcada3lxf+V5B1HV9SutSu1izu8r7RcyyyCPP8G7bWdrnwL8F+IPGsXi+50qe18TLCIJdR0zUbqxe6iU/Kk/kSos6/7Mu4V6bRQB4cvhf4P/ALJfhzxN46i0Sw8H6dLKZ9X1a1sJZ5m8yXd85RWk2b5Pu/dXPQUnwvbQvil8QtQ+LOnaRNDaSaZDouj6td2MtrcXlvvaWWXypUWRYt7oi71/5ZOw+Vq9wPekpomys/MSvOtb+BvgzXtQv76bSri1utQl87UG03Ubqx/tA7Nn+lLBKguV2/Lsl3LjtXpFLUWu2UtFY8/8ZfB3wj8QPDeneH9Z0WNtL0yaK509LOWWyexli/1TwSwOjxMuP4GWs68/Z2+HN94u0XxPqHhW01bX9HjWOx1DU3lupoNrb/M3Ss26Xdz5rfP/ALVeo0lHVsDyHwR+zT4C+HnjnUfGGgWet2viDUZPNv7qXxLqdwt620onnxy3DJLtVvl3qdnG3FVPFv7K3w78cePovGerWniCfxPAGFtqFv4q1a2e1V/vLB5V0qxL/sxBRXtNFPqmJ6qx5zrXwN8HeIfGVh4vutLmTxNZ2n2BNTtdQubd5oP+eU/lSqLiPP8ADLvpvg34I+Bvh3b65b6B4et9Pttbup7y/tQ7y28ksu3ztsTsyxq2xdyIFWvSaSnrayH1ueJ/Df8AY++D3wl8XXXijwp4C03R9duCzfbI2ll8rd18pZGZYP8Atltq98ZP2Xfhf+0B9hl8feDbTXrqx/1Fz5stvcKvXZ5sTI+3P8G7bXrvbilqddNQMLwr4V0fwR4estD0HTbfSNHsovKtrK1i2RRJ/dVa5v4gfBnwn8TptGn8Q6bLcXejzm60y+tLuezu7OX+IxXEDJKu4fe+b5q9Cop9bgtDypv2ePAa674g1mHRZtO1TXbaKy1G603Ubq1edI92x/3Uq7Zfmf8Aer+9+f71P+EfwC8HfAnT7nTvBdnqGmafcNv+wz6veXtsj7mZnSKeV1iZi3zbNu6vUaKb1DpY8P8AH37HfwY+KXjWHxd4o+H2l6p4hjYO10/moJ/+u8SMqT/d/wCWqtXU+M/gr4Q8eap4e1HVtKcan4fffpd9p11PYXFtu+V0WWB0by2GA0f3fUV6PQRmgfW5514Y+CngzwX4x1rxRoeiLpmt6wYnv5YZZdlw8SsqOYt3l+ZtZ/m27vm5rqPFXhnTvGPh/U9C1a2W70vUraW0urd/+WkUilXX9a3qSk/eVmJaO54n8PfA99a/D/8A4Vd4oXVp9P0m3htbLxBp2o3Fk99ZRHEJaeB0linVY0SRd3z9eVdlWDwz+x78NfBOmvpugR+LNC0+SRpXtNM8b63bQtK3332pej5mr3OlpuzdxRXKrHBfDf4PeDvg/p9zb+EfD9ro32qTzbqdd0tzdP8A357hy0srf7Ts1Y11+zr4CdLj+z9KuvDZup2urp/C+rXmivdzN96WdrOWLzW/2n3V6tRR1uM8+1D4O+E77wDP4IXTH03w3dbvNs9JvJ7BnDPuf97A6SfM3L/N8+5t2d1W/h78N9D+Fvhu38P+HIL6HR4BiGC91O6v/LX+6rzyyMq/7I+Wu2ooDrc8M1j9kP4Z+IfiMnj3UtK1eXxkrBk1mPxPqkU0P+xFsuh5Ufzv+7T5eam8ReB774u/Erw3qGr2k1h4Q8G6i2oWcF0m2bVNRVWijm2/wwRb327vmd/mxtVGf22k96XYTVxtUb2xt9QtprW6iWe2mVo5YpF3K6t1WtGilJcw1oeKf8Mp/C5vBa+E38OTy+H4rxb61sZNVvH+wyq+5fsrNLutV3L92IotdHr3wS8I+Irp72ewurHVJIEt21PSdSutOvTEjl1ia4t5Ul2bnZtu7+Jq9HoqutxW1uYvh3w3pnhHRrfS9IsYNN0+BcRW9uu1ErWPQVIfeijrcErO54z44/Zd+HvxI8aWni7XrLXbrxHZuXsr638UapamzJXY32dYrlVg3L18sLu711HjL4SeFPiFoenaZ4i0x9Sj011msbuS4lW9tZVXaJYrpHEqS/7avurvqKI+6DV3c4bw38MfD3heyvoNLtbpJb+PyrzULi/uJ9RnULtTfeSu87bQTtbzPl/hrkPA/wCy98Pfhp/wkI8MWmuaUfEHm/2m8PijVGed3+9Nua5ys/H+uX95/tV7Qe1Ie9JKwzy34P8A7P8A4K+Btlf2fgrT77SrG+k86e0uNWvLyJpf4nVJ5XVWb+Jl+9jmq+m/s2/DnSb6eay8Pva2ktx9rfR01C6GlGXfu837B5v2bdvXdu8rNeuUUPXYFo7mZqGm2+rWNxZXcCzW88TRSxv911b7y1yzfCXwlN8MR4AfQ7eTwetgumLo77vK+zKm0J13f8C+9Xd0UuraEtDA8ReE9I8VeHrnQtX0221HRbiHyZ7C4i3wyp/dZP4l/wBmsDwz8IfDHhPXDq1jZXM2orG8UE2oajc3ps42xvS38+V/IRtq/JFtX5a7+iqVxvU4vwv8MvDngvxB4o13RNONlq3iW4W61W4FxK/2mZE2I21m2r8v9zbXaUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAI3ShelDdKydY1qx8O6Vd6lqN3DZafaxNPPdTybIokX7zM1AGtS141pfx8/4Sm1tNQ8K+APGHijw1dEPFr1lDZ21u6buXVLq6inkT+LckTB1+7uqTT/2hNJ8UeEfEPiDwpoHiHxYND1BtOvtLtbNbK+ilWNHk/dXz2/3N659f4d1TLRN9hHsFLXiH7Pf7R1n+0d4ft/EWheC/FOjeGroSNa6zriWcUNw6PsZUWO6kl67udgX5W+avbKb91tME7j6KZRTGPpKbXDeKPHttoesadoVtAdS8S6gsklrpsL42xKcPPK//LOJdy/N6ttXcaFq7Ceiud5RUQ70qqFpXGP9KPWuN+I3jC88C+D9T8QWeg33iSWxjE503T5YIpZU/i+aVlX5Vy33qpfBH4lJ8Y/hP4X8bxWL6ZHrtkl6trJJ5rRq38O6ktU2g7HoFFct4X8S/wDCRz660dv5VpY6k9hDceZuFx5aJ5rf7O2XzYvrFXTVS1VwejsOahaYRmuS0nXfEN74017TL3w02naDaQ27adrhv4pP7QZ93mr5A+eLyvk5b7272oB6HYUtR/drkvG3jKXwTpI1ebSbnUNLt2zevY/PNbRf89Vi6yKv8QT5/wC6rUnoriOxorL0vVbPXNOttQsbmO7srmNZYLiJtySI3KsprUo6jCiiimAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAN7CvjX/go/rF1c+HfhN4IMjR6D4y8a2Glaxsb/WWu/d5X/A//Za+y/avHv2lPgLZ/tEfDeXw/Nfvo+q2l3FqWkavEu9rC8i5il28bv8Ad/2qFo0w8j1Ozs4NPtY7eCJYbeNdsaIu1UWsG78OWOkw+JdQs4lhm1NfPuyir+9lWLyt3+9sRF/4DXA+EfiB8UdPt9P0fxh8L7/UNVUJFc694V1Owl0yX+Ey7bq4gnT+9t8pvbdXS+JtY8VaP4Tv7xfDV74l1Wc+VDomhXVqvlrtwG826lgVv9rp22p1ZpkuZNdxLQ8g/wCCaX/Jlvw8/wBy9/8AS24r1n49fFKP4L/DDVPFTWy3txA0VraWsr7EluJ5ViiRm/u73WvCf2QR8SvgD+z74W8CeI/gt4su9W0kXCyXGlanoUtu4kuJJV2tLqSN/H/drpfiB8M/GH7UXwj+Imh+J9Iu/htdX0kEPh61ury3upYGtnWeK6k+zSyorNL8rKrfciSrk+aTYJWOj1LQvjH4X8aeENT0nxL/AMJno19erB4m0fUYLO1gsbdkz9osmiiWX5G/glll3bv+BVyOjeLvil4m/aX+Jnw2n8ZWOm6RZaDb6lpl9pejxpcWLTyyiL5ZWlWV12fM7fK23/VLv+XW+EXiz9oHxALfw/8AEL4e6P4bWz2RXniy18RLcf2jt+89vaRRb4t+P+Wsqbd3/AaxvB+j+PtL/bI8Y+MLr4a61b+ENa0qy0WHVW1HTGEbQSynz2iW68zymD/3Wk/2aOqG/hZ9G+G7O/s/D+nwatfrqmpRQIlzeJAIBcS7fnk8ofd3HPy9q+eP2UPETfEz4tfHjxpdsZp7XxT/AMIraK//ACwtbGL7q/70ssr/APAq+oSPlr5l/Z48LN8I/jv8ZvCNwjwweINWXxlpUzfcuYrhNlwqf7UUqDf/ANdYv71Jbk3tAbafED4iyftpan8N7vxJp58Ky+EW12zSz0tYp4Ga7WJVZnd/NdVV/n+Vfn/1VQ/B3xh8QfFHxU+Mfwu1rxvcXUPhG4svsPimGxs01V4ry381EdPK+y7ov73kfN/dqkvh34hf8N0SeO/+FcawfA7eF/8AhGP7X/tDTfv/AGvzftHlfavM8jb/ALHm/wCxUHwX0v4i+Hv2jfjR4x1r4V65p+heLo9Pl0+RtS0qWYtZ2rRGOREvDtaVvu/w8/Nsopr3dfM1srteSNj4K/FLxD8Sfgn8V7TxTeLquqeE9W1nw02rJAtu1/HAvyTOq/Ir7XG7Z8tWv2V/EH/CK/sNeANWEf2ia08NxPFb5/1sv8EX/An2r/wKuD+Cfh34o+A/AfxxstU+EmuLe+KPEGq65pFtDqulP5iXgVUilf7Z8jL95v8AZ+7ub5a7L9m3wN40sfgr8L/BPi3whdeGZvDLxLqq3V5ZzpcfZl3W7ReRLL96bym+bb/qn/2MqKSUvOz/ADM5fFEq/tLa94++APwT8N6j4O8QabZyWt/Z2WqG700XEt69zdRI8sT79sXzyyN/qn+9/DV743eNPiD8LPi38KpdN8VLqOi+MNZ/sG+0G/0+D7Jbs0TyJcQOipPuXZ9x5W3f7NL+3J4V8b+PvhbY+GfA3gu+8VX82q2d/LJDe2drDDFbXCS7GeedG3Nt+XYrd/u1i/tF2vxH+IHi34Map4f+E+v31v4Z12HxBqccup6TE8aeVLE8C7rz5pV3/wC5/t1K+FEu7kzqJvGni/wP+1X4Z8E33ie48TeG/F+i398ttqFpaxSaZcWzJxC8ESbonSX7svmN8n3qp/CD4j/ETXv2hvjT4F8Q+ItLv4PD1tpsuiyWulfZ4oPtUcsu6VPNZ32/u1x5nzbP4N1ZfxC0n4g6l+1x8NfGGnfDPWrvwroGmXmn3+of2hpcZD3SRYeKJ7reyxbfm/4Hs3fxN+FWk/EXQP2oPjB411T4Xa1ZeHPE1np8enT/ANpaZJMzWcDoVZFvPl81m+T/AMf2Vr0Kp2s7lf4FeMPin8Zfhb8SW1Xx8mj+INB8UappFnqeiaTarn7LtVP3VwsqeU3Xb9/5v9bXq37LvxOvfjh+z74O8Z6xBDHqOrWRa7SFcRNIrtE5Xr8rbK8i/Zr0f4l/DXwH8VLfXvhNrUOpar4k1LxBplpb6rpcv2qK8lXbFv8AtW1HT7z7vl2L8u9vkrsf2KvDvin4Wfs1eHvCnjnw5N4T1Tw5FLHPJdXtrPDLF5ry+arwSv8AKFb+Lb0pO3I/kSr3Rm/sSa1cWlh8U/Ac4H2TwX4zv9O035vu2cr+fFF/wDzWWvqDuK+bf2MPC1xF4Z8cePLxJIW+IHie81+0hmTayWLN5dp/31EiP/wOvpLuKcug+rFoooqSgooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKZSvqA+krn/F3i7SPAvhrUNe16/h0vRtOhae6vbhtiRIvevNPDfxU8d/ETSrDX/CPw+s/wDhG71BLBceKNefTb2eDPySpBFa3HyuvzqJXjb5uQtHcD2yivGfDfxl8R+OrDxfaaJ4Dk07xV4bvY7KbR/FGopZJcFkWTzYp4EuP3W1vlbZ83+zXPfss/tD+L/2jfCcXiu98CaZ4U8NTS3FvC6eImvb0yxS+W37r7KibNwf5/N/h+7T62DZXPoeio+5FLQA+imUn8NJ6B1sPXpQeleb+LPiA2l+KNP8G6FbpqfirUYXu/KmY+RZWqvta4nI/h3fIqD5nb/gbL6L93vTAf6UYxTPSuY8b3+uaZ4V1C78P2Nhf61DDutrfU7p7e3Zv9qRY3Zf++azvZNh1SOqFGK8e/Zb+LGpfHH4F+FvHGq2MOnahrEc8slpaljFEFnlRVG7n7qrXY+EfEVx4j1LxGxSMadY6i1haSKfml8pEErN/wBtfNT/ALZVbum12JjLmSfc7GioSMin0J3KH0VyFp/wl3/Ce6h9s/sj/hDPsUX2DyfN/tP7VvbzvN/5ZeVt2bdvzferrKYD6KZXEeHfFV9rUvim6itBdWGnXrWdjHabRLdNEieb8zPt/wBb5sXO3/VVN9QO5zS14z8DfjdcfGTUPHtnL4duPDtx4U15tDliublLhpWWNHdvk+Vfv/3m/wDZa9joT0T7pP7wejsPor5j8W/H741w+JtVtvBH7Od14x8NW9w0Ftrlx4ws9L+27fvukEqb9m7cFb+IfNXTfCX49a148+FeqeL/ABT4Hm8IX1jqV1pq6JYammryzywSeVtiaNFV2aXenyf3fvU1qD0PdqTFfNXhD9qbxT/wt7RfAvxG+EWr/DlvEckqeH9Sk1W31K3vGiR5XSUwfLBJsTO3c1fSn8NN7XFcdRUf8NC0rh1sc54q8aaX4L003+qyzpEzbI4rO1luriZ/7sUESPLI/wB75UVvu1T8B/Ezw38UtDbU/DOp/wBoWsczW06NHLbz28q8PFLFKqyRSDP3XVWrS8TalYaDZpqV7F5jwHZBsi3StI/y7Y/9puleYeFvDOtfDPRfFes6dY2OteMtc1b/AISDWdFim2uYnQRJBE395IoFVXf5ZXR/ub/la3sDdj3CiuU8C+NtJ+I3hbTtf0G5W702+j3xsfldP7yOv8LK3ystdXS6jCiiimAUUUUAFFFMpXAfRTKKVwH0yin1QDKKKKACiiigAooooAK5PxV4J0zxYbCa9hlF9p9x9psr61k8q4tpO+x/9r7rL91h94V1lFC0dwE3DmkDdKdRU20SQIaWp1FFKzQBSA5paKaAKRaWiqFYK5bxT4L0/wAcWcVlq0k9xpiyebPp6ybIbv0SUfxx/wCx91v4t1dTT6T1VgsQQoqJtVdir/DU9Mop9Rj6KKZQA+imU5ulAC0Ui9KWgAooplAD6Sm0nfNAiSivFv2hvj3P8BfDNprb+E7zXbSW+tbJpo7yKCOJ55fKXdklv/HP4k/2tvs4pLVXC+th1Fee/F3xvrXgHwjJf+G/Ct1438RSzpb6foNpcpatdSsf4pn+WJFTezM392vCf+GnvjppHiLwvp/in9m1fDFjrmrW+lLqTePbK68ppPvP5UUTM2xVdv8AgNMb0PrY9qU968U+MPxe8ZeD52svh78L9R+J2pwKs16sGqW+m29sv9zzZfvy/wAXlorcfe27lzu/AX4z6b8ePAEHiWw02+0aZbqewvNK1KPZcWd1A+yWF/8Adahaibsen0Uyn0DCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKZT6KTV0B8Xf8ABUC4nb4QeBNKkLJ4f1fxpptlrX9z7L877X/2d6pX2NBDHBCkUS7IlXaqr2rifjJ8I/D3xv8Ah7q3g3xLGZtL1CMK7xfLJDKp3JLG38Lqw3VxngnS/jT4DtbLQLw+E/H2n2qpAniC81K50nUGiXj97bpa3EUsu3b86yxbv7q01bls2Q90ev8A9nwRXl3eJGFuriJIpH3feVN23/0Nq+Zf+CafH7Kek/8AYW1T/wBLZa9y1aPxpp/h+8udKj0jX/EczL5VnqF5Lp1hGv8AvrFcP/4783+x/D4T+zN8MPjf+zv8K7TwY3hz4f8AiL7Pd3Nyt4viy+tP9bK0pXZ/Zcv97+9RG922bu3I4nrf7S3xYn+CPwO8WeNbWGO5vdNtR9mimP7ozyOsUW//AGd7rXLa18GfGVrq3g3xF4Q8f6uddtr+3fxCuvaldXFhq1mVxcKtnu8iCToy+VFFS33wb8TfGvwf8QtF+LUWjWcHiK3XTtPsvDV5LdJYWq/OsvmywRbp/N+f7m391FWD8H/hp8f/AAzDa+FPGnjXwdrXgjTYltY9UtNOujr2owL/AATM0vlRHGF3r5rf8C+al0Zk+ljBWHxPrP7bnivwLqHj3xJceErvwR/ai6dFdLbNZyz3bxYglgWJotioux/ml/2/vV9MeDfDjeEvDOm6M2qahrTWNutv/aGrzedd3W3+OV9q7m/2q8Jg+FvxSt/2vr/4oLp3hOTwpdaJF4aNp/bd0t6lut0ZftW37FsMnzN+63bf+mvevpYDFD0iiUnzNs+Wf2X9Wfxv+0B+0V4jvWke7tNftfD1ssnSK2tbf7q/7zyyv/wKk1mbxRa/t1aN4ffxvrs3hnVfCN7qTaKzRJb2sq3EUX7rYi/w/wATb3Xc+1l31t+BfDv/AApj9qLx3HchYNA+JC22q6ZKx+QajBF5V1a/77psmX+9+9/uVW174X/FG+/a00T4m2Vn4TPhXTtGl0D7NcazcpeyxSyrK9xt+x7Fddv+q3nO3767vlLvRldTA+Ftjqsf7SPxj+Gd14w8R3vgfT7DTdRs7O71m4lurVrpZfNRLxm+0qvybv8AW/LWt+zB4l1q70z4z+GdW1q/1608J+KLzStNudVuXnultvs8UqRPK/zy7d7fO3zVN4B+GXxa0P8AaV8c/ETVdM8GjQPEtja2K2tnr1493a/ZUk8pvmslV97P8w+Xb/t7fmyfhN8K/jZ8O9Q+Ld7caL4FvJPGeqTa1Zww+I7zbazskUXlSsdP+ZNq79w/ubdvz7lLXQ+zG/sWeIv+ET/YL8FaukX2mW10u4eG3/57S/aJdkX/AAJtqfjVL9tKz8TfCn9ki41Pwx401nw5q+im3NzLpLRxfb5Z7iNJ3lfb5i5aWV/3TJ8zV0P7NvwM8e/Dv4M+Bvh94wPhxrbwzqHnyXOjX09z9ujVpZovkkgi8pkneI/xf6qtr9sr4U+Ovjt8HNQ8DeDE0GKTVJYmuL7W76eBIEimilXYkVvL5pbZ/s7f9qnL3pN93cin7qUexx37Ttx4g+Gviv4NeJfD/izW7LU9b8XWPhrUreS+lmsrq1uFl3/6G7eQrrsG2VE3fWr/AIyvtU+GP7YHwk0vSde1q40rxza6vHq+m6lqc97bs9rAssUsUUjMsDdf9VsX/ZqL4/fCv4y/F6y+Gf8AZ+leB7C68M67ZeJb0XHiC8ZZJ4HlH2eLbYfcZXX96/P+x8u5rXxT+Fvxb8Z/Hz4VeOtL0vwbBp3guO88+0vdeufNumvIFhlVNthhdmz5W/i9Eo7+pp3Ynw01LxRa/tgfFTwvf+NNa1nRo/D9hqGn2980RWxeeWXesSJEqfJswu5Wb+9urnv2ZNJ174n6b8b9A8X+PvFmtw6R41vNHsr1NVlsruKKKK3KP5tr5Wz/AHE2r8z7k+aur8K/DH4raP8AtQeL/iNeaZ4QPh3XNLg0iK0t9cumu4ktzK0Urf6Fsbez/Mv8O/7z7Pnofs/fC74wfCWX4pXepaX4Iv38Wa7deJdPhstevNsVxL5S/Z5Waw/1WxP9ao/4B82VCUW/2WvjNrniL9j3S/GfiG4bW/EFnHe2zzY+e+lgupYIP+BPsi/77r3nwL4dHhXwrp2lNKJ7i3jBuJ/+es7fPK//AAJ2dv8AgVfPv7MfwC+IPwv+FPhrwL4zbw3JZ6PrkuqPc6Lfzz/aVaWW4RNksEWzbO8X8Tfcr6O1WS8h026ksIYbu7WNvJhuJTDFI38Ks4Rtq/7W1qmW1wW588/se8fEP9ov/sfpf/SS3r6cr5w/Zt+GHxO+Gvjr4jah4ssPCa6T4u1uXXd+i6zdXFxZysiRiLZLZxLIvyff3L/u17D/AMVp/wALK/5gP/Cv/wCzv+m/9q/b9/8A368jZ/wLdTS91LskvuVhvcqfGLxnJ8P/AIaa/rdtF9p1C3ttlja/897qX91bxf8AA5XRak+E/gdfhv8ADXw74aSQzS6baJDPcP8AeuJf+Wsv+877m/4FVXx/4PvvG2teD18yCPR9M1X+1L6GU/PcNEjfZ1X5e0pSX/tktXviKfGa+FZ28Ctoo8RKVeBPEPm/ZHXeNyMYsMny5+bDbf7rUtk13DqmfNfxC+LXjn4e/tJ+AJPiT4C0VvAOpan/AGR4e1vRNRlu30zULjdGslxvii+aVTs+78n735mr7EHSvI5vAvib4lTeGJ/iFZaJpkOhagmrJpWi3st+lxdxD9xK08sEG1E3O2zyvvbPm+X5vXataJIVveufI/wTt/EfiT9of9oXwT4k8d+J/EOg6T/ZCWaT3v2OWJZ7eWV/KltVi8r5n+9Fsb5E/u1B+zTaa78Vvh18TvDXinxp4mvrTwv4u1TQNM1G31e4s9QW3g2eU0t1E6Syuu/+Nvm/j3Vu/Cv4WfFzwT8cfiv481PS/BdzaeNY7RoLK08QXnm20lnA0USO7WHzK+fmb+H+49V/gD8KfjD8H9L+JsepaV4J1C58T6/e+I7JLXxBeKsUt0y7reVmsPuqqffT0+4PvUiurLn7LS2X7Tf7KfgPV/ijo2leOb11nLtrmnRXSvLFcSwLLtlTb5hVPvD1r3TwX8OfCnw50+ey8J+GdH8K2c7+bLb6LYRWccjf32WJV+bFeT/sb/Cjx38CvgzpngTxmnh+V9Jll+x32h3884nSWaWVvNWW3i2Fd/H3t3+zXuGq6tZ6HptzqGoXUdnY20bSz3EzbUjRfvM1Kb10JR82/skajNpfxa/aH8GAf8S3RvFq39mn8EX22Dz3RP8Age5v+B16l8atLOrafpyjwt448SlJG/deC/Ep0aWLj70rfb7PzF9tzVyH7J3gq9tLTx34/wBWs5bDU/HmvzatFb3CbJYrBf3Vkjr/AAt5S7/+2tfQlN7Aj5U/4Q4/9Eh+P3/h1P8A8JK98+HNqbLwbpsB0nXNF2Lj+z/EWpf2hfRfN/y1uPtE/mH/ALatXX0UDCs3VNUt9H025vruURWttG0sj7d21V+9WlRQB86/Dn9vL4G/F/xbZ+GPCPjY6zr12sjxWi6PfRb1jRpH+aWBF+4jUnw7/b2+BfxZ8baZ4U8J+ORquvak7RWtp/ZF9F5rKjOfnlgVfuo38VfRdFC0A+ctN/b8+BWr+P7fwTaeOzP4nn1L+yIrAaPfLvuvN8rZv8jZ97jdu20uvft+fAnwv47u/Bmp+OvsviW0vv7NnsTo982y437Nm9YCn3v9qvoyik1cD52+Iv7eXwN+EPjbU/CHi7xv/ZPiHTmRbqy/si+l8reiunzRQMv3XX+Kr/xW/bX+DPwR8Q2ui+N/GX9iajeWMV/BF/ZV5cb4JN2x90UTr/A1e9UUwPnfxx+3d8D/AId2fhy68QeOP7NtvEGnxaxprnSb6Xz7V87X+SBtudv3W2tV7xh+2h8G/AngHwr4y17xiLHw34pSR9Ivf7MvJBdBPv8AyJFvT738arXvVFAHzxeft4fA/T/h1p3ju58bGLwrqV7Jp1nqX9k32JZ413OmzyN/H+73q/aftqfBu++Et78S4fF+7wRZXy6bPqn9mXny3HyfL5Xleb/Gn8Ne8UUAfP3hr9uL4KeMvA/izxdo3jT7X4e8MJA2r3f9k3qfZfPfZF8jQB33t/cVqXwD+3B8FfibpninUPDnjQ6nZ+GtPfVdVm/sm9i+y2q/eb54F3f7qbmr6AooA+f/AIY/txfBX4ya1eaT4N8ZnWdTtLGXUZ4RpV5Bsgj+++6WBBxuFQfDH9uv4H/GTxnp3hPwd41/tjxDfb2t7T+yb6DftRnc7pYEX7qtX0PRQB86eD/2/PgT488cad4P0Hx19v8AEd/c/Y7ay/si/i8yX+5veAJ/49TH/b8+BCfEL/hCG8eY8TLqf9jtp/8AY9//AMfXm+V5e/yNn3+N27bX0dRQB85eN/2+vgN8NfG+o+E/Enjv+z/EOnT/AGe6s/7IvpfLf+7uSBl/i/vVZ+KH7c3wS+DPi668K+NPGh0XxDapHLLanSr2fasi70+eKB1+61fQlJQB4L8UP21Pg38G7jRIPGnjA6NLrNimqWKjTLyfzbdvuv8Auom2/wC61VvF37cXwV8C+E/CnibXfGn2HRfFVvLcaPdHSryX7VHG21m2pBuT738YWvoSigD5+1T9t74LaD8NdF+IF/4xaDwjrV1LY6fqH9l3j+ZLFu3p5Yg8xfuN95aRP24/gm3wtb4kL42z4LXUv7HbU/7Jvf8Aj72eb5fleR5v3P4tu2voKigD580j9t74LeIPh5r3j6w8Zi48KaDPDBqeoHSr1RDJK22JNjQeY3zf3VqTwX+298F/iJ4d8WeItB8Z/b9F8LWqXurz/wBlXsf2WJs7X2vArN91vubq9/ooA+e/h7+3F8Fvi3NrieE/Gv8Aaj6Hpsusah/xKr2LyLWL78n7yBd33h8qfNTvhf8AtzfBX40+KE8N+CvGf9ta2beS6+yjSr63/dRrudt0sCLxX0FRQB86fDv9vX4FfFrxvpnhLwn45Gq+INSdorW0/si+i81lRmPzSwKv3Ub+Kmab+358CtX8f2/gm08d+f4mn1L+yIrAaPfLvuvN8rZv8jZ97jdu219HUUAfOfjj9vj4D/DXxtqHhHxH46/s7xBp8/2e6shpF9L5T/3d0UDL/F/epfiJ+3r8CvhH4y1Lwl4q8cf2V4g05kFzaf2PfS7NyK6fNFAy/dZe9fRdFAFGyvItQtYrm3bfDKqvG4X7y1eoooA5Txt4Vt/G3hq+0W5v9Y0uK8TH2vR7+Wxu4Wz8rJLE6sv+d1fHXwkt/EeoX+rfs2+N/FviiHxho2p/2ynjGDxXeR3uraXv3J5Unm+bv2N5Txf6pPv/AH9tfZHjp/EqeF9R/wCESj0yTxJ5X+grrE0sVp5n96Voldtv/Ae1fOnxo/Z8+IfjP4d/D+78LQeGdI+L3hu+TU28RXWqXHlRS/8ALx86Wu64W4/jRkiX/vmpT1uJ7WPpzS9PTTdPtrWEzSJbxrEGuJmmdtv952O5m4+81aY6Cuf8Jya/J4dsW8S2un2muGPN5DpNy89qrf7Dyojbf+A10NV1uC2sfMf/AAUM/wCTeV/7GLRv/S+KvpxPu188ftefCn4hfGvwJa+FfB9v4bS3+3WuoXF9r2pz27o9vcLKqJFFay7t2z729f8Adr121n8VXHg93urHSNO8WtbSFbeG7lurNJ/4P3vlRO6Z27vkWklaNhW95yOqrxvVIm8b/tJaVAy79L8E6U97I38H9pXn7qL/AIElulx/4ELXofgn/hI/+ER0r/hMf7M/4SfyF/tH+xPN+xef/F5XmfPs/wB6sH4ZeDb3wt/wk17q0tvLq2uaxcahO9qzMnlf6m3T5/7sEUW7/a3U1o7lPUT4r3fxA0/wpcSfDrStD1jxFg+XFrt9La26/K3z/u4n81t235P3f++K8t/Yn+Jp8dfDvWtM1HwrL4M8X+HdbuLHxFpsknm779m82W43/wAXmtKW/wDQfl2V6DqV18Xrfx9cjTtL8G6r4KkEJtpLrU7yx1K1/wCeu9Vgnin/ANnDRf8As1anwz+G8HgG31qd5fteu69qLapqt9sMazTsip8q/wAKpGiIv+7R1bE1ex3tPplPoGFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFMp9FACHFNzmn0UAMpDjvUlFD1ERjHagHNSUUrDOd8SeHdL8Vab9g1SyhvrNnWTyplztdW3Iy/3WVsHd/Dit4Hb8tSUUwGUU+ipSsAyin0VQDKKfRQAz5c8UL96n0UCsMzik7c1JRQMjHIpacvShulAdRtFPooAZSntTqKAGUi1JRQBGtc7r/hfS/E8dtBq1ol7bWlwt4sFxkxeavKMy52ttPzfN/EFb0rpqKAGU+iigAooooAKKKKACiiigAooooAKKKKACk4rL1D7VJZzJYvHDdNGwjkmTzVVv4WZNyll/4EK+Zfhl8Sfjb8Qfil8T/Bb+JPAOmnwVd2VqL5PCd9P9tE8Hm7tn9qL5e3p95qmPvNrsrieiufV1LXzl4G+P3iSx+PDfB34haVpqeIp9JOtaVrvh9pUstRgVyrq0Eu54JV2/c3y/71XG+L3ir4h/GHxn4A8Az6Foc3g6Oz/tbVNespdQ82W4iaVIorWKe3wuzYfNaXr8u3vTXR9xvQ+gaK8z8A+KvGOo+LPE2g+KdBsNOj0yO1ls9S0+5aWLUVl83e2xkBi2+Vt2/P/vVtfErxm/gHwPrGuQWDanqFvF/oenw/fvblvligT/ad9q/jQ9HYSdzsqK8f/Zh+NMX7QXwR8NeNWjS3v7yEx6haxfdt7qNikqfN/tLXrtN6DH0lNpv8JqewD+1J6/Sqtz5rQMI2VJSvysy7lDV8/wD7LfxC8Z+NtW+Kum+NdXs9ZvvDPil9ItrjTtP+xReUtvE3EW52HzOzfM7UKV032VxN2sfRlLXP+JLK+1DRNQttM1D+yNQngkS2v/JWfyJSvyS7G4baf4e9M8L6fqGl+G9Os9Y1X+3dUgt0iudTa1WD7VLt+aXyl+Vdx52r6077+QXOipaj7VEOjUm7Ow+tizRXC/ET4l6J8MbDTbvWbqOJtS1G20uyg3fPcXM8qxIqf99f+O12vXFUK+lyWivL/iD8Rp9P8XaP4F8PIk/ivWYpboSTLuh06zi2h7qVf4vndERf4mb/AGWrv7GGS3tYopZnu5VVVeV9qs/+18tDG9HY0axNe1q38O6Xcahc7jbwrny4l3O5/hVF/iZm6VsVh+LPFGkeCfDuoa5rl9BpWkWETT3V3cNtSJF/ipX7AtTifBPxssvFvjbUfB194e1zwh4stLX+0F0vX44N11a+Zs+0RS28ssTJu+X7+5f7teqV86/DXx54I+K3xA1rXNA8e6DqXjPUtM+yWNrouoW+oy6XYRNuzIsTMu5pZdz7v+mSfwbm734X/EiXxNqGv+GNaWG18Y+Gp44tUt7fd5UkUi77e6i3f8spVz/usjp/Buo3dhdT06imU+hO6GIelMapKKErAMop9FMBlPoooAZRT6KAGUU+igBlPoooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooARvu18X/AAl0/wAcX37WH7SbeEvEHh/QVXU9G+0Jregz6k0n/EvTbt8q8t9v/j1fX+oLeNZzLZyQxXTRt5bzRGVFb+HcgZdy9f4lr518D/s7fFbwB8QPHnjCx+KHhO71Lxlc291fw3fgicwxNBF5UQi26orfc/vs1EfdbfdW/FCPN7eN/hD+3F4ZvvinqQ8ZeKvGuly6V4Z13Tbb7BZ6YsXzS2v2MvK3z78+f5r/AH9u1etdd8ev2TL3x18Qbz4o/CDxvN8PPirap9lu54cvZ6iVRdkV1Fj+7s+ba/G35GwK7PR/2ZLnWvjFovxM+JHiv/hNPEugxSx6LZWOmDTdM03zPvukHmyu0n+08rf+g46Sb4T+JNB8WeKPEHhDx1Jp154gniuJdN1/T11LTLeRIYot8UUb28qsyxf899vP3KVrJLsN6u55r+zP+0V408ZfELxD8Mfi14Th8M/E/QLGO9a60599lq1nv2LcRddvzP03fxfw/Mo7v4jeMNWHxK0e00nwPr/jTTdBje+uzok9hF5V5Iu2BG+1XUG7bE0rfJu+/FV3wh8HbrQ/FGveNtT1qHW/iDqenLpi6s2n+VY2cKncsUNr5u/yvNbzWDSs7f8APWpvgz8O/Gfw9g1qLxb4x0/xnLqN81+t1a6E2nSrI7fMr/6VKrqqiJEAVdqxfxUS1Vwjo7nzx+yvr2ofCn9qD4l/DbVfD2peENI8Xs3jPw7pWsS2rzK7HZeov2WeaIDf8yru4RK+36+bP2gP2Z/F3xe+K/gbxx4f+Idh4LvPBs0kunbfDjXk8jS7VmSaX7Um+JlTbsCr95/m5r3vR11SLS7WLVbm2u9SWNftFxaW728Usn8TJEzuyr/s7m/3qG7xQratnxv8XPFlp8J/in41v/jH4D1S48Latcf8SD4paJCbqbQbV7dIngdov39ntdXbfF97zau/HrQfDbftAfsreJtLgsby9vtUkt01yCFDLeWq2LNF+9/iX59y/wC9XuOv/CHxVqFprumWXjeKLQNflumvrPUdFS6mto5x86WcolRYupf9+k/z/wCz8lZfjr9muz1vwh8ONH8Kau3hW9+HtzBPoF3cW/22JPKh8jyp4t6eYrRNj76t+tLaPoJ6uxwGoeHNJ0H/AIKK+Hr3T9KtbK71PwNfzX1xawKj3Uq3cSq8rL95tvy7nrO/Z5+Gnhj4jeNP2jLTxPotp4i0+Tx1LE1lqUfn2/8Ax62/z+U3y7/9v71em6p+zxqmsfHTwr8Tbrx7fWWq6NpjabNY6bp0C290jyiWVf3vm+VE+3H/AD1/6a07SfgD4g8A+PvFuv8AgjxvFpWm+LNQ/tLWNM1fR1v9k+1EZ7WVZYjEdqf8tfNX/Zpx+FLyt+KYdPRpnhvhF9R1D9nX9ozwbqOp6xead4D1TVLTQ9QOp3EF0kUVuLiCJ54nWR/Kdv4/vLt3cVfbx9rPgz9iT4AWuiSxLfeJl8OaAZZ797JQkqJvQ3CK7xb1Tyt6ozLv9q9d8efDfSPhX+zB8R9F0oXEzTaJq17eXt25ee+upbeVpZ5W/vu+f/ZaxvAXwL0v4ufsV/D3wF4xt7i1V/DWmlmt28q6s7iKKJklib+FkYVXNzRl8ipL4fNtnOaZ8CfiDofxr8I+MPD3hfwH8LtIhnlh8UWvh7xBc3H9vQS/d82L+zYEadHyyyu275vvU34U+EvD37W/w48Xa942todU1yfXNX0yxvJYkluPD6RTvFB9jP8Ay7yoiRS71wzN81d/8IPgb478F3yDxz8YtZ+JGk2R/wCJbpd3pVtYrFj7jTyx7pbl1/2mC5+bbwuObm/ZD8Q+GPifrXin4XfFrVPhlpPiK7+269oFvpNrqMFxcfxywefuWB2/iOxqHqreVgb1v2OH/ao+Eel2fwh+DGn+KjY+P9a0vxboOjT+INV0+J7i6ie6RJ1fO75Zf403fN/Fur678NeGdH8H6La6ToWlWei6Xarsg0/TrZILeL+L5UT5Vrzj4sfAJfiV8OdI8M2fiC40rUNG1S11qx1W5g+1MbyCUS7513J5u9t+7ayffr0vRYb+DT401C6+23ef3kscHkoW/wBlOdq9erN/vNUv4WvP/ISWyPmX4J6lN4g/bu/aDlvh+80TTNB02x3fwwPFLK//AI/VL45eF7e3/bg/Z/uY73VU/teLXFvIP7Tn+zt5Fl+62Rbtsf8ArZfu7fvV3Xirw6fhP+0Y3xSZDH4V8SaRHoviGYLj7JPE+60upf7sWxpYnf8Ah/df7VL8UfgB4x+IXxz8D/EXSvHuk6LB4PF1/ZulTeHJL3zVuoljuPOl+2pu+78mxF2/7VVB2s35l395s898P+CtH8N/t+a/4W0a0XSfC+teBl13UdBsk8qxvL37d5XnyxL8rMyfe/v/AMdbP7LdnD4N/aM/aD8D6JBHpfhDSbzSLvT9Gs12WtnLPabrjyovuRK7ru2JXTw/s8+OV/ag/wCFvS+PdGeBtM/sJtCXw3KubDz/ADdvn/bf9b/012bf+mVP+FP7P3jH4e/HLxv8Q9U8eaTrcfjE2/8AaGk2vh2W0EX2eLyrfyZTey7f9rcrbv8AZqY6KzI2TPoSvlfWLqfR/wDgoz4eW0mZItc8A3EV5D/e8i63RN/4+9fTl1dRWNvLNPKsUMa7pJHbaqrXhvwv8Jnx38fvFHxhuIyuk/2ZF4b8Mu6/6+1V/OuLtf8AYllfan95Yt38dH2r9gWsT37Py0q0lKtMa2HUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUyn0UAMop9FADKKfRQAyn0UUrAN/hpKfRTDrcZRTh0obpQHU811z4D+CvE/jr/hMtS0m4m8QSWaafcTJqV1Fb3dsu/bFPbpKIp0+dvllRvv16LtCLtHAqak4pW0sJq42inGgU+tx9BtFPooAgkjSZWVlV0b5WVqjtreKzhjggjWKGNdqoi7VVat0UAMziin0UAUNQ0+21OzltryKO6t5RteKZN6N/wGrnl0+ilbW4DKfRRTAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiikoAWiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKSgBaKKKACiiigAooooAKKKKACiioz2oAd25o96+dv24fA3h7xh+zL8RbrW9EsNUuNI0K/vdPuLy3SaWznWFvnhdv9W3yr92s34M/sw/CbWvgj4FuZfh14cg1K70KzlfVtP0+K11ASPbrvlS6i2yq3zffV91Sne/ql94bW87/AIW/zPpukr4//Z78beIvhf8AtK+LfgF4k1vUfFOlwaYniHwxq2rTedex2jPsa2llbmTY3Ct/sH8PV9c/aQ0fT9P1DW7Lw14l8ReENLlmh1HxLo9tBJZWzRPsmO1pVnnRGVlZreKVflf+7Va2XmLq12Pa6WvOtT+L3h218F6V4n064k8QWGtGJdKXS9sr6k8v+qSLc6rlv9plVfm3Fai034uWV1Dqy32g+IdH1HSLCLUb7SptONxdLHJ5uxYvsrSrO37l/lgaTsKnV3t0GdVoPibSfFVm97ouqWerWsc8tu9xZTrOiyo2103L/Ercba368F+HPx0+Hc/wX1bx94T0PUdN8I2t/dGe103QHW4adZf9Il+zQKX++XZmZf7zNUdx+1t4XtvhRovxL/sPxJP4Fv4opp9YhtYymnRM+1ZbhfN8xl6bvKWXbzuovpdeX4j62PfqWvPfHXxW0TwDp+lz3f2i+u9XuFtNI0ywj8y41CdlLqkS/Kv3UZt7sqL/ABMtct4f/aY8M6146XwPqOk+KfDfjZo0nbQb3R5bp4oGfYs7T2fn2yxZ43mXb/exTd07ErVXPa6KytU1a00HS7vUL6VLeztYnuJ5m+6qKu5mrxjT/wBrLQLy48J3Fz4e8SaP4Y8XXUVpoPii+t7f7Ffyy/6lQqTtPF5v8HnRR0LXQLnvW6sWLxJpVxq0+kxapaS6rbx+ZPZJOrSxr/eZM7ttct44+J9l4N1Gx0iKx1DX/EWoiWay0HSY4mu50j273zI6RRqu9PnldFyyrncRXzp8BZtBh/bV+MVzovhxvDRbw5ptxqenrYJDPFeNLO8u9Ityyyt9/ehffn7zVCk+q6N/cPp/Xc+stF8TaR4ie/i0zVLPUnsJ2tLtbSdJTBOv3o5Qv3X5+6a3a8H+FXxm8HeNvD/jvW/AXg3VvO0nWJrfU9Oh0yLTL2/v9kTSuYp2i/e/MmWn2N8tV/D/AO1boXij9ndvjJpfhjxJf+GYo7m4ns1js0v4ooHlSaVke4WPC+U3CyFv9mqd0r+n4gunmfQFFeTf8Lw0u+8G+ENf03RtX1m58WWSX+laDaLAl9LE0Sytu82VIkKq6bt0u2q3jL42TaT8OfGPiDw94U1bWNY8N74bnRJxFZSpKsCzfM8rqjRKsqZeJnz/AA76JaX8tQWtvM9izRXy/wCAP2rv7A/Zm0P4k/EPwx4m023fTLW6mvraxivEvPNi815oltpZWii/2rjyvvLXXeLf2pPDXgbSfCWva1o+vWnhXxG1vFF4jNtEbSzln/1SXA83zV3cfOsTR/7dXKNm12diebS57nSE15Hq3x90vw78RvDfhTVtD1zSU8RO8Gj63dwRfYbydU3+QAkplifbv4liT7taXi74uQaDeX1jofhzXfHGqadGs97p+gRwb7ZGzt3PcSxRFvlP7pXMnfZSKWp6V0ox1rwDxJ+2H8PPC/wTX4nNLq+o+G2laCT+ztKllnt5lfY0U6f8u77/AJP3rL8zVv8AiD9oLRPCvijwnpmraTrVjpvim5XT9L8QTQxfYpLpvuW7fvPNRn2/KzRbG/vUMFqk+57Bmj+Kvmn4jfHzxd4a/aQ8LeB9P+Heuavo93p97fibT7vT1l1FoljX90st1EFjj807vNZWLbNqnGa+i4zvZWZSn+y1JJ8ql3/zFfWxj+LvGWgeBdHl1PxHrmneHdNjYI9/q13HawKzf7chC1d0XWrHxBpsGo6ZfW+oWN0m+C5tZllilX+8jL96vkyP4reJdW/bd1bTJ/h74pvbDS/CMVvDpn2nS8wefeN5t7815s8uVYol+95vyfcr0/QfEfhH4Mw6n4M+G/gTV9fi0a5e51PTPC624i06W4LTtue6uIk3Hfu8qJmdVdPkC7apaq4r6281+J7y3aha8fT9pHwRe/CW7+Imn3Woar4es3aO8Ww0yee5tZI/9ak0Cp5kTJ/HuUbe9TfDv9oDTfiZH4RvdG8N+Jm0XxLpJ1W21p7JTZW/3f8AR53SRvLl+b02/I3zUtbXRZ65RXF/En4kaJ8J/CM3iLX52gsY5YrcLFE0sss8rrFFGqryzM7Ktcp4T+Plj4g+IA8D6v4a1/wV4rksW1O20zXI7VzdWqsiNLFLbTzxHazD5N+7/ZpJ32EeuPIqLuY/LWLoniTSfEEdy+manaanFbT+RO1rMsoil+9tbb/F8y8Vwfi74oaVcatrHhK18K6t45mt41h1q30u2t5be0hlTO2fz5Yll+XrDF5ku1l+T5hn5l/ZU+K+ifBH9nr4reL7Tw3qWqeEdJ8da3KbTw/BbRPZ2aMmG8qeWL5FTb8q/N/s0urXb/gCk1FJ93Y+8ehArD1jxJpXh2Szi1LUrOwmvJVgto7m4WN5pG+VUTdy7H0ryvx9+01ovw7+H/hTxpeeG/EGo+G9fFqVu7BbVmsRc+Utv56STo3zGXH7rzPutXm37Z3hvSf+Flfs+a//AGXa/wBuH4gWFl/aQgX7R9n8q4fyvN+9s3YbbVdbediXJKLkuibPrinV8w+JPj94u0n9qXS/AFl8Ptbv9DTQ7nURJY3lh518wmii+0bZbpNkMe5uG/eOzcJ8tfTS0dE+/wDwwKX9fIlpM14F4g/a58L6Lp2seII9A8Ran4I0S7lsNT8X2FtA9hZyxy+VNlGnW5dUb7zxQOvoxxW78SP2jPCfwv1vwjpWrpq0s3iq7itNMuLPTpZbVnkbCbrjiIcZfbu3bR92j0KbsewcUeteTab8cNMuviunw+v9H1nw/rVzZPqOmtqcMX2fVIEP71oHjlf5k3LuSXY3P3e9TeLPipYWeuXfhjT/AA1q/jbUo4UbU9P0eGB1s4Jd4V53uJYo/m2P+6VmkYfwYqE27abq4dbedjt9D8SaT4ke/TS9Ts9U+xTeRcfZLhZfKl2K+xtv3W2srf8AAq3M18e/8E810mGy+Na+H7GHT9GX4h36WlnBb/Z1giEVuAnlf8s9v92vf/iZ8UNH+FOl6beaubma41K+i0zTdPtEDXN7dSf6uCJeF3HnlmVePmYVb0S80n99iurXZtfceh1XuLiO1iaad1iiRdzOzbVWvMfAPxw07xz421fwjdaHrXhPxbpdrHfz6Lr0cHm/ZpGZEnSSCWWJ13qy/LJWd4v+J/h7XpNf8OyeD9R8c+HrTdZeILm3s4J9Ps/l3PFMksqvPxjcsEcu3+PFK/8AXzJvrY9M0HxBpviexa90rULXU7QyvEZ7OZZULo+x13L/ABKysv8AwGtrrXxz+wd4y0PwL+xDouv6pex2Oi2NzqcrS7WdUX+0Ljaqqv3v4dqrXrzftGaRpHirR9G8VeGvEXgf+27n7Do1/r0VuLTUbgn5IkeGeXypH6qk6xM3bnirkuVtdhy0bXa/4HpV94m0nTNWsNNu9Ts7W+1CTZZ2s9yiSzNsZv3afxfKjt/wFq3/AEr5D/aB8N6XY/to/s2a3b6baQaveXWs29zfRwotxcIlh8iu/wB5lXe//fde4+LPi3BoV3fWWh+HNc8cappyLLfaf4fjg32yNnbue4liiLfKf3SuZO+ylbYfbzVz0telDdK8o0n9oDwb4i+Gdr410q+ur7S7y5WwgtkhZbpr1pfKFr5TYKy+b8uxv/Qea2PCfxKi8Tao+k3ehax4d1qG2W8m0/Voo8xRO7Kn72CSWCT7rf6qV9v8W2kI9Aorw3xl+1R4a8E6PL4kutI1688BWtx9nvPGVjBBLpts3m+V93zfPlTzfl8yKJ0/2q7TxJ8UNP0GSwgsLe78U6tqNq15Y6To/lPNdQLs3Sh5HSJU+dPmeRV+daAO9o9a8V0X9qDwpqPhfxTq9xZ+ILG+8KTeRrnh+XS5Z9S092G5d8EHm7l24bzUZo9vzbsZxlXX7W3ha2+FGifEsaD4kn8C30Uc8+sw2sZTTomfastwvm+Yy5xu8pZdvO6p2TYbux79xxR3zXzX+0x8ePEXwu1D4a2nhzwpf69ZeJvEFnYy6nY3Nqnys5k+zxLLKmZJUif5n2xBc/P6ei3fxdNjcaTpkXhHxBf+Jby2W7n8P272ZurCDfs82d2uvI+9/clZm/h3Yo7+tg7eaTPUaK5fwZ4ssPG2gjVNPS5S1M9xa7Lu3eCXfFK0Uvyt8330auM+JH7RXhT4T+LfDPhvXINafUPEN2lnZS2mkzyWvmNu+Uz7fLLfI37pGaX/AGORVMD1rpgUZryLTfj5pTfFO28A63o2t+FNev4ZrjSP7Xig8jVo4j+9+zyRSy/Mv3vLfY+3+GsnxN+1FoPh+TxVLp3hnxJ4o0jwlO9v4i1jRYLZoNMlRFllVllnjllKowdvIjk49+KT0sC12Pc6wfEHibSPCNjHd6zqdppVm00cCXF/OsCNK7bUTc38TNXgX7Rn7SGreCfA/wAPdb8DeHrvxPpPi7VtLgXVrSeCJFguJYtqKksqMZZUO1c7UXd87rW/8WfjV4O8H+FfC3/CyfBWsJHrWowQ2ulajpEWoLbXXnosXnSxNLaxPvKsn73/AHfu0K9r+dvyD0PezQK4TxZ8QYPC15babBp19r2v3UEtzbaLpaxG4lij2723SvHHGuXVd0roNzjFcfo37TnhPUvDPirWJrPX7G+8Ky+TrmgSaVLPqWnu2GXfBb+buXbh/NiLxlfm3YBpSbUW7bf52EtXY9s9aK8AuP2tvC9r8KNF+JX9h+JJ/At/FFPPrENrGU06Jn2rLcL5vmMvTd5Sy7ed1UP2gvj54n+Hfjb4Z6J4e8Iahrmm+JdWWGXUrG5s1+0KsUsv2e3WWdPncR53vsTbn56et7eYX0v6/gfRvpSkV5jqvxYOn3ek6ZD4T13UfEV9arfz6HZNZ/aNOgLBd87PcLFw2VxHI+7Y2zdium8F+L7DxvoY1TTkuUtTPPa7buB4JVeKVon+Vhu+8jU+77AnsdTRXj3xC/aAtfh58TPCPgy78H+Jr2XxTcfZdO1ixSz+wGYK7ujvJcK6sqIzY2fN/DuqNv2greL482fwon8HeJrbVbq0l1KDWJFs/wCz5baLh5Vb7R5v32RNnlbvm+7t+apWthnstFeaWfxdtLjXvGFjfaJq2g6Z4XXfd+INSktRYSDyhL8jRztLwjhvnRawLz9pDRdH8RaBYeIPD/iHwzpXiC6jsdH8QapaxLZXtxIu5IvllaeBm/hFxFF92m9GHS56XceJ9JtfEFrok2p2Ues3cLzwWDzqtxLGn32WL7zKu5f++q3q8Wufix4Fvv2iNP8ABMmh3Z+IUGn3E1tq13orRrDa/J5vlXUqrvR/lH7rcu5fm6VqeJvjlYaT4ovPDeieHtb8a69psEV1qen+H0tg1hFKXEbyNcTwrubY2I0ZpD/coTuNanpV/fW2l2slzdzJbW8a/NLI21Vqnomt2HiDTbXU9LvYNRsLqJZre6tJFliljb7rIy/eWvnL4k/Ff4fftI/s3fE8aRaXWvafZaHfzMdZ8O3UFvFdRRPwjXECxNLFKn8DMyMtZnwZ+OukfCX9lv4OX+taTrsnhp9D0uyu/EdrBE1jp8jRRRJ5oaVZdu9tu+KJ1/vU4+9Fvs0vvF0Vut/wsfTWteKNI8OzWEGqapZ6dJf3K2Vol1OsRuZ2+7FEGPzuf7ordOMV4l8X/i34C8H+OfAvhzxXod3qmraxq1vHodzJorT2sF4zFUdLpl8qOVV3t8reZtFXfE37RPhnwv8AF3RfhxdWutSeIdZhlntGh0uX7MyxR722SsNsvG3/AFW/bu+fbSV7287ClKyfkrnsNFeVeBvjbpXjTx54g8GTaVqvh7xToKRXM+m6ssW+W2lJ8q4ieCWVHjYo3G7cMfMq1k61+09oGlt4hu7HQfEGv+HPDdxNa654k0qCKWy02SJd0qsrSrPLsH3vIil20k9E+4dz2uiuF+G/xO0D4teH4vEHhqW/uNJmH7ie+0q60/7Qu3crxLcxRs6/Nw6/L71zPjj9ojwx8Pfih4Y8C6rBrH9s+I3dLCWHS5XtW2xO7Dz8bWbCfcTc3zp8vNPql3C5693o714xp/7ROiXHxUv/AIe3+g+INE8VxWZ1Kzsb62iYana79olt2ildfvD/AJa7GX+ILWr8NPjdpnxK8R+JPDjaNq/hnxL4dMP9p6LraxC4iWVS0UqtBLLE6Ntb5lehbJ9xnqlFeGa5+1HoGj6Tc+JB4d8Taj4EtGlF34xsbKKbT4BEzrI/leb9pljVl/1sUDp/tdasfEr9p/wT8LbXwff6jNqGo6Z4qura103UtKsZbiybz3REdrgfulHzb8Ft5VW2q2KqzewHtVHFeYQfGKwtrXxNda5oev8Ahi00K6itjPqtltXUPM2eU1r5bN5u5nVNv393y7c1Q034+6YfiNp/gjxBoGueC9b1ZZZdH/tuO28nVli/1nkSwTyrvC4fypdku3nbUq7sJux69VW6uYrWBp55FhijXc7u21VqhrGoT6bpdzdWthc6pPHGzx2Vm0Syzt/dXzXRd3+8yivm74HfFPVv2lfh/wCNrXxz8OrqDSpNQ1O0lGoNYXWmr9nm8pbXb57yNKuzcW8rytyvh/u1N9/Irt5n0joOuad4msI9Q0u+t9TspGdEurWZZImKttbDLwfmWtqviD9k343ad8Hf2Hfh/rWqaBrmq6Fp1pM2pappEEUsWnxfapsyyq8qOyp1bylk219JeOvjVoHgmPw3Hi813U/E0jRaHpWkxq0+ousXm/ujIyRKuwbt0rqv+1WklytrsZRlzJPuemUV5H4J/aC0Pxh/wl9sdH1zRfEPhMp/bXh68sfP1C3V1Z4ii2rSrPvVTt8pnrn9H/au8P8Aij4Y6j488OeG/FeuaLpk9zFfQWthFFcQJAxWV2jnlQ/Ltb92uZf9iol7pp1se+ZzQe9c54N8V6X468L6R4j0W4W80nVbaO8tbhB/rInXcpryT9ra68XP8P7bR/Dvw/1D4g6RqtyLfxDZabqkVhOunH/WojswYs/3fk/h3/Mn3qUm1dWFF8yTPfKNvSvkD9h/wr8Ao5vEOs/CjwVfeB/Ftsqabr2ia7Ldf2nYfxrG8c8r7FbH3l+9t/2eHfAnTdH/AGpfEHxS8XeNtMi8QadpvimfQfDtlqA82LToLRUXz4F/5ZTvIzt5qfOPlAbitGraLsGl7H19msDxB4m0jwzFbTaxqllpcc8qQRSXtwkW+R22KiburbnVf+BV4d+xh8SNU8b+DfGPh7XbyXVNV8D+J7/wy2p3D75b2KBx5Usrf39rbW/3a4n/AIKCeHdLm0/4P65Lpto+r23xA0a3hv2gX7RHE8rF4lb721iqnaP7tJbxXdr8Sopu6ejV/wAD7HoPavMdd+Kl7o/jiPw1pvgTxL4mIijluNR0l7D7Labn+5KZ7qJ1bb8+3Z90/Lu6VU8QfHaw0/xVqnh/Q/D2ueNNV0ZYZdZh0GOBl0xJELL5rTyxb22ru8qLfL935PmFLt5iWp61SE15l8Jfjt4T+OWlTap4Lm1K/wBOjwDd3Wi3lnDIdzLtjlniRZdrIwbyy22sz46fHm0+BEOh3N94Q8R6/Z6xfRabFdaItm0MFzK+yJJfPuItm9m+/wDd/vMtD00Eev8AXmlzXjPj79oS1+HfxL8IeDL7wX4ovLnxZP8AZtO1W1Wz+xGVV3yo7vdK6MqKW+5838G+tvUvit/Z/j7UfDMvhXxDLFY6aNUn1e0jguLURHdtURRStctIzI6qnkfNtOM0O8VdgtXY63Q/E+keJI7v+ydUs9SS1uHs53s7hJfLnT78T7fuuv8AdrTv7620u1kubudLa3jX5pJG2qteCeAvjj4X8RfCvxn4u+GPge9vF07VLqK60mG0g0i4vL9NhnldZWXby3zvLh/kb5W7+e2vj68/aI/Yf8Sax418D3EH2jwvdawlzq62dxZXMpillR7dEmlkXyvl2mVI24Wk3vbsvxHH3nbzt+R9Y6Lrlh4g0211PS7231Gwu4lmt7q1kWWKWNvusjL95a2K+Rfgz8dtI+Ev7Lvwc1DWtI12Tw02h6XZXfiO1hiax0+R4ook80NKsu3e23fFE6/3q+tlYMua0lFxbT6OwlqrmJceJ9JtfEFrokup2UetXcLzw2DzqtxLGn32WL7zKu5f++q3q8VuPiv4FvP2idO8ESaJdN8QYNPuLi21a60Vo1htfk87yrqVV3o/yj9zuXcvzdKZ4f8A2l/Dfi7x14w8I6JpPiLUPEXhqBJ7mzk01rN5mffsSL7U0X9zdvfbHh0+fms7/k39xXS57ZR614d4S/aa0j4heHdc1Dwz4V8T6xrWg30unar4XS3gi1CzuI/vo7SzrAcf7Mrbv4d1Z+v/ALYngLw/8FbL4pyJrl34ZvWaNRZ6VLLLBKr+U0U/8EDeZ+6/esi7+9PXTzt+IlrbzPoD3pa8c8QftEaL4O8SeH9P17Rdc0XRtdnWz07xNdwRDTZbh/uQP+98+J3/AITLEi/7VXfF3xwsvDvjCbwnpHh3W/Gvii2sl1K80rQltUe2tXZ1SWR7meCP5mVhtVmfj7vek3+dhRfNY9NurmKxhknnlWKGNdzO7bVVao6Dr+m+JtJtNU0fUbXVdNuo/NgvbGdZYZV/vK6/K1eaWP7QHgvxH8Gbv4hwJquo+GFE0V3bQ6TPcXcbRu0csL26IzfI24N/DgddtYX/AA0Z8O/h3+zloXxE0/RNT03wHLZrPY2GjaGzfZrf5mXdFB+7gTj7zMqe9V38gi728z6BoryfT/j1ol40t1c6Zrem+Ghoq66vie7tVOmSQH+BZUdj5vIOxlG7+DdVOT9ozRtJ8baJ4e8QeHvEPhX+3pvI0XU9Zt4FtdRnKbxEvlSu8Um0H5LhImo2dgvpc9i9axdI8SaVr1xdw6dqVnfS2beVcJazrI8Lf3H2/drkfF3xWstC8QP4asdC1Txhr4tlu7rS9FEG+2gd9iPK88sUSb/mwu/e2xtqtXg37CttoVn40+Pdv4Y02HSNDi8WokFhBZ/ZFg/0WLenlf8ALPa+/wCWhatrsrhfRPzPsGivK/jl8cNA/Z/8D3HivxLb6xcabASrHSdOku8f77L8sQ/hDSui7mHNSWvxn0o32sHUNL1jRtD07TItX/4STULVF0y4gbJ/dSo7fOu37jqrfdxuo7+Qz1EUda8bk/aM0fSfG2ieHvEHh3xD4UOvzeRoup6zBAtrqMxTeIl8qV3ik2g/JcJE1Jpv7SHh7XPiN4l8DaXpevXvibQbdLie0bTmtfPDO6L5TT+XuXKH97/qufv1L/zF1sey0ZryPwR8fvDHjDwf4n8QzteeHYvCtxcWuv2utRrFPpksC75Vl8tnRvl+bdEzKw6GsTSv2otD1HVfCdtqfhjxH4c0zxfKsXh7XNUgtja6i7J5sSqIp5JYmdfnUTxx0b/h+Ir2/H8D1q88TaRYaxaaXLqtlBqV1/qLKS5VZ5sLu+VPvN8qt+VFfMfxU8NaTpv7e3wS1a00uzs9U1TTdd+33sMCpNdeVbRLF5r/AMez+DdRSlLlSff/ADNIx5rrsfXVRntUlFWSeJ/tk3Udr+yv8WHmkWJT4av0DN/eaFlX9TWh8HfEel+GP2b/AALq+rala6Xpdr4bsJZ726nWKGJPs6fMztwFrrvGfww8H/Ea2toPF3hTRfFMNuxeCPW9OivEib+8vmq22ub039mb4RaPfQX2mfCvwVp19C26K7tPD1nFLE3qrLFUJb+qf3E2u0+1/wAbf5HzZ8NNB1P9ob9pT4g/GnQo7qx8Kw+F38KeFtUuI9n9oSt873cSt83lq5+Vv4s12/7EvjTRrP8AZJ07Rtfa30TUPBUE+keJLG+fY1hLE77/ADd33d6/P/wOvqZIVt0VUXYirtVFrldU+FvgvXvEtr4k1PwjoV94htVzb6vd6ZBJdwf7krJvWtI7JMr7XMfIfwh+EGlr+xP8NPCHxC17UvA19f60914e1O1ufst3pdy8txPZfO/3H8r5dv8AtbK9Q/Z78QfE3wz8W/FPwy+Imr6f45n03SbXVbTxnY2i2s7QSSyotveRL8qS/I7p/s7/AL1fRGpaPZ6tAILy0hu4f7lwisv3dp4/3WasDTPhV4M0nwndeFtN8IaFp/he7VhPotppkEVlKrfe3RKuxt30qVo2D1dz5o/ZN1K1/wCGTfiLNHcwtbx614ld5Vddijz5X/8AQK5eS8tv+HRTSeevk/8ACFeVu3fx/d2/99V9T2v7PHwq0vRdS0i1+GvhC00rUvK+3WMOg2qW935TbovNQJtfa3K7ulN/4Zz+FH9if2J/wrHwd/Yn2n7Z/Zn9gWv2b7Rt2eb5Xl7d+35d9JK1/O34C+0pdjwv456l4Y0rQP2fPE954v0nwx4g025iuNFvtculi0yeJ7L/AEhJ5f4VeL5Vf++6ferX+DmreHvih+0RdfEKbx74E1XxVH4d/sO08NeCPEyat5Fr9o82WeWUrE0uX2f8slCerbq1vil4F0HwxqnhHQrn4S2Ov/BiwguZrjTNE0KK9jsr9nURStpsS7pYtr3H+qic733Ff4qv+E/gv8Jtc1DQvEPgj4Yaf4Qu9OvUuotVXwi2g3cW1vmj2SwRS/P937u3a7VfW7Bq6sj0z4xeKIPAvwr8X+JLnTm1i30nSbq9l00KG+1LFE7eV/wKvi341P8A2x8Jv2cPEd94htZ7jVvGnhy8stF0dktdKsIGb/VWtun31iyq7pd3/Afu1+g8kKyI6uu9W/hrh7f4K+AbXRLjR4vA3huHR57pb6XTYdIt1t3nVtyytEF2mT/bPNKPuy5vT8B6aeR4dbeKI/C/7fF//b11HDYeK/CFraeGbp2/dTywXErXFurf89Pn37azfBPjTw7a/wDBQb4jWMuu6fDqGoeGdLtba2kuI0lup42nZ0RP+WjouM7elfTPivwH4b8daKdJ8S+HtL1/TFKsLHVbKO6t/l+78ki7a47xtrXhz4Ly6Vqlt4A1TUDfzrp0t54R8Pm9msolVtjSpAvm+UvK/KrY3Umr29GvvGtL+dvzueVfsYr5urftDxr/ABfEnVf/AETBXk3wNkh8P/8ABLfxlpl/LHa31np3iWwnhdvnSdZbr91/vV9I/sy/DHUPh5D8QtU1ENDL4u8XX+vx28i7Xigk2JFu/utsi3bf9uvQf+FTeCzqOu6gfCGg/btej8jVroabB5uox7duy4fbmVdvZqu+lvJfgioyUbadbnyd4X0nwd8cvgH8ArbQ/iU/g/x7p2hIPD+taJdxPJFdRWtut3ayxbv3v3k3wfe+Wuv+HfjDx5rHwt+OfhHx9/Z2r+IvCVvNZN4k0WLy4tV32G9WZP4Z0TZvX/aSvo6/8BeHNU0H+xL7w9pd7o7QNb/2fcWMb2/lN95PK27dv+zV3w74b0nwpolvpGj6VZ6RpVuuyDT7G2SCCJP7qovy/lUy96LXdWM7belj5A1XVrJv+CVpj+1wlj8NYhtEnI/0UJj/AL6+Wl/ai1K2/wCGGvA0zXEJgln8NOkrSfKw+0W7f+givpW++BPw61LQRol38PvC1zov2pr/APs6fRrZ7f7Q33pfLKbfMO5vnqjcfs4/Ce+0ux0+5+GXg640+y3i0tJdAtXht/M+aXyk8vCbu+KJe9Jy7tP7uhPLol5NffY8k/a/v7W2+Iv7OJlmjiB8dxFdx+9/osy/zda82s9Y8BeD/wBpr4u+H/i74l1zwJqGs6lFrmh38vjHUdB06+sPssMXyNBcRRNIjRbfn+f/AL4r6n1D9nL4U621mup/DDwbfpZWq2lqLvQLWXyIF+7FHui+RRub5R61u+KPhd4O8eaZaWHiTwnofiCxs2V7a11bTorqOH3VJF+WklZW82/vBRad79Evu6nx7+0h4U+Hvgv9g34sn4dxiLw1qV5Ferf/ANrT38WozyXFr5k8U88r79zcblf5tjV237bGoW3/AAgfwPkNzCIpPiH4fdXaT5WTcx3V9FeLfhb4M8e6ZaWHibwhoXiSws23W1nq+mQXUUHG35EkXC1g3/7Ofwp1SxsLO9+GXg+9s9OjeKxt7jQLV47ZWbcyRIYvkXd83y1XNaxqnaKj2v8Aijzr4iXkVl+3F8I3lkWNJfC+vIrN/vWrV9FwzJcbJYnEiMu5WX+Liub1L4b+FdYt9Gg1Dw1o97b6K6y6ZFcWMUqWDKu1Hg3riPav92uuovol2VvxuZ21v/W1j5Y8N3kH/DxbxxD58fnt4B0791u+b/j6l/8Aik/76ql+x5qkvhTx58b/AAL4llFt4rj8YXviFVnBV7zTrrZ9nuELfeT5Nn+xtC17NH+zf8JYtYGtJ8L/AAamsi6+1jUV8PWv2jz92/zfN8rdu3/Nvro/GHwz8H/EM2knivwpoviM2b+bbNrGnRXRgb+8vmKdv4VNt/SwW1v5p/crHyT4P0R7H4Wftb+J7Xy08K+IbzVLjSnB/dT7bLyri4T1V5d3zfxba99/Y9kWb9ln4TlW3L/wjGnj/wAl1r0DxJ4B8N+NNAOieIfD+l67o2VI07U7KK4t8qfl/dOu39Ki8F/Djwp8O9PnsfCfhrSPC9lO3mSW+i2EVnFJJ/fZYlX5qSuk15JfcNq7T82/vPMP2uPiEvw7+HOjyf2RpWq3GreINO0q2n16Dz7HTriWX91ezL/diZN38PzbfmWvLdQ0+Hw3+3p4BS68U3Wtaj/wiGqC+u9RuU/dfvomX90u2KLv9xP97d1r6z8ReHNK8XaJd6RremWesabdJ5U9jqFus8Eq/wB1kb5WrItfhb4Os30R7fwlolvJoKNHpLxabEh09W+8tvhf3X/AKaVreQNHgH7IHiE6L4u+Nng/xNcrb+Mbfxlf6xLDcfK9xYT7Ps9wn96LYu3/AGdleIfDvWtJ8VfslftYaBoep2N/rP8AbXii+TTbWZXuDA33JfKX5tjbDtavvHxF8NfCXi3VtN1TXfCui61qmmsWsb3UNPiuJrX/AK5Oy7k/4DV7QvDGkeG4byPS9Ls9OS6leadbW3WLzXdmd2bb95mZ3b/gVN6tvy/yFy6Wfe58WftGeKtIt/8Agn38OLptQt/KaHw1cK/mr8yJLa73/wCA12v7XPinRtcvv2bdV0/VrO+069+IenXNtd21yrRTxeVL86OvDL8y19BWfwd8Dabp9xp1n4N8P2mnXN6t/PaQaXAkUtyr7knZQvzSBtrbzzVfxd8C/h38QL6G78UeAvDHiG5ghW3huNX0W2u5Y41+6qvIjYX/AGfen/nf8ieTRryseReJLyDTv2+vC01zIsELfD7URvlbavy3tuzf+O19NeYu3cvzL/s1zl58PPC+pSaPLeeHtJvH0V9+mNcWMT/YDs2/uPl/d/L/AHa6ep+yl2/zuXbW/p+CSPzw+I3iiH4ufsR/FXxhNfweEdGlm1SDT/CWjbLBYZ47h932zb+8lupWRpWT7vz/AHW++fQP2j9Us/7J/ZWVryFNnjfRlb94v/Pq/wD8Uv8A33X06fhL4JF5rl4fBmgC616LytXmGmQb9ST+7cNs/er/AL9ZniD4CfDPxPHYRaz8O/CerxafB9ls0vtCtZxaxf8APKLcnyL/ALK01p+ApLmPHfjJdQxftz/s8wtLGkjab4g+Vm+b/j3i/wDiKi/Zd19tB+Nnx98I+JrxYfFlz4pfXbaKf5XudLkt4kt5I/7yosW3/Zr2S8/Z9+GGqeIItZu/hx4UudXgMRi1KbQ7Z7iLylVYtshTcNqqoX+7t+lbvib4beE/HF1p9z4i8LaP4hutNk8yzm1TT4rh7Zv70bOvy/8AAad9Euyt+Nxpa387/hY+Y/2F/GGg3PjH4+aRY6vp8upzeP8AUdTSwjnTzngZYU8/yvveVv8A469H/ab8eN4Vvfhjo0FlpJ1LxJ4oisLPWNat1li0lxFK/nxK3/LxtDJF/tP/AMBPs2i+F9J8OSXTaZpdnpzXUzXE7WtusXnSM25mfb95vc1D4u8F6B440aXS/EWh6d4h0qQq8lhqlpHdW77fu/JICtJ62XZJfdYq+rfdt/efKvgGwsvD/wDwUG8TWg8SXOu3P/CAWourzU7xZZvtH2/bt2rsji/g/dRKi/P93562P2F/E0Gl/CDxH4U8UXsNt4w8L65qp8Rw3X7pkeW7luPtDbv+WTpKrK9fRdt8PfDFpq+n6tb+HdJh1OwtfsdnfLYRLcWtv/zyifbuVP8AZHFR6l8M/COu+JrHxLqXhbRb7xFYjba6vdafFLd2/wDuSsu5fwpPVNf1vcm2t/T8rH5teDdcivP2AfB1z4fvINUi8C+OIte8TaPp5WWeCwi1S4l/exL8yLt2S/7qV9QftsC2+Lf7P2h6Z4Rv7XUtY8UazpbeG7m0k3+Y32iKVp4iv8KwrK7N2XNfTGheF9J8M6YNP0nS7PS7AD5baztkii/75Wsbwt8LvB/gfUr+/wDDfhTRNBv75t13c6dpkVtLcN/00dE+ar5r3Klq2+9/xPA/2i7yC3/a2/ZciluI1lF/rn3m+Zv+Jft/9CNec2eteAfB/wC018XPDvxd8S634Gv9Y1KLXND1CTxlqOg6bf2X2WGL5WguoojIjRbfn+f/AL5r6y8TfAX4c+NtaXWPEnw+8K+INX2qrahqmi211cfL93966bq1/F3wz8I/ESyt7bxZ4X0XxPbW7ebDFrOnRXSRP/eVZVbbSbvYT2XpY+dNS+FXwSf4E6hoOh6rfeF/BXiDxFFd2PirT9euJWfVG2tFew3U8r/8tVRd27azimfD25+Lfhn4ieKPhJ4w8Q2Xj5n8Lz6nonjCC0W2vbfdL5SW94i/J85+438XlN/wH6kbRLCazitJLG3e2j+WOJ4l2L8u3G3/AHaz/CfgLw18PdPks/DPh3SvDlnJJ5sltpFlHao7f3tka8ml1DofJ/7J/wC0T8KZP2cdE+HfxA1vQvD/AIj8P2v/AAjeueFPFU8UU8ssX7p08iX/AF+/H3UDfe21Q+MeueGPCH7Vvh/Vfifc634L8FeJPB8Gm6Vqljr9/o1pa38VxLK9rcS2ssWz91Kn3/l+WvrmT4ZeEZvF8XiuXwtos3imNPKTW206Jr1V/u+ft34/Gr/inwnonjXRbjSfEGj2Gu6VcD97ZalapcQSf7yONppdbg9rHzx4R8L/AAh0vRfih4q+G98uvyahozrrXig+JbnWYp2ihYRRNPPPKrMif7Xyrsry6TULb/h0WZPOj8keCPJ3bv4/u7f97dX2Hd/C3wZeeD18JT+EtCn8LJtQaHJpsT2Q2/Mv7jbs/SsP/hm/4Uf2L/Yn/CsPB39ifaftv9mf2Da/ZvtGzZ5vleXt37Pl3UW3Xe34CtZp9jwr9oO9h/4Qj9mK889fsj+N9BxOrfL81rNtrpfjV8O4fid8VbK78B/E65+Hnxe0nScWs1n5V1a31l9ol3RXFq3+tVJYn/3Gf+Kvaf8AhUPghfBX/CHjwdoK+Et2f7B/syD7D9/fnyNvl/e+b7tWPEXw18IeLtHOk694W0XW9K2xr9h1KwiuLfbGfk+R1K/L2o7+bb/ILWt6Jfcef/sp/EPxH8SPhnc3Pi/S9OsfEGl6ve6PeXOj/wDHlfywTMj3UH+w77v+Bb68/wD219WttB8a/s8ahfXCWtjB4+iMsrt8if6LP8zV9PafYW2mWMNrZwx2ttEmyOKBNiqv+yor5U/bF1aaf4jfBi3s/C/ijXrfQvFMWr6rLpPhm+v7eC0MEsRbzYonRvv/AOrTc3+zSb1SFLRM3v2itJ/4TL49fAXS9K/faxo+uT6/eNCPntdOS3dHd3/hR5XiT/a/4DXnPiDxYnxU+E/7ROpPfW/g3RdFu9Y0V9E0vyrOXULmK3KG6v5v9azS/LtVGT5eG82vrHwR4B8JeBtMkHhDwxpfhm2vD58tvpOmxWPmsf4nRVX5v96pG+G/hT/hIr3xCfDOjf27fQfZ7nVP7Oi+1Txf88pJdu5l/wBmnKN1ZMdPSzfR3PjTxJeQL+xX+zMRNHst9a8HPOd3+r+eL71emft9atYr8GtAle7hSL/hMtGXf5i/eW9Td/3zsb/vmvoD/hWng/8A4Q7/AIRX/hFNF/4RbZ5X9h/2dF9h2f3fI27P/HazfFXwU+Hnjm3sLfxD4E8N+IItMi8ixXVtHt7hbSP+5FvT5F+UfdqpO6fm2/vtp+AoxtbyVj5i+PGreG/A/wC2BpWpfEvVNa8NeCfEHheLTNM1/T/EN/pFrFfxXE0rxTy2ssX30lVvn+X5a7nwr4X+D+l6H8UPFfw4v012TUNGddZ8Uf8ACTXOtRTvFE4ija4nuJVZ0Q/3vl+Wvdrz4c+FtQ8Ix+Frrwzo934ajiWCPRLiwieyWNfup5RXYF9ttQ3Xwt8GXng9fCU/hPQ7jwsm1BocmmxPZDb8y/uNuz9KmSurf1uUfHjXdt/w6K8zz18r/hCvJ3bv4/ubf++q7r4v3kBm/ZLukmRrZvElttl3fK27S7jZ81e2/wDDOfwp/sT+xP8AhWPg7+xftP2z+zP7Atfs32jbs83yvL279vy761f+FQ+Bf+EPi8J/8IT4fHhWKTzY9F/sqD7Ejbt+5YNmwNu+b7tNu7b7u5NvdS9fxPFvjR8OYfid8VrC88CfE+6+Hnxc0zRd9rcWYiurXUbBpn/dy2r/AOtRZYm/3d/8Xbtf2VPiH4k+JHw0ubnxbpmn2PiDS9VvdHvLnRubK/lgmZXurf8A2Hfd/wAC316F4m+HPhbxvpbad4h8NaRrunsqqbTU7GK4i+X7vyuv8NblhY22mWUVrZwx2ttEmyOKBNiqv+yopLS/mxtXt5I8V/bJ8J6hrfwZufEGhxGbxL4NvLfxTpiJ955bVt7p/wADi81P+BV5H8YvEMV7pPg/9qLTftb6b4c1CB1RFffL4enXyLp9n+/L5/8AuxLX2dNbpPE0cqq8TLtZGH3qy/8AhGdK/sD+w/7Ntf7G8j7N/ZvkL9n8nbt8ry8bdm3+GnH3WOWqsfOf7QHhPxFrX7GHjkaZZXV34l1m3bXJrG3DrPLvuFna3Xb825YF8r5fm+QVxHhm6/Zl+OnhXw/PD4s1TxXqtxLFe2HhLVfiFq1xqC3ifMifY5bxm3q38Wzb1b7vNfbe35a5PSPhj4Q0DxPfeI9K8JaHpniC/wD+PrVrPToYruf/AH5VXc//AAKlbcO3keE+Ory3X/goF8LoTPEszeD9X/dbvm/1sX/xD/8AfFcnr3xG8N/Bn9pz4nanoPjXwLaazq9tpy65ofjnxMuiolysT+TLBL5UrN+62b08r+JPmr6N1D4E/DfU/FA8TX/gHwveeJ/tCXZ1mfRbZ73zV27JfOKbty7U+bP8NeKa5o/hHUfH3iq5+MvwefxBqk188Oi63D4Ml8R28unIqCBVaC3naBvmfekqp82/G5aL/Cu3+dwWl/Mo+G/Dfh3wv+x/8W30DxfpHjQanBr2salqeg3Mc9itzPFLI8UWxnCKvyriuA+Ll9An/BI/TX+1RoB4R0aJW3fxb7X5a+jvDv7OPwv3aw1v8N/Dth4f1SOBJ9Ek0SCK0unid2Sd7XZt3fN8u9d1b0n7Ofwnk0WLR2+Gfg1tFhuGuo9PbQLX7OkzLtaRYvL2biqqN2OdtC0uu7T+7/hwjoku1/xPEf2utRtftv7NUn2qHbJ8QdLkid5Pvp9nl+b/AMeWtL40XcMf7dH7PMLTRrJ/ZniEbWb5ubeL/wCIr1q8/Zs+E+rR2kF98LfBt5HYw/ZrRLnw9ZultFuZtkWYzsXczNtHdie9W9V+Afw11/XI9Y1T4d+FNR1mNY/L1C60S2luU8vHl/vWj3fLtXb6bafZ+dzKUOZvXdJfceN6Tdwj/gpFr8Jmj8z/AIVvajy93zf8hB//AIuvLPCfxH8L+AdM+Jngzwr8TPhrbaDrHiHVF3eNvEi2OoaRJK2y7/0Xb/pUXm+b5W54Plx8z76+uE+B/wAPNP8AEUvimw+HvhSLxV5rXaawmj2yXZnb+Pz9m/cx/irwfwP4V+HetJbxfFj4GRP8S76VpdVvLjwE2r291cM7fvFv4reWLyuPl3yrsXbuxStol2NLb+Z7r8BfDPh/wf8ABvwboXhfW4fEeg6fpkNrZ6pbzpKl0iLt8xXT5fX7teQftPaha237SX7MkUs0aSt4g1FkR2xu/wBCZf8A0J0r2X4V/DPRPhdpWpWnh/Rbfw7pd/ftfxaPZRJFb2e6NE2oifKu4xbzt/iejxZ8Cfhv4+1gat4n+H3hfxJqpRY/t2saLbXc+1furvlQtTerT7DjorHjniC+gX/gop4KtzNH558A3/7rd83N3F/8Q/8A3xXKSWd74i/ak/ac0TQruO28Qah4I063sX3fOkv2e4VW/wC+nSvomb4BfDK68THxBN8OvCcviLzlujqz6JatdGVfuyebs37v9ql0f4DfDbw/4lTxHpXw98K6X4hjleZNXtNGtYrtXf77eaqbtzbm7/xUPW3kLv5njf7Lvj3w1c/sU6Zb6vPb6dF4X0N9D8Q2V7+5awngRopYp1b7rfL3/vV4Vq3hbV/hv+xt+y7ovilnttVt/HmhyyxXH3oEa6llSJv9xHT8q+7rj4V+D77xXD4oufCWhXHieD/Va1LpkDXsf+7Ps3iofGnwf8B/Ey4tZ/F/gzw94pnt02QS63pMF40Ssc7V81G20JuLT80/u6B0t5P8TxX9vL7Xp/wl0PXTa6hd6H4f8S6fq2uRaTPLBdCwik/etE8TLIpTcr7kdcbKy/Bdv+zt8RvF3g3WfC/iu4+IXijTrlb7SLaXx3qeq3Fhu4kne3nunMaqh+bzE/2fSvp3RvD+l+H9EtdI07TLTTNJtofIgsbWBYoIo8fdVF+VV9qy/CPw18KeAZ7+bwz4Y0bw9Pfy+beS6Xp8Vq1w396Qog3N9aI3je+t3cJLmSXY6nHAr5Y/Y31C2T4NeO7VriNJU8YeI0ZXb5v+PuVv/Qa+q++K4m8+EPgbUBrn2vwZ4fum11l/tcy6XA51Hb937R8n73/gdTa9w2S8j47+GV7bf8Okb8+fFtXwfq8TMG/i3XHy/wC9XZWnxEePSf2ZfBum/wBm2eq+KND8228XXsEVxNpyRafFvWz8zcn2iXfs+b5cBvleveI/2cfhRHo8ujD4Y+DV0eW4W5k09dAtfs7zKpVZGi8vZuCsw3Y43VpN8EPh6vhe38N/8IJ4Z/4Rq3n+1RaP/Y9v9kjm/wCeixbNqv8A7VV9py7siMOVJdj52/ZtjsNH/bH/AGhreDWZdVU2vh9Gury+895JPs9xuG4/7X8K/dqP9k3UbX/hk74jTLcwm3i1rxK7yq67FHnyv/6Ca+nL74Z+D7+6v7m68J6LdXF/Z/2ZeSy6dE7XVr/zwl+X54v9hvlrnrX9nP4U2OlahpVr8MPB9rpepeX9ssoNAtUhuvKbcnmp5W19rcruon71zVvW5yH7DVxFP+yT8KzFKsipokSHaf4lyG/WvWtQ8baDpfiax8PXWsafb67fRvPa6ZLcotxOibd7JHnc2N1QeCvh34U+Huny6f4T8N6T4XsJ5POktNGsYrOJ5P77JGq/N8tJ4y+GPg/4jW9rF4u8K6L4ojtm8yBdZ06K8WJ/7y+arbab1k33IiuVJHmmjfD+0m/an1z4gaVhLf8A4RxdF1VrfmK6uluN0PT70sUSsrf9dUWvP/2QdOj+DFz8Y/A+uzw2E+leKbrXoGmZY0fS7pEeG4/3fklVv9pDX1ZZ2cOnWyQW0SQQxrtWONdqrWB4n+HnhPxtJp83iPwzpOvT6fL59nNqlhFcPbSf34y6na3+7UJaajsr380eC/sJeEbrTfCPj3xpdQNbx+PfFt/4hsYnXaws3fbbsf8AfVd//A6x/wDgok0beB/hXA139iaX4h6Oqyqyb0+d/nXd/dr65VNqba4zxp8HvAfxKmtpvF3grw94ontk2Qy61pNveNEvXavmq22n1i+zX4FJvVyd27/ieR/ADxZq3gLxZqXwc8dzrP4ms2m1HRtdZFi/4SSxdt7T/wDXzEzFZR9H/irzmX4meG/gz+0B8WZfDnjvwFb3WrXlm2raL488RjRXtr9bb5pYH8qVpYvKaL5Ni/Pu/e/w19Ia18Afhd4hm0+TVvhz4T1WSxt0s7P7bolrM1tBHnZFFuT5EXn5V4rxVtD8G6j4y8QyfGX4LLrfiS61WaKy1lPBUviC1nsEfZalJYIJ/I/dbNyS+X85lNLqkJaHov7J/hfw74T+EFrZeG/Fml+NraW+vLy61nR50ltJbqeZpZVi2O+1VZtu3dXQftD/AAyf4v8AwV8XeE4sJfahYv8AYZT/AMsrpP3lu/8AwGVEpnws+E/hj4d6prWoeFfC9j4QstWitkfTNOs47OF2i839/wCVH8qswl2njdhF3V6lVy3BaHw14u1jVv2kP2edL+KVjb3Nv4l8BWtrrFjaMrJu1e1ZJdQi/wBr/VNb/wDA5a+jfgXr0PxD8OXPxAgDi38WNHfWaSptdLJYlSBPx+eT/trXf6Po9ho9i9lY2UFlas8sv2eGJVTc7lnbav8AeZmb/gVRy+F9Im8Mv4fl0yyfRHtvsbaY9uv2XyNuzyvK+7s2/Lt6Um200xNXaaPln9jmaK4+FvxzEMsc5/4TvxGf3TburDFRfCjUrSX/AIJnWkSXCbl+H97uTd83y28qv/49X0f4J+EPgX4ZzXM3hLwX4e8Lz3C7JpNF0qCzaVc/Lu8pF3VHL8FfAV1oN/ok/gbwzNot/c/bbvTpNHt2t7m44/eyxbNrSf7Z5pNe60uqX4f8OTCPK0/Nv8j4++LGoQL/AMEj9Mf7TGg/4RHRYlbd/Hvtfkr7n0CdLrQ7CWNlkRoEZWU/e+WuFl/Zy+E8mixaO3wz8GtosNw11Hp7aBa/Z0mZdrSLF5ezcVVRuxztrsvDPhnR/B2i2ukaFpVnomlWqbINP063WCCL+L5UT5VqpScr36tv7y+iS6f8A+ePHN9AP+CgXwvhaeJZj4P1bbFu+b/Wxf8AxD/98VH8Lb62l/b0+OUKTxtIugaCjRbvm+5L/wDFp/33XsmofAn4b6n4o/4Sa+8AeF7zxN9oW7Os3Gi2z3vmrt2S+cV3bl2p82f4ar2v7PfwusNcl1m2+G3hO31eQymTUIdBtkuH81WWXLhN3zKzhv7wc+tQlp8mvvBaX87fmeR/sfahbXHxD/aM8u5jcr4/uC21vu/6PEP/AGVv++a+aNWv4Jf+CV/jho5llWLxNP5u35tv/E9R/wD0Cvu/T/2c/hToovl0z4Y+DbCO+tWs7pbTQLWL7RA33opdkXzqdq/KfSvnr9t74VeGPBX7N/inw18NPhYbfxD4kks9lp4H8Iu/2j7PdxS/v2toCi7V3lfN9W281pF+8l6fgVFqP33/AK+86r9tRLb4nfs32Hh3w/cR6lrXi3U9Mi0Bbdt7SyrdxStKv+ykSSuz/wAKrWj/AMJcPGX7T3jjwlFc2ng+Dw3odhPqut20EUWq6xHLvZE89l+S1i+fOPm3y/KyfxeqfDXwz4KeL/hMtA8F2nh7VdZiV7u8m0D+zdSm9p1aJJf++639X+H3hfXPEWmeINU8M6RqOvaXn7Dql3YRS3Vr/wBcpWXcn/AaUrarzuRHT7rHyt+yJd6fZ/sk+PYI7tXgttT8Susstx5jNEtxKN7Ozbm42/O1c5JdwP8A8EiWdZ49n/CEeTu3fx/d2/8AfVfXV58HfAl9ouq6Rc+B/Dt1pOrXX22/sJdJgaG8n3b/ADZUK7ZH3/Nubms3/hnf4W/8I/8A2B/wrPwh/YX2r7b/AGT/AGDa/ZPtG3b5vleXs8zZ8u6l387fgJK1vK55D+03Yanr37EfmeH7O71eWCw0nUpLTTJ3iuLi1glt5ZlieL5t3lI33a5zwyv7M/xqt/Ct5p3iu/8AG2sLeQapo/h/UPH+rXt9BeL9x/sUt6zo8WTudk+Vd/8ADX1P4T8C+HfAGjrpPhjQNL8N6UrNJ9i0m0jtYNzfeby41C1X0H4X+EfCetX+t6H4U0PSNYv/APj71DT9Mht7i5/66yom5/xoHbY8F+A3iE+G/wBqj47eFfEky23iLWdRsta0pbj5ftum/ZFiXyv73lMmxqyf2R/Gfh27+Pn7Quk2ms6c2qXfidbyCxW4TzpYVtIlaVY87mTdn5vevpTxb8OfCfxCFn/wk/hjR/EX2OXz7Uarp8V15En99PMU7Gq/o/hfSfD1xdz6dpllYXF43m3ElrbrE8rf3n2/eo/yt+QNXVvNM+f/APgo0yp+xn8RQzKu+C1X5v8Ar7hqb9sTTdW139k3WJNBs7vVZrVLDUpLTTpXiuJ7WC4illWJovm3eUjfdr2fxl8NfCPxItoLbxb4X0fxRb27+bDDrWnxXiRvjG5VkVttWvCPg/QvA2hQ6R4d0PT/AA/pMZZk0/S7SO2gUt8zbYoxt5pR0v5s0crxUbbN/ifKvhlf2Z/jRb+FL3TPFt/421hbyDU9H8P6h4/1a9voLxfuP9ilvWdHiydzMnyrv/hrqfAt5A3/AAUC+KcCzRtKvhDSd0W75v8AWy//ABaf9917vofwx8I+E9c1DW9D8KaHpGsX/wDx96hp+mQ29xc/9dZUTc/41jWPwE+Gmn+JJNftfh54Vt/EMksty2rRaJarePLLnzXMuzfubc24999N/wCf4mfR+Z8u+FfH2neBbX9srxFcafb+KItK1l57jSW2slyn9nonlS/7P3lb/ces74xQyFv2XtX1TxXFrGral4y0u4g0/TpEg0y1ge3b5bW3X/lknybHl81/9v59tfW3hL4F/DjwPfT3vhj4e+F/Dl5NA1vLNpWjW1q8sbffjZ405U8fL7VNbfBXwBZaHFoVt4F8OQaJBdrqEWnQ6RBHbx3S/dlWPZt8z/b60uqfa34EuN1b1/E8Q+LeqWcv7b37PLpdROJNL8QNGVdfn3W8eyivZ9a+Avw18S+I217WPh54V1XXXdJG1W90a1muiyfdPmsm75dq0VMo8yS7f53NI+7fzPR6KKj9KsRXubqKzgllndYoo13M7/dVa8ii/aX0BvEXha0bQ/EA8P8AiqRbfQ/FiW8UumX0rfcT5JWli35+V5YkVv71U/2uG8RQ/s7+PptA1Ox0trfQr+W7e+097oywC1l3pFtni8qT/bbzMf3GrxWx8cfFL4JfsJ6J460zW/B+pJo3hjTbuz0248OXS/6P5CKYnlW/+eT5k/e7V+6/yfN8sp6OXa34jt8K73PtunV83fHL40+NPhz4N+G/ijRG0J7PXtX0vStTsNQsJ5XzeOil4JFnTy9nzfKyvVzx58avGvhf9pLwJ8O7XQtGfQPE9nezxalJeSvdbraIO+6LYixfMyj70u7/AGapJv72vuRm5WV/K59DfeorwTwD8YPEyfH7xZ8LvFq6VdXFho8HiHTNW0m2ltVezllaJopYpJZf3iOn3g+Hz91ax7z4x/Ejxj8K7r4lfDXTNG1XQofPl0/w5dWcs2oa3BFLs3RXEdwqwM+x9qeVL/D/ALtKN5JSKbs2j6Mkmjh272VCzbV3VzHizxo3hfVPDVgdD1rVhrV99iN1pdn50NgNjv5t0+791H8m3fz8zLXzP8ctd+JGrfGb9n19E8QWnhXT9durmU6Fq2iy3D210unSv/pXl3UXnbd7J5amPY/zfPXf/Ez4zeO/hr8VPhP4Zk0jQL7QfFl//Zt1q/nzpcCdYWll8u1+6i/J8v72Sm9NymmmfQtFeM+IvilrPiD4qal8OvAs2m2mt6Tp8WparrGsWst9b2fmu3kQ/Z45YmlZ1SVv9amz5PvfdrB8EfHbxXq/jPxx8NNY0bRk+Jvhyyi1CydLqW30zWbWXhLhflllgG/5XT97s/vNQ77C7H0HnrS18jeDf2i/ib8RP2VLz4sWGneGdL1LTP7RvZdLuIbieK8gtZpVaFH81PKfbF/rW3/N/wAslr16Hxt4r+JfwQ8NeLfhzDotvrmuWdhqUMPiUz/ZY4Jdjyq3lfPvCM23/aoknG6W6G04792evUykbpUlLrYQyn0UUwCiiigBKWiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAplPooAZT6KKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooASm0+koE1cb0p1FLQCVgooooGMp9FFABRRRQAUUUUAFFFFABTKfRQAyin0UuoDKfRRR1AKZT6KYDKKfRQAyn0UUAFFFFABRRRQAUUUUAFFFFABTKfRQAUUUUAFFFFABRRRQAUUUUAFMp9FADKfRRQAUUUUAJS0UUAFFFFABTKfRQAyin0UmAyn0UUIAooopgFFFFABRRRQAUlLRQAUUUUAFFFFABRRRQAVH6Vx/xS+Knhr4M+B9R8YeMNQOkeHdO8r7VffZ5J/K82VYlOyNWf77oPu968H/4ei/syf8ARTv/ACg6n/8AItAHd/taam9r8APHGlwaZrGs6lrOjXum2NpomkXWoSvPLbuiblgRti5/ifateSw6Dq3xh/4J+3fgHT9A13T/ABba+D7XS5NL13SLnS3a8it0/dobmJFk+eLG5Mr7it7/AIeifsyf9FN/8oOp/wDyLR/w9C/Zk/6KZ/5QNT/+Ranl0a72/Ad/h8jkPjpfeIviN+z58NF8M+AfFmo6no+v6HdXmm3OkS2dxEbZ1aVNk+zd93/W/wCq/wCmtaHxU8WX15+158ENeHgvxr/Zui6bqSaxcQ+HLy6isJbyCIRRtLAksT4PD+U7qn96t/8A4ehfsyf9FM/8oGp//ItH/D0L9mT/AKKZ/wCUDU//AJFq4+797f3qxm43VvKxi2OpT6n+3rr18/hbxZF4dvfBqeGk1yTwzfpZNeJdyyOvntFsCbW/1v8Aqm/vdM5P7Ovjj4ifs3aNafBbxP8ACTxh4vfR55bfQPE3hmzgl028stzPE1xcSyxJA3b567D/AIehfsyf9FM/8oGp/wDyLR/w9C/Zk/6KZ/5QNT/+RamN4xSRTSbb7l748aR4jh+JnwC8XT6NqGr2mg6xeNrP9j2ct41n9psniR/KiTzWiVm27tv+/WF+1P4muf8Ahb/wLnt/Cfi/VLfQddbV9Vl0vw3eX8VnBJbSxLukgidGbc33EZmq/wD8PQv2ZP8Aopn/AJQNT/8AkWj/AIeifsyf9FN/8oOp/wDyLTetrlXbDUNB1z4I/tV+I/iP/YWr674E8caVa22pzaJZy393pl9a/LE7WsSvK8To5/1SNtb71aPh/wAN3Fx8ePF/xz1DS9YstEj8LW+g6XZtp07X95EszXEs32NE89fmZFWJ0835G+UcVnf8PQv2ZP8Aopn/AJQNT/8AkWj/AIehfsyf9FM/8oOp/wDyLTuLt6nl3wL1PVfDn7AHirwrqXgvxtYeJ4rPV7VdHm8K6j9ollvJbp7fYvkfOvzruZPlX+Pbur2P4A/EK4+Hv7KHw+nvfBnjS71LSdO0/Qr3Q7bQJ0v4pwkUTt5EoTdEp+bzV+XZWb/w9D/Zk/6Kb/5QdT/+RaP+HoX7Mn/RTP8Aygan/wDItDbbb72/Acm5b92/vPqnGRmpK+U/+Hov7Mn/AEU7/wAoOp//ACLR/wAPRf2ZP+inf+UHU/8A5FpCPqyivlP/AIei/syf9FO/8oOp/wDyLR/w9F/Zk/6Kd/5QdT/+RaAPqyivlP8A4ei/syf9FO/8oOp//ItH/D0X9mT/AKKd/wCUHU//AJFoA+rKK+U/+Hov7Mn/AEU7/wAoOp//ACLR/wAPRf2ZP+inf+UHU/8A5FoA+rKK+U/+Hov7Mn/RTv8Ayg6n/wDItH/D0X9mT/op3/lB1P8A+RaAPqyivlP/AIei/syf9FO/8oOp/wDyLR/w9F/Zk/6Kd/5QdT/+RaAPqyivlP8A4ei/syf9FO/8oOp//ItH/D0X9mT/AKKd/wCUHU//AJFoA+rKK+U/+Hov7Mn/AEU7/wAoOp//ACLR/wAPRf2ZP+inf+UHU/8A5FoA+rKK+U/+Hov7Mn/RTv8Ayg6n/wDItH/D0X9mT/op3/lB1P8A+RaAPqyivlP/AIei/syf9FO/8oOp/wDyLR/w9F/Zk/6Kd/5QdT/+RaAPqyivlP8A4ei/syf9FO/8oOp//ItH/D0X9mT/AKKd/wCUHU//AJFoA+rKK+U/+Hov7Mn/AEU7/wAoOp//ACLR/wAPRf2ZP+inf+UHU/8A5FoA+rKK+U/+Hov7Mn/RTv8Ayg6n/wDItH/D0X9mT/op3/lB1P8A+RaAPqyivlP/AIei/syf9FO/8oOp/wDyLR/w9F/Zk/6Kd/5QdT/+RaAPqyivlP8A4ei/syf9FO/8oOp//ItH/D0X9mT/AKKd/wCUHU//AJFoA+rKK+U/+Hov7Mn/AEU7/wAoOp//ACLR/wAPRf2ZP+inf+UHU/8A5FoA+rKK+U/+Hov7Mn/RTv8Ayg6n/wDItH/D0X9mT/op3/lB1P8A+RaAPqyivlP/AIei/syf9FO/8oOp/wDyLSf8PQv2ZP8Aopn/AJQNT/8AkWgD6tor5T/4ei/syf8ARTv/ACg6n/8AItH/AA9F/Zk/6Kd/5QdT/wDkWgD6sor5T/4ei/syf9FO/wDKDqf/AMi0f8PRf2ZP+inf+UHU/wD5FoA+rKK+U/8Ah6L+zJ/0U7/yg6n/APItJ/w9C/Zk/wCimf8AlA1P/wCRaAPq2ivlL/h6F+zJ/wBFM/8AKBqf/wAi0f8AD0L9mT/opn/lA1P/AORaAPq2ivlL/h6F+zJ/0Uz/AMoGp/8AyLS/8PRf2ZP+inf+UHU//kWgD6sor5T/AOHon7Mn/RTf/KDqf/yLR/w9F/Zk/wCinf8AlB1P/wCRaAPqyivlP/h6J+zJ/wBFN/8AKDqf/wAi0H/gqL+zJj/kpv8A5QdT/wDkWgD6sor5S/4ehfsyf9FM/wDKBqf/AMi0v/D0X9mT/op3/lB1P/5FoA+rKK+U/wDh6L+zJ/0U7/yg6n/8i0f8PRf2ZP8Aop3/AJQdT/8AkWgD6sor5T/4ei/syf8ARTv/ACg6n/8AItH/AA9F/Zk/6Kd/5QdT/wDkWgD6sor5T/4ei/syf9FO/wDKDqf/AMi0f8PRf2ZP+inf+UHU/wD5FoA+rKK+U/8Ah6L+zJ/0U7/yg6n/APItH/D0X9mT/op3/lB1P/5FoA+rKK+U/wDh6L+zJ/0U7/yg6n/8i0f8PRf2ZP8Aop3/AJQdT/8AkWgD6sor5T/4ei/syf8ARTv/ACg6n/8AItH/AA9F/Zk/6Kd/5QdT/wDkWgD6sor5T/4ei/syf9FO/wDKDqf/AMi0f8PRf2ZP+inf+UHU/wD5FoA+rKK+U/8Ah6L+zJ/0U7/yg6n/APItH/D0X9mT/op3/lB1P/5FoA+rKK+U/wDh6L+zJ/0U7/yg6n/8i0f8PRf2ZP8Aop3/AJQdT/8AkWgD6sor5T/4ei/syf8ARTv/ACg6n/8AItH/AA9F/Zk/6Kd/5QdT/wDkWgD6sor5T/4ei/syf9FO/wDKDqf/AMi0f8PRf2ZP+inf+UHU/wD5FoA+rKK+U/8Ah6L+zJ/0U7/yg6n/APItH/D0X9mT/op3/lB1P/5FoA+rKK+U/wDh6L+zJ/0U7/yg6n/8i0f8PRf2ZP8Aop3/AJQdT/8AkWgD6sor5S/4ehfsyf8ARTP/ACgan/8AItL/AMPRf2ZP+inf+UHU/wD5FoA+rKK+Uv8Ah6F+zJ/0Uz/ygan/APItH/D0L9mT/opn/lA1P/5FoA+raK+U/wDh6L+zJ/0U7/yg6n/8i0f8PRf2ZP8Aop3/AJQdT/8AkWgD6sor5T/4ei/syf8ARTv/ACg6n/8AItH/AA9F/Zk/6Kd/5QdT/wDkWgD6sor5T/4ei/syf9FO/wDKDqf/AMi0f8PRf2ZP+inf+UHU/wD5FoA+rKK+U/8Ah6L+zJ/0U7/yg6n/APItH/D0X9mT/op3/lB1P/5FoA+rKK+U/wDh6L+zJ/0U7/yg6n/8i0f8PRf2ZP8Aop3/AJQdT/8AkWgD6sor5T/4ei/syf8ARTv/ACg6n/8AItH/AA9F/Zk/6Kd/5QdT/wDkWgD6sor5T/4ei/syf9FO/wDKDqf/AMi0f8PRf2ZP+inf+UHU/wD5FoA+rKK+U/8Ah6L+zJ/0U7/yg6n/APItH/D0X9mT/op3/lB1P/5FoA+rKK+U/wDh6L+zJ/0U7/yg6n/8i0f8PRf2ZP8Aop3/AJQdT/8AkWgD6sor5T/4ei/syf8ARTv/ACg6n/8AItH/AA9F/Zk/6Kd/5QdT/wDkWgD6sor5T/4ei/syf9FO/wDKDqf/AMi0f8PRf2ZP+inf+UHU/wD5FoA+rKK+U/8Ah6L+zJ/0U7/yg6n/APItH/D0X9mT/op3/lB1P/5FoA+rKK+U/wDh6L+zJ/0U7/yg6n/8i0f8PRf2ZP8Aop3/AJQdT/8AkWgD6sor5T/4ei/syf8ARTv/ACg6n/8AItH/AA9F/Zk/6Kd/5QdT/wDkWgD6sor5T/4ei/syf9FO/wDKDqf/AMi0f8PRf2ZP+inf+UHU/wD5FoA+rKK+U/8Ah6L+zJ/0U7/yg6n/APItH/D0X9mT/op3/lB1P/5FoA+rKK+U/wDh6L+zJ/0U7/yg6n/8i17x8Lfip4a+M3gfTvGHg/UDq/h3UfN+y332eSDzfKlaJjskVX++jj7vagDtKKKKACiiigAopKbS62AcK4PxJ8bPh54J1aLSPEXjzw1oWrScR2Op6xBb3Df8Ad91eN/tzfF7Xvhz4F8K+GvCt6+leJfHniG28OWuqRj57FZW/eSrz97HC/71eu+DvAnhD4F+A5LLTraz0PQbGB7m9vbl1TzMDdLcXUrffb7ztI/qaV3y8zQdUu52VlqlnqMeba5huEKq26KTd8rfdNaFfOXw+8Z/Brwlqni5/hRr/hfxLrevt/abeE/Ces2LXF7dRJ87wxGdUVmTbu+79zdU/wAF/wBozXvjj4N8L+KdA+H0yaFqeq3VhqDXerxRzafFFLMi3CqV2z/6tdyo/wAu75d+01QdE/Ox9De9LxmvDm+NfiHxYus3vw78HWvi/R9Fv5bG6u7zWvsD3csWPNSzXyJVl2tuT968C71+9j5q4n4hftmW2g/s2j4y+EPDQ8S6FbyiDUtN1LUH029s5POWBotnkS7pFlfDDK9MhmoWo0nJ2Xex9T8UeleGfGb48ap8JdW+HOPC9tquieLtds9Ae7/tRoJ7S4uN21vK8hlkTap581f60mrftBahYftB2/wqTwRqT3V3pUuq2msXF9brbzrG8SblRGZlTc7Bt+1vk+VH3VCbvZrq19wj3SivFPhz8drzxJ8Uta+G3izw/F4U8a6ZZpqi29pqP2+0vrJm2efBOYomO1/lZXiUg4617VT6XEncdRRRVDCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAoopp4NAC9a4HxF8bPh/4R8QQ6Drvjnw3pGuTMiR6bf6tBBdSbm2rtiZ95y3tXjf7dnxW1zwL8P8Awr4Y8L30uka/498Q23huDVIR89nFK372VefvbeF/3q9q+H/wz8O/DXwda+GNB0uKz0mJPLkj27muGx8zTMf9Y7/xM33t1LVR5mDumjqLfULW73mOeObYcNsbdt+Xd/6C1aG6vnPVdL0f9jT4e/EXxV4V8I3GpaBJePr8+h6NLb26Wf7hPtDr5rIqxfut2xNzfP8AKldL4N+Mmt+JtJ0LxJqHhBdE8Daj4cGuz6/PqibrKXaj/Z5bd4kbZsZmWX/Y+ZEqtLNroJXur9b/AIHtFFfOfjz9p6/+HPhvTPH2veCmtfhjeNbpLrC6oP7Rs0uHVYp57LytvlfMmdk7Srv/ANVXR+JPjRrc3xHvPA/gbwxa+I9csNLg1m6m1bVW06yW3ld0iWKVLedpJG8p/wCFVx/HSegz2jiue8WeKdN8E+GNT8Qaxc/YtK022e6u7jy2by4lXc7bV+btXjFv+0BrnxG/Zt17x74F0W1s9f08XkUth4iumSK1ntWZbj54lk8zaUbb93f/ALFcn8PPj/428D/sg6F8RvFng3/hIUtNAtdSeTQ9YSWe4g+z+bLdXCzxQLF2OyJp/ve1KTsm+1vxBdPO/wCB9NeHfEFl4o0Ox1fTp/tNhfwJc2821l3ROu5W2tWx/FXzt8Rv2oJfh/8AC7wD41fwVqGp2Xib7Csn2a7i8rTmuvK2LJu/ey/60/6qJvuH7tbviD45an4O+LfhHwr4g8LR2Gj+L5JbTSNYt9S8+VbmOLzDFdQeUoiLKDtZJZefSm7r77ERlzKLXVXO/m+IWgQ+P7fwS+oFPFE2nPqkVn9nl+a2V1R337dv32X5d26ut614jp/x9kvf2lpfhLc+D9R0uZNEl1uLWry5gMN1Ek0US+UkbP8Axs/39rLsHy/NWX4B/aH134k+LviN4X0nwBPpWv8AhCa3t2h17VYoopmlRpV3ywLceWu3Z9wS/f8A4dtSrtX8m/xKbs7eaX3n0F3H0pa8P+Hv7S2jeLvhHq/jnVtOuNBfQby60vV9L3i5lt7yCTyngjZf9YWfZs+7u3rVPxN+0Rq/w18XeFLDx34Oh0HQPFGoRaVpesWOri8aK9kXdFDeReUgiLYK7onnTP8AFT6pCvue90nakb5Vr5+8U/tG6xYeDNV8feGPBY8VeAdKEzXN8upNb311FE+2WWztvs7LMo2v9+WLdt+Wm9mF9vM9D8ffGrwR8MdX0TR/EniSx0nVtauYrTTdOlfdcXTvKsS7Il+bG50+avQvavkP9szXrTxT4B+BesWPmfZb/wCIfh26g82Py32SO7JlX+7XvHjD4hy6J4gsPDWi6fHrPirUrae7trK4uvstvHBFtDSzy7XZU3ui/Kjt833fvU7e5fza+6xfS/lc9Epa8B8L/tPWbt8RtN8YaLN4a8TeALM6nrGm2c/2+KWz8rzUntZdiGVWVTwyI27is61/aW1vS9S+HU/izwPDovh7x9dRWWjX1rrP2q6glli82JbyBoIli3Kv/LKWX5hSWoulz6OorwLUv2htTj/aCm+E9p4GvRqbaLPrNjqV7qMMdteKjqi/6oStGhZnG59rfJ9xt1TXHx28Vy614X8IW3gCKD4iato8utXmlalrPlafp0UUqROrXsUEvmNuf5dkX+9sqbuydtw6XPdqPUV4J4P/AGl5fF3wx8aeIYPBepTeIPB+o3Gkav4dsLuCV0uoNvm+VcStEkke1w+/5W2/wbvlrAuv2tdST9n3RvjJb+A2m8JSWceoapbtquy9tbZn2s0EXlbZ9v8AtPF/s7qbur+VvxFfY+nKTFebeKvitaaXPoGkaPbHXvEniKOWfSrAzmGN4kUO88su1vLhXcnzBWb5l2o1c98OfjhdeIPGHjDwb4q8ON4S8SeGraDULyS3u3vNMmtZd5SaC6eKIt9xgwaJcMrfexTasC1V0e08UtfO3jb9p/UfBfge2+JU3gvzvhWRFLPqy6l/xM4reVtqXQsvK2tF8yNxP5u1v9VXvWm6jb6pYwXdtKstrcRrLHIv8St92jpcNb2NCimjvTqBhRRUQ70mwPNda/aM+FHhfU7rSNc+J/g7R9VtJDFc2WoeIbW3ngf+66PLuU1ueC/i94F+IzSr4T8Z+H/EzRHEg0fVYLwr/wB+3avBvjJZwN+3d+z/ADvDG0r6V4hVn2/N8sMW3/0Ou3/ac/Z60H43eBb6ae2Wx8X6dA91oniK0TZe6ddIu9HSVfn27lX5anmXLzev52FF3k0e6UetfJv7Ov7XC+Jf2R/CXxF8WLLd6/dTjQza2Kp5upaj9o8iJIl+RN0vyt/CqZf+Fa7rVfj/AKt8OfF3hzS/iL4Tt/DWmeJb3+zdK1rS9Y/tG3W6b/VW91ut4mgd/wCHZ5if7VaOLTaBaq57v6UeteWXXxS1TUPiFq/hvwtoNnrX/CPrA2uPc6r9luIvNi82JIIvKfzXK4/1rxL833qkuPivDB4Z8G6g2k3p13xX5S6doEzKs6SvEZnWVvuqsSK7M3+xxuYqCnorh2PUaK8P8G/Hq+uvixN8MvGXhyHwt4vl0w6vp507UzqNlfWoco5SV4onWVH+8jRfQtXttOwD6SvPvjJ8UrP4P+C21+7sbvVN11b2FtZWS/PPPPKsUSf7PzOvzVx/hn45a/8A8LetPh1428J2fh3X77SptX06fRdYbUrS4ijZUlRnkt4HSRdw/gK/7VRfWy8xnuFHrXz94B/aH174keMPiR4V0j4fz6Tr3g+W3gMOvarFDFK80TSrvlt1n8tduz7nm/f/AIdtaXw9/aS0Pxb8HNc8fa3bv4Xi8N3N3Y67ZTyic2d1avslRXT/AFn+zgfNuWnqt+1xX1Ot+Jvxo8D/AAbs7S58ZeJ7Hw8l4/lWqXbnzbp1/hijUbn+8v3RXoO7dXw5+3B428Xa7+zPey674Oi0LSNR1LR2spl1P7Tex/6ZC+y8t/KRYm/65Sy/8Br7dU/u0qre7fzt+Qk/eS7q5geKPGWleC7RLjVLiVWk3LDb2ltLdXU7Km5lhgiV5ZW2KW2ojHis74d/FTwr8XNBfV/CWtR6zZxTvazhY3imt50PzxSxSKrxSL/cdVavmzx94l+JR/bo8KWFl4d8OXps/CmqTaZbXXiO6ghlhe5gVp5WWxfypcIn7pVl/wCutd7b/Gx/Dvx+1D4V6V8NG07W7/SrjxL/AGn9rghtNRlVootzNErv8zb082VVf90vyNvqVrCMl1Tf3f8ADDvv5H0dRXjdn8WfE+qW9hodt4Mt4fiI+mpqWoaDqGtKlrpaM7Kqy3sUUu7fsfYUibdsbdsrP8A/tP6F4k8PeOLvxPaf8IZqngOV4fEtjc3C3CWW1N/mxyp/rYnX7rbVb/Zo7lPR2Pc+KBivmr4lftPeJPhb8Mbz4k6v8M5W8Dw20dxH5WtKdVTzXRYvPtfK8qNSzrkpPKy/3a3PiJ8fNX+H3xY+GvhmTwxaXmieOLprO31RNXZbi2lWHzX32v2fay/7Ql9fu0+3mTrZPvf8D3rIozXia/GrWLT9pW3+FuoeGrWCyvtGuNbsdbttVaV5IonjiZJYGgXa25/4ZW6VH4g+M2utouu6v4K8H23i/RtCuZ7e/kuNaFlLO0B/f/Y0EUqysjB0/evAN6H5sfNUN2+6/wCNh/1+B7f1xS18yeLP2xtI0rwN8MvGGgeF9V8T+GvHWoWmmwalDPBAtnLPN5RSVS/meYuJeFTbuTbvXNdlqHx0v/Dnxs8LeAvEvhpNLtPFcFxLoWrWmqfaPNmgi82WC4i8pPKYL93Y8qtWjTBa/dc9qorx7XvjBr2oat4j074eeFrPxZdeHZlt9Uk1PVm02BZ/K83yImW3naSXa0XGxV/er89eb+NP2vtW0/8AZ4034xeE/h7c+INCw51fT9U1F9LvdLCy+U7eX9nl81Vffux02/x/woD6porx/wAffEvxb4V8B+HdW0Xwto/iTXdUubS0Olf8JA8EG+fq0Fx9lfzVT72Xii/dK7dtteqWskzW8TTqsMpT5o1bcqt/vUdLgXKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAEptPopdbgfNH7bnwI1342fDfSbvwjLFH418IarDr+jLMcLPLF/wAst3+1x/wJVrb8I/taeAr7w3Zy+M9asvhn4haPbd6D4zuU0q4hlX72zz9nmpu/5axblr3uilry8rYdU+x8Yfswyab4U+Kf7Snj/U7ceHvB2pata3Vn4g1GD7FaXNusT75Vll2oybn+9/t1Z/4Jp+NvD/iL9mqx0PTtZsbzWNNvNQe8sra5V57ZJb24aJmT7yKy/dr7G4o9qoadlbzufF/7JfjzSv2d/B+q/Cb4japD4Y8RaPrd4NMfWJfK/t22nl82KW1Y/wCvdjLs2Rbn3fw5rgPF/wADfE3/AAwT8a4odKvl1LxT4ivfF1po72r/AGiK2a9ilRPK+8reVFu2/e+av0P4zRQroItxlfzufC37V3xa8MeLfBHwD8Q+Gr8+KdKtfH+k3stxoNvLf7YoklaVP3SN+9XY37r7/wAv3a6T4gePdI8L/t0eANd1m8/svR5vAV+0t7exvAlqjXETbrjf/ql/39uz+KvsQ96+VfEWj+P7r9tTw941tvhrrM3g/TtCuPDs2qrqGmLvaW4R/tCxfavN8pdv93f/ALNJb692/vVhPb0LnhS2i+LX7W8XxJ8P3EepeD9B8KNo0et2x3QaldT3Cy7beX7sqRInzOny7pdv9+vp6mfw1ItJN/D2/wA7iXcWiiiqGFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABTTyadRQB80ftvfBXXvi38P/D2reEIY7zxj4L1y18R6XZSNtW7aJvng3f7Q/8AQRXTeFf2rvhx4it7C31LxRZ+DvEtwqLJ4X8UzJp2pwzN8vleRKUZju6bN27+GvcBRz2pL4eWWo7nzd+158QNJt/2VvifdaldR6NY3mhXmn2EupSfZ2vLiS3kCokbDcd54Ufeb5uAvzVQ8GrYfH79htvD3g/W9O1S+vvBi6Lut7lJEt7xrFV8qbb91ssu5G9a+n+KaBik1o/OxGqcfK/42Pz4+CXjT9nfXtP0rwL4o+Bui6d8ZbK1W1vvClx4DSW4kuI/keXz1t2i8pm+bzWZfvV61f8Aj/8Atj9pPV/h/wCO9V/4Rjwtp+j2c3h7QbV3tIvEMrLuuNjLh5/KK+X9lTr/ABK9fVpGakquiL2dz4h/ZLit5v2S/iV4a0i12XVrqfiW3XSbeBke3/ey7IfK/wCWTfMu1Kzrz4oeFbP/AIJivZ3OuWNrcL4EOhPHcThG/tH7G8f2P/rvuR/3X3v5193UgpSXMmu9vwJS2fr+J+ePx2+Mfgdv2KPguyeLNKcyXvh8iJbtWZvsrwfavl+9+6/j/u8V237Vfxt+Htr8Xv2dLt/G2g/ZY9fbVZLhdQhaJLSW1lSK4d93yxMzff8Au19sbRxS1Tlf77ijFRSS6Kx8VXnxU8Gt/wAFK9It/wDhKNKM48Dy6OUW8T/j9e9V0t/+uuz+D71Q/s4fGvwDJ+1H+0pcL4x0Q2891pt7Bc/2jEsUsEFhtuJVfftZItjb2/hr7ZzSbaX2VHsmvxuN6/evw0PzO8Bx2/x0/Zf+P/hzwNd6T4s8Rp8QL3xDBorzLL9vtVvYbhPk/jjlWJ0T+Fq9V+C3jP8AZs+K2rWGm+DPg/odj8Q7V4pbrRbjwGtvNo0uc7p7j7P5cWzB/j3Nt+X5q+3dtLQnb7hW39blDU7X7bp9xbK/lGSNkD/3a+JP2V/2ktD+AXhDSfgd8TbPWNC8f+HZZdPsbWz0W8vV1mASu0U9r5ET7kZf5V900tK2/mFtEux8V/t7fEjQ9B8P/Bq38RatYaJqZ8daNq0+n3NyizQWsUrebMy/3Ezhn+7VP9qGTwp4d+Nng34u+MfB+m/En4N33ht9KvNQXS4tXi0t/O8+K927H/dsny71r7gxS+tNaK3m395d9LeVj5C0fxt4C0/4PeOviF+zr8PNHiNroc72mpaf4TbS/wC0LhfmiijXyopJ0XDM/wDD93n71eV/EbWPCGu6X+zf40svFT+NdUl8b6XJq3ieeZ5UgdonDxf88rP97s/0dPK6fdr9EabRe136EvZI+JtX+Lngu3/4KQaKLrxVpNsf+EEk0p0ubyKPyr2S+R0tX3/dlZf+WX3q7r4n/Eh2/aa0XwB4t12fwj8P7zQzf2kqXD2X9t6l9o2fZPtK7WGxBu8lW/e7+dy/LX0/S/xVO6iuw46XPgr9n/xV4V+G/gP9p+C/u7XwtpsHjDVJIre9i+xeVFLaxeT8j7du/d8m771cxN8XfBP/AA6bNmPFejfa28Nf2L9k+2L5327H/Hv5Wd3m/wAWz+78/wByv0cFGOapu9/O34KwaXT7Hwj44+JUXgHxF8EPjxpccni34YWvhyfw9rt7oJ+2HTUkWJ/tG1P4FeHbL/d2f3q90t/iTo37VHwv8V2vw+uLq40fVNIurGLXLzTbqyiaeWLbF5XnonmrydzL/s175SUO7VmHofnV8DPFP7Ptrofh34c/EP4J6PpXxj061SwvdBl8BLd3GoSxfuvtEUqW7q8cuzd5rvt5+9/FX354csxp+h2Ft9kt7LyreOP7Lartih+X7q/7I6Vs8Cjg0dLB1uIO9OoooAKiHepaKTVwPiH46fG7wDov7cnwYXUfGmgWS6DY69Bqsk+pxJFYSyxRKiTvv/dO2z7r16J8XP2ndH13wTqOifCGeH4peNNWgezsYPC03220tJXU/vbq6i/dQKmd3zurNjivpj0oFTyrk5fX87iiuV3Pgnxl+zL4h+Bn7LXwbtPD1rP4i1X4b+JLPxNq9hpsXmvf/O73XlJ/Ft81tv8Au133x+8QeHf2rPB/hTwp8PdatPE15L4l069vptObzv7Ht4H82V7rH+ofauzY+19zba+uaPatHJybuK2lj41/aD8C/DfxR8Rtc19vG+qfBX4o6U8On2niqC6a1i1bNuksUG1v3V5jft8pP3vyfhXG/F2Lxf4k+FvwB+KHxN+HMfjiLw+9x/wmHhptJW6YwXMXlLdfZZF++m1Jdm35d38Nfff8VHrSeqsV2Pl39nLXvgJ8RNcttd+C3gfw/CbZXW88Q6f4Q/sv7OjKyeUk7wRb5GbGVQt8u7dj5d31DT6KHqB4H+158R/Efwu+Ftrqnh6aXTIrjWbOx1XXorf7Q2jWEsv+kXmxvk+Rf4n+Vd1eOxyeCtF/bY+Fur6Be/b7DVPCWqKmumeW9/tRt8Tpsu33favlZvlRm219vU32pLR38mvv0A+Jv2b/AI2eAZv2pP2lZ18ZaKbe4utNvredtRiSGWC3sNlxKjb9rJFs+d/4a8i8HY+OH7Kn7QXhz4f6taa74lHj2/1+20uyuV829tVvYp02L/clVH2t/FX6bdKBVN3+6xKWnzufCn7XXx48I/GT9kfUpfC2oPq2qvqOk/adEt4mk1Cwl/tCDdDdQL80TfKU+b7zfdr7N8NeIrPxZ4fsNW0/7SlleQrNELyzltZdrdN0Uqq6f8CUVv0gpN3VvO/5Ao2afZWPiXxv8cvh9oP/AAUC8MTal428P2Udj4Pv9KvLi41OJYrW6+1RN5Erb9sUvyP8jVLrnxU8F6b/AMFJ9KiufFejW7p4Gl0hzLfRL5d618jJa8t/rWX+D71fatL70Q9yKjvZNfeO2/mfCf7RSeDvhP8AtOX/AI7+MPgDTfFfww8RaHZ2EfiO90RNUTQ7yBpvlkjKOyrKsn3l77BWv8Sfh94V+MH7JfxIi+BPgXTdFsNc061uLSXS/D39ktrbQTea0XlNFEzLsXarMvzea+yvtSm/w1K0Vim7u58QftafGzwj8XP2EvHVz4e1SCe9Szs4r/SlP+l6bL9qh3wzxffiZfmX5lrqv2qJI/Dvin9nvxrqUn2Pw34f8Rj+1dQkQiGxjntWiSWVzxHFv2rub++K6v8Abm8I+MfiR+zz4g8G+DPCl34m1fXRFCpt7y1torZUlSXfI08qf3MfLu/CvYvAOoajqXhXTZ9U0S68O33kqkunXssEssLKNv3oJJIz/wABarvokVK3LFep8yeJPH2lD9vL4eapaJfahpV54NurKC/0ywnuoHaW7i8pt0SN+6+X/W/6r/aryPwRffBX4I+K/EXgP4+fDLRl8TXGv3l1oniK98I/2v8A2/bXNy0kflyx28sjSp5mzZ/u1+j/AGpalWVk+it97uR/X3aHwd+194q8F/Dz4b/BDSjbaR4Ctk+IOl6rDoEUcVkLWxiuHd52gT/VqFdWf+6z1r/tGfGjwJa/tXfszXDeMNEW3tZ9Uup5lvonSKC6sFW3ld9/ypLu+R/46+3NtFNN8tn3b++w07L5WPhjwb8atP8A2RPjJ8U/CvxUj1PSdG8WeJpvEXh3xDBpk95b3/2pUDWv7hHbzU8rbt/+xr6r0qSz+K3gS+XUdMnTRNbgktxa6jbPBLNbOgQ+ZE4DLv8Am+Vvm2la72vNvi94s8d+EdN0ubwN4Aj+IF9cXawXVrNrkOlpaxc/v90qtv8A91fm+tBFtbniX7J8PiaS9PgDxPBOy/CO5n0qDUblf+Qj5q/6FKjf7Fk+1v8ArrX1r3rhvhvoGo6Jo9zLrrWz+ItSunv9Qaz3eSJW+VFXd8zKkSRRbv4tldz60x9WLRRRSGFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFACHpTac3ShelADacvShulC9KAFooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACimrTc9KBCNIqLlvlrnPCvjKz8aWb32jmS601X8uG+xthuf9uI/wAaf7f3T/DurxP9tLxhe6X4P8G+CdPma2uPiD4msvDU8yNteKzlbddFf+2Ssv8AwOtv9qP4l+I/2ffgXqvijwZoGkanDoUC+ba39zJAlvB9xfKSJPn25X5N0fyj71K/u3Ho5JI946UxjxXzV8Yvjl4++Ett4B8THTdC1XwzrurWGj32jxxyrfQvdfKs8V15vlN83/LLyv8AtrWt4s+LHjT4d/HL4f8AhrXF0HUPDXjaa6s7YWNrPFd6dPFB5uHlaVlnVtr8+VFTSb+9r7lcV/yudZ4e+Pfh7xN8XtY+HFraaxH4j0mxN/cve6ZLawNF5oiVonl2+arPu2um5fkb5q7XXPEkGg6ho1tOkksuqXn2KGOJc/N5Tyszf7KpE9fPmk/8pHdf/wCyb2v/AKXy164Gl8QfE7ULqACSHw1ZfY41d9qveXCpK27/AHIli/7/AL1KfuKXlclO8mu3+Sf6no9HrXzR8H/jF8UPjBD8UNNNh4U8LeJPCuuto8ExW51KyZ1iif5vnt3l3bz8/wC62/J8jVm+C/j98SPih+zdcfETRrDw34d1nSlvTe6dqEM95BetaNKkqxOksXkKzRHa7eb/ALtJvlvformi1Pe/iD4z/wCED8MT6uNF1jxEYpIY/wCz/D9obq7be6oWWLP3VDbm9FrrV+YV8pfFX9qjxV4c/Zn8JfFzwx4Z0uey1i3sJ7uHVLyTfafamiRBFEifvsNL3li+7XWfGj41eMfhr8Vfhl4f03QNGv8AQvF+onTpL64vZVuopVill2CIJtVfkT97vf8Aj/d9K05WvvsQnfXyufQNYGueIoNB1DRraZJpZtUvPskMcS5+bynlZm/2VSJq8l0/4r+K9B/aQtvhv4ki0e/sNY0WfWtH1DS7aW2lh8qVUlt51eWXf99W81dn+7XdWezxJ8WL25U5tPDdt9iU+t1Pskl/74iWH/v+1TG+jfUObW3Zhrnxo8F+H/HeieDNQ8R2kHifWpmhsdMUs8srLH5jj5fufLg/Nj7yf3lz6FXy/wDtOKv/AA0h+zK3/Uwal/6QPX08O9Naq5T0djzn4yfHTwR+z/4ct9e8e69HoGlT3C2sUxgluGklb5tqpEjN0Vu3avPfh1+3l8DvjB400zwl4R8cHV/EOoO6W1kuj38W7ahdvmkgVV+VW+8a9zutGsbzVbTUJ7aKa9s1dYJmX5o933tv/fNeWW4Pjb9pi4l+/pvgTSPIXH3f7Rvzuf8A4ElvEn/gVQD0Vyb4r/tX/Cb4F65ZaL458c2GhavfbfLtHSWWVFb7rSiJX8pf9t9q16do2t2PiDSrXUtOu4b7T7qJZ4LqCTfFKjfdZWrxP9o74leDPgX8Odeute8Japrdhq6XE17Dp+iz3tvMcBWe8l2eVEmCo/euPlX5M7a5Twn44tfhL+xDpXiH4Svp3jnRfDug/aornVrqWzWeCFHad8LE7ebuVl8ptvuwxzN9G+w7apdz6roFfJfxB/aU+IPgb9m/wb8aBp/h660qez0661vQBBP9okW68pd1rcebti2tL9x4pf8Aerr/AIrfGLxn8I/Gfw5uNQg0O88IeLNdg8OyafDbSpqFjcTq5il+0eb5cqfL8y+Un+9VOLTaZKd7eZT/AGhvgtpHim2s30mwDfFHUdTgfSfFEZ/4mOlxpMjSyxT/AHooIot/7r7rb9nzPL83slr4+0ubxVc+Gp5ZrPWoYxMtvdx7PtUP/PWFvuyL/e2fd/i21x2tfBfWNS8Wanrdn8VPGWhtqRVDZ2EGkvFBGv8AyyjaWwklRep/1n3mrif21r68+H3wRj+IOkSTPrfgTUbPVrV9/wA80XmpDcxO38SywSy7qW1kVH3j6VpazNI1KLVtMsr6AfuLuJJY/wDdZd1aP8NN6Ep3Vx1FFFAwooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACmU+igBrUDoaUGhqFoIRadRRQMKKKKACmU+igBlPoooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiuL+KXj1vhn4G1DxKvh3XvFosDFnR/C9j9t1C43SrH+5i3Lu279zc/dVvSvCP+G+j/0bl8f/APwhv/t9AH1XRXyp/wAN9H/o3L4//wDhDf8A2+m/8N8H/o3P4/8A/hDf/b6APq2ivlL/AIb4P/Rufx//APCG/wDt9O/4b6P/AEbl8f8A/wAIb/7fQB9V0V8qf8N9H/o3L4//APhDf/b6P+G+j/0bl8f/APwhv/t9AH1XRXyp/wAN9H/o3L4//wDhDf8A2+j/AIb6P/RuXx//APCG/wDt9AH1XRXyp/w30f8Ao3L4/wD/AIQ3/wBvpP8Ahvhv+jdPj9/4Q3/3RQB9WUV8p/8ADfDf9G6fH7/whv8A7opf+G+j/wBG5fH/AP8ACG/+30AfVdFfKn/DfR/6Ny+P/wD4Q3/2+j/hvo/9G5fH/wD8Ib/7fQB9V0V8qf8ADfR/6Ny+P/8A4Q3/ANvo/wCG+j/0bl8f/wDwhv8A7fQB9V0V8qf8N9H/AKNy+P8A/wCEN/8Ab6P+G+j/ANG5fH//AMIb/wC30AfVdFfKn/DfR/6Ny+P/AP4Q3/2+j/hvo/8ARuXx/wD/AAhv/t9AH1XRXyp/w30f+jcvj/8A+EN/9vo/4b6P/RuXx/8A/CG/+30AfVdFfKn/AA30f+jcvj//AOEN/wDb6P8Ahvo/9G5fH/8A8Ib/AO30AfVdFfKn/DfR/wCjcvj/AP8AhDf/AG+j/hvo/wDRuXx//wDCG/8At9AH1XRXyp/w30f+jcvj/wD+EN/9vo/4b6P/AEbl8f8A/wAIb/7fQB9V0V8qf8N9H/o3L4//APhDf/b6P+G+j/0bl8f/APwhv/t9AH1XRXyp/wAN9H/o3L4//wDhDf8A2+j/AIb6P/RuXx//APCG/wDt9AH1XRXyp/w30f8Ao3L4/wD/AIQ3/wBvo/4b6P8A0bl8f/8Awhv/ALfQB9V0V8qf8N9H/o3L4/8A/hDf/b6P+G+j/wBG5fH/AP8ACG/+30AfVdFfKn/DfR/6Ny+P/wD4Q3/2+j/hvo/9G5fH/wD8Ib/7fQB9V0V8qf8ADfR/6Ny+P/8A4Q3/ANvo/wCG+j/0bl8f/wDwhv8A7fQB9V0V8qf8N9H/AKNy+P8A/wCEN/8Ab6P+G+j/ANG5fH//AMIb/wC30AfVdFfKn/DfR/6Ny+P/AP4Q3/2+j/hvo/8ARuXx/wD/AAhv/t9AH1UBTPSvlj/hvk/9G5fH/wD8Ib/7fR/w30f+jcvj/wD+EN/9voEWP24/D8h0H4a+PIkD2vgTxlYaxqP+zYb/ACrh/wDgG5X/AOA1Z/bynvdS/Zd8YaFpGia34h1nXrVbOxstE0u5v3dtyMd/lI2xdoZtzbeg71gan+3Ba6tYz2d3+zd8ebq0njeKaCXwNvSRG+8rfv6x/Av7Xp8C6KdJt/gT+0HeaZA3+hRXvgnfLbxc/uvM8/51XHy7vm5HLVNvdsPRNNFT9qDxdP4s+Dnwri0Xwb451W9i8Q6TqtzZQ+EdRE1rb2sv7/zV8j5W+X7n8f3lyvzVq/tHeM5dR+NnwC1jTPCfjXV9J0TULjVNTubHwjqkotree0aKLf8A6Pu3/N80X3l/iWtz/hvg/wDRuXx//wDCG/8At9J/w3wf+jc/j9/4Q3/3RVLTXzb+9WF0t5WMXTPFEy/t9azr58K+MF8OzeD4tAi1l/C2orateR3byMnm+R93af8AW/c/2q+hPh3b3Gk+BjqWpW89vqepPLq19C0TPLE8rb/JKr8zNEmyL/tlXin/AA3u3/Runx+/8Ib/AO6KX/hvhv8Ao3T4/f8AhDf/AHRU8vuKPlYLe833/wAkYP7Lfjc+H/FXx41DWPCfjbSLXU/E8+u6c114Q1NTeWflRR7ol+z7mfcn+q+/g/d+9XPfs76/feHP2N/HGh6t4N8aafrqzaxs0ubwnqJuJ/tlxcNb+Uvkfvfv/Nt+5/Htrvv+G92/6N0+P3/hDf8A3RS/8N8H/o3P4/f+EP8A/b6OXmWvVJFXaseG+OrzWdT/AOCeXgvwPa+BfHk/jC2i0uym0dfCOpebE9pcW8szOfI2hdo+Vv4j937j49V/aS8aPq3xG+AWs6b4U8bapp2l6y2tajJaeEdRk+x2r28sSeankblk3N/qvvf7P3K3f+G+P+rcvj//AOEP/wDb6P8Ahvj/AKty+P8A/wCEP/8Ab60cn173/IhRS+6xkeOfFEkP7cHgPWIvC3jK50LTvD99pd5rFt4V1GW0inneJ4k81YDx8vzMvyrn5iPnr6J+Ful3Nn4RivNRhkt9V1aWXVL2GVdrxSztv8pveJNkX/bKvDf+G+D/ANG5fH//AMIb/wC30f8ADfB/6Nz+P/8A4Q//ANvqeiXZBbfzMz9pjxRI37QXwVubTwz4v1ex8Lavd3Wr3ul+FdRvbe3insnRG82KB1l+Zv8AlluK19GeNPHH/CE+BdR8SpoOua+trAJl0rQ7Fp9QuB/digbb8/8As14N/wAN8H/o3L4//wDhDf8A2+l/4b5P/RuXx/8A/CG/+30o6RSK63PpeG+87S0vGt54t0fm/Z3j/fL8v3dv96uA+A+h31j4JOt6rZzWeveJLyXWr+C5i8qaJpX/AHUUq/3ooBDF/wBsq8n/AOG+j/0bl8f/APwhv/t9H/DfR/6Ny+P/AP4Q3/2+q6WE1c9Mtfjpaapr+teGrjwN44g1GzmktY47vw3O1lqO1T80V4oa22N/01lSvHdb+F83wJ/Yl8Z+D7TRtS1LVtcsdWFto/h3Tri/eG6vPNZLdUgVsRxb1Td8q/J/tVrf8N8n/o3L4/8A/hDf/b6T/hvk/wDRuXx//wDCG/8At9ZuLs0nuUtGn2PJPjTqWqeIP+CdnhzwVpng3xveeLJtL0nTn0dPCWo+fFNavavcb/3GEUbDtf7rY+Xdiu1/a48YT+LdP+CVzoPhHxxrB0/xjpfiG/jtPCGovLa2UXmrK8qeR8jc/wCq+/8A7FdN/wAN8H/o3L4//wDhDf8A2+l/4b5P/RuXx/8A/CG/+31pzNtsUdIpdj6U0u+TUNPtbqNZkjniWQJcQvC/zf3kcblbn7rV4N+3lHc63+zlrHhHTE87W/F95Z6Bp0O378stwm//AL5iSV/+AVh/8N9H/o3L4/8A/hDf/b65Fv2sLe88cReJ9Y+Afx71W7sdy6TbN4G2QacrLtdkT7R80r8/vW/h+Vdvz7l1uOPun2J4f0lNE0LT9NR96WUCQK3+6u2tVa+Vf+G+j/0bl8f/APwhv/t9H/DfR/6Ny+P/AP4Q3/2+myUrH1XRXyp/w30f+jcvj/8A+EN/9vo/4b6P/RuXx/8A/CG/+30hn1XRXyp/w30f+jcvj/8A+EN/9vo/4b6P/RuXx/8A/CG/+30AfVdFfKn/AA30f+jcvj//AOEN/wDb6P8Ahvo/9G5fH/8A8Ib/AO30AfVdFfKn/DfR/wCjcvj/AP8AhDf/AG+j/hvo/wDRuXx//wDCG/8At9AH1XRXyp/w30f+jcvj/wD+EN/9vo/4b6P/AEbl8f8A/wAIb/7fQB9V0V8qf8N9H/o3L4//APhDf/b6P+G9/wDq3T4/f+ER/wDdFAH1XRXyp/w3v/1bp8fv/CI/+6KP+G+j/wBG5fH/AP8ACG/+30AfVdFfKn/DfR/6Ny+P/wD4Q3/2+j/hvo/9G5fH/wD8Ib/7fQB9V0V8qf8ADfR/6Ny+P/8A4Q3/ANvo/wCG+j/0bl8f/wDwhv8A7fQB9V0V8pf8N7n/AKNz+P8A/wCEN/8Ab6X/AIb4b/o3T4/f+EN/90UAfVlFfKn/AA30f+jcvj//AOEN/wDb6P8Ahvo/9G5fH/8A8Ib/AO30AfVdFfKn/DfR/wCjcvj/AP8AhDf/AG+j/hvo/wDRuXx//wDCG/8At9AH1XRXyp/w30f+jcvj/wD+EN/9vo/4b6P/AEbl8f8A/wAIb/7fQB9V0V8qf8N9H/o3L4//APhDf/b6P+G+j/0bl8f/APwhv/t9AH1XRXyp/wAN9H/o3L4//wDhDf8A2+j/AIb6P/RuXx//APCG/wDt9AH1XRXyp/w30f8Ao3L4/wD/AIQ3/wBvo/4b6P8A0bl8f/8Awhv/ALfQB9V0V8qf8N9H/o3L4/8A/hDf/b6P+G+j/wBG5fH/AP8ACG/+30AfVdFfKn/DfR/6Ny+P/wD4Q3/2+j/hvo/9G5fH/wD8Ib/7fQB9V0V8qf8ADfR/6Ny+P/8A4Q3/ANvo/wCG+j/0bl8f/wDwhv8A7fQB9V0V8qf8N9H/AKNy+P8A/wCEN/8Ab6P+G+P+rc/j/wD+EN/9voA+q6K+VP8Ahvj/AKty+P8A/wCEN/8Ab6av7e5X/m3P4/n/ALkb/wC30AfVtFfKR/b4JH/Jufx//wDCG/8At9O/4b6P/RuXx/8A/CG/+30AfVdFfKn/AA30f+jcvj//AOEN/wDb6P8Ahvo/9G5fH/8A8Ib/AO30AfVdFfKn/DfR/wCjcvj/AP8AhDf/AG+j/hvo/wDRuXx//wDCG/8At9AH1XRXyp/w30f+jcvj/wD+EN/9vo/4b6P/AEbl8f8A/wAIb/7fQB9V0V8qf8N9H/o3L4//APhDf/b6P+G+j/0bl8f/APwhv/t9AH1XRXyp/wAN9H/o3L4//wDhDf8A2+j/AIb6P/RuXx//APCG/wDt9AH1XRXyp/w30f8Ao3L4/wD/AIQ3/wBvo/4b6P8A0bl8f/8Awhv/ALfQB9V0V8qf8N9H/o3L4/8A/hDf/b693+Fvj1viZ4G0/wASt4d17wkL8y40fxRY/YtQt9srR/votzbd2zcvP3WX1oA7SiiigAooooAKKKKAPHPjr+0FH8BfD154i1XwP4q13w7ZQefearoK2csVqu7+OKW6il/4EqMvP3q7fwX420f4h+D9P8UeHryPVdH1KBbq0uIT/rF/+K/hrnv2h4Yrr4P+II5VWaJ/s6sj/db/AEiKvmaTzv2APiy82Zv+Gd/GN/8AvF++nhTUpW/8dtZf/Hfw+eVK75Qs9+x9C+AfjlfePPGuq+GpPhn4x8OyaS6xX2oax/Z32WB2i81E3RXkrS7k2/6pWxuG7bXsFeM6H4s07wz4g+MPiW8mX+yrBrW/lmj+b90umxPvX/gNcBoetfFT4mfBWy+Kfh7xZJo2sajpjaxpnhJtOtpdJlgbfLbw3DtH9p81oim6SOdF3dF/vC1TfYOqv1PqWjvXxh8RP2nvGPif9m34cfFnwBqOn6DBrl/YWV9pV5Y/apHlnult3RbjftjVGEvzeU27j7tdH+1LrPxd+DHwh+IXjnw58RLK5+yRxXdtp+p+H4W+xpgRSxwSq65+dxIvnJKfl2/Nmqd4pt9Hb8hRfM0l1PqziivlT4+/EL4ifC/Rfhr4x0jxRFcQ6premaLqfh+6sYPsU6XT7fNRtvnpKvy/8tdv+zW14/8AGfjP4X/tBfC3TZPFk+teH/HF1eWF5pN1Y26xWEkVr5qyWrxosvLJjbK0v36Lb+Ta+4fS59I15T+0B8ZJvgP8MNU8aDwtqHim101DLdW+n3EEX2eILzI5ldfl6fcV2+b7teZ/Fjxh4+0nUPHOoap45b4b2mnBj4S0zSbazv5ddSK2WWWWeCSKWd/3u9NkPlNsX/gdc98XPiJffFr/AIJp+IPGOqQRRajrHg83VxFb/KiyMo37f9mlrZvsLql3Pqrw3rH9veH9N1TyvJN7axXHlbt23cm7bW1XMfDn/kn/AIY/7Blr/wCikrp6OtgTuFFFFMYUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAZ02oW0N9DaNcRrdTqzRwtJ87qv3tq+1aNc/4k8K6R4ttVttV0+C/WJvMiaZPmif+9G33kb/aWvNvEGpal8J7iGLT/FC66JYne28La08t1qE6r/z7zxK87Lzz5sU55++tAHtFeaeMvixa+GvES+GtO0HWPGPiWS1F6+kaCIPOhg3hPNllnliiiBbdtDShm2PtztrrvD+oXWuaHYX11pt1ot3dQJLLp926NLbOy/MjlGZdy/7LV8vftF6X4z8E/G2w8f8Awhni13x3Lo62+ueB7hAYtU0yGV2SXzf+WEqu7Iv9/P8AsNUt2aQ+jZ9BfD/4naZ8RV1SO0ju9O1XSLpbPVdHv4kW6sZ9iS7H2M6t8jr86MyN/C1cbdftSeGrdbvVE0zWrnwTZXLWl540ggi/sqGVZfKcf63z2VX+VpViaJcffrxXw78VtA1/9ln42/E/wre3z+PrrT7yXxCt7bfZbvTr+C08qK3MBf8AdJEq/J87fxfO7Zrrfhb4fspP+CcuiaW0CvY3fw+Jli/vebZMzf8Ajz1UvdUn2t89xdvM+pI5FmVWVlZG+6y1YrwL9iDXLzxJ+yb8Lr/UZJJrttHihZ5W3Myx7o1/8dQV752okrNoSdxaKKKBhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUygDzf4y/F6y+D/hyLUZPD/iDxXezTeVb6L4U077fqE/99liz91f4mqL4L/GRvjPot/qX/CDeMvAiWs/kC38aaYun3E/y7tyx72+Xn71cl8cv2efEHxN8UWHirwp8VvFHgHxNpdm9lYpp/lTaaCx3OZrdk/e7vk+838C1xngH47eN9R+Bfxet/GNjbWXxL+HdveWt82n8QXjpaefb3UX90SoVb/4ntLfKm+wLV2PRtR/aX8OWP8Aat5Dpetal4S0a4ltNY8X2METaZYSxf63dulEsqp/G8MUiJhtzDa2O18dfEfw/wDD3wi/ifWtTEOjL5WyaFGlad5TtiSJVy0jOzqFVa8K/ZQ8P2P/AAwL4T0+WFZrbUfDM8l0kn/LTz/NeXd/321fMXwx8Yan42+F/wCw5omrCSWyn1+9uJXZvvNp29LT/wAd/wDQauzbkl0aXrcl3Svbo39x97eD/jNZ+IfESeG9T0PWvBviO4ge9sdM8QrAst9bIVDyxNBLKvy713IzeYu75kr1DNfIv7bepT+HfiN+zZrVjlNSTx9BpnnL97yLqJ4pk/4EtfUd9BPe2s8MVzLYyuhVbiFVLxt/eXerL/30ppPSLl6/gHNqoktnqFtfz3cUE6yy2c3kzKv/ACzfYj7f++XX/vqtCvi39kEXngXw58ZPFOu+OvEep6PoPi7XUvLXUPscqTpBs/0iV1t1l83Yn8Eqxf7NdhoeufFX4lfBWw+Kfh3xa+ja1qOmPrGl+EX0+2l0mWBt8sENw7RfafNeIpukjnRd3ROPmTdtell+I+9+ja+4+pBXJfEPx1YfDXw1e6/qdvf3FlZxPNKun2cl06oiFmbYvoqtXPfAD4wWnx4+Dvhfx1Z24tE1i1Eslpv3+TKrlJU3fxbXVxWt8aP+SReNv+wLe/8Aoh6mbcE7rVIa1dib4ZfECw+K3w/0HxdpUFxDpOt2MV/apdKqzKjruXdtZvmrsK8U/Yu/5NR+Ev8A2Ldl/wCilr1y8he5s5YVmktpHVl82M/On+0u6rmuRtdmKLPB/Hn7XVt4O8ZXfh3TvhT8UPHAtZhA+seFfDf2rTTLn50E7Sou5G+V/wC6wb+7XqHjv4laN8N9Fs9Q1x54nvLqKztLG3Tzrm5upMbIIkX7zH/H+Gvlvxh4P+J/7EekDxn4b+IOt/Ev4ZabP53iDwv4r8q4voLV5P3t1bXSKjfJuDeVt2/frovjDqx8Sft0fs7aU0jvpNvpmr61Ev8ABLO1vsVv+Ar/AOh00r2Bux7n4L+Lun+LdevNAvdK1Twp4rtbZLuTw/rYgNx9mZiqXCtbyyxSJuUjKStt/i25qn4g+OenaX4o1Dw7o2ga7401jR1ik1eHQooCNOjkyyvK00sSsxVd3lRb5cdErxj9orUJ9B/bV/Zou7Lck2o/25ptztbb5sH2eJ9jf8D+anf8E976fXfCvxZ8RXzM+pap8QdWad3++NvlIif8BVaVv6+4bvF6n0l4H8baN8QfCuneIdAv49S0nUIhLb3UROHXHpj5W/2a6fpXyJ+wLqVz5nx10bDf2bpPxH1aGyj3fLEjPuZF/wCBEn/gddT+2V8QvHnwp+Hem+JvBus6fpkaapZ2V7b3Wn/aJp1nuIov3UpfbFt3N96J/wDgPdX287fiHV+V/wAD6Q96K+Y/jd42+IPwt+LHwrl07xWuoaL4v1n+wb7QdQ0+D7Lbs0TyJcQOipPuXZ9xpWDf7NXpPGXi7wP+1R4Y8FXvie48TeHfF2jX1+ttf2ltFJps9syZ8l4Ik3ROkv3ZfMb5PvU93b1/BEc36fifR/Wivlnwr4+8cfG6f4o6noniubwS/gzXr3QtP0ZLG2niuXt4kbzb/wA2Jpdrs5/1DxfL/E/Wu5/ZT+I3iv4wfBPQPG/iqbSTda7ALqK10nT5bNLVfulG8y4lMp3Kfn+T/dpR1TY7/r+B63qWqW2lwrNdTLBG0scCsx/jkdUVf++mWtIV8iftsaHqt94k+CUth4v13Q47nxzYWJtdO+zeVuZZX+0bZYn3Sps+Xfuj/wBitv43ah47+FPi34S6xF8S9cbwVc63baF4jtrjT9MLTebvFvcPL9l/d75fKjl27RtYbPLbmkmuVPuU9HbyufUVMY/L8o3V8ueKPHPi7wf+2l4O8O3XjzVJvAXiKxuMaO+n2C28GoqjtFb/AGjyPN2PFFK+zfu3p97a22u/8O2fjLXrzx/qmn+OJmtZLqTT9BttV0u2uLSxli+SWXZEsEsv73zYtry/wU3dAdz4B1vX/EXhuK+8S+HG8Jas80qNpbXsd4URZWVH82L5TvTa3+zux2rrq+RPg7+1Frdr+xPc/F/xu8esazZNfl4raJbeGWVb2WC3iX+6v+qTd7/xV3ms6H8Z/Duq+D9b0XxKni6G61CCHxJ4dvIbO1srW1df3s9k6RefuQ/Nslll3Zq2rOw2mtz3+k+tfNPxC+Oxuvil4j8B2ureKvDUWhWNpPdap4Q8J3Ot3Rup9zrFlLO6iiRYkTPmx7n835duytj9lv4neNviBo/iew8b6Pq9rd6Jqr2VhrWp6FcaR/bdn/yyuPs86LsbruVfao7kt2Pfu5rxT4xfH6f4ReN/AegS+EdQ1C08Waxb6RFrSXMEdpbTys3yMm7zWbajP9zb/tVf/aA+Kc/wx8O6NBpawnxJ4m1e10DSDc8wJczt/rJV3LuVEV32g5bZt714H+094b8TeHPG37Pw1Lxhe+LLK5+IlnIW1O0tIJbaXypcLF5EUX7r7/yuHf8A6aULUUtItn2p/DXKfELxBr/hvwzPfeGPDZ8W6ussSx6Ut7HZ+arOqu3myfL8qbm/4DXhfxY8XeO9J1LxzqGp+N3+HVrpoY+EdN0q2s7+XXUitllllngkilnf97uTZD5TbV/4GeN+KP7RHxIX9jXwX8XNC1XSNE1O/trB9Stv7N8/zHuZYov3DPLti272b51loinJpLul94m+VK/n+B7Xrnx4udB/aE8J/DK68IajHH4htrq6tdekubcW7rbxebJsjVml+VmRPnWP738Ve0NXy18YNzftxfs9/Nj/AIlXiP8A9J4al+FOvePvC/7Ufi3wB46+ImoeKNNm0eLVvC0d3p9hbpPb79lx5rQW8TNPE+z7rbdsu7Z/crt53/B2FGXNf0X4n1FS1498HbbxNc6t4y1vVfGWoa7oV1q08GiabqFpZxpawxNsdt8ESvJ+9SXZvb/Vqn+9XsNJ6FoKKKKBhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUmB4v8AtIXnii48Az6R4U8Dap4z1C+Kc2V9Y20UGyWJj5r3NxH95d23Yr/8BrqLzRbH4wfDu60vxl4UubDT9Wha3vdD1iSCSVU/2mgllj/2tyv6V37Uz+GoktLDT1Pl/wDZz/Zhv/hr4D+J3w88T6lN4h8L6pdNZ6Vd3DbpW0xrVIkif/ai+ZP+A1F8HNE+K/wg+FMPwqufCH/CRz6Tay2GjeLoL+2h0yW3G/7P9qiaX7VEyrsVliil6cNX1L1NLV73t1t+BN/eTfQ+LPjB+z74p8E/sx/Dv4VfDzwne+NLjRdQsb+5vLa7s7SIm3uVnlZvPnRt0rbyu3d/tGvQf2uNL8bfFj9mHXvDnhfwBq1z4k8SWq2v9m3N7p8Taf8AvFZjcP8AavLPyrx5TSdRX0lRRK8k0+rv+X+Qo+6010Pjv9onS/iX8SPhP8NtL0L4S65Lq+m61pmsaha3GqaVELVLOXLJv+2fO77fl2/wv821vlrU+PVn8Q/F/wAWvgp4m8P/AAp1/UtN8KXk2q6mJNR0mKVPPtTF9nVWvfmlTcd38P8Addq+sKfRff1b+8pbWPlXwj8N/H2g+NPjbFqfhg63d+MLia40fxVLqEC28dk0SpDp8q7vPj8r5/uRPG2771clqXwy+JVr/wAE+bX4V23w+vb3xlcaEuhvYxanYqsDc7pZZGuFXyz/ALDM3zfdWvtaijVJruK2qfY4P4UyaxJ8O9Ch1nQbrw1qtvaRW02m3k0E7RsihfvQSyqy/wDAv++a7ztS0UAFFFFMYUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAcv4k0HUvEDQwRa3daRYR5NwunKqXFx/sea2fLX/d+b/aWk8L+C9F8HRzR6RYx2sk5DT3Ds0tzcsvy75ZW/eSt/tOzGupplAD6+etZ8F+LPhz8fvEHxD0bw/deNtG8R6PZ2F5punXMEN/Z3Fq8oieL7TLFE8bpM24earLs/i3V9BUYxStcOh4D4B+Cbal4o+KninxHocehJ8Qba1sLjQUlSWVLeK3eJnuGj/d+e/muG2M67VT5mrirL4W/ErQ/2frj4D2OkG4T7BLodn46e8gSyj053ZFd4t3n/AGpLdh8ixeWzr/rV7fWXWloerfmJaP0OV+HvgvTvhx4E0DwppAZdM0axisLfefm2RpsH48V1a0lPpjCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKZT6KTA8w1Dxv450r4gyaSPhrd6r4Xkije28RaZq1mdsn8S3FvO8Tr/AL0Xm1N4V+HtvCniq91WCOXUvFM4l1NYFLRhFt0gSJWP3gsSct/EzN/uj0aio3uhXs7nyf4Z+G/xI+GPwTv/AIL6Doj6kqRXun6H40lvLVLK0s5WfyWuo9/n+fErldsUTI2xfnTcdux4y/ZbTT/hL8LdD8GTxprXw0u7TUNGkuxtW8eL5Z4pf7vnqz/N/CxFfS5FFaXa17u4NO2r6NfefO1/4D8RfGz4teBPFPibw7d+DfD3gmS4vbbSdUubW4ur7UZUESSn7PLLGkUS7ivz7mZ/uptr6E/iPvU1FQ72afW4W95M+ZPgx8Ide0ez+MvgbxV4ez4e8U+ItU1KHVobqJ4Lmzvk+4qbvN81PuvvRV/us1VPg5oXxW+D/wAKYfhRdeD/APhI7jSbaXT9F8XQahbQ6ZLbfOLf7VE0v2qJlXZuWKKX2avqVe9Ox0p+XSy/AO9+rb+883+AvwjsvgX8IfC3gWxm+1Q6PaeS9zt2+dKzF5X/AOBOztTPjhNrc3wu1+z0Lwvf+J9V1OynsYbLT7i1gZWliZd7tcyxLtGfdv8AZr0vpSUSXOnfdqw1o7o8P/ZH0nxP4X+A/hHwr4r8K6h4W1nw/p8GnTJd3NnOlwyJy8TQTy/L/v7WrW8G/Ezxv4o0fxfBe/D0eG/Feju/2DTL3WYp7fUUbf8AZ3+0RK3lb9nzKyblz3r1qsjRtDstHheOzi8nzm82Rmdnlkf++7N8zN/vZ+7Vy95tvqJaKx5a58T/ABt+Hl54e8V+ArzwLBqkX2XWLfU9QtLrfA3+tS3a1lffvXem+Xytv3th+7VX44fB298QeK/h1498LW8M3ijwPeSvBYSyeUl7Zzx+TcQbvuq23DKf7yV7nRQtHcN1Znz7o/w51r4m/HbRPil4n0C48L2nhnSriw0TRNQnt577z53xcXEvkNLEnyIiIqSvwzbtv3ao+C/Afin9nvxV4/HhjwjP4u8N+LdX/tu0h0+9trd9OvJV2zrcefKmINyI++LzW+d/3Xr9IUlIcrvQ8e/Zr+DcvwX+H9xYahcw33iLWNRudc1q7t12RS3tzJvl2D+6vyovstcN+3B4V8b/ABA+F9l4Z8D+C77xVqE2q2eoSyw3tnawwxW1wku1nnnRtzbfl2q3f7tfTdOqbaLyt+At7363/E+Sf2irX4j+PvFfwa1Tw/8ACjXr638M67D4h1RJdT0mJo18mWJ4F3XnzSrv/wBz/bqf4gaV8QNS/a3+GvjDTfhprV74W0HTLywv7/8AtDTIyHuki+eKJ7reyxbfm/4Fs3fxfVvfFNZdy4qtnf1/Enlt+H4anwT4wtPihr3xE8a38H7O/wDwsHT7jWJbeLXNC+Iq6Db6laxfuooLqBCn2nZ86P5oddxlX7tfUHwJ8Zal4o8I/wBn6v4Bm+Geq6KyWc3hxrqC4it02fuvIkg+R49vTAX7vSsvwT8IPG3wrjt9F8LeP7KTwbbztLFp/ibQXv72BXldniiuorq3+X5vl82KVh/eevWdJ0iPSoZB5jTTzNumnb70jUR91WKav+P4nif7U/gHxJ4ys/h3qfhXSf7evfCvjCy8QT6bHcRQTXFvEJUlSJpWSPf+9/iZenWuo+NHw1l+NfwZ8TeFbuJtPvNTsnFqfNV3trhfngfcP4kdYm+X0+81er07tUrRJdhvV38rHy548+DPj3xv+zpZ3bCzh+M9rdWvii3bcvlRarFs/wBH3/3PKXyN26vabCwvPh38OLa2sdLuvEl/YWnzWWnvEk15Pj5yjTyovzPub53713dFVe6sB8S/A/8AZz8W+Kf2Kdf+C/xA8O3XgjVZzeeTdy3drdRO0t091DKnkSt9x9m5G213fwZ139oq4tbbwf458A6Lpq6fHHa3nju28SLINQRfvSwWaxF/Mf8A6atF97d/s19PYopdWxtt7nyj8UPAvxc+E/x01b4p/CjQdP8AH2meJLG1tdf8I3morYXDSwfJFcW9xJ+7X5G+bd/d/i/h9v8AhvceLtU0ttV8ZaXa+H9VulX/AIkFhfG9isVXd9+fYnmStu+bYu0YUDd95vQKSmS1c8K/am+Dut/Ffwp4dvfC81tb+MPCWtW/iHR1vT/o9xLFnfBK38KujMu6vPfjloPxU+M0Xwm1PSPhqdD1Lwz4st9avtN8Qa5ax4WKKX7stq8/7pmbbu27/wDplX1v3ptTsg3Vj5R8D/D34h+HfF3xoi1rwqurah4wle403xV/akD2kVq1uqRWD7v36+U3m7dsGxt38FeaeNvhP8V7j9hTwf8ACqw+Gl/qHiuGKwiuY49X05IrU2t1FK+93uOd+z5dm7vv2/xffX0pKabi0/NP7gav+P4nyN48tfiR4n/aa+EPjay+EevroPhuy1CDUjLqmkrKjXkUSjav235/K2nd/wCO7q6v9rnwJr2pW/gXxn4KuIbPx34c1uK3sXm+5cQXjpa3ETf8BdZf+2NfRteOeDPhH4rsvGt3r/jb4mX3jq3t7+W50PRhpNrptrpavuRd3lfNOyI7Lvdv+A7qeunlf8XcEl07Jfcej+E9BtfCXhzTtGs/M+x2FslvFvbc+1VH3v8AaroKZT6b1BBRRRSGFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRSYHi/7SHxe8VfBHwDc+LtA8HWvjWz09Q17Ztq72V1hnRF8hBbS+b97puX/gVdD8Dvi1pfx0+FXhzxtpC+Xa6vbCZrcsGa2l+7LE3+0jhl/CmfH/AP5Jfef9f2nf+lsFeBfBFY/2d/2qPGvwilU23hHxgr+LvCw2/uopf+X21T8t+3+7Uxa1i+opJqzPUP2mP2jD+z3ofhySz0E+Kde1/VoNKsdM+1/ZULyMq+bLL5T7FUug+7/EtdhrU/xGm8F2Eml2XhnT/FbXVv8AbLS9vLi6sooPN/feVKsUTvJ5X3f3ajd1r5w/awT/AISDwf4V8YStvi1P4geHrfTP9iyiuvkb/tqzSy/7rxf3K7T9trUvEvhTwd4V13w94t1jw95XiTTLC5stNaNYb2Ke7jRvNbZ5v/fDr99vvU43cFfRt2/LUqVr3XRHR/Hr4z+LvhP46+Gdhp+jaPd6B4t8QWuhXN/dXUv2u3kl3s2yBU2lfKi+/wCb97+CveT9018v/tpf8jR+z1/2Uiw/9J7it7xB4pufih+0PqPwxXVdQ0vw/wCH9Di1fVRo15LZ3d3PcOyRQ+fFtliRFRn/AHTqzb17ferpb+uhkn7/AMky78O/jJ4s1/8AaM8dfDrxDo+kafY6Hp1rqVjcaddSXEsyTySqnnMyIFban3Nv/Amr3uvkL4M6Hc+GP24vipYS6jeanBF4V0b7JNf3DS3Cw75cJJK3zS7Tu+Zzv5+bd96vrykvhRd7ti0UUUxhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFMoAx/Emu2fhrRb3WL5mFpZxNLLsXe2F/ur/AHq8W+Hfxg+N3izxvbad4j+AQ8F+GZWfzfEF34ysrp4l2/J/osSF9zHb8u7jP3q9M+Kvwp8NfGjwXf8AhPxfYS6loN7sNxaxXcsG/a4dfmiZW+8B+VfOPhHwV4m/ZP8Ajv4M8M6X4n1jxN8JPGss+mwaXrt091PoN/FbvPF5ErfN5DpE6bKSaYPQ9n8VfGa9j+IUvgHwXocHibxfbaeup3y6lqH9n2NjAz7IvNnWKV/Ml+fYqRN9z5tgra+FHxWsPihp+r+TbTadq2h6jLperaXcHM1pcxfw/wC0rrtdX/iVxXhP7K7yXn7WH7Ulzetv1BdV0i3Xe3zLbrav5Vc/8L/Glj8O/wBsL9q3W9XuzY+FtMsdF1HULhY2lWIpZZd9iqzfd31fWwl7yb7H2PrWrQaJpd1fzhjDbRNM+1dzYWvlTWv2pvj/AKHod/rc/wCyy1tollA95LeXXxB06Jo4FXcXeLZuU7R92vSPg/8AtnfBz49eLm8NeBPGH9va0tq901r/AGZeW/7pdoZt0sSL/GtaH7RUcnifQvD3gG3XfJ4v1WKxvNv8NhF/pF7n/ZaKLyv+2y1ml1BO6J5/jdJpfw58D65q3h+Sz8UeLRaxWXheG5WWb7TLF5ph81kTPlJvZ228bGpuh/GLUrH4haX4L8feHbXwtr+rwy3GkXGmak+o6ff+VzLCkrwQMs6LhtrRcr91m5FcV+1J4S8SDxd8JviL4Z0i68QJ4F1ee41HRNOG+5uLO4g+zyvBF/y1li4wlcj8avGkfxY+Nn7OuneHdO1y2uk8Q3WuStqWlXGnTRWdvbvFPviuESVV3Sov3Nrb6oHorn2FT6iX7tPWgFqrjqKKKBhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABTKfTKTA8U/aA+KWv+F7rRPCfgHUvB1r8RtaLz2Nv40v3gtDbxFfNbZF+9lb59qon+038Fbfwdk+K1r4f1Gb4vzeDV1NZ82x8HC6S3WDYP9Y1027duzUXxY/Zr+GfxuhlHjbwXpevXbwfZ11GSDZexx/3VuF/er95ujV4d8OdF8aeD/g78f/hdc6reeIX8JxXFl4b1W9bfcPaz6f59vE7/AMbRb9tCFu7HW6T+0D428ffDnVfix4T0rSpvh/YC6ls9GuoJW1PXLWB2V7iK481I4N219kTRS7ti/Ou/5Om8dftL6Jovwp8IeLPDUX/CR3XjW6s9P8NWXmeV9rnuvub2P+rVRuZ/7uyuV/ZPvrSL9gnwVMXiS1h8LOZX/hXar7//AGavlL4Q6drOnfDv9haTVhIumDXdU/1y/wAcvmvafxf3N22qtuvNL7wvp9/4H2xb/FbxH8PPiZ4X8IfESXSbseLvPTR9Y0Wzls4VuokDfYpYpZZfmZN7JLvXdt27Fr3KvkX9t+3u7/x7+zdZabu/tJviHa3CKn3/ACooneVv93b96vqbVLO21WxubS7gjubWaMxyQypuR17qy1H2b9r/AIAnql3/AFOf+HvxM0T4nL4gl0K8jvrXR9Ul0iW5ifejTxIjShf91n2/8Brtq+Gf2ZPDvhT4U+A/jz490nwZpKa34c8VeI0s5bTTYkuFt4PmS1iZE3LF8v3Frp/h78GfD/xw/Zk0DxnrW2X4ka7oX9qjxvCWXVLC6lVpcQXH+tiiid9vlJ8u0bdtP07J/eK+9+7X3H18MVw/xb8Ta94O+H+ua5oFhp+o3um2c955OoXTwoyxIz/wo392uI/Y1+KGsfGP9mnwL4s18MdavbNku5du3z3ileLzf+B7N/8AwKu4+NH/ACSPxv8A9gW9/wDRD0pvkTZUbSdkZf7P/j7Uvip8F/BfjHV4be31LXNKt9QnhtFZYkaVA3y7mb5a7PxFr9h4V0PUNY1KZLPTbCCW6ubh/wDlnEq7navK/wBi7/k1D4S/9i3Zf+ilqr+21a3t3+yf8U49PVnuToFz8i/3Nvz/APju6qqe42t7OwR945VP2iPHC/CBPjXNpOlR/Dt7ddTbw+kEv9qpprP/AMfv2rzfK3eV+9+z+V/21ruPid8dbfw3a+ArDwstrrniDx1dpBoSGfbbvEI/NlundesUUXz/AC/e+Vf4q4HxFcWi/wDBN+8nRk+xH4a/I38O3+z/AJf6V4j8K9P1PS/jH+xR/bcciJ/wgt/Fb+cv3JfsSts/3vK2U1rKS7WJv7ql3ufU/h34taz4f+LVl8NPHsumXOtaxpz6nomsaTbS2dtqAib/AEi3+zyyytFLF8j/AOtbcr/w7az7D4u+K/ip428ZaT8O20LT9M8HX6abf6prVtLdfb73bultYkili8rYHX963m/M/wDquK89/aSW4vP21v2YIdPZjd2765PP5f8ADB9li3M3+zT/APgnhDLb+B/ipb3ismqxfEPWUvN6/N5u6Ko5vdv5X/4BT6eZ7Z8C/i5Z/GnwKuuW1u2n6hb3M+m6rpckvmPYXsD7JoGb+LDfxf3SteoZr5C/YFW4a++P198z6bdfEvVmtG2/K20oG21Y/wCChmiQ3XwasdaS91G01Gx1zTYYPsuoTxROkt7EkqyRK3lS/KP+WqNtob1j52/EWibXa/4H1r0or49/ab8G6Z4X+NfwJ8R6JDJo2v6t4q/sTUdT0+Vo7u/s5LeVminl+9KnyJ98/J/DV/VvD+mfDv8Abq+H8fhfTrfQYvFXh7Vm1qKyi8lNReBonillVfvypvf52+b56Fq7ev4IE0/uT+8+sz1ptfDDN4Nl8SfF62+Pkum2vjT+3bj/AIRW71KXbdxaa8SfYv7If7yS/wCzb/vfN+9/BXuf7HvhPxJ4Z+AfhaTxlNrc/jHULNLnVf7c1a8v5ll52/8AHxK/lNs27kTau7PFX38v+HFfVI9A8ffEzQ/h1JoEer3ccVzrmqQaRp9vv+eeeV9vy/7q72b2Wu36V8jftveBPDniTXvgdPq3h7S9Vnn8eWGmSzX1hFcNLaMk7PbuXXmJyPu/dqp+1f8AB3wP8PZfhl8V7HwZotnD4E1qzjvkt7CJUj0uRvJ+4q7f3DSpKn9zYdtSndF9bH2JTG+71218XfErwv4e8D/tp+BPidaeGNNTTLqd/Cmr6wtsu8aldRebb3H3fv8A3IvN/wCm+2vYfA3wn8K+KIfHfif+xIdOn8ZXU8U99pQ+wXctpH+6Q/aINkv73Y0u7d/y1py92zErXsz0bwDomv8Ah3w3FY+JfEbeLdWSaV21RrKOzLo0rMieVF8o2JtX/a257111fn18Hfilq/wl/wCCZOqeMdNu55tasp9UWC+uD5rrLLqssXnvv+8y79/zele/a1+zB4Zurjwb4s8K6i3g/wASaNewahe+KLOJZbvW7VV/ewXk7ndOkqfxys+2m1Z2HJcp9D0V8ieKtU1/4vftDfETwW3gvwn490Dwxp2lxLofi7W5bW3V7hGnafyFsrpZW+4m9/u+V8n33ru/2V/ht47+FOk+KtE8X3OknSn1Nr3w9pWmanPf/wBk2Uv/AC6ebLBExRGX5fl9aOlyW7Hvx7V84/tK/Efxz8OfH3wfTQ9asbTw74l8U2uh6lYtp+66kD75WZZ2faq7Itm3yt3zfe9Lv7Wfjq98OaT4D8M2Vzcac3jXxTZeHbi+tHaOaG2kLvL5Tr912WLbu7b68q/ac+E3hX4e+OPgBc+F9Gs/DaXHxFsvtdvpkXlR3jPFL+9lVP8AWy/LjzW+f5utSujCWkWz7TLfLXKfETQte8ReG7ix8MeJT4T1h5Ymj1VbKO88pVdWdfKk+U7l3L7bs18u/Ezwb4X8XeJvjB5mmx/FzxJAhlhk1CBYrXwfts/kt4rptzRSb083/RU83LpuXjfXnnxelu/F3/BN34e+L9U1XVrnxBb2uk77v+07hftHm3UMUvnor7J9yf8APXdT5XJ2XVpfeJS5d/P8D6D8beP/AB14X/a8+GfhFddsG8FeJbHU7h9Nj03ZcI9tAp+ednbfueXd8qxfc/ir6Or5b+MmG/bi/Z4U/Mv9leI//SeKud8B/DHwd+zH+2Zcw6d4f03RdG+I+kO+lXkVrGn2O/tfnurWJv8AlnFLFsl2f3oqfRfP8HYmLu2/JM+x6fXivwB+G3hfSX8SePtI0LTdM1LxpfSajJdWVssTyWudtv8A99ovmt/tzPXtVD0LQUUUUhhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUlFMAxQJux5J8ftB+IPizwpDo/gjT/DdzLPcwT3Fz4h1Ke1SIRXEUqqqRW8vm7tjfxJt4+9XOfGj4C3fx/0X4f3uryReE/Fvh3WYtRNxo95LOsUR+W6t4p/Kidlli/i2J8wWvoD8KSotqmujuU9VY+av2pvhH8SPipo3hfQPAlh4TtNK0TVrDWRca1qt1A7NauWWBYIrV/l+783m/wDAaT9pb4a/Fb42fDnw5o2j6V4P0vVINVtdX1AX+vXMlvE9tOJEiidbLdKG2g7mWPb02t2+lf4aWq16dHcmSvc+Yf2hPhf8VvitqXwwvNF0zwbaN4V1u18R3i3+vXgEtzErq1vFss/9X8/+tb/v1xzs+NPg94ytfjDpfxY8Cvo8fiS40pNF8Q+G9Yu5YrLUrdX3o6XUcTNFLExba/lNuX+Fa+hsCko6/wBeQW97m8kj528K/Bn4haX+05rvxNutb8OxaNrmlWum3ekQ2089wiReay+VLvRV+Z/vsrbuflSvosU2nU9lYPMWiimUDH0UUygB9FJ1paSdwCiiimAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABTVp1FAHBfE4fEBNHtH+Hr+HpNUiu0a5tPEgnWC5t/40SWLc0T/AO1sk/3aZp/hvVvEGs6LrniqDT7e/wBLVpLfS9One6htZ3TY8oneKJpPl3Kv7pfvt6/L3tFTygzwvXvhX4i8J/FvVviP4Ai0m71LXdPi0/WtE1m7ls7e6eJv3F0txFFKySIjOm3ym3Lt+5W/8EfhB/wrBfE2q6hepqnijxRqbanq1/GpjiLbQkUUan/lnFGqoteq0eXTV07sNOgVwK+Db68+MTeKr14G0+z0f7BpkSM3mpLLLvumf+H/AJZWqr/uvXfUUtgOU8aT+MILS0Xwlpui6hcSTBbltb1KW1SCL++ixW8vmt/sZj/365f4d/CBfDPibUfGXiLUj4n8d6pbpaXOqrALeGC3U7ktbWEu3lRBvn++zM3zMxr1OiqAKfTKfQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFJgeYX3gz4iJ8QJdX0r4iW8Phi5jjSTw9qugJc+Qyn5nguIpYmXcP+evm11Hhvw3beG7OWKF5Li4upnubu6n/ANZcytgbmP0VVH91VVe1dJRU7qwdbnz3/wAMx3Nj4Z1vwJoPiv8AsX4X6xLcPc6FDp2+9t0nctcQWt55u2KJ2Z/laJ2Xe+x1+XZ2Xjz4I+GvGnw90nwkts2j2ejTWs+i3FgqpLpc9sR9nli3d02/9816lRVvV3Ftp6/iePaD8G7+9+IGl+NvHWu2vijxBokE9ro62GmfYLSyWXYJZfKaWZ2nZV2F/M27fuoua9bmGd30qaik9dA3afax4n8L/gTP8M9Z8coNfXVfC/ibWLrXW0m409fOimuV/wBIia4D/vYt3zKvlqw7s9Y3gz9mrX/hn4bvfBXhb4hSad8Op/PFvps+l+fqemJKW3RWt6ZdiRru+TzYJWX+9X0JjvTqTv07ISW9+7f3nO+CvBukfD3wnpXhvQ7ZbHSNLtltbW3X+CNawviz4T8Q+OPA2q+H9C1qw0G51KJ7Wa8vtMa+RYJEZH2xrPF8/wA33t3/AAGvQB9KZ/FSknK67ouOjueU/s8/DHXvgz8L9G8G6x4isPEtvottFZ2N1Z6S9g/kIuP3qtcS72/2l2/7tRfCPT/E89r4osPGHim3+IOj3Vy32HUv7IisEeCQNvt9qMyzoi7V83+L5/7teuUCtHq231M1poj55H7LE/8AwhcXw3l8WtN8JI3AXw+2n/6e0Cy+atk175vzW38G3yvN2/8ALWu5+KHwh074hW/h8xzy6NrPhu/i1DRdTtolY2cq/Lt29GjdSyMnHy/3fvV6bRUq6dy3qeTeDvg/c2PxAk8feL9at/E3jIWB0u3nsdPNjZ2drv3slvA0srqztt3s0r52DG2qV58FtV0Hxh4h8QeA/FFv4Uk8TyxS63b3ml/b4pJVXYZ7f97F5U7LtXc/mp8i/uq9mopJWSQHC/C34Z6L8IfA9h4X0KORbK13O0s775riV2LSzSt/E7uzMx9TXCftO/AnxD+0B4RsfDOmeMbLwlZRXkF/cyzaK2oSyywSrLDs/wBIiVVDL82Vbdx92vdadTavbyFbfzv+J82fF39nz4h/FbWfh7qUnxF0DSLjwffRasixeFJZUurxVZGZt1/8sZVvufe6/PVvxl8BfG/iX4+eEviQnxA0awTw3by2cGkjwzLIs0c6ItwJJftoyzbflO35Pl+9zu+htvUUnei36/iJKz+S/A+MfCfwp+LHxEk8QeMfhn+0dP4Z8HeI9Xur+ysp/CVjqr7d3lb/AD5WVtv7r5F/hQJXvnwV0/x7ouk6po/j7xJaeM9T0+7CQ6/aaalh9riZFf8AeQIzKrrnHy/7NNi/Z18D2euT6vpllqnh66luPtc0Hh/W7/S7SeXduZ5bW2nSKVm/i3od1em2NlBptsltbRLDBGMKifw0IGrs8v8Ajv8ABmf4xaX4ZWw13/hH9X8O67a6/p19JafaovPg3fJLFvTcjK7/AHWXrXR+LfAsHjzwDrHhLX2/tKz1azmsbtjGETbIuPkUf3f4c+n3s12tFDVyjw3Xv2ZbDxJ+zX/wqjUNavJJWtYlbxIF/wBKN4jrL9t+99/zV3/er0i68O3+m+B00XwvfW2lXlrZraWF1f2bXUUW1Nqs0SSxbv8Avta6qn03qrAfN/wT/ZRf4e/AbV/hH4x8Q2fjrwxfeeitDpD6dKqTu8kqv/pEob5nyrLt2++Kr/B/9l/xv8M3tdG1L426/wCKPh9pxSPTvDNzpdnG6wofliuL3a0sqfd+VfK+7t+7xX0vxS0A7vc+dfjN+zDfeOPiFa/EPwD491L4Y/ECGz/s+fVrGzivbe9tt+5EuLWX5Zdn8PT/ANBr074b+CdR8F6T5WteI73xjrswU3utX1vFA85ydqrFEqxxqufurXeUykroTVzzj44/BfSPjp4KPh/Vri506a3uotQ07VLFtlxYXkTbop4j/eWvNPiD+zX4x+K+neCP+Ep+KQi1nwprKavban4f8PxWnmypEyKzRTy3C+buYnd9z+Hyu9fSnFM4pK4NNqx8++Ev2b9W8F6t8QYtN8cSDwv42uJdSvbO40yN76C/ljRJZYrnd5Wx9v8AqvI4/hZa4zxR+xv4p8Qfs2eGvg3a/Emy07TNLSBbjU38M+bLcLBMksARftS+V8yfN97d/s87vranYo95NNPqn9wNJ6+v4nzL4m/Z7+I3ir4xeAviFc/Enw/Df+Erae1hs4vCEvlXPnxqlwzlr/cN235dv3f9qug/au+HGmfFnw14T8Nz3s2n63L4hsrnSru0fbcRPE+64ZP+3X7RXvPGa8s+HP7Ofw5+EvijXfEnhPwraaXruvTyXF/fs8ss8rM298NIzbV3fwLtWmr2V+l/xdwSXTsl9x6TZWcVlbR20CLDFGu2NE/hWrZFNp9MEFFFFAwooooAKKKKACiiigAooooAKKKKACiiigAooooAKZT6atAHhP7VyePrP4Xahq/w88ZXfhPxLZtElrEtpZ3FrdyyzRRKs/n28rL9/wDgK9f4qk/ZB+NV38cPgxp+qawgtfF2lyyaR4hsyuxob+Btkvyfw7vvf8Crqvj9/wAkxu/+v/Tv/S23r5917UoP2Vf2yJtWvJE034c/Fe1/0qdzths9btk+9/s+bF/309RHdx7hLozpf20PjF4y8A6X4S0bwDq6aHqmqa/ptlqWreRFcS2Frc3HkoUilRkZnbd97/nk9fQWmQt4T8NxrrPiOfUvscW+fWNY+zxPJ/ty+VFFEv8AwFVr5W/aq02Zvhf4I1vULeSDVNd+Ieg388UnLwL9oVIov+ARbf8AgW7+9XT/ALRPiKSX9pz9n7wdqqE+ENYvdSvbiKZd0NzewW+61SX/AHXbev8Atqv92qhrG/m191hyetj3zwX8RvCnxE0+S+8J+JtI8UWUTbZLnRtQivYlb+6WjZsGqPjrxp4e8L2cFlr3jKw8H3WrM1nY3F3e29vK8rZC+R5+VaTp8u1v92vCf2g9Jl8J/tTfAnxX4bV7bWtc1O60DWEg+X7fYfZ2l/e/3/K2b1/u1c/ZU1aP4la58Z/EWu2sNxr3/CYX/h2ZLhFd7ewtdiW9v7Jy77f4mlZu9HfyQr2XzSLP7EfibxD4i8H/ABBHiLxBqXim80vxtq2lQahqMqvK9vA6JGuF2ovr8iqte1aZ8UPB+veKL3w1p3ivQ77xFZruudItdRilu4f96JW3LXwr4N1y6+Fv7Ff7R9z4deSwk03xvrdrBJErO1tA11FEz/L/AHImY/8AAK9g8Zfs9+LfiN4U8Dai3xJ8F6NovhK6tdd0fVPDfgy4glihjTlIpX1SX908f3ht+YYpv9ESut+7/A+j9W+IHhbw9/aQ1PxHo+mnS4PtV99rv4ovssX/AD1l3N8i/wC01VPEnxS8H+C9Dtda8Q+LdD0HRrxlFtqOqalFbW8+75l2Su21vlr5x+Hfw/8ADNh+3h8XLe10LTre3uvCunTT2lvbIkNxJPNP58ssQ+V2b+Jn+Y72/v11moW+g6X+0vFp/gvQ3v8Axtp3hOPT5LSadbbRNE0trjKHasTMJX2fJFFwyxfN5X36XVeY0020j1rxj8YfCHgP4ezeOdY8RafB4Wig8/8AtRbhXhmXqvlMv+tZv4VX73asn4H/AB28LfHTwNp/iPQNZ0u7mks4rm/sbW+inm05pE3+VOqN+6fr97+6a+c/2Y457P8AZl+PGnztCXsfEXii322sfl26/ez5UW9tib9/ybqz/E/iq+8OfsJ/s/2tvqFppdjrLeGtL1O81C1a4tY7WRE3+eium+JmVEdd67ld6E9JeVvxQlK9vO/4H2D4Y+JXhHxte39l4b8UaL4hutPbyry20zUYrmW2bptlVGJX/gVdcBXzJrnwB8aax8WPAHxC8QfELwxZTeGJ3tRH4e8JXFg+o29xti+yyyvqMvy527fl+Vq+m6drJD6sWiiigYUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQByHxAbxTJob23hKSys9UuD5S6hfxedBYr/z1aLcnm4/ub1rw/4O6l8avAfx0l+H/wAQfFVl8TNAv9Ek1m28SQaRFpdxZSJKkXkSxRfJtff8p+98jelfSN4jz28kUc0lu7KyrJHt3J/tfNXyFovhf4lfAj9rbwvYSeOtW+IXgv4hre/bI9dji+16dPawb0lR4kRfL+6u1ERfn+781AHoV58SPEHxW+PHiv4ceF/EM3hXSfCNhaXGsazpttbz3zXlzuaK3i8+KWJVWNdz7omb5/4a2/gH8XL3xl4g8e+CPEPlt4s8Eaitpd3MKbUvLWVPNtbjb/Azp95f7yNXmv7MNjNof7WX7Tmm6gWW8utS0vUoA/8Ay1tpIH2sv+yD8v4Vg/Cldeh/ar/av8X+G9IfxFJb2+l6fZ6et0tqt/exWW77P5r/ACr/AALv/h30dUiU7pvsfadfL37YH7QHij4V2PhzT/Be2K8uNf0y11fU5IlZbO3uLjaIlV0ZWll2t/uL838SVc8O/Hz4zNb63d+NP2er7wlpdhp0tzFc6b4lt9cuLmcbdlultaxead24/MvTZXhv7V3xE0Nvgz4Usja+LZtck8Z6RqWp3t54J1mxS6l+0fPsae1X/cii379qIi1LV5WGtVc+qvjd8ULzwn4g8BeDtEnhtvEfjTU5bO2uriPzEtYIImuLiXZ/E2xNij+861zF5428T/A/4peCPDXiPxJc+NfDPjSeXT7PUtUt7a3vrHUUi81Ef7NFFE8Uqq//ACz3KwHLZp/xi+Gdx8ddL8CeNvBt5JoPizwrqJ1XRH8QabdWqS7v3U1vdQSIs8SSrn+EN0auB8aN4r+Mf7Rnwp8Lapp+jWU/gmeXxX4hi0i7n1COyby2isk+0PDB80u538ryv+WXXFV1sDdo3Pr+n1Gv3af60dQTuri0UUUDCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiikwPBfi38EfFHxo1G5juPiZ4u8A6HaOqWEPgm9isp522/PPcT7WdvmOwRLt+5/t/Lj/sf+KPHF9p/j/wv461o+KLvwf4jl0az8RPCIpb+DYkqmVV+Xcu/b/nn1/xl4iuLPbo+iGGbxFexk2scu7yoF/57y7f+Wa/+PfdqD4f+E9I+HelxeG9PufPulMt9cyTPunuZZZWaWeX/AH5Wf/K0LVNC2aPjHxR8RfCfxs+Nk+j+M/ih8Z/gXrcl4+m6Ho9vPL4e0/UIo2wkqs8TebLLv3fPs+8i7f73u/7Q3j7Vvhfofw3+H/hXU7qLxD4v1i18O22s3cv2q7tbVV3XF1ul3ebL5S4+f+J91db+1F8O/DvxW+BPizStehjuLJtOluLafaGeGdU3RSx/7W7bXgvxw8M+IPD2ofsneLvE7NNceHdWg0vX7gfciuLyCKLzW/2fNTb/AMDpJ6JeaX39Ql8Xyb+7p8zvvGXiC5/Zp+LfwzsYdX1fVfBvjjUZNCvrfXdVnv5be/ZN9vcRS3DMyq210aLdt+7sSvozUNQjsbGe4dZmjjjZ2W3ieV/+Aqo3N/wGvln9rzRZ/Hnxe/Z28KaeWa+j8Wf8JDMBu/dWlnHvldv++0Qf7TivrZv9XT3i35tfcSnrbyT+88C/Z6/acsPjtqXiu2j0XxBpUmn6zdafaxahol5CixW6xK/mztF5SS+b5v7pn81f7tdPrn7R3w78PXUsOo69JDaQztaT6r/Z902mQS7trRS36xfZon3/AC7XlWvE/wBnt9ZT4M/tHt4a/wCRhTxn4o/s7b/z8f8ALL/x7bXTfswnw543/YT8NW900N1o03hmWy1VJjv/AHqo6Xfm/wC1v83dQn7rfa34ldbH0xDMlzGssTK8TfMrJ/FXjfxs+Aup/GrWNN3fEvxl4B0bT4n2Q+B9V/s64upXIy08uxtyqq/Kv+01Y37BcOtw/si/DOPxEJBqK6Z8vnfe8jzX+z/+QvKr3TUtSt9J0+5vrqVYrW3jeWSVv4VX738qclaVgjK6ufL/AMA/g/e/Dz9orxVbW/xQ+I/jjQtC0e3tp4fGPiN7+H7fct5vypsVdyRJF/4EV5x8afil4U+IHxsuvDnjr4h/GD4FWtldf2Xo15pLy6FpWrHq8zXLRPv+cMqs+xNirt+81fT/AOzro1xD4CfxLfRNHq3i+8l8RXSypteLz/8Aj3ib/rlbrBF/wCt34reC/DXxK+HWu6F4rtre78N3lpKt41wfliXb9/d/Ay/e3/w7amW6YdGjyb48eOr79m/4D+HdI8Oaxeav4l1W+sPC+i6t4huftlxLdTttFxK7f61lXfJ/d+Wsr4rapqP7LOo+A/Elr4i8Qa7oGr69b6H4kg1zVZb1G+0/Kl7F5r/uGSXb+6i2RbHf5Pu15L8ZfAniXQ/2R/2dtY8QvNJceA/EWh6prTSq3mxWaN5W9v8AdV4t/wDwKvUf2/tKm8beDfhn4J01Wm1XxF4105IFi/gii3yzS/7qItaaOSYbRPqt5FjjLM+1V+81eX6F+0r8NvF+na9eeHPE8PiaDRTtvToFtPqDocbvkSBGaX/tlur1L7qmvl/9l+KNf2iP2mGULx4ksM7f+vBKxu+Zryv91hX0Xmz0mP8AaY+Hd14Dj8a2GuTax4ZkiaVrzRtNur94FGd7SwwRPJEF2tu81V27ea7CT4keF7fwWvjCXXrGPwu1st0usGdfs7xN9199fNv7Hdui/Ar4tKsaov8AwmHiUfKv/TVq8/8ABnhqTxh/wTp+DpttUt7bVNPu9Lv9Mtbx9kOo3UV4fJs35/5av8u7+H7/APDVJ3b9E/vFzO9rdWj6hj/ag+GIujaan4vtvCt8Svl2fi2KXQbif/biivkhaVf9pNy16fdXQtYXmbeyou75FZ2/75Wvn3UPBHi74sfH/wCHXje98LXPgbTvBEWorOdUvrWWfVJbqJIlji+yyy/uBt37pWRs7f3VfRzfcqnorldT5y+EP7XGmfE7XfH9s+geKrCDw/qstlCknhjUWdooreKR3fbb/u5WZ2227fvfufL81dd4d/ae+H3i34f6t450jUNYvvDGkyvBd3kXh3UtyMv39sX2fzGVP4mVflx81cb+yL/yOX7Qq/8AVQ7r/wBJbWuZ8N6lP8IPjZ8W/hvbFYX8ZSweJPDKNFuTzbr9xe/73lSp57f7LUuyXUdtWezWn7RXgXUPhOnxItr/AFKfwXIvmJqEWiX7O0e7b5og8jzfL/29m2sLxn46+D/iT4gfDvTfEerW/wDwmguU1Tw1pNy09vepLJFKiyta/Ky/L5o/er6968h+AFnJ4R1LUP2dJ7h5z4S8Sf2jb+a3zy6D/wAflq/+1/pGyB67H9q1F/4Xd+zVLt+ZfF0/zf8AblLRJ2egLU9s8XePtD8DQwyatcTebPuEFjp1pPe3c+3l/Kt4EeWXb/sp8tM8B/Ezw18UNDbVvDeqx6naRTtbzDY8MsEyH54pYpEV4pF/uOqtXhOneOrXQf2/vEGgeIrtbKXWPCFinhj7QNiyqk0zXcUTf3t21tv/AEy/2av/ALQnhXSvBPwM+Pk/gDSjY+KdT0241TVH0wOHknaHbv6/LL5alvl/3v4qL6AtT0mP9ofwFJ4m0vQ21ySK81R/J025uNPuotPv5f7treNF5E7f7MUrV6nXxyvwl8L/ALQ3wA0fVbz43eM9d8CRx2uoRRWq6JB9nlg2MiB4tOVkkRvl2bv9mvr+H/j3X733f4vvU+lxdbHE+N/if4c8ETQWGp3tzJqF2m+PTtLsbq/vWiztaXybVHlWMH/lrtCr6184fsjeI/DPgbWP2hNSbxD/AMUdpviSN49W1bVZbpYrf7JE3zXE7s7fe/iaut/Z712XUv2kv2hrTWzs8Q2up2CWsc3310v7L/o+zP8Ayz3+a3y/xu9eILrXhDwraftOrr/hmLxPpt58QdOt7bRUufs6XV/Ktv5W+Vf9Uvn/ADM/+/8Aepx1dv63Q3omfYHg74+eCvHHiY+HtOv7601zyPtUen63pN5pc9xB082JLqKLzU/2k3VyfgG4+D3xX1T4nL4J1mDXNQ1cwReKL3Q9TuU3PseKIJcRP+7barD90wryzxhp/ia1/bc+A1x4i1u1vby60vxBi102z8i1tVWKI7U37pGJ+Xczv/D8qRV0n7OaKv7U37UW1dn/ABM9G/8ASCqtdLzv+dieZxdvT8Thf2TPjr4S+B37FvhjX/H2tX9hp8+q6pE2qNY3moDzf7QuP9bJFFLt3Y+8/wB7NfTniX44eFvBngGz8Y6zNq1poNyIykv9h30lwvmfdMtusHmxdf40Wvnr9inwLp3xQ/YVi8Kawhl03WJtZs51B5Ktf3Hzf73+FX/2evHGo/Ezw94Z+GfiR2m8VeBtUltfFBxt83+znX7JL/28O9rL/teVLU2d2mXJx+z3sfU+l6gmqWNvdQrKkc8SSBbiFon2t/eRxuVv9lq1qZ/DT6QhlPoooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigApq06mUAeZ/GD4Ry/GDRbfSJPGfiTwrYxzLNKvh9rNWuXSVJYt7z28rDY0YI27c/xbhTvEnwb0fxz4W0DRvF0114tfR9Rt9Whv8AUUgS4luYH3o7eVFFGP7vyIvy16VS/wAVZ+ncHqrHiPx4/ZvtP2gF02HV/G/ivQdO026gv4NP0KSzii+1ROzpOzy2ssm75/ub9nyr8ua2PFnwM0X4h+DtL0DxhqGq+IbzS7pL2x8QyvFa6lb3Kt8s8UlrHEqOP9lP96vV9optWuoPe55r4Z+ENrouvWuva1rus+NfEdjDJb2mra48CvbRSY3rHFaxQxLu2LlvL34H3jWRN+z/AKTa/E2/8b+Htc1zwhqurbP7at9Gkg+yavs+608UsUuH2/L5sXlvj+KvY/Wm0d/QVjxX4Z/sueCvhfpvi7T7AarqemeKbm6uNT0/WdSlu7Wbz3ZpR5D/ALr+LZu272VV3O1c98L/ANizwd8J/EAutH8R+OJ/D8D+ZZ+EtQ8Qyy6JZt/sW38X9796Xr6M4pKHfYEu54dpH7M8Wi/GvU/ihD8QPF02t6miW95Yy/2d9imtUffFblfse5VXpuVxJ/t1tax8CdO1L4sp8Q9P13WvD+vyWKabqKaZNF9n1K3ViyJOssT42Fn2vF5b/Mfmr1encCn2C1ndHj3w5/Z38M/DDS/F+j6bdatfaV4ovrrUL2y1O781I2uR/pARtu8hsdZWdv8AaqLSf2afCdj8H3+GGrzal4s8ItZ/2fFZa5Ir+TbL/qolMKxY2cbX/wBb8q/P8vHs1LSezXcErKx4V8Hf2VdC+Deom8tfFnjXxOsHy6dYeJtdlvLTS0/uW8Hyovy/Lubc3+1XutFFMYUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAcF8TfhvN8RrGwgt/F3ijwfdWdyLmK+8M3qwSN/syrIjxSp/sujU/wz8P7bQ9Qi1bUdS1HxNr8dt9l/tjWPK8/y/vMqpFFFFFu+Xd5Ua7tibs7a7qigDzLxl8HLLxX4htfEVjrWqeEvFMFqbD+3tDMH2h7bfvMLJPFLE67um+M7fn27d1bfw/+Hei/DHR5tK0SKVIri6lvrme5kaWe6uZW3SyyyN9529a7KmUthWENedfGT4K6R8bPD+maLrV3fWdpYara6vG+nyKrvNA+5FbcrfLXo1Jt+Si75kU9rHK+N/CN94qtLSG18Va34Xjhl3zf2ILXfdJ/zydpYJWVf+uWxv8AaqLwN8OdD+G+lyWOg2TW0U0puLieaV57m6lb70s80hZ5ZOPvOxrsKdSTu7k9LDadRS1QJWCiiigYUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUyn0UmB89fFL9hn4L/GjxZc+KPGnhGbxDrdwiq91NrWorhV+6qqtwFRf9lV710/wd/Zl+GvwC0fWdL8DeF4dF0/WGX+0IWuZ7rz/AJdoDNO7nbhm+X/ap/xo/ae+GP7PaWZ8f+LrTQJbv/UWvly3E8i928qJXfbn+LbXY+CfHvh74keHbfXfCur2evaPcHEV5ZyeYjc/NREmWiuc38P/AIC+CPhfGtr4e0y7tbGKTzrfT7vVby8tLZlz80EE8rxQffP+qVa7TxD4a0vxbo11pGs2UOo6ZeRmKe1uF3JKvvXkPxe/bO+DvwH8UL4d8deMk0XWjAtz9kXT7q6dY2zt3eRE+3PvXpLeO9Bs/BSeKr3U49M8O/ZVvGvtSLWqJCV3b383ayf8Co+JJjejt5GZ4H+EPhfwDdz3mlWVxLqVxGIJNQ1TULrUrsxDBWLz7l5JVjzz5e7aPSu+9K4Pwn8XPDHju8ubLSby6jvoFEj2Wpafc6fcNGeBKkVxEjPFk/61AU/2q7vsKbVlcE9UvI4Twv8ACLwp4N8T694g0nSjp+oa3dfbb/bdStbvdbNj3C2+7yopXX70qKrN/ETWLJ+zj8PG1rUtRj0BoBqkrzalpkF/cx6bfyN957iwWUW07NnlpY26CvUEmWVnVGV9jbWH92p6V9mhrcrwwx20SxRIqRJ8qqv8NZfivw7p3jDw7qOiarCbrTdQge1uYPNaPzI2G1l3L83f9a3K5X4heO9A+F3hDU/E/ibUo9J0PTYjLc3sqO4jX/dQFm5x8qii/cErKx0kMCW0CxRLsiVdqpXmvgz9nfwF8Pri7bw/os9hbXVx9qfTDqd1LpyS79/mxWbytBE275vkRazfgt+1V8L/ANoe+1K2+H3iOTxDJpqpJef8Sy8t0j3fc+eWJF/hrZ8UfHjwN4N1qbS9U1pkubdQ17Jb2dxdW+np/fvJokaO1X/andKfUDt9U0uz1zTbixv7aO7sbmJopredN6SI33lZa43wj8FPCXgXWP7V0rTZm1FInt7e61HUbm/ezibG6KDz5X8iL5V/dRbV+WuuvNa0/T9Jm1W5vYbfTIY/tEl5LKqxLFjdv3/3a5Lwf8a/CfjrVP7O0nUZxeyRNcW8N9Y3NmbyJcbpbXz40+0xfOv72LevzLR1E/hO7kj8yEr83zf3W21494R/ZX+HXgnVtf1XRLLxBYanr8bRapejxZqzy3fbeztdbvNX+GX76Z+VhXtA6UtF7AlojxDwl+yj8N/A/hvXvDmhWGtaXo+uyebf2tt4q1Yea27LPu+1bkZ+d7Jt3j5W3CvNPi18Dfhl8LfhX4f+Hc3g7U3+E+qawp1dnvL+/h0aJUaVZU3SSvbI0u1GdNqrvdzt+9X11SdKh73GrK58VeB/2Sf2Zb64i1/4MPanxVp0ytYa34V8U3WofYJf+mv+kPHt2/eSX765XvX2sf8AViiiqcrqwutzhdG+EXhfw7401fxTpmmtZazrEqXF80NzN9nnlRdvnG33+V5m35fM27q1r/wRoereMNJ8UXenRTa9pME9rZXj/fgjn2eao/3vLWugSaJ3eNWVmT7y/wB2pKGtvIZzcXg3Rbbxnd+K4tOiTxBdWcWnz6go+eSCJ3dI/puleuM+Jn7N/gL4teJdL8QeKLDVL7V9JbzNOntNf1GyWzcZ+eJILhFST/bVd1er1ynivxo/hbVfDOnnQ9a1f+2r/wCxG50mzM0Nh8jv5t02791F8m3fz8zLSaA5v4vfs9/D749aRZaR498L23iO1tW3W0k8ksVxB/uTxssi/dXPzfN3rofAfwz8L/CvwxbeHvCmh2WhaRBytrZQ7V/3m/vNx95q66im9gWh4j4b/Y3+DPg34kHx5ovw+0vT/FO/zlu4zJ5cT/34oN/lRNx95EWvbW6UtFPpYVtbnnXi74HeD/G3inTfE+paZJB4j09DFb6xpV/c6fdrH/zyeW2lid4/+mbll9q5jUP2Rfg7qba9Ld/D7R5rvXvkv7p428+QfKfllzuj/wBWjfIV5WvaJpfKjZju+X+6u6vMvg/8dvD/AMabrxPBoFrq9s/h2+Wwvk1jT5bCZZdu7HlS/vP++1WhaA1zENx+zt4Cuda8O6vc6RcXuseH4pIdO1K71K6lulikTa8UsrS7502/wys9Yug/snfDjwvqmv6rpNl4gs9T8QR+Xql6vizVhNef7Tv9q3bv9vO5a9vX7xrg3+J0drdeMo7vw74mgg8NCNnu/wCyJZk1LfFv/wBCWLc8+z7rbV+9UxloO2q+X4HnFvafBv8AYW8DmaN9Q8HeFL6+S2igNxqeqw/aG3NiKLdP5W/5s7VXcRzn5a6b4K6DYX2q+LPiCmgzaNe+LbmBgby2e3uprS3iEcDyxsNys371trfNtdd1b3wX+MOhfHb4f2Xi/wANx3aaTeTTwwm+g8mVvKlaJ22/7yV6BVpy6k8qTfqLT6ZT6RQUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAlMBzUlMoE1c+av28PEviXwX8CW1fQItSmsINVs38QnSJXivRpPm5u/KdPmQ7fl3fwqzVkeAfDPwX+N/gWx8QfBa6s9AkttRs9QnPhNv7OuJ2ilR5Le/iXZ5u9Nyt5+77+76+3fFj4p6J8JdN0bUfEVzBY6NqGpxaXPeXL7IofNR9jM3+8ir/wKvkP9rr9mjwz8NbS3+MXwaum8C/E1bqBNOsvD52W/iB5ZU/0f7OnD7/vfJ8rY+b+8COjt3G9bH2N4w+IFl4VntbJLW+1nW74Smx0TTY1N1deUuZMGVkjVeVG+V1TLL83zLXGaH+0Vp3ifSvFpsfC/iSbxZ4UkVdU8FLFapq0W75kdVa48iVXT5lZJW3bTt+b5a8M/aJ1jR/Bv7TvgHX/AIoXmseHPBGs+GJdFj1rStdv9Lhs9U+0LK0c8trLE2xk/vtt+T/Yr1n4HeFPhCvjzW/FHwz1L/hLNVvLNLXV/EUXiu815CFZfKt3llnmXdjcf7yqPR6S25gb2R0Hwf8A2hbP43fCib4gaD4T8Q2ul/vzZ2eo/Y4rq/8AKLIwiX7Qyr86uv71o+V/u/NVrR/jpZ614K8P683hrxBp99rytJpXhy5S3OpXS7d+7bHO8Ualf4pZUVNy7yleIaDHd/DX4zePfgdBFOmleNrpfEvh+VVbZb2s7/8AE4i3/wAGxldk/wBq4Wof2sbzQ/Av7QXwt8Q+N5Na0b4cy6Zf6C2s6Jq15piadeyvbvEZ5bWWJ1iZYtv3tv8A3xRfYOp7X4X/AGjNA15/FNjcaN4i0PxL4YiWfU/DF9p/n6mkTfcliitWlWdX5+aJnrP+Hf7T2hfFbRvDmteFfDninVNF1vU59L/tCHT1KWEsTuu+6Xzd8UTeV97b/Gm7ZurG+Dfhn4LTfELUvF/w61lvFuvNprWWo+JI/Fl5ryQW+9HW3eWW4mVW/iVf9hqw/wDgm7Kkv7J+gpG6uU1HVFbb/wBf9xVdH5Dto32PRPGn7RWk+EdO1PVYfDfiTxD4c0aSWLVte0W3gltbDyj+9Lq8qyyqnzb/ACIpdux/7teleHPE2m+MNB0/W9Iu4dR0nUYUurO7gbek0TLuV1r4E/Z71D4Pw+Ddb8BfGHxnqngrxromoX9jrWkax4/1PSLS8WSeVvNii+1RRNFKkv8ACvOf9qvtn4O+GdB8H/DTQdG8MabJpPhyziaLT7SWSWVlgDNsO6U7/mX5vm/v1EddRS0djvaKYRT6oAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAKlzdRWUDzTyLDFGu5ndtqrXC/wDC0G8RQj/hBtHl8Vb0ympPL9l0o/3W+1FW81f9qBZal+Ivwu0/4jf2fLd3d1b3umz/AGi3IRJ7ct6S28qvFJ93723ev8DLUTeLPE/hK3I8TaI2rWsQ+bVvDMEs2f8Aaaz+aVf92Iz0Adjo5v106Aam1u98F/etaqyxbv8AZ3V5N8Zvgrr3ximaBviX4q8BaNbrmCPwbeLZXEkh+8887IzFegESbenJO75fXNL1W01ywhvrGdbm0nXfHKjfK1cZ8WvhLoPxm8Kz+HPEb6mumTgh10zU7iyZtylfm8p18xfm+4+5f9modrpscVfRnnXwR8YeLfAv7O2r+Ififqj61L4cbU5U1dovKl1HTrZ5PKuHT1liTf8Aitef+H28b+Nf2Y2+NreJdWtfiHd6TL4i07TodQl/smCD5pYbJrPd5EitFtVpWXzfm++tZPwv+FfjCb9m34/fCiXW7zxRp9jdajoXhnUtQbdPLF9kTbFuz83lSt5X++r/AO7XSfD7xtp+k/8ABNmy1mTd5el+BZbKeJ/ldbiC3eB4v97zU2VUk1GTvroZ7pP1Pffgz8Sbb4wfCvwp40soRb2+uafFe+Vv3eUzL86f8BbK13orxP8AY88D6h8Of2Zvhv4f1VHi1K10eJrmGT70TyZl2f8AAN+38K9spy3sEdri0UUUFhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUmBy9r4R0vTdU1vVhAr6hquw3dxMN7MiLtWL/rmvPy/wC0/wDerxT9jv4c2/g3TfiPrelWy6b4d8VeKbrVdHskXZEtrtSJJUT+FJWR5V/2HSsj4+ftHy6H4xk8GTfCT4p+L/DUcedUvvC3hWa6t7tz/wAuqSu0StHg/My7t33P71eg/Bv43Xfxas9Xuo/hp428EadpcaJFb+LtLXTbq6Yg/LBFv+6qr97d/GBTj3JlroeJ+MLz48/soNr3je81TRPiv8OZNQn1bXLG30o6bqunwSFdzwbXdZViX/nqzNtT/vjQ/am8YW3jrx1+zN4Zsbj7T4b8W+JE1qUp/qrqC1iW4hR/9lmdG2/7FesR/Eqb4zeAtY0ew8H+J9F1i9tJbC6sfFGiT2UdoZFZGZpXTyp1Xn/UPJu49a5L43fAG4tfCfwk1HwVZtfat8MNStbmysXdfOvbBE8q4gVv+erRfMv+0lKF0rMuWr5vKxh/tja1J4G+Lf7OniewDJqMvi8aBK8X/LSzvItssbf3lyiN/wAAr6gvo7xrG4FlLDb3bI3lSzReait/CzIGXd/30tfOnivw/cftKfGL4Yajb6Nqum+CPBN7Lrt3ca9pc9hLdaiF2WsMUU6JK2z55Wk27PubXavp3+GiburE21T8j5E/ZB8QeOPsvxX17xt400nVNE0rxbq1vqM0miywXDPapEhlSX7UyRRKsX+q8pvu/frqYfi38T/FXwrT4reEtM8Oz+HJrJ9Vs/Cl9bz/ANpX9mNzI/2xZfLgleLa/lfZ5f7u/wDu858Efh/qF1oHx6+GviLRta0uTxB4n1meO8ezlW1lsL5f3VxFcf6pu/yI29f4lqb4E+KvFfwv+Ctj8LvFHgjxFceOPD1g+lWP9m6bLcabq0UW9beWK/2+RFuRV+WeSJl/u9KUdIg3Z3Pefg/8TNJ+M3w38P8AjXQ/MOl61bLdRLN9+L+8jf7StuX/AIDXFftAfDn4j+Pl8OXPw+8b6f4QvtEvDfmDUtF+3xX8oUoqO5f90gDPyqs3I5XbWl+y78IpfgP8B/B/ge5nW5u9Ls/9KlQ/IZ5HaWXb/s73atHxp8XF8A+LtM0i98I+Lr7TtQj3Lrei6NLqVpBLu/1cq2++WP8A3jFt/wBqqklewJ3PPfgB8ffFHiq78Y+C/iVoFvoHxI8HRxzXi6YzvY6jbOrmK6td3zbW2ONp/wAVXl/+Ce8n/CffsyyeKdXjW81HxrrGqajqpmO4TM9xLFtb/Z2Iq17H4d8AjUviZrvj+/sWt7i+0q30O2guE/etbRTSys0o/wBp5fuf3U/2tq+N/BnT9Y/ZU8B698Nx4V17XGtdRvrjwk2j6bLc297azu8sUUtwn7q1ZHd1f7Q0S/xLQvha69AW9z5ms/iLquqfsc/DLwBdXNxc6ff/ABRi8EzyzO++XS47p3SLf/d2KkX+6lfTv7fmqSeBvBfw18YaYWt9V8PeM9Oa2e3HzeVLvimi/wB142K1z0n7Gus6H+yV4S8L2Ulrf/Enw1rUHjFJHfZFdaos/myxb/7rK7xbv92uo+LGi3/7UmqfDzw5Z+Hde0Xw5oniCDXPEU+u6VLYJ/oynZZxrKq+fvkZPni3xbUPz1St7vfW43qfUjFvK+X722vnP4R/GP4m/FTxH8VvC9zpvhfwprXhG/t9PguUefVLfdLD5u5l/wBHeX7y/wDPL/gVfRMj+TCzfN8q/wAK18gfs5+NH0v4zfH7WdT8KeNtK0vWdRt9U0y5u/CGqRrd28FqkT7F+z7t+5f9V95/4UrGTfM/S4ttDqvhf8cPib8YvglrXiDTrTwz4b8VeH7+/wBNvPtkE97Y3lxZu6N5SrLE8SPt+8zPt/utVxv2sUb9mfwT8TY9FX+1fF8tjYWOkvcYiS8uZfKw8pX/AFaNubdt+6nvXnH7L/ii58M/BL4pQ6z4P8baPey+ItW1KCxuPCOom4ube7mb7O0SeR+9PzfMq/c/i2rXLeErq50v/gnn4a8OeIPhn4s1S+0qey03VdFl0e6s9Stw11/x8WSy+UZZ0yvleU3+t2Va1TT7J/eTrzI9o8T/ABk+KXwx+K/gfwJrOmeEvGFz4z+1/wBn6na3F1oMVu0EQllieI/bXkbZ91ht99tfR915skDiF1SZl+R2XcqtXxD4D+N3h9/iZoWu+MvAXx7S8tTJZ6d4k+IfhSGDT9ESfYrjdaou0PsRPOlR25+Z9u6vudqbslGw/tM+Qf2X5vitrvi341NqPjnQ9SbT/Fl1Yhrnw5PzKtlb+U0W29/d265QeV87Ntb9781dN8J/ix8U/Hnw7+JC6rqXg/S/iD4S1y60vyxpF1/Z8SxbWV5U+273WWJw6tvTbu+6+3mf9nKx1bwT8UfjRo+raFqtu2s+LpNasLz7G/2KeyltYVR0n/1fDRMuzdu/2ah134Y+IrH9p3VJtKsJJ/BPxC0qA+Ibgp+6tZ7F1X5v9q4gl8r/AIA39yiTtYoi+Fnx58b/ABS/ZT0jx1ZXnh228e6pcrZJbyaRdfYYrr7V5H2d4vtXm/8AA/N/2tn8Fa3xJ+MXj74afFL4TeFbnSPD+oaN4svf7MvNZilniuBMkLSy+Va8+WvyfL+9lrN+H/wo8ReD/wBpPxfp62DQ/Da4vF8aafcL9xdUnie1uLf/ANDn/wB51rD/AGstfuYfjR8EHtPDHivWrTw7r7apql3ovhq/v4LaBreWJX82KJlZtz/cXc1D0sB674m+I+s6x8Rrz4feDZNOstfs9Ni1S+1PWLZ7q3s45XdIl+zxyxNKz+VL/wAtV27O9YHhP42eI/D3gL4g6x8VfD0mgP4JnuBPqdrC6WWrWsUXmrdWqszN84/g3Ntb5d9eb/Fz/hOfgP8AtJS/FbQvBetfEPwR4l0W30vXdN8O2wn1Swngd/Imig4aRdsrLt/392K9D8aaL4g/ac+AfjPRZtC1LwGPEOlPZ6baeIUiS6jk2nEs6RPL5a79ny7t/wAnbNOS90Dyzxl+3ZYeA4tA8TT+O/hl4n8P391BBqPhfw/qizaxpiS/L5qSrcOtzs/iTyIv96vsxHSaHcv3Wr5Z+D37QXxK1q2sfAPib4M+LtE8dWtuLW68QC1i/wCEc3Ku37QLppfmX+LykVm/hr6mQNs+b5qnaIHj178SvEPjf4h+IfCPgOXSbBvDJt01fWdatJbyL7TKvmraxQRyxZbyirtL5vyb0+R/m2+B/Bfx94q8G3P7TviCx8HTeI/FcHjKCCLQdPkd/Nla3t4t+/Zu8r/lr937ldr4Nt9a/Z//AGhPiS+q+Hdc1bwX49v4NX0/WtD02fUfsd0IvKlt7qKBXliT5EZZduz/AGq8f1qH4vaOvx/Hh3wD4z0sa54otdUTU9OjiS4l05Ft47tbX975v2hot2zykb+L591C6P8AroB75pvxu8WeEf2jPDfws8W6n4W8RXPiPTLq9guPD1nLYT6c8C79lxFLcT7ldT8r/J9xvlrR+Bfxo8Y/Eb4lfFbwp4r0XR9EufBt1ZWsa6PeS3Sy+fE8u7zZETPyeX/yyX+KvMtW8OwWP7R3wH8R+D/h/r9n4NsLHXFuLiLQZbdknnt02efE6pLEzsjfvZ0Xcz/epPgT42k0X4+ftCeJdT8H+ObDRdcn0690u6n8H6on2uOC08qXyk+z7t27+H7zVSilb5/mKLuzivgL4u+JPw9/4J82Xir4aW+h6hqmjXWsXtzpmt2M9x9qgXULjf5Rili2Mq7m/i3/AOzX0br3xC8W6j8D/CHiHwZrPhvUvEuvmwFtc3GlTtp959oK/dhS68yIKrmX/WvtWJ64P/gnqt/Y/s62XhfXfDWv+HNZsby8a5svEGiXVhuWe7nlXa0qKsuVb+Ddt/ip37M3w/8AEXgv4heJfAWoQP8A8IR8P9TnuvDNx/z1ivl82KL/ALd0e4i/7arQ/iZUvePpnTI72Gxtl1CaO6vFRTNLbxNEjv8AxMqF22r/ALO5q16bT6VyUrBRRRQMKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAplPpqrigCrNbRXO1Z445tv99N1cloXwf8DeEvEFzr+ieDPD2j67dbvO1PT9Kggu5d33t0qJuau1Y4paXW4GN4i8N6T4x0W50rXNLstb0u6TbNY6jbJcW8q/7SPlWpvhfwro3g3RrfSPD+kWGhaVbj91ZabapbwR/7qINorbooW1hdTGOi2E2sW+ptY2/9pQxPBHeNGvmpGxTeqt97a2xP++VqTXNB03xPpN3putada6vp90myayvrdZYpV/usjZVq1ax9J8SaVr091Bp2pWd9LZv5VylrOsjwv/cfb92i2gzFsfhT4N0/wdJ4RtfCmh2nhadGWTQ4dNiSylVvvBoNu2m+B/hJ4G+GMt1J4Q8HeH/Csl4ipcvoulwWfnbfu7/KRd33jXaUUwOQ134Z+EfFGu2Oua14S0TVtZ0//j01G+06Ke4tf+uUrruT/gNdgtJT6A63EbpS0UygB9FMooAfRTKfQAUUyn0AFFNWmjtQIkorBh8SaVcatcaVFqlpLqsCeZPYrOjSxr/eZM7ttbn8NHS4+tgbrSt0rI1vWtP8O2Mt9ql9b6bZxfNJc3cqxRp/wJqqar4u0XRbKwu77WbGxtb6eK3tJ7m6SJZ5Zf8AVIjMfmdv4V/ipJ3B6HR0Uw80+hO4BRRRTAKKKZjigB9FMxxT6VwCiimUXAfRTKKYD6K5208UaRf63eaHb6pZXWr2KRyXenwzo1xAkn3Gli+8itz1rfoAfRTKKAH0Uyn0AFFFFABRRRQAUUUUANNeW6p+z34J1Lx5c+NDY6pYeJL1IlvLrStcvtPS68r7nnxQTpHLj/bVq9T2ig470rCexl6Po9joGmQWGm2kNjZQLtiggj2In/Aa4a4+AfgW+8QtrFxofmTNci8eye7n/s97ndv+0tZb/szT7vm83yt+f4q9Ooo63GtCL1qRaKWmJKysFFFFAwooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKZT6atJgLTa57xf400LwRocmq+Itc07w9pUbKsmoardx2tupb7v7yTC1U8GfE7wf8SrWe58I+KdF8UwW7bJpNF1GK8WJyM7WaJm21KuDOsorldQ+JPhXS/FFl4XvfEuk2fiW8XdbaPcahEl3P/uRFtzV0M0scEbSysqRIu5mb+Gi7sBZorlfCXj/wx8QILqbwv4k0nxHb2snkXE+k30V0kUn9xzGx2tXVU9d2AUmelLRTXcBM9aWiqeoahbaTayXV5cx21un3pZZNqrSSstWBcorL0XXNP8RaXa6npd/b6np91GJYLq0mWWKVf7yMv3q0tvSk9FcBdtLXL/8ACxPCTeMD4T/4SjSP+Ep8rz/7C/tCL7d5f9/yN2/b77a2r+/ttLs5rq8mjtoIk3yTTNsVF/2mqtmHoXqTiuc8J+NvDvj7SRqnhjXtN8RaYWKLfaXeR3UDMv8AtxsVqPxT8RPCvgVrEeJPE2keH3v5fIs11bUIrX7TL/ci8xhvb2Wm0JO50/FeY/FvwH4m8UXHhfV/C2t2tjqnh/UGv1sNTjdrLUd0TxeVLs+ZD8/yyjds/uNXp6kMu5aKS0Gef6Pa+M/Fml3Fn4z0Xw/ocEp2yQaRqs+qi4j/ALpaW1t/L/75avQKKKGKwUYxRTvalcY2induabTWoBRRRTAKKKRelLyAWms3zYp1I1KS0Fu7CbvmAp3FcB8RPjV4J+E9xpNr4s8S2Oh3mrz+Rp9pct++un3Kv7qNcs/zOn/fVd/Ss0rth1seefF5fiT/AGBbj4Wt4WXX1uVM7eLVumtfs/O7b5HzeZ92rvw38JXvhXQ5zqmpf2vruoXDXupahHB9nWWdgq/u4i7bI0VERVLP8qL8zVf+IHxB0L4X+E7/AMTeJr3+ztE09PNuroQSy+SnrtjVm/SsLxZ8cPA3gnxJoHh7WvFFjY6/4geJNM0xn3XN15r7E2Rr823d/F+tNMfS56JT6jPIqSqtYAooplAD6bkV8/8AwdW8+MmneJvHl1qN1p95qGq3ulaYytuOnadbXTQMkS/8spZfIdnf73zp/cWqngb4fzTfE74h+FzqmteIPhgmn2UXka5qt1fzQapulaZILqWVp12oLd/v/K7fJto6BofRm6lrx39nnxhqPibQPEujazcSahqvhPXbrQJb6b710kWyW3lf/b8qWLd/t7q9io6XEmnsFFFFAwooooAKKKKACiiigAooooAKKKKACmU+m9jS6iPmP/goF4D8OeJ/2X/H+q6toOm6nqukaPcTafe3dmks9k/y/NC7fNHnaudtW/h/+zj8E2+EPhvVdZ+F3gcq+i2stzeXHh2z3sWhUs5byt26tT9u6RYv2Q/ipuZV36JKnzfhVH4Xfsy/CDVvhX4Q1J/ht4Rt7+XSrO7GrW2i2sd0svlI/mrOqbg+75t2amO0r+QpX5o/P9DU8V/EnwX+yJ4C8IaDqNvrB0jfDo+nyafp8s8UA3rHEksv+ri+8o+dhu2muiuvjxpmlfE3QvBmr6LrmjXXiJZTo2pXsEQtL940DvEu2VpI5AnzbZUj6eteKftqePtC8V/AfQtW07U4JdM/4TjSLaK88xfKmaK9XzWifoyrsf5v9h63v2r76C1+Nn7NKyzxwu/i642q7bN/+hSr/wChOn/fVNaJFdWet+LvirZaHrz+GrHQdU8YeIBbLd3WlaKIC9vbs+1HleeWKJN3zfLv3NtbarV4T+wja6FZ+Mvj5D4Z06HStETxaiW9hBZ/ZFtv9Fi3xeV/yy2vv+Stb4C+Ij4d/ao+PHhXxJMtt4i1nUbLWtKW4+X7bpv2RIl8r+95TJsauT/Z78QWXiP4nftP+F/CfjLTdD8X6l4gafTbhfKupYP9CiT7UtuzfvUSX/gNabaCeh9haxqlnoOm3OoX06WtlaxPcTzycJGi/MzGuB0X40W2tXGjRXPhvxDocetXPkaRcahbR+VfJ9nefzf3Ur+UuyJ/ln8p/wDZrzTR/hd8SfA+j+Kb/wCL3xvPxL8C/wBh3iX+iL4Rs9K+TZ87+bA24/Ju+X/argvCOn+O/wBnPxl8MdK0jx3H8Xvg/wCKNQTTNKs9VEU2q6SvkM63EF0v+viREfd/dT7oqErNj7M7rwR+0R4x8TftNeN/BF38PdattF0SDTkimjvNPb7P9oeb/SrjN19xlRdqRea3yfMqM22ur8TftRaFoE3iqXT/AA34k8UaP4Tne38R6votvbtBpkqIsjhklnjll2owdvIjl4/KuV+G+oW1j+258cvtM8cLvovhzZ5rbd3yXC/+hMtedeIPFifFb4U/tE6k19b+DdF0O61nR30XS2is5b+5ityv2q/l/wBYzS/LtVWT5eG82iTtfyX+RSV36n05rnxu8J6D8P8AR/GNxfvc6LrX2VNL+zxM8189zt+zxxRfedn3jiuTtf2otAt/Glh4P8R+HfFvhPxbfx+fa6RdaO9/LPBu2mVZNO+1RKisMNvkXZn5q+ftWk8LN+xT+zve6z4qsPC+p6S/h+90XUb6VUtIb9Lfei3Xzrti8rzd3zCu78C+KPD3xp/aD8LeLtU+IXw5uNd8O6fe2Wj+GvBnitdXmuvP8oyzyPsib5Vi/wBUsTD+LfVtWclfZ2M76I9q8VfGKLQbvUrXRfDHiDxve6SU/tO28Ox27PZ7k3/N58sSu+za3lRbpfmX5PmrY+G3xI8P/FzwbpvivwzfrqWi6iu+KXaysPm2sjK3KMrAqy+1fHfgvXPh34T+OHxd8LfF/wAXax4D8Q3HiS41rTrm48bapoNhqGnTonkvEYrqKBmXbs/vfL/sGvp/9n/wf4H8H+Avsvw4s2tvCE95Ld2dwuoz3sd4ZNpa4jlld2ZWcN/Ftb7/APFUtXixp3YnxE/aJ8K/C/x14U8Ka7BrKap4juFtLCeDTJXtGlbd8n2gjy93yf6pWZ+V+Wrln8ZLGbTLm51bw/4g0C6GsNoltpep2Kpd38/8Jt1R2WWJl+YShtu1H37djY8t/auuYLf41fs1+ZKqM/jCXb83/TlKv/s9Y37bl9Z+EfGHwe8XeJ31i3+HmlateWmuX+iahdWUtg1zb+VbztLaukqpv3qx3fx4/iqU7JIZ674V/aG0bX/FWq+FdW0TX/CPi3TrI6o3h/V7aKa6nsxn9/B9lknScbgV2xuzZ421ieHf2rvD/jrwP4g8U+FvC3i7xFbaHe3FhfWNvp8dvdo8G0y/urmWL7u77h/efK3yVznwv0D4HeIviZpnibwP4g/4TvxXY2kkDanH4zv9dfTrSVW4k826lWPe3G1x/wCg1z37F9/bH4efGuUXELRRfEDxA7Msnyqm/OaJPlTa1srk9vN2/A9ruP2g/BVv8JNM+JR1R5vC+pR272UsMDNNO07KsUSxff8AMZnVdlU/Cfx6sfEHxCPgbVvDWveC/Fkti2pW2n64tq5urVXCNLFLbTzxfKzfdL7v9mvlX4T/ABKg8C/8E8/hDcxabo+syaprFto8E+tQefY6dcS6hLtupl/6ZMm7+H5tv3a7vULGDw7+3h4CW58UXWt6h/wiGpi+u9Ru0/dYmiZf3S7Ioh/uJ/vbq15dXG/f8iOZ8iduxs/CjwzpHhX9u74vxaRpdlpkVz4a0m9mWzt1iWSeSa43yttH3m/ievqm4uYrWGSWdliijXczu3yrXzJ4Fu4X/wCCgHxVgWeJpU8I6Rui3fMP3sv/AMWn/fdeiftZaHrviT9m34laX4YWWXXLrQ7mK2ihPzy/Id6L/tMu5fxrBSfKnY3lrJ+iPB/21PiN4Y+Jn7LPja8n8H6nfeH1097nRPFWpWNu1k9z92KW3/e+fFu/hlaJEbeNrfNXpni74veBfAHhP4T6T410O81qbWrnS7fRw2i/areK8bYkTeey+VFKud/39/yttrz742fEbwr45/4Jt6/rGkXts+l3HhdLSKIsoaKdUVfs5XPyyI6/c/2Ky/2kvGXh/wARfA/9njUNJ1zTdR01vHvhxVurW8ili3RM2/51+X5Od1XH3W0R8SjL1/Q+pPGHxIi8M6tYaNa6NqnibX7yJ7qLSNI8hZfs6OivKzzyxRKqtKn8e7+6GpF+LPh//hE9Q8S3L3Wn6XZXL2cqXVpLFc+esvk+WkX3nZpPlXaDvJG3dury/wCP3wytPiR8S9BXw18R774bfFnTNNnn0e8tXjlW8tXf97FLav8A6+JXSJm/u/LXg/xS8eeOPF/7Ok2seNNJ+2zfD/4iW6eJr3wbNcWq6nY2rL517bvE6yKy703bG+R4X+7t4YPRn1Zp/wAftMPxI0/wR4h0DXPBet6ussujjXY7bydWWP8A1nkSwTyrvC/N5UuyTbztrJ8TftRaDoEniqbT/DXiTxTo/hKd7fxFrGjW9u1vpjoiyShllnjll2o29vIjl4/KvO/Blr+zr8R/Fvg3V/C/iq5+IXijTrpb3SbaTx7qeqXGn7uJJ2t57t/KVU+9uT/ZrlPEHi1fit8J/wBonU2vrfwboui3Ws6PJoml+VZy391FblftV/L/AK1ml+XaqMny8N5tLq/JFRXM0j6b1j4vaHa+DfD/AIh01rrX4vEflf2HZ6cq/aNUeWJplSISsiLmJXb96yKu35iKteHfiZp+tR6qt7YX/h260m2iutRt9WjWL7Ksiu3+tV2if7j5aJ2Xj71fM/hrwf4U+Jn7JP7Pfh/V/GF14J1z7Dpcuga3pV2sFzbaitiXRBu+9vj8z5P4qx9cm+MPiD4ZfH74ReJp7Hxz4p0zwvFJp3ijRbX7JNqUU6S7bWeJfuz/ACP8if8APX/bqpbyj2dv+CSuj7n0BqX7TWheH9R0E61oHiPRPDGvzxWum+LL61iTTZ5ZceUjfvfPg3/wtNFGvPWvYp5hDC0rBiqru+VdzV8O+E779mb47fDXSbfUPE+razqdysWfA+sfELWHvftqf8sBZy3u53R/7qdt1fcUK7YVXbs+X7tQ9Ioe8rHinhL9qjRPiFZ+KpPCPhHxf4hvfDt59jvNKXTEsbvftR2+S8lh2/f+6+122PtVsVtaR+0p4C1T4O6h8TP7Wez8L6esv9oNdwMlxZyRvteCWL7yyq3y7K8q/ZD17T0+K/7SGmtdRpeReN5bpoXb5/K+zxLv/wB35K840nxRF8J/gD+0D8Rj4fsNd8K+IvGk95o9lqsW/T7q3lmt7X7VKmP9QZd8v+0i7qpK1n3Sf3q47apH0nov7Rmnah480XwhrXhfxF4O1XxBBLcaGdbjtvJ1RYk3yiN7eeXY6ph9kvltiuI8EftC+NPFH7S/jXwPd/D3WrTRtFttOWKaK804+Qs7zH7Vcf6V9x1RdqRea/yfMqbttee/FDT/AOxf2rP2aJtT8XSeJdYln1maZpZkit4o2sPl8q3i+WKL+6/zN8vzO9d78M762s/22fjeZ544fO0Pw40W9tu75Lhf/QmWrkrJMSeiZ2nwr+LngT4h/Frx/o3h7QrzTfFuhpaJrl7faMbCacP5v2dC8qrLKuxWZdy7dsqlTzUvjP8AaQ0XwXpd7rzaB4i1jwfps8sep+KNKtopbKw8p9krOvmrPKiNu3NDFIq7H/u15n8IbiO7/bc/aXtre5j+1Npnh5FVZfmV/skv/wAWleMfs53nwR1D4NnwF8WvGGreE/GWj+foniTwz4g+IOq6bHO25w+y1+2pFJFKrA7YlK/OagqSs7H1r4s/aa8FeEfFXgzQrn+1r2Xxht/sq+sdNllsZldHdcXH+rb5UHyIWf51+X5qv6F8dtM1D4nXvw/vtE1nQfEkVh/alnb6jFAV1C1V9jSwPFK6/ex8r7G/2a8H+L2n+H/Bvij9kzRtFtBoei2fiRrewsLiV2ljh+xSpEv735/4k+9/erqvHN5Av/BQP4XwtPGs7+D9W/dbvm/1sX/xD/8AfFL7SXe/4K5DdkXvgd+0B4s+JHxb+IOh6r8P9a0ax0bU4tOSQ3emyw6cvkeaHuNt1v8ANl83/lkkq/d+b71d5Y/HrS9SEV8mga9/wjtzeQ6fY+Ikt4pbO8mln8hPLVJWlRd5/wBbLEic/erz39nK+toPjl+0ZBNNHFL/AMJXZnazbW+bT7cL/wCg15F9l8Q/AHw3o/xA+EHjiLx18HNS1a1SX4f63tnmtnubpE22E6/MsiSv/qG+7tf7xqmrS5fT8UmCd48x980tQhtwxU1LrYE7q4UUUUDCivLvjT8E/wDhdOj6dYf8J1408CfY5zP9q8Fav/Z1xPlNu2V9j7l71P8AB34R/wDCn/C9xoh8Z+LPHImumu11Hxnqn9oXablRfKWXYv7v5Mhf9pqAPSqKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigApq06igD5e/ao8J/E/xRr+j3eg/DnwP8UvA2l28kt14V8TXTefe3TfdeJJIjArIvCs+7/WP92pvgn8ZPh3/wz14u8YeBPB9j4Eh8PJeya14ah0+KwazvreLdLFKkaou75V+evS9Q/aC+HuiePpfBGqeKLTRPFKxRzRWOq77T7UG+75Dy7Vn5z8sTNXL+Ffg1a6xH8Yb64t59OsviJNtNtIrrKkS2S2vmsp+ZXfDt/wB81Hl3B6nmX7P3gG2+IH7DU114gk+1674202813VtVYj7RLeS72il3f3osRbP7vlLXln/C9NV+P3wP/ZZ8OaxeNPL4+1v7P4jP/P8A2+nM32iJ9v8ADK6xbq9E+FvxE/4U7+y23wv1sp/wtjw9p13otl4Wj+a91d1Z0tZbWL70sEqtE3mr8qfPu+49Y+p/s06t8Gfgz+zrqFnaSarqnwu1JL7WrS03Su1vdH/T3iX+Pynfd/upVvWTfoS9Wkd9+094gHwe+NnwH8V6ZmzbV9dHg7UIoRtS6s7pP3SP/wBcpUV0/u5f+9X0zf8A2uOxmayjimuljZo4ppfKRm/hVnCttXr/AAt/j8t/EttL/ak+NPwdtvB9/b+I/Cfg/VpfE2ta3psvm2sEsSbbS181fkaVpG+eL7yqh3V9Zn7tD0ihL4mj5e/ZJ+JnxF8aXHxFvPGun+H4tNsfFOpWVxqNnrE5a1e2WKPyo7drVF8pVX/WtKreqV0d3+0b4huvA8vxD8PeAj4g+HUEUt013Fq3lapc2sW7/SLWz8ry5Y227l3zxMy/wV5j8CtOh8SeDv2jfhqb19L8U6h4u8QKtm3y3MEN0v7i62fwxN/BL92rv7Ovxs0Lwb+zzpPw88YyHQviN4X0htGuvB1yn/EyvWgVoka0g+9dLKqfK0W5am9otjvpc+oPAfjTSfiR4R0rxNoV19u0bVbZbqzuFXbujauX+P8A4d0rxB8HfGMGq6baalDFo966JdwJLtb7O/zLu/irmv2OfhXqnwZ/Zt8C+Etbwur2Nmz3UY/5ZSyyvK0X/AN+3/gNbP7R3jXQvA/wZ8W3fiHWrDRbW40u6tYZNQuUgSWd4JNkS7vvO39yorXStHyKTMr9i4/8YofCb/sWrL/0Utbf7SXxEuPhP8B/HfjCz2Lf6RpFzcWu7p52zEX/AI/triP2FfGWheK/2Wfh5b6NrNhqlxpei2llqENncpK9nOsQzFKq/cb/AGWxV7xJ4g8FftffBT4jeFfBviOG/E8F1odzMqSxtZ3W0rh0dVb72P8AerSom20h7O55defD+30n/gnQ9wsjJ4gg8LDxYNYU/wCkDVvK+2favN+95vm/x1z198Wbv9oLxp+yp4Z1Iq2l+JtMl8Xa7aY/dXUttb74lZf7nn7n2/7C1p6h8RH1j9jl/hPBHn4xzeHE8LS+Dv8Al+S42fZXuGi/htf+Wv2j/Vbf46veMPglN8D/ABF+zp4xs/O1DRfh/ZP4b1xo1aVorWe38r7V/uJL9/8A2X/2aro7rsZR5lTS9f0Og+LHiST4X/tsfB+bT2FtaeP7DUdG1qFR8s/2VEltJf8AfRndd3916q/sdX0fxi1L4zeP9ehh1G61TxTdaBbeaolSLS7VFSG3X/Z+eVm/vb6kvrOy/aI/at+G3i/wzfQ634H8A6df3La7p8qzWV1f3P7pYIpVysuxEdm2/d+T1qp8B9Q0b9lXXPid4P8AGuqW+g2OoeKLjX/D91fsYl1SC8VW8i3/AOes6So6eUm6X7ny/NR9lFpp7Gz+wn4vvNQ8J/ELwVeTPc2/gPxff+HtOllbc5sEfdbo3+4rbP8AdRa7n9oz4/zfs9+HdN1pvCOp+JrG4u4bOW6tLi3hhtHllSJPN3N5nzM/8ET/APAa5z9i/wCGWqeC/AvivxBrtjcaXrXjjxPfeJ5dOuV2vaxzv+6iZf4X8tF3f71cf/wUm8eeHvC3wOsdN1XWbOw1C813S7m1tJp1SaWKK9ieV1i+86qv3qQz0j4gfH7V/hf8SvBuga54Mlbw/wCLbptN0zVtP1BZrtL3bvWKe32IqK+1vnWV+27bV6x+Nuq2vxysvhz4p8L2+jzavp8+paLqVlqf2xLpIGXzYpUaGLypV3o3y+av+3Xhf7Xfxw+Hv/Cffs7XC+NtBltk8W2+rPNFqcTIlm1vKiXDur/LFub7/wB2rXxW+MXgaw/b0+DsM/i7Rka30fVLKf8A0+LZBLcLbvbrL8/yNL/B/e3LQ+hEZXPVZf2hta16fxhc+B/BkHivRPCF/Lpuq3Uurm1uJriJFeWKzi8h0nZd2397LF81dj8D/jJbfHbwPZ+MNM0DWND0a/QS2T6w1tvuYj/GqQXEu3/ge1v9mvjbVv2kvhp8G/iN8VdCtPiePhS2pa/O2raFq/hC/wBUl+0bUSW9tZYtqxebjf8AP5q/dbb8+2vqv9lfV/htqHwT8O2Xwo1dNe8H6XD9it7ldwl3Ly3mqyqyy/NuO5V+9QtmD+JI6b4kfFK1+Ht14f08QTav4h8QXn9n6Vo8Eiq08m0u7szfdjiRWZ39OAGYqp5bR/jzf6X8UtH+HvxC8NweE/EGu28txot1p2pNqOm6j5Q3SxJM0EDrKi/NteJc/wALNXA/tUaXrHhH41fBj4uQ2d3qXhrwvc3+n65Hawee9lb3kSxfatq/NtRlG/b/AA0fECTS/wBo/wCMXwXv/A2sWniTRPC2q3WualrukTLdWkCrB5S2/nrlPNd3H7r72xWbtSvojS93Y6rwl+0Xrfjj4qfEXwBp3gS607XfCUVtKj61qcUcF154laJmeBZvLjZUQ/xt+9+4u2tj4W/tFaX48+H/AIt8Ra3af8IlceDdQvNN8RWs0/2iKyltfmldJdq+bFs+ZX2L/u14h8E/jH4Hk/bm/aBjXxZo2bqx0ZLdvt0WydrW1l+1bH/j8r+L+789ef8Awjm0v4//AAr/AGvPBHgrxBpupa/r3ibV73TLe3vE/wBKgeKJYpV/6ZO6bN/3aprQdj6S8SftHa34LHhfX9b8ByQ+A/EN/a2EGoW+oPPqdq9z/qHurPyNsce4jOy4dl3L8ld94o+Il/beJpPCfhTSrXxB4qhskv5be+1E2NpbQs+xPNlWKV1Z9ku3bE+fKf7teL/Af9tLw1460PSfB8ula5pvxas7WK11HwncaLebrSdV27pZfK8qKL+Pe7r8tcH+0ZD4N+FH7TV744+MXgLT/FXww8QaFZ2C+Ir3Q01RdDvYHl+SRNjNGsqyj5k/i2VG1kTHW59IfBL452/xafxNpN3pM3hzxh4VvRYa5oslwtwLeVl3o8Uq/wCtiZfuvtUn+6tdh8RPHGk/DPwdqvifXrhrfStOi82ZkG5z/CqIv8TuxVVX+8wrz39nmP4b6lpV54g+FngrTPDHhbUY4Wj1HT9A/sZtSYF/m8toomeNQ3yuy/xPtrF/bc8IeIPF3wIupPDVnNqmpaNqthrn9mW/376O2uEleJf9rav/AI7VS7Exep5h+2Z4u8Waj8L/AAqniXwZB4fs7/xhobWU1tqyXssX+lI226TylWJ/vf6p5V/269q8RfGrxFc/ELxF4N8C+DbfxDq3h6ytr3Upda1V9Lt8T7/KigZbefzJf3XdVT/arw79rb44eEvit8BfDWo+FNSbxAqeK9Hmu7PTYJJ7uyZLpHeKe3T97FL/ANMmXf7V0em/FjT/AIofHzxb4a8a399o/huzsrC68K+Gbq3utPfxBFNb75rh4HVJbra/7ryNu1dnzpvqtLJMpbmx4p/bWsdI/Zit/jTpPgrWde0WXetxZfaYLdrGVZfI/eu7/c835d0Sy/3qrftiTfbNc/ZxudmzzPiNpz/7v+j3FfKl9408OeGf+CUus+HL7VLPTtZlvr2zg024bypmlXV2fyli/vKo3bP4Vr2z9rD45fD2eT9m67i8a6HNbDxlpusPMl9EyCyWK4ie4f8Auxb/AJN/+9/cpNLdDqLRJHtWl/Hzxev7TI+Fms+BdP0nT5dPm1ey8Qr4gaT7bao+z93bm0U+buZN8e/5eu5uN3ZaP498U6p8YvEHhd/DOnp4X0q2guDr0ets9w0su7bbta+R8jfIX/1v3WiP8e1fOf2uLG5i8DeGvjB4VVdQ1f4f3i+IIvsrbvt2lsuy9iVl/heBt/8A2yWvVPg7azzeEl16+iaLUfEczazcQuu14vNVPKif/aiiWKL/AIBS3Rmvd0O/op9FBZ4D4L8B+KPAOmeMfh/oF2uiR3d5eav4e8TTad9vtbeO6maaWKWJXi/exSyy7N7bWTZ97ay1veFdF8afDPTZbjX9Z0vxHpVnaOlto/hTwzPa3E07Ovzu0t7cNK33/wC795mdq9fxRijpYDy/4G/D2+8C6Dq93rIjPiHxFqtxrmprCd6RSy42Qq38flRLFFv/AItleo0lLR0ElYKKKKBhRRRQAUUUUAFFFFABRRRQAUUUUAFN/hp1MoA4zxz8J/BXxMa1PjDwfoPiw2e4Ww1vTYL3yN2N2zzVbbu2r09K5z/hlL4I/wDRHPAH/hLWX/xqvVqKOg9zz7XPgX8OfE2naPpmsfD7wrqum6NF9n061vtGtp4rKL+5EjpiJflXhf7tVNS/Zz+FGufYxqXwy8H6kLS2SztftugWsvkW6/ciTdH8qr2WvTKRRiptYRyvir4a+EfHK2CeJfC2ia+uny+bZ/2pp0V15Df34t6nY3+7WjpPhnSNAuLufTdMsdPnvG82eS1tljeVv7zlfvVzfxW+LWifBXwXeeKNfi1ObTLMb7j+ytPlvHjXb99ljU7U+U/O21fetzwb4mtfG3hPRvEFlHNDZ6rZxXsCTrsdUlQOu4dm+amr79iW1dJ9TZuraK+t5IZ41lhkXayOu5WWsDSfh34V8P8AiLUde0rwxo+na9qOPtmqWlhFFdXX/XWVV3P/AMCrpl606jcad0c7deC/D994otfEVzoenz6/aRNBbarLaRtdwRN95UlxuVfaqbfDnwl/wkV94gbwzoo128g+z3Op/wBnRfap4v8Anm8u3cy/7JrrqKNtR9Uz57+M3g2y8P6L4S0Gz+Gtp4i+Fdvcyy65oOj6TFN5Koga32WQx5sXm8ukSM/yr8rfNVPw78Fvgz40jtb3wl8KLDwzf2d5FcRatJ4JfQLuzeN1fdF59vFL/wB8/LX0hXJ+IvGR0HxR4Z0b+xNb1Aa3LLEdQ0+zMtpY7It+66kz+6Vvur6tSV931B7Jdg8YfDTwl8RFtD4o8LaN4j+xyeda/wBsadFdeQ395PNU7WrpYYUhiWONVREXaqqv3am20oqugkupwHi74I/Dz4g6ouq+KvAPhnxNqaRLAt5rGjW91MIh/BvlRm2/M3611LaJpzaOdLbTrdtKMXkfYvKTyvL/ALuz7u3Fa1LjFJKyH3OK0H4XeDvCvhu68PaJ4T0PRtBuwy3WmadpsVvazq/ytuiRdrbhWHp/7OXwo0yw1DT7T4ZeD7Sz1BUjvbeDQLVI7pFbcqyqE+cBlDfNmvUNu2vJvh38evDfxO+IXjDwho8GsRar4V8g6guradLZLmUy7Niy7Xb/AFW/dt27WTbnNHR+gJXub+k/Bf4feH/Deo+HdN8B+GtO0DU+b7SrTR7eK1uv+usSpsf/AIFVy3+F3g+zbQ3tvCeh20mgo0WktFp8SHT1b7y2+F/df8ApPCvjYeKrzxDAdE1rRv7I1JtPEur2ht1vNqo3n25z+9h+fG//AGWrrzzU8ztcSS2POtJ+A/w20HxN/wAJHpvw/wDCuneI1na4/tm10W1iu/Nf77+aqb9zbm5z/FXogOcV5Rqfx88NaX8ZtH+GM1trH/CR6vHLcW00mmypZMkUfmuVuHCpJgbf9Vv2s3NesVVrolaM4lfg74E/tLVtR/4Qjw5/aGrLt1G7/sqDzbxf+mrbMyf8Cqv4s+CXw88dGzl8S+BPDPiJrOLybb+19Ht7ryIv7ieYnyrXfUUPV3BbWOS1j4b+E/EHh1dB1Xwxo+p6IsUVuNMvdPiltvKiP7pPKZSu1P4V7Vsabo9jpWkw6ZZWNva2EMXlRWsESpEqf3VXptrHs/Ghu/H2q+GDoesQiys4bz+2ZrPbptwZHdfKim3fPKu35lxxuWutpl7qxyPhX4Z+EvAFxfz+GPC+i+Hp7+TzbyXSdPitXuG/vSFFG78aP+Fc+Ev+EivvEDeGNF/t28g+z3Op/wBnRG6ni/55PLt3sv8Asmuw7iuU+JXixvAnw78UeI0h859I0y6v1iH8XlRM/wD7LSbsJLVFPTfCvguy05vCen6JocFjYw7W0S0tYFigik/6YKMKr7W/h52n0qbw54f8L/D+1s/Dnh7TtH8N2zeZLa6RpkEVojbfvtHEm3+8N1eKr4Bs779jXU11K6uZtS1bw8+uapqdneS2txeX7W/nvM0sTK33/wCDO3Yqr90Vcg8NjxJ+x74aaJja6tp3hO11DStQjP72xvYrJXilRu39VLL/ABUr35l2t+JnF2cV6/gevWHwv8IaV4suvFNn4W0S08TXS7Z9Xt9OiS9lX/alC7mrb1C8Wws7m5dZmEMbSFYYmmfp/Cqjczf7K1g/CfxlJ8Qfhf4Q8T3EXkS61pNrqDxL/A0sSPt/8ertKHHSxcWm7o+Kf2a/DGgfEL4ifF+28bfDLUbu11HxdL4h0OXxl4MuYrdovJii86J7qALHJ8n3flevry80XT9S0mbTbqxt7jTZYvJkspolaJ4+m0p93bWz0NLVX0Xkkvu0K63OFtfhH4IsbHRrC28GeHrex0ic3Wm20WlQLFZy/wB+FQv7tv8AaXFa1x4J0C88TWviK60HTp/ENpG0Ftq0lpG11DG33kSXbuVfbNdH6UvrR0sK2ljzzw/8Cvhx4T8Qt4g0LwB4X0XXfmYapp2i20F1lvvfvVTd81amqfC/wh4g8SWXiPU/Cmi3/iCzH+japdadFLdwf7krLuWuvopMb1dzz3xh8EPh58QNUXU/FXgLwx4m1NIlgW81nRre6mWJf4N8qM235m/Oobr4CfDHUvEi+I7n4eeFbjxAssdwury6JbNdrLHjYwl2b9y7V78ba9IbpQvSmBzX/CE+Hl8UP4l/sLTV8RvB9mbWPscX2tof+eXm7d+3/ZqpB8NPCFt4nh8Sw+FtFh8Qx2/2WPVk06JbtYv+eXm7d+3/AGa7GkoBaKw2n0UUCCiiigYUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAMop9FJoBlFPooQDP+BU09BUtFMOtyP1paceKF6UCSsNop9FL1GN7VzGiaA+n3t7f3dx9tv73YJpY4hEiqmdqKvXaNzN8zNyzV1NFNXQPVWId/wB72py47U5aWm2Azilp20UbRSDQbRT6KAGUxkzU1FJ6qwHz/wDDXWPiP8PrVPD/AIo8Aah4nvpLyWWfxR4a1CwFpdeZM372WK5nglibbs+RFl+78rGvV/Dfh1NLvdT1OS2gtdQ1WRZrpbfp8qhV/wB5v9qupooWisKwyin0UJWG9RlFPopgMop9FADKKfRStrcBlFPooYDKZU1IeaOgmrnhHiS6+Jnjzxhrfgm58CWmh/D0PEsvjC41uK4l1K1wjSxRWSJuiZ/mi3yv8q/N83SvckCqu2pqSmtFYGri0UUUDCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKZT6ZQB8+/tWfF3xl8EtI8Ja34bfQp7C+16y0W+s9WspZZXWeVU82KVJ02bPm+8jVY+K3xU8Y/D/AOPfwo8O2suiXPhTxjeXen3MU+nyi9tmigabck4uNnzfINpi7e/y0P23PA+t+OPg3aP4f0y51q/0TXdN1k6fZLvuLiKC4VpUiX+Jtu75f9muN+P2seIfF3xN+AHjHwn4B8VeIdL0bVr25u4k0x7K4iSW18r54rryvK+9/wAtdn+zuo6Adt4d+M3j7xJ+0N46+GkukeH9Ji0XS7fUrHUklnvNyzvKqPKv7r5vk/1Se/72rnwb+POo69pPxKi8eJpthqHw/wBUnstS1DTVdLWaBIlnS4SJmdo/3T/d3P0+9XnvgPxPcr+3N8QtVn8J+MLXRdQ0Gz0q11i48L36WUs9q8rSp5vlbdvzfK/3H/hZvl3cr8L/AA7efF64/aj8JXOg+LPC0fjq6uJdK1PXfDt9YW88DWiQebvliT+P/lk3zbf4fv0L4kS9jofj14y+IPjz9kTx540Npotn4V1jwpeTweH3tpv7SjtpYn8q4e683yt3lMjtB5HqPNrptN+PGi/B/wCDfwW0nUNb0Hw/qXiPQ7UQX3iK8W1srWKK0iaWV9zrvPzIqx7k3M33lritR8QeK9Y/Yz8U/DLUvAHii2+Imk+ErjQpbG20ieS0vWS38pJbW62eRKj/ACvsV/M/h2VV1bw/8TvDvg/4GfE3w54C1S51vwHpkuh634MvXgS+vLOWKGKWWDynddyNBvVfvN/cpxVnL5Cla8ZNbX/Q7D4U/tZ3njb4q+Ifhlbax4I8feIoNF/trRtd8L3zxaVejdsa3uNr3TW8qtt+60vyfN/s1rfAj4xfFH44+EbLxBDpvhbRGs/FF1peq2s73EqT2cErRu1rKrf61dv/AC1T58N8sXDHr/h58ctV+I2j3fiGf4eeM/Aug6fBLLPB4m0gpqF4y/wwWcLSyt/H/Duf5ditXnP7BWoXln8Pde8P6v4a8S+GtV/4SHVNSWPXdAvLFJIJ7ppYnWWWJVb7/wB3dupXXQs6mx+LnjX4qeLvH+n/AA+k0LTrDwTqZ0i5Gu2U88mp3SRJLKkbxXEX2Zfn2eayy887P73P+Cf2xrzXv2fYPifrPhTT9L/te/TSND0ay1t7ua8v2uHtfs8rPaxLF+9T+Dzfk3N2ry3x58SpfBvxq+JYtPh38a9NubrUIre6vvhbottqFlqcK26bJZ2l3+VcOJT88Xly7PK+atbxJ4RsPjh+zHpWk/CTwnr3g3xF8OdZsta0zwh4ts5NOvftEDGVEl81vm81Hl2y7m3P95/v00tGHWx6l8S/jF46+AM2i634+Tw/rvgXVNSt9NvLrQLW4srjQmlfbE8plnlS5i37Ud/3HrtbOyr/AMSPjR4w8D/tG/C3wRFoukv4V8YS3cZ1OS7ke9V7e1eVl8nYqp83lfNvl4VvlWuS+MyXX7Wvwtt/AGn+FvFGgzalqlg+uNrmj3FgmlwRXCSy/vZVWK6b91sX7O0q5ZT9z5qzv2kdYuoP2pvgLdWnhjxZqum+F7nUZdV1HSvDV/dWlqt1aeVD+9iiZX+b+5u24+ahqyRUd7M7ex+NnjvUP2oPEXwsk0XQLHTbbw+mtWWprdS3ErK9x5SPKm2L5vlf90v+z+9q98F/jbrfiTXPij4b8bR6b/bfgC9SK51DR7eWG1vLaW38+KVYpHlaNtn3k8x6890/XrmH/goNrOsSeF/Fg0CbwlD4fi1r/hGb/wCwtex3bSMvn+Vt2bX/ANb/AKr/AG6h/Zz8QXt1+0h8fdQk8I+LLPTvEc9hdaRc6x4ZvbC3vkgsvKlXzJ4kVG3fwvt3UjJX5mT3v7T/AMQo/wBn2b476fo/h3UfBf2RtQj8KSJPDqH2Pzdgla/3vHv2/O0X2f8A4HX0j4H1jVtc8J2Gp6vp+n2F/cp5xg0y9ku7dUb7hSV4Imb5dv8AyzWvz38K/EDS5fAkHhvV/gx+0H/wiU0zT33grw54bguPDksjXDSulvP/AK97bcfuJKsTf3Pmr9A/hz400r4geDdO17RI54tNuoz5UNxA0EsG1tjRPEw+RlZWUr/s0P4WV9pHHeJ/iNreufEm7+H/AIGfTbXXdP0+LVdW1jWLWW7trCOVmW3i+zxSxNLLL5Uv/LVNirn5/u141+zzqGuT/tjftI/2laWo1qCx8PR7IpGS3nZbWXa6/eZFf/gWz/arbvtN1r4E/tXeLvHc/h7W/EHgjx5plhDc32h2M+pXGl3tmjxIr28KvL5To2dyK3zVU+FY8S6F+198ZfEt54E8SQ+Fdds9L+y64bZfKxa2r7/3W/zX3bl2rFE77/lfbSjsvRmitrc6D4K/tEeMfHngn4u6r4h8J2kmueBtb1DSodB8OSS3El41rbxOER2X940ruwT5F/g+XvWTqH7QXj34b+K/hPbeOW8LzRfEC9i0/wD4R2xtZ7TU9HeWLcrM8k8v2lUb90/7qL52rzf4O6l49h8BftOp4R8L+KtB8Z6x4g1TX/DTa14durFLqKWKJIXja6RYvM+XPlt83+z1pvjDwsNQ8J/ADVPDPgDxd5uneNNL1PxNfajod0mpeYlu8Us115q+fK27Z+92sn+3RbfysR0XkeqfGT/k+j9nr/sGeI//AEniq9D8Ufibov7V+meA/EN14Xh8E65p11qWjXsGlXK3ty8TfPZM7XWxZUR1l3iPDqn3F/h5D4yeJblv2yfg5qsXhTxhcaVoNjqlvquo2vhi/urW1lu4IhCvmxRMrcrhmTcq/wAXt3/7ZHhHUdS+FcXjXw8o/wCEt+H94vifS/8Apr5H/Hxb/wC7LD5q/wDfNX/KZx+1cl8YfFTxj4K1z4na/ey6Pf8Aw88HaML37JaabOmpy3QtzM9v9o+0NH8q7H3eV/y8Jx8u5tr4c+OfFniiDw5q39o+GfF3h3W5pJf7X8OQSxJYxfZ2dE+eWXzvm+Xzf3X/AFy+arWhW+t+H/g5e6rNocmt+KNQt5tWutEfZumupfm+y/PsX5fli+b+4teD+D/gro3g/wDaC8OeIfg1oPiXwDavdSjxpol1Y3Fnosts0DbNiSr5Usvm+Vt+yuyD5+n8UvVtFPZPserfDn4zeL/Ef7Rnjv4d+ItE0nTbLQ9MtdRsLjTbyS6knjmllVWldkQKdqfc2/8AAmqn4F+N3iX4oabrOv8AhO48M6zp+n6pLpc3hZBL/aVkYrvymmln81l3+UvmrB5C/wDXWuP+HfiC6uP26viBqDeF/F1po2p6FYaXZ6xd+GL+CxluLZ5WmXz2i2KvzfK7fK/8Dfc3ch8WvhLZeNL1PF3g7wP4m+HX7QpkWS11TS9Ont7G7PmoGe9uIt1s0Dqu9klfz9v8G75KF0iVy2bZ9zVnavpNtrmlXenXsYntL2J4J4m/jRl2sPyq1beb9nXzNvm7fm2/3qs1MlfQE+p4hoHwp12b4P3fwu1XVtQ0nTLO1XSrLxFpLQSXF1p+Niqyzxy7JPKxG+U/2kbJ+RNT+E+s6X8GbP4X6Dq+palZ3Vm2jzeItXe3+0afYBNhCrFFF5svl/JH8n+07cfP7hjikx61T1T8xJWS8jI0LQrPw1othpOnwC20+xgS2ghX+GJF2qv8q2PWilpdQStoFFFFMYUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAcX8Uvip4a+DPgfUfGHjDUDpHh3TvK+1X32eSfyvNlWJTsjVn++6D7vevCP+HoX7Mv/RSv/KBqn/yLX1XTKAPlX/h6F+zJ/wBFM/8AKBqf/wAi0f8AD0T9mT/opn/lB1P/AORa7X9oK4l1D4gfBXwzO+3RdZ8TSy38W35J/stlcXVvE3/bWKJ/+2VY3x78P6XH+0J+z9r66Za/23/b95Zf2n5C/aPI/sq9fyt/3tu75ttNK6uBif8AD0L9mX/opX/lB1T/AORaX/h6F+zL/wBFK/8AKDqn/wAi12XxmvJfDfxw+Cmrae4iutT1W80C8C9Z7OWymuNv/AZbWJ//ANqvd2oegj5SP/BUL9mT/opn/lB1P/5Fp/8Aw9B/Zk/6KV/5QNU/+Ra+nr69g0u1lu7qVYbeBWlklf7qrXGfBn4w+G/jt8P7Dxl4TuZLrRL9pUiaWPY6skjI25e3K0txtnif/D0L9mT/AKKZ/wCUDU//AJFpP+HoP7Mn/RTD/wCCHU//AJFr6q3V4N8Xv2qrH4T+Lj4ft/hx8RfHt7HAk9zN4K8P/wBow2e77iStvXaxUbttJuwLU+ZPBf8AwUP+Hvwx8/RrL4k+GfG3h+fVLq9XUtWtdb0vUIEnnaVkZU024Wdl3t8+6L+GvUtN/wCCkH7NFhNNfz/EmOXULxUWeSLQdUVdqfcRf9H+6u5/++m/3a9Y+A/7S1n8dtW8QaZb+BPG/gq80RIGuYvGWlLYO3m79m1PNdv4DWR8Sv2t7T4eeMLzw/afC34n+PPs22ObVPB3hv7bYrL/ABReb5q/Ov8AEP4eKb3sC3OW/wCHof7Mn/RTP/KDqf8A8i0//h6F+zL/ANFK/wDKBqn/AMi17p4v+JWieAfBL+J/Ek0+jaeqxFoZYjLcebIQiQLFHv3y72Vdqbst+dY/g74zWXiDxIvhrU9E1vwb4hnge8s9N8QrAJb22QqHlhaCWVG2703IzCRd3zJQtUJvU8i/4eifsyf9FN/8oOp//Itc34+/4KKfs2+NfA+v+H7X4u3WiXGqWMtompWegal5ttvXbvT/AEfqtfZtIGoFdHwJ4G/4KbfD7RYLHRda8a+DZ9PsoEtxr2n2muxSvtRV3fYG03av+79qr0DRf+Ck37MOi2XkRfEnG6R5ZG/sDUvnkd97v/x6/wB5mr68opNtFaHyr/w9E/Zk/wCim/8AlB1P/wCRaP8Ah6F+zKf+al/+UHU//kWvqqqF47wW8sscMlw6qzLHHt3P/s/NSulqC3PmQ/8ABUL9mUdfiZ/5QdT/APkWk/4eh/syf9FM/wDKDqf/AMi16L+z78dpvjpD4zkn8MXPhO68N69LoVxZXlzHPMZYooncsYsp95yvys33a9lFDurabpP7wdkz5W/4eg/syf8ARSh/4IdT/wDkWvGtT/4KE/D7xh8QNVsdf+L3hOz+FPnwT2tvpnhfW31m9RSrtDcPJF5UcTOvzbEfcny/Lmv0PPNFV5hbQ+Vv+Hof7M2P+Slf+UHVP/kWm/8AD0L9mY9PiZ0/6gOp/wDyLXvfxH8XXngXwdqfiC00G98Ry2MYnOm2MsEUsq/x/NKyp8q/N97+GuS8G/GDV/iN+z7pnxG8MeEn1LVdS0r+0LDw2+oxwtM/8MRnZdi/71LfVd0DWyPMv+HoX7Mv/RS+v/UB1P8A+RaB/wAFQv2ZR/zUr/yg6n/8i19LaXLdXGn20t5b/Y7p40aW38zf5bY+Zd38ValCd7ivpc+VR/wVC/Zk7/Esf+CHU/8A5Fpf+Hov7Mn/AEU7/wAoOp//ACLX1SeaKYz5V/4eifsyf9FO/wDKDqf/AMi0f8PQv2ZP+imf+UDU/wD5Fr6p9K8W+MPx9n+EXjTwHoUvhHUNQtPFusW+kR60lzBHa208rN8jJu81m2ozfc2/7dHWwns32OA/4eifsyD/AJqb/wCUHU//AJFo/wCHov7Mn/RTv/KDqf8A8i19SD7hqWh6Anc+Vv8Ah6L+zJ/0U7/yg6n/APItJ/w9C/Zk/wCimf8AlA1P/wCRa+qqKXUZ8q/8PQv2ZP8Aopn/AJQNT/8AkWl/4ei/syf9FO/8oOp//ItfVNcl4y1zxBotzoi6D4bPiNLzUI7fUH+3R2v9n2rffuPn/wBbt/uL83zUN2A8D/4eifsyf9FN/wDKDqf/AMi0h/4Kifsyf9FN/wDKDqf/AMi19Ur0paYI+VR/wVE/Zk/6Kb/5QdT/APkWg/8ABUT9mT/opv8A5QdT/wDkWvqqigOp8rf8PRf2ZP8Aop3/AJQdT/8AkWj/AIei/syf9FO/8oOp/wDyLX1TRS6gfK3/AA9F/Zk/6Kd/5QdT/wDkWk/4ehfsyf8ARTP/ACgan/8AItfVVFHUD481L/gqp+zpZ69pVhH4v1C+tLoy+fqdvo10Lex2ruXzdyLKd/Kr5SSf7W3rWz/w9C/Zk/6KZ/5QNT/+Ra+qqbt4NHYD5Y/4ehfsyf8ARTP/ACgan/8AItH/AA9F/Zk/6Kd/5QdT/wDkWvqjHI9qWknfcD5W/wCHov7Mn/RTv/KDqf8A8i0f8PRf2ZP+inf+UHU//kWvqmiqA+Vv+Hov7Mn/AEU7/wAoOp//ACLR/wAPRf2ZP+inf+UHU/8A5Fr6popXsB8q/wDD0T9mT/opv/lB1P8A+RaP+Hon7Mn/AEU3/wAoOp//ACLX05eTPDaySRRPcuqsyxxldz/7PzV5L+z78dpfjva+M5J/C914TuPDevS6FcWV7cxTzGWKKJ3LeVlPvPt+Vm+7TWt7dA7Hn3/D0T9mT/opv/lB1P8A+RaP+Hov7Mn/AEU7/wAoOp//ACLX1JJ94VIvSkne4rnyv/w9F/Zk/wCinf8AlB1P/wCRaP8Ah6L+zJ/0U7/yg6n/APItd98K/j4/xD+LPxA8B3XhPUfDl34PWzeSbUbqCV7r7R5pRlSJnVV2RK33s/P91dte10yno7Hyt/w9F/Zk/wCinf8AlB1P/wCRaP8Ah6L+zJ/0U7/yg6n/APItfVNFAj5V/wCHon7Mn/RTf/KDqf8A8i0f8PQ/2ZP+im/+UHU//kWvqqm4woFLpcOtj5X/AOHon7Mn/RTf/KDqf/yLR/w9E/Zk/wCim/8AlB1P/wCRa9n+JHxOXwH8N9a8X2GlXfiq30pZZLi1024gRgsTt5/zSui/Jtb/AGvlq38H/iA3xU+F3hXxi1j/AGb/AG9plvqQs/N80QeaiuE37V3fe64ptOzfYXS7PDv+Hov7Mn/RTf8Ayg6n/wDItH/D0X9mT/opv/lB1P8A+Ra+qDjvS9qB6WPlX/h6F+zJ/wBFM/8AKBqf/wAi0v8Aw9F/Zk/6Kd/5QdT/APkWvqC6vIrC3knnkWKCJd8jv0Va8Ik/aG8VajZ+F/E/hb4b3XjDwL4ikWGz1TTdS/02Le+yKeW1aLals+N/m+azKrfMi1N9LgtTlf8Ah6F+zJ/0Uz/ygan/APItL/w9F/Zk/wCinf8AlB1P/wCRa+gvA2p61rnhDStQ8R6CfDGuXNusl5o/21Lz7HL3j81Plk/3hXT1T0dhLVXPlb/h6L+zJ/0U7/yg6n/8i0f8PRf2ZP8Aop3/AJQdT/8AkWvqmqFnqNtfT3cEE6yy2c3kzov/ACzfYj7f++XX/vqgZ8yf8PRP2ZP+im/+UHU//kWl/wCHon7Mn/RTf/KDqf8A8i19U14z+0n8fpv2ePBcPiMeEb/xLZNcxQTzWl1BBFbPK6xReaWbf8zuo+RGo62F5nnn/D0T9mT/AKKb/wCUHU//AJFrG8T/APBVD9nPRNFur2w8W33iG7h2smmadot0k83zbflNwkUfy/e+Z14Wvr8SfJup9HWwX0ufK3/D0L9mT/opn/lA1P8A+RaQ/wDBUT9mT/opv/lB1P8A+Ra+qqKBo+Vv+Hov7Mn/AEU7/wAoOp//ACLR/wAPRP2ZP+im/wDlB1P/AORa+qaae5qW7IOtj5X/AOHon7Mn/RTf/KDqf/yLS/8AD0T9mX/opv8A5QdT/wDkWvQvFXxu1f7V4rtPh94Vj8d3/hKWOLVrR9T+xyl2i83yrb91L5s+0r8j+Uvzffr0bwhrj+JvCukaxLpt7o0l/ax3L6fqUXlXNqWXcYpU/hZfumnfS/p+IuqR87/8PRf2ZP8Aop3/AJQdT/8AkWk/4ehfsyf9FM/8oGp//ItfTWm6la6rardWsyXMBZ0Eqn5cq21v/HlNaFUM+Vv+Hov7Mn/RTv8Ayg6n/wDItH/D0X9mT/op3/lB1P8A+Ra+qaKnrYD5V/4eifsyf9FN/wDKDqf/AMi0v/D0T9mX/opv/lB1P/5Fr6innW2iaWVlSJF3Mzfw1Dp+oW+pWdvd20qy208ayxuvRlb7tHcTex8x/wDD0X9mT/op3/lB1P8A+RaP+Hov7Mn/AEU7/wAoOp//ACLX1TRTQz5W/wCHov7Mn/RTv/KDqf8A8i0f8PRf2ZP+inf+UHU//kWvqmikxXPlb/h6L+zJ/wBFO/8AKDqf/wAi0f8AD0X9mT/op3/lB1P/AORa+qaz21S1h1K309rhPtk0byxw7vmZU27m/wDH1/76pjPmb/h6L+zJ/wBFO/8AKDqf/wAi0f8AD0X9mT/op3/lB1P/AORa+qaKAPlb/h6L+zJ/0U7/AMoOp/8AyLR/w9F/Zk/6Kd/5QdT/APkWvqmuT8Q694hsPE/hyx03wwdX0m+mlTU9VF6kH9mIse5H8pvml3t8vydO9AHgJ/4Kifsyf9FN/wDKDqf/AMi0D/gqJ+zJ/wBFN/8AKDqf/wAi19NPqVtFqFvp7XCLdTxvLHFu+ZlQrvb/AMfT/vqvKPhf8epfiL8XPiB4CufCt/4euvCIsmkmvrqCV7r7QZSjqsTOqrsiVuX3fP8AdXbQO2h57/w9E/Zk/wCim/8AlB1P/wCRaT/h6J+zJ/0U3/yg6n/8i19VV5T+0D8ZpvgT8M9V8aDwvf8Aimz01DLcw2NxBF9nj28yOZXX5eB9zc3zfdoegR1PK/8Ah6J+zJ/0U3/yg6n/APItL/w9F/Zk/wCinf8AlB1P/wCRa+kfDesf29oGm6kYvJN7bRXHl7t23egbb+tbFBK1Vz5W/wCHov7Mn/RTv/KDqf8A8i0f8PRf2ZP+inf+UHU//kWvqmigZ8rf8PRf2ZP+inf+UHU//kWj/h6L+zJ/0U7/AMoOp/8AyLX1TWfb6la3t3dW0cqy3Fo6pMit/qmZd3/oLUAfM3/D0X9mT/op3/lB1P8A+RaP+Hov7Mn/AEU7/wAoOp//ACLXvnhDXde1e616LXPDX/COxWeoNb6dL9uiujqNqFXZc/L/AKrcdy7H+b5a62gD5W/4ei/syf8ARTv/ACg6n/8AItH/AA9F/Zk/6Kd/5QdT/wDkWvqmkXpQB8r/APD0T9mQf81N/wDKDqf/AMi0f8PRf2ZP+inf+UHU/wD5Fr6pooEnc+Vv+Hov7Mn/AEU7/wAoOp//ACLSf8PQv2ZP+imf+UDU/wD5Fr6bn1G3t9Rt7N50S5nR3ihJ+Z1XG7/0JavjigLnyt/w9E/Zl/6Kb/5QdT/+RaT/AIehfsyf9FM/8oGp/wDyLX1UeaKTBHyt/wAPRf2ZP+inf+UHU/8A5Fo/4ei/syf9FO/8oOp//ItfVNPpjPlP/h6L+zJ/0U7/AMoOp/8AyLR/w9F/Zk/6Kd/5QdT/APkWvqyigD5T/wCHov7Mn/RTv/KDqf8A8i0f8PRf2ZP+inf+UHU//kWvqyigD5T/AOHov7Mn/RTv/KDqf/yLR/w9F/Zk/wCinf8AlB1P/wCRa+rKKAPlP/h6L+zJ/wBFO/8AKDqf/wAi17x8Lfip4a+M3gfTvGHg/UDq/h3UfN+y332eSDzfKlaJjskVX++jj7vau0ooAKKKKACiiigAplPplAHCfFH4fR/ELQ7OOG6Gna1pd5Hqmk6iI/N+y3UWdrbf4lZWdGX+JXasrxJ8E9C+JWp+Gtf8YWd8PEeihZrZtH8Raja29rPhtzosUsSt9913Mm7a20/LXqdFC0A83bwDc618ULXxRrMtvNHosMtvoVnGGcQGXZ51xKzdZWVQi4+4pf726vRafUEmVjZtpfC/dX+Kk9QPHPj98SPCXhWHQfDPijxTofhiz8QzstzLreoxWqNZxfPcL+9dd2/5Iv8Atq1eAfsh/ETwl4R/aY+LPwu8MeJNG8QeFNclHi/w/JpGoRXsURlwt5b7o2ZE2v8AME/u1778JNa8Z+IPHfi7VfF/w61jwcZmittLnvb+wuYjZx/cQ/Z7iV1laSWV2+XbjZ8x215f+194J+JOqfE/4V+M/hd4E1DxH4j8J373E97/AGnZWVrNYyoVntW824STc+1P4NvWhO0ku4pfCz64B+WqTC10+GefbFbof3sj7dv/AAJqzvC+qXuu6HbXt/ol54dvJRmTTdQkgllhYfws0Eksf/fLVznxr0vWfEPw11XRNCWRrzVfK06WaORY3toJZVS4n+b+5E7tinKNxx0SOa/ZytX1nwhrPja43QX3jbU59ZRyuHW1/wBVZfe/6dYoW/4G1eGePfh58Uv2P9B1Lx/4L+IevfEXwfpssuqa/wCEPFpiuJWgdt9xPaXCInlMvzP5W3b9/wD4F9ezW1xo3h6W30GxglmtLfZZWcsvlRMyr8ibwrbF+7/DXmUF940+MvgDU/DnibwBdeAp9St30/UWvNTs7yHyJE2zfZXgldnbaflMqRf3v9mn9rmBHkv7U3iZfF/xg/ZW02EtN4f1rxI2tf7LtBb+bb/+jau/tuatN4d+I37NetWPy6knj+DT1lT73kXMTxTJ/wACWvSPj58EZ/HHh7wbc+GFt7HxF4H1W21jRYpyVt5fK+V7Vm/hWWLcm7+H5axr7wF4i+N3xc8B+K/FHhy58GeHfBLz3ttpOqXNrcXd9qUq+Ukp+zyyxJFEu7b829mf7qbaUdGkS1dM9z1BLuSwuVsZo7a7aNvJlmiMqI38LMgddy/7O5f8Pl74AeKvif8AGjwH8VbTWPHw0bXdA8XahodjrOhaTbJs+zLFt/dzpKvls29mRtz/ADf62vqHUr6WxsLmeCyuNRkhRmW2tWQSTN/dXe6ru/3mWvlT9mXTfiT8MdC+Lz+IPhNr0N5r3izUPEmmWtvqekyGeK5aJVi5vNiyryzbvl4Pzs3y0vtlpR5NSn4Z+MnxI+JX7D6/F5fFC+GPE+l6Veal9m0uwgltL9rV5VZLhZ0dtsvlf8smiZd33q7X4hftF6xp/wAD/hN4j0y1hsNX+IGoaNpv2qVDLBpf2xd7ylf49v3F9WdK8z+Ffw9+KPhP9gnWvhZqfwu1hPGDadqWlQW0Oq6W8UpunuGSXzftX3U81d+75v7qtWtrtn8RNK/ZD+H/AITl+F8WreIrWTTdC1HwVrGq2SNqlvBCvm/Z7hHliXPlbt7bWRElb5flq3bUT+zy+f6HU6t4q+KPw/8A2hvAvw5g8b2viTRfE1je6gdS8TaFHPfQfZTF5kX+hPZxKjrKNrvE21v79fULV8Y/CTxN46+HnjOLVPE/7NGreFLG8ZLC88XXnxCi8TXdnE7qEX96zSrb79u5Im2r97ZX19fzy21tNNFbTXrxoWW3hK75f9ldzKu7/eas5RvFCi1zM+S/2Z/Glj8NtG/ak8Varu/s/RPH2s384T7+yK3id66S41v4uax8DIfivpvipY9el0ka3H4JbTrV9Iki2GX7Kz7PtPm+XhfN8/bv/wCWX8Nc58BPhF4u1rSfjz4S+IPgDVPCmi/EDW9R1S3vJL7TrpEguoki8plguJWWXq/3dv8AtV0Hw90H4seD/gjH8KL7weuo6tYaU2iaf4xj1C2GlTW6r5UMsqeb9qRvL27lWJ/u/eq09NeiS+5CqO7TR0Mvxc8T/FT4Q/Dfxj4Ikh8N6F4m8q517WrqW3M2hWflO8rRef8Au2k81Fi3Mjr827ZXPfBH446tffGD4keC7/xdJ418N+H9Js9ZsPEmo2MVrcNHL5vmq7QRRRSxfJ8ksUX/AH1VDx1+z3rvgbw38B9K8K6PP438JeAbz/ib+HFuYIJtS/c7YrpfPkSJmil/e7Hda2tE+GPi7UP2oPH/AIg1rwwkXhDxT4XstKW7TUYm8ry3l82KVPvebtl/gV0/6a0K2jY+jILTxJ43+M3wJ1T4mWHiV9IsNU0y9u9I8LraQNaS2ex/K+1SsjTmV1XdviliVN4+Rtvzef6H4x8ZfDn/AIJo+FPFvgfV7DR9T0PwxFeyNf6f9q86JV+4nzqqN0+Zlf7v3a7f4SeC/ih8LfhBqXwevvCZ16DS7G6sNA8WW99axWN1atv8pbiNpfPilVXC/LE6cferjtQ+Fvxas/2Bp/hTJ8P11HxdNpX9hW1vo2uWrose1f8ASLh7jyFj/jXZEZf4fX5YWnMl3T+4E9Y/P9DsP2hPiv8AEHwJ4R+DereHNf0+yh8Qa/o2karDdaZ50s/2pld2WXfsiXajrt8rPz/Ky7a2/GHjvxj8L/2lvhf4fm8RzeIPDnjxb+1n065tIIxp1xawecstu0SLLsb5tyytL/vVwfx48M/E7x98K/gtZ6N8KNbl1jQfEGl61q1jcarpafZEs/vJu+1bZWf+Db/D97Y3y1u/G7S/iJ4q/aA+Bni3Rfhbrt5ovhVr261Vn1LS4pU+2WvleUqte/M8Xz7v4f7jNVK3Krd2y3ZaHUap428T/Ej9oHxX8NNK8QXvgSx8NaPZam+oaXbW0t9qEty0v3ftMUsSwLs/ubt38S039ln4m/EL4l3HjtfF1/oc9r4X8R3nhuJNM0ma3lneAp/pDztcOrBlf7iRL838Vee/tBL8RNW+OWoy6B8Hf+Fm6dp2lWtpa6nonjYeGtQ0t5XeWeKWdXSVvN/dfulbaERD/wAta9N/Zr8Va3b2s/gzX/g7J8Hbq0ja/tLGHVoNTt7yJn/ey/aIv+WvmP8AOH+Y7t25s0GbdjpP2gfihP8ADTw7o1tpYgfxJ4m1i10DSPtR3QJdTv8A62Rdy7kjRXfaDltm3vXgf7T3hvxL4d8bfAEap4uvfFllc/EWzkL6naWsEttL5UuFi8iKL919/wCVw7/9Na9j/am+D+t/Fjwp4cv/AAvNa2/jHwlrVr4h0hL0/wCj3EsWd0Erfwq6My7q88+OWg/Fj40Q/CXVNI+Gh0TUfDHiu31u+07xBrlrHgRRS/cltWn/AHTb9u7bv/6ZUuo3s13R2w8e638WvjJ428B+HfEN54P0vwfb2aajqem28Et7Pe3CmZIovtMUsSRpEvzfu3ZjL/Dt5pfCz40eLbf4gfEf4Y+K0j13xH4QtIdV03VrW38htaspVfZvhX5UlR12Ns+Vv4UWs1vhn40+Dv7QHij4m+GvDo8V6J40srRNe8P6ZewRXttfQLsWe3a5eKKWPY7htzxN39q6rwl8Ltch8ffEP4oXVpDp3ivxDpkGm6TpglWV7KCBGKea/wBzzXlf5gu5V2L8z03q7iXT0OS/Z5+Ndz8bNN0XWNA+Jlrr2rSzxSeJvCN9Z28Fxo/yMssNvEqxTxbZf4rjz9yo21qq698e7nxx4k8baRpfiPxl4Qi8O6o+k2134X8DXWuLczxRfvXnl+xXEWze4Tyl2S/uvv8AzVB42+CN/wDEb4l+BfFLfDyPwH4+0HV7W/1Pxvp99btb3kCf8fFvF5T+fcCUfuv9It4vvf8AAWrXHhH41/s9fFjxnqPw58IWHxQ8CeMdU/tqTSrjWl0u70m9kXbO3myh1eJ9iN8nzf7PHzJ7oroetfsw/ErxZ8UPhJYax468NX3hjxRHNLa3lnfafPZeaY3wk6RSruVXXa1cp+0p8RPHXw78f/B+PQ9csbPw34m8U2uh6hZHTfMu2D75WZZ2faq7Itm3yt3zfe9PY/B41+TSRceJBbRardv589nZTPLb2fyqPKjkZVZ9u3721dzbjtWvBP2uPDnj3xV4q+EzeFPh/qfiqx8M+KbXxFf3dvqFhboYollRokWe4iZpfn3/AHdn+3/dGryQn8LZe+LHxzs/DPx50rwH4h8e3Hww0ubTINT03U3hthFrM5mlSW1e4uopYkVVWL5U2St5v369w8C/223ha1PiCe0u9UMkxkuLGPZBKnmt5TIu5sL5ez+KvN/ipo+o+NodU0nxN8LE+Ivgi7tLdo9JjnsjfQ3R3+Z8lxLFFtQFP3iz7g27bWh+y/8ACrUPgx8H9P8ACmpTM/2S6upLW1897j7DayTu9vaiVuX8qNlTd7UPZoSeiZxHxt+I3xD8IftJ/B3w1o2vafF4W8XXN7b3Vg2m/wCkL9ntXlZ/tDO277yNsVE/1X3vnqx4++JWv/BGDwl4W1nxTqnizWfFGr3nkaxbeGmury0sIkMrp9ksYn82RFKRhxEF+be6/L82H+0N4f8AiDq/7RHwc8TeHPhzq3ibQvBc9/dahdWl/p0Xm/abfytsST3UTMyf7W0V1H7S3wo8aeNG8EeNvh3c2tp498F373tnYasxW3v4JYvKuLWV1Py71P3v9j/gVPaKLa6nM/Cn4xeNLf42TeF7xvGXjD4f3WkNfx+LPE3g+fRp9Nuoz89vK/2O2ilVl+ZW8pSOnzVZ03xV8T/jh8Gx8TPh94lbR9RvIp7vw74Xa1tX0+9iSUrEl7LJF5u6VE/5ZSxBfMH93dXa/CnXvip8Rbf7R8RPh/Z/Da0gVkOmW/iBdUnvmZWQ7/KRY4oxuLY3MxO37m35vH/gt4V+P37NJ/4VhpHgXR/iH4AtbyZtD8VXfiNdPfTrR3dliuovKlllZd3/ACyShaoR6R4m+KfijWPiZ4K+FtnJF4W8U6toMmv69eW6x3T6ZAuyLyrXzP3bytO/3nR12o3ytWdpvxM8Y/C/9obRvhV4l13/AISrTfFelXV74e8RahaRRXsV1b/NNb3SQLFFKmxlZWRIv7v+1R8Tvgz4w0z4ueBPi/4Sgt/EviLQ9Ol0bXtGadbR9WspPn/cNJ8qypL86pK6p/tLWtH8PdZ+Ivxo8M/FLXfDN34ch8J6VfQ6Tol1c20moyXNztWV5PKleBV8qLYn71s+b82zZQBy3wJ8V/Ev4sP8YPDviPx0mnal4c8Ry6PY6x4f0iCJkVIomV0in89Nvz/Mj+afn++tYfwz+I3xP+LX7KN/42ufGi+HfFuirqS/atG0+1eG/ls3lT9+k8TfKxi+7F5X+/V79nK1+JPgDxJ8aNV8QfCPX7SHxJr8viDSoodS0mV5E2RRJbv/AKb8svyb/wC59/5/u7sX4HeE/ib4F/ZU8YeDdZ+FWsQeKJ31P7HaW+q6XIlz9ulnddsv2r5fK835t+3/AGd1RJ2TaLiWPix+0N8R1/ZV+HHxU8O6lpGh3WtR6T/adlJp3nuz3ksKHyJXk2xbN7ffik/Sur+N3jb4g/C34t/CqXTfFQ1HRfGGs/2DfaDqGnwfZLdmieRLiB0VJ9y7PuPK27/Zrx/xR8O/i/qf7GHgH4ZW3wi1mTxTo82mpeJJq+krbhLOWKXekovP49u1fl/hbd/Du9I/aLs/iN4/8WfBjU/D3wo1++t/DOuw+INTSXUtJieNPKlieBd1580q7/8Ac/26uSV3Z7P8LI59dzp38aeLPAX7VfhjwTfeKbrxP4a8W6Nf6gtvfWttG+m3FsyN+5eCKLdE6S/dl81vk+9XFav+0RrPxC0nxLqnhjxD408N3en6heWmj2ug/D681ixvPs0rRf6VcCylSVZZI3/495YtitgtvrV+IOk/ELVP2ufhp4w034Za1d+FtA0280+/1A6hpcZ33SRfPFE91vZYtvzf8D2bv4sfwr4V+PH7NPi7XPD3g3wTpvxV+HWsaxcanp0lxr0WkXGifaJfMljlLoxlj3s7fIrNyf8Ado+JpFxKXxD/AGgPiz/wqf4I+MYbaPwDqPiTxHpuha94a1jR5UukllnKPtaVv3UR8tuDEW2yD5q9B8ZeOvGPww/aX+F3h+bxJN4g8N+PFv7WfTbm0gjGnXFrb+cstu8SLLsb5tyytL/vVzn7Vfgv4leMvDHwystD8HXXjHVdI8XWHifVZ7DULOC3hjglZ3t4vtM8TN9/amV6J822pPjdpPxF8U/H/wCB/i3Rfhdrt9ovhOW9vdUdtS0uKVDeWvleUqtd/M0X8X8P9xmoTTim13LsdroPjHWvjZ488caf4c8U3PhLw94O1RNHluNMt7We51C9SJJZ0c3EUqrAglRNqKr7g/zLXi/7MvxCl+Enw7/ah8ZeI4o7y40Hxzq97dJafIk7xW8P3N33d/y/99V6V4D8A+NfgD8XvHsmj+F5fF3gHxxq39uq+l3drBd6VfyLtuPNSeWLzYn2I25GZ/8AYrjvht+zr461rwz+0B4M8Z6Vp+h6B8QNZ1HUrXUbPU/PuImn2RL+48rbt/db9xl3dtnOadktu1vyBNWs+5V8ZfHrx5oNv4f8VeGG8eeNr+SeBNY8FN8NdRtNPaCTb5r2tw1gssTp9797PKrf3a9f1bx5rXxK+Mmt/DXw3r0/hOLw5plrqGs6vZQW8t6Jrl3+zwRLOksS/JE7uzxN99Nv96uO+Eer/tI6fFa+APGPgfQ/s9nALRviRaeIE8qaJRtWVLAJ5vm7f73lruHar2vfDvxj8J/2kNb+JXg/w63jTQvF+nWtlr2jWNzBb6hDcWvyxXUXnyxRSLsbayb1qZPourJ/4BzH7ONvrFn+2Z+0Vbaxdre3cVn4eRL1Ylj8+L7PLtZkX+L+9/7LXuP7RHxeg+BPwj8QeM5Lc3s1gqR21oG2+fcSukUSf99OteX/AAr+H/xE0f8Aau+J/jPUfDGnWvhDxbbadDFdPq/+l2/2W3Zf9UqNu3u+1vnTbt/jr0j9pb4LwftBfBfxJ4HlufsUmoxq1tdbd3k3Ebh4n/76RaqT2Rcnd3PNfjX4g+KHwB+HMnxOHi2TxiukLBc6/wCGLjT7W3smtcqtx9jeOLz4mX7372Weo/F3xY8cr+0x8JNB0LxDpo8D+NtKv75bX+yv9IXyIEfc0rS/Nu83d8qxfc/jqx4p0H4l/G74M3nwx8U+Dn8OanqVtFp+teJft9tcabLF8v2iW1SKXz2dlX5Uliixv+9WT8TPBfjWx/ag+D2ueGPhtq2s+CvBOn3um3N9b6hp0W5Lm3iiQxRy3SSN5W35tyr0+XdTSTZlK/Q6n4fePvFOj/tSeLvhfrXiCbxRpCaBa+JdNvb+2giu7YS3DwS2zmCKJGTK7k+Td/eZq9m8a6Pc694X1TT7bWNQ0G5uIGRdR0to/tMHH3o/NR03fVa+edF8P+Pv+G4tV8bzfDjVYPBd14bTw1HrD6hp3EkV28v2jyluvM8pt393f/sV9R3UPn20sf8AfXbUPWw436nw1+zzouqR/wDBOrW9X1DxXrGsRX/hPWGWw1BbXybZt11udXWBZWZ+d3myy09fGnjP4O/sH/Db4k6J4ma2Xw54f0eWfw99jt3stStW+zxOsrunmrJtfcrRSp/utXR/D/4e/EXwD+xfq/wvuvAN9qXiSz07UtEtvsOpWOy/89pfKuImlnXbFtl+bzdkvy/6pq534hfD34o+IP8Agn/p3wosfhhqzeMY9LstFlt31TTEhi+zfZ2a4837X/q32MF/j/vKv3qqMtJ362NOVaJ+f6HrnxS+O6af8TbbwHbX3iLSBJoS6zeap4a8MXWtXkXmymK3SNIrW4ji+5KxaWNs7FWj9mn4n+N/GHiTxx4a8V6fr99peiXFvJoXi7W/DdzobavbSplkeKSKJfNicbW2Iqtwdi1yPjzwL8W9K8beGfjP8O/DEdx4iOhpoHiP4f65qNvA9zAjs8TxXUbvEsqO787vut/wGvcPhVq3jzxRpo1fxz4etfBV/JEI4/D1rqQ1Iwf3nluFVUZv9lPu4PzNuoTV7oyl8VkVv2htJ1PVvg74oXTvEGqeHZ7fTrqc3GmLbs8qrA/7pvPil+Vv9ja3+2teJ/s7aH418NfsUeG9Y8PePZ31E+FLW7srfxBptrd2Wn+VFvaKJYEt5W3L8u6WWXbj+Lv7p8bJtck+FviCx0LwtqHijVtSsp7CKy0+4tYHVpYnXzXeeaJdoz/vf7NeRfCO3+IXhX9ku08Han8Ldeh8V6HoEejx2Uep6U6X0vlNFvik+2bVVPkZ/N29fkV6hfb+Re7S9TjvHXx4+Jtr/wAE+dG+LOkeItPtfFP9j29/e3E2lLP5/myrF+6XesUTL5m/5kl+5jbXqvxO8TeOvhP8PfFfxGn8Qtr1hHo0Ei+HotLjddOn3j7RdRSx7JZUWJi3lP8A88vvrmvD/EHwv+Ker/8ABPC2+Ekfww1ePxstlb6O1v8A2rpnlL5U0cv2jzftWPKbZt/v7v4dnzV9SR65401L4X2t3pPhSTRfFsb26/2L4hvbdRtWVRNult3uFVWjEu1l3N0+Wre1wj8KXr+hy3wd8XP8RrO01Hwl8WY/iH4SuLK6S51H7PZ/2lZ3jeUYf9VFEi7E8391LBu+7u3V51+w14Y1mz/4WhfXfjrxJrNtZeOdZsGsdRFm8d06Oi/aJZFt1l83j+CRY/RK2PA/wF8v9o+x+JOg+A5vhbDFaXtjr8K3Frt8QNJtMLrFbSyJtVvMcyyeVK2V+Wug/Zr8C+Lvhfr3xL0XWdC2abqfi6/16x1pLuJ4J7a6+dEVN3m+ajfK+9FX+6zUr7eYS2aPQPjt8V7b4J/CnXfGNzB9sfT41W3tN23z55HWKKLd/tSOor5i/bi8M+OtH/Zl1C+17xk2vtdajpH9oaY2n2sFlbN9tt/+PPanmqu/b/rZZf8AgNfRH7Tnwbb49fBXX/BkF8mmahdrFcWV843LBcxSrLEzD+7uQV4x8ePDfxh+PX7N914Pl+HQ0fxit5p32qa81a1On3XlXcTyy27xStLs/d7v3qxNsP8AE3FC+L0F9hHqHxg1jxda+MNJtf8AhJYvAHw5+wtLfeKIZLP7c1+0yLb2sS3SSr8y7z/qm3fd+WuG+A/xE8dfH74W/EnR4/Gl1ovijw14kvPD+n+KodHgjuLhIFRopbi1ni8rc2/51RE/2dlXtQ8I/EQ/tIeE/HmseEV8QaF/wjR03+zdK1iKVfD+ovNvluF8/wAjzUeLanmIvm/J9yr/AOyz8OvGXw78RfF0eJtDjsYPEHjC612zu7e+iuIpYJYotu3+P7yv99Vo+0KOqsYXwR+J3inxH+y34h1PxF4t1S8+Imjz3mlarNFbWKXVnqkT+WsEEX2fyvnbytvmo3+tr3r4e6Nrvh/whptj4k1+48T6/FF/puqXEEMBmk/iwkCIqr12/LnFeHv8JdW0/wDa91CfTp4z4G8SWlr4j1yx3fc1Kzfyrd/+2v7p/wDetK+ndvy0r6JjW6R4F/wn2t/Fz4yeOPAnhzxDeeD9K8H29nHqGp6bbwS3s97cL5yRRfaYpYkjSJfm/dOzGX+HbzS+E3xQ8Vav8SfiH8HvGGpb/EegW0F3p/ifToIoZbywuFbZM8TK0SzxPw3yeW39z+GqM/wx8W/Bv9ojxb8SPCegSeMfDvjSztY9a0XTrmC21C2vbf5Yp4vPkiikV0b5laVW/wB6uq8C/DfU9L+JPjv4r61pUi63rVja2FjoFpNFLPHa2yMyo8hZYvPlldj9/wAtcJ8/VqmWvzTC9mzyX9j7wfrkfxX+N13N4/8AEd5HpvjeaK5s7iDTvK1L/RYvnn2Wqsj/APXJol+Vflr6X+Kek3OtfD3XbSz1nUfD07Wcmy+0to1niwn8Pmoy/wDjteEfsx6d8Q/B/wAR/ijL4n+GGuaBpPi/xLJrVjfyahpk6W0RgRNs6xXjvu/dfwK/3q+l9esW1bRb+0iZUluIHhVm/wBpacukf60E3bU+K/hZe/ED4b/8E9bPxz4d8f3FzqNn4W/teK08QabbXUFqsUUsrRW/lLBJuf5fnnefp9zmvULH4geLvB/wXsPjL4p8WPqGkWvglNS1LwxDYQKk955SyrNHOqpKjnJVl5T5vlVa4+18AfErSv2D7/4VN8Pr688WQ6DceGYobfUrDyp2ZHRLpGa4VfI6fe2y/wDTKvQfDPw21n4p/slt8NPF/h7UvA+oyeHYtAuVuLi0uGV1t0Tz4mgllVo93Tdtb5D8o4qr3v8AIlprl+f6HmXjL4/ePtBh0DxX4Zk8e+Nb+Se3TV/BD/DfUbSwaF9ole1uGsFlieL7w82eVW5+WvWPilq3jH/hPLq1vfGDfDDwFHp8D6frVgtjLf6pqMjy77fy7qKb5UVYvkWLe+77/wDDXJ/CPVv2kdPhtPAPjHwPof2axgFo3xItfECeVPEo2rKlgE83zdv97y13DtWzbeCfGnhn9qrxF4wuPDcvi7QdW0W10/RdTS+t1GgtFu8+KVZXV9kr7W82JZW+T5lo6It6tnjnib4leKPjp/wT38f+JtS8RX2j6xpMOr2091o9ulk1+ts8sSrLFLEzRb12b1Xyn/h+Sum+Onij4j/AD9kWLxZ4U8fyaje2cVk8sviLS7O4mWKcwQJFbtAlvEuzfv8A3sUrNT/AvwH8ft+yZ8WPhrquhQaRruu3OvPYyy3sUkE/2qV3t3Vot3yfOPv7H/2Kd+0p4S+J3xM/ZDtfA+i/DHUn8UajbWFvPaNqmnIlk0EsTy+a/wBo27X8r5fK3/7WymvzYfaijqP2gviB8QPhD4r+FmsaX4mW+0/xR4ktfDGoeHryxg+wr9oV9lxE6p56Ouz+KVlb+6tXvEXjvxl8N/2o/hz4VuvE0/iPw147tdS83T720tYv7OuLWFJVa3eKJH2P842ytL/vVyP7TGk/Er4mWfwffw78J/EFzLoHiew8S6nFcarpMXkRweaj2+ftnzy8hvl+TDff3fdt/GTTPiJ4i/aX+DPjLRvhbrt/oPhKPUG1OU6lpkb/AOmWqoFjRrz5miYfN2/uF6e/yuXb3mM1j9oC++IVx4wXRPEnjTwo+h6vcaVpjeHPAd7rNtcywfLK11L9gnRkaXcNkTROqp975657xl+0J8Y2/Zr+Hnj02MfgDxJdazZ6Rr2ha1oksdxI8t0sG+Iyt+6VvvfNE33/APZrY0/wn8cP2a/iN4rt/AXgzTfij8O/FWsS6zb29xrkel3eiXE77rje8qv5sW75vlVmrQ/as8I/Ezxr8J/DWjaL4NuPFviGbX7LWb9dP1K1gtLJbedZfIV7mWJ26bF2r2Zm2/dpdSHqdH8RfG3jP4V/HL4U2z+JpdZ8OeM7+fR77R5rOBIrWRLdpYp7V1TzeqHcsssnHSuJPhHXLr/goLqkafEHxJaw/wDCFRamtvAti6RIdQ2Naqstq+2JvKXlf3v/AE1rU/aDs/iH4y+InwX1vw/8KdfvrDwzqf8AbWq79S0mJkWW3eIwKrXvzypv/wBz+67V1OreBvGGj/tcWnxBsPD51bw9qPg/+wJ5o7yCJrG5S7edHlR23eW4bbui81h/cqftIVrJnt2rWdxqWmXNtBe3OkzTRsI721WJ5YGb+NBIrpuX/aVl6V8zfCXxJ4813wL8YPD3iz4o6pbeNfB+tXFv/wAJAmmacjW1r5ST2sqwfZfKZXi+/uVm+/sZOK+r8fLXz74n+DOut+0tB4o0kxJ4S8RaTFB4ojkZcyz2cu+z2r/0181kf/Zio+0VH4Ucb8HPiR43+JH7KOlT3XjPWLD4m3WrNod5qBsbBbizv0uvKli8j7P5Xloqs+3Zv2/xfx1sfErxx8Qvh/8AtH/BDwhF4qh1Dwh4n+2219HNp0S308trZM++W4X5P3rujfuootuz/arb8H/BXWPDP7S3jDxGjw/8IBqixa5a2iP88WttE1rcPt9PKX/vqWub/aC8O+Pte/aT+DfiDw/8OtV8QeG/Btxfz3+pW+oadEsourcRfuopbpGbZzu3Kv8As7qcug4vXUwD4Q1q6/4KB6pFF8Q/EtrB/wAIVHqaQQrYSxxodQ2vaqstq+2L90v3f3v/AE1qf4c6dqesftqftHWmn6zNoRl0zw8j3tpFFJcRf6LLtMXmo8X/AH2jf7tdxrngfxfo37XFr4/0/Qf7b8O3/hH+wZZoryKNrK6S6e4R5Vd93lMrbf3Syt/s1y/wy0b4g+Hv2q/i54w1L4Z65a+G/FFpYQ6bd/2jpbvvs4JU+aJbzcvm5+T/AMf2fwtu1hwesr9TtP2Vfih4h8f6J450vxTqC6vrHg/xRe+Hm1SO3W3+2xRbGildE+RX2uN2z5ad+3V/yaL8Vv8AsBTf0rkv2QvC/jzwf4i+Lp8X+ANR8L2nibxXd+JNPurnULC4Ro5fKRImW3ndkl+Td02/7Vdj+2L4d8VeNv2fPF3hPwf4Wu/FGteILN7CKO1u7WBLfd/y0laeWP5f9zc1KXcmLszK8bfGn/hWPhX4U6FCb+PUPEsSxC4sNJudUntoILTzZXS3gidpX+4n3Nq79zfd55v4efEzx5qnxfvvAsd/468Q+DNV0SW4s/G2veDJdJu9Hv1/5ZO0thBbS/L86bovvfI26mfEL4X/ABI8eeAfhZ4v8KaavhH4oeAZPMh0HxBcwSw3cTxfZ7i3eWCV02yqnyv/AOgfw+l/B7xN8V/HXlXvj/wDZfDKOyJ26fba8mqXF4xXbl/LRYooxktt3Ox+X7u35l0bElbQ4r9mTxD44j8XfFrwp8SfH154j17w1qKJafaLGzs4l0uWLzLe7XyoE3M371X3bl3Q1DffFLxJ8GvhXoGp694p1jxfrfjTXVstHmvdDS4lsbWXzZYv9EsLeKWV1tYtzrs/1v8AcWtT41/A3XPE3xt8HeLPC/kQ2Op2k/hrxh5hX99pTfvU2f7W5Hj/AO29bf7UHwc8QfFfwTok3grVINH8a+FdWg13Q5bpf9FlniVl8qXb/wAsnR2Wi+iY+p574b+LnjeH46eH/DunSePvGngXxFDdC81XxB4IutIm8O3CpuiZZ2sLeKSJ/uYdGZeu7+E5n7IHg/xBZ+N/jZI3xA8Q6n/Z/jW8tRBq0dnPDeS/YrfbLcbIFl3r8vyxSxJ8i/LXqnwj8YfGXx5PEnj/AOHen/Da1sXzLNb+IItSm1B1/wCeSRJtii3f33Zv4dv8dZXwZ8F+Mfhh4/8AjAt74ZkvdL8QeIZfEWn6naXkGyeJ7eJPs+13D+fui/jVYvm/1tS9Ob0f6DRxnwb+KHxV8YfDn44f2j4p0dvFfhDxPe6VY6l/Yn+hrBbRRP8A8e6yq3z/AD/elbbv/i27a6/9mzWviJ8VPhb8MPiBrHi+NRd6Y8+q6HFp9v5Go71/dN5u1XidW5+T5P4dv8dedfBvw98TvB/hv48pq3wi16G88V65f61pFtDqukv5qXSrGkTt9s2oy43N/DtH8Tfe9M/ZV8PeNPCv7M+heC/Efhq/8HeJNF0n+zlmubizuIpJdrbZImgnl+UfL9/ZVLb5L/gkvdHkPxQ+OnxH+EPgOx8Z+IPGsUPjxdTtU1X4a21tZ3WmWdrPdeUqtNFE88TeV83mvPtZx93+CvfPHXxD1LVfjFpPwt8P6g2g6heaLca7f6xDEktxbWqSLAiwJKjRea8r53SqyqsX3H3/ACfOWtfAz4n6t+xK3wzg8AtB40sb63uL66n1e1ZNblivUnluopfNyzy7N3+keVXpvx2+F/xMh+J3hL4zfDHS7PUfFOmadLo2q+EdSvUt/wC0bB381ES4+5FKr/8AAf8Aa+X5r/lId7ux0+j+KPiB8HdN+KV/8RbtfEngvw3Z/wBq6L4ixAuoXkCxM80U8UCRR74mT7yqu7dXkPjL9of4g2fg/RfG3hNvHPibxGxtZbvwEvw51FNKuIJHXzUgumsFlWREbiVp2Rtn3Pmr2yz8O+M/jn8M/Euj/Erw5beAI9e0qXSxo+m6x/aU0CSrteSWVYkj39NqruH3vm+auB+Ddx+0h4KtNN+HXiDwPoOr6bpsH2OD4kLryxRNbp8kTNYbWlafZjjcif7Xqn1NLpctjG8QeFdZ1n9uzw89t4+8VaOL7wTdahFbxx2LfY0+12qvbpFPavtV+NzMPN+T71dx8TfEfji38UeLpNU8cyfDTw5ZpHH4VXR7azvrzXpRAZbjdbywzyvsf5BHEisQrH3q34u8A+LNN/ag8H+O9H0V/EGhQ+Gbrw7eOl3FHNayvNFKk0vmsm6P91tbyt7Z/grK8I+A/HPhf45fFrUr/wAJtrsXigW7aL4mbUoFhs7VINv2CVWfz4kWXc/7qJ1bfTvflFe9zh/E37RnxJ179gCx+M2galo2g+KI9PN3frLp32iKTbM0D+SGl/dN/H86y9Nu2uu+PvxA+Ivwu0b4aeMtH8UR3EOqa3pejan4curC3+wzxXT7fNR9nnpKuV/5a7f9mvMLn4OfFXSv+CeSfB6H4eXeoeMprOXTTbw6nYLFD/pTy+cztcIvl7Nu3bubc3zIldh+0TpfxM+JHwn+G2l6F8I9dk1XTdb0vWNQtbjVdJiFqlnL80W/7Z87Pt+XZ/C/zbW+Wo+0xr4Udr8QPGfjP4XftBfC3TJPFsus+HvHF1eWF5o91YW6xWEkVr5qy2rxosvLJjbK0v36+kq+Tfj5Z/ETxZ8Wvgn4m0D4U+INR0/wpeS6pqe/UtJilTz7Vovs6q9780qb/m/h/uO1e+WPiHxHJ8Qr/Sbjwk1r4Wj0+K5tvEh1CJ/PuGb57f7P99do+bf92mB21FMp9ABRRRQAUUUUAFFFFABRRRQAUUUUAFFFMoAy9c1yx8N6Pdanql3DY6faxNLPd3EmyKJF/iZqwJPi54LttQ0TT7zxRpOmarrcay6bpmp3aWl3dL/0ygl2yt/3zXnv7QNzLf8AxC+Cvhqd9ui6z4nllvotvyT/AGWyuLq3Rv8AtrFE/wD2yqb9oD4d6d8Q/BeueAdPsbZ9W8YyK1zcuNz2qrsVr1v9qJFTyv8AbCULYD03TPF2l6tq2qaTaXyyapprqt3ZkMs0W/7rbG/hbqrfdroq8D+L0j+EfjN8EL/TX2Xd/qV54dutz4e4s3spbja397bLaxN/+1XvEjNHFu2s5/urQ9FcOpJRXz1pv7V1xrPxA1rwTZ/CHx9L4n0a2ivb/T2k0RfKil/1T721LY/3f4Wrt/BvxcvfFPjCfw7qngHxR4OvEsTfxza2bF4J494RtklrdTgsu9fl4+9SWquLrY9OpKWvFv2kfj5L+zz4NTxEfCWoeJLFriKCaW1uoIIrR5XSOPzd7b8M7gfIjUru6XdpD6M9porxP45fHqb4J33gqJ/Cd/rlp4l1mz0L+1IbyCK3tJp5VRd4Lea3y73+WPb8uCy7q9r7mq13DsL5dFFJxQHkLRSNXKeIte8Q2Hijw1Y6b4XOr6RfSyJqeqi/jg/stFjLI/lt80u9vl+Tp3pXC2h1leZfEz4WXfjnVfD2v6N4lu/C3ifw+9w9hdJEt1av58Wx0uLd/wDWp9z7ro3y/K616Zj5cUo4oW4tlc4Tw74f8VSWoTxfr2j63Kkm9F0XR5dOibaV270lurhm2sP7613WBSnmik9wtHcQ4oFJ/FXjXgX47XHi/wCOHi/4dXfhDUNBufDlpFei8vLuB/tUUrusbqkTvtVwm75m3f3kWh6Ct1PZicUtch4a1zxBq2teJbbWfDZ0WxsLxYdMvft0c/8AacHlKzS7F5i+feu1v7ua670oW9v66BzaXForxn4mfHmX4b/FTwJ4Qn8Jahd2ni28+xW+vfaYFtYpRFLIy7N/ml9qf3FX5vvV7NUra5T0dgoopGqkB4tN8IfFvhPxZ4g1nwD44t9Ki8SXn26/0nxLozataxz+UkW+Dyri3li3JEmVZ3X5P4a9M0nR7i1c3N9Ol9fFQjTLD5SqvdUXkqv1ZqorrniD/hYcmkHw2V8Lrp63CeIvtyfNdb9v2b7P9/7nz7/u/jXWCmmS9WFFFPpbMdhlFPplO4bBSfw0tfO3xP8A2zvCPwt1y7tZ/C/jjxDpmmyPFqviHQPD8t1pWksn3/PuPlX5Q2W2bttJsb2PohulLXOeCvHGifETwrp3iTw9fx6no2pQ+fbXkX3ZFrxe1/a6tdW8eQ+GdK+E/wAUtUs7i9Wzg8U23hwf2LKrNj7Qt00qjyP4vMx703q7Cekbn0XRXAePvitpPw9vtH02a2v9Y1/WWlj0rQtKhVrq9aNN77C7JEiqv8Urov8AtU/4f/E7SviE2p2ltBeaXrejyJBqujakirdWEjLvRZdrujblOQ0TurdmqY6jeh3lFGapabqVrq9hFeWc6XFpKu+OVG+Vlp2Fcu0UjULQ/IL62Foryn40fHKz+CthpsjeE/FnjW+vXdU0fwZpX9oXqRr96Vk3JtiXKru9XStP4U/FQ/FLwe/iG48K+JfAkCySp9i8YWK2F2FXrL5e9tq/71Ppcb0PQ6i3/fP0rxvTf2mvDWppp2qjTtas/BWqXK2lj4yuYIk0u6neXyolX9756q7/AHZXiWJv7/zLnsPiJ8S9G+Gdjp82rtcz3ep3S2Om6ZZRGa6vrlvuRRL/AOzNtRfvOy9abWthNdmdoX+ValrzrwH8WrDxxql/or6dqHhzxVp6JNeaDrBhF1DFIXEUv7qSWJ422P8ANFI33K9GxRcfcSiikAxzUtX8gFpF6UtFVYewUU5qbSuRbUM4ooopjeoUUUUmMKTrilrxn4N/Hqf4seOPiJ4YufCN/wCE7zwfc2ttPHqN1BLLK06PIhxCzqvyhG++33qTfXsJto9l+9S009qVulJaJrsMU0eXSL0pavoAUUUUrdgCkz0pazbfVLa8vLq1imWS4tXVJ0U/6tmXcP8Ax01LV9BNtK5oE8E4qWouua8c+Jnx5n+G/wAVPAXg+bwjfXlr4tvPsNvr32mBbWKYRSysu3cZWfan9xV+b71C95jeh7Pim0hPFZGrXkthp91c21jNfTRxtJHa25RXmbqFXeypub/aZabVgWtvM1jS+leOfs+/HI/Hnw74i1M+H7rwvLpOt3Why2N7cRTyiWDbv3GP5PvMy4VmHyfer2MU7bExkpJ+TsLXKfELSNe8QeEdT07wz4ibwnr1xEUs9aFlHe/ZH4+fyJflk78V1dFS02h3secfCv4d6j4F0yebxB4mvvGviy/WJdR8QXlrFa+eI87FSCFVSKNdzHZyfnb5mr0egUi05PqC1ForkfCOva/rV1r6a54b/wCEfis9Qa306X7fFdHUbXYpW4+T/Vbm3Lsbn5PeuwWhuzsG42il206qCwzGaKfTKTVxhRRR/DTAKbuwKdRUtNgN3c0q0tFKzXUbYUUUVSJQUUUUN21GFFFFG6uAUUVj6teTWGn3VzbWM9/PFG0kdrblFkmbsq72VNzf7TLRsHVWNfNFeO/s+fHI/Hjw94h1M+HrrwxLpOt3WiS2N5cxTTCWDbv3GP5B8zMvysw+T7xr2Icim9rkJ817dG0LRUczbI2dUZ/9lf4q8g+B3x2n+M+reOdPuvCl94QvvCuqJpVzaahcwTzM/lLLn9yzx/x/wu1JXbsVY9jozxQfvU+ktUMZniin0U7AMop9FD1QDKKfRQlYBlFPopgMziin0UnqKwyin0ULQYyin0UwGUU+igBlPoooAKKKKACiiigAooooAKKKKACiiigAplPooA4H4o/D6P4haHZxw3Q07WtLvI9U0nURH5v2W6iztbb/ABKys6Mv8Su1c/e/AHQvFWoS67rcviSy1/UI4/7RTQfGesWdq7qmzakUVxEuz/gC169RQtAPL7D4YvN4+07XNREC6f4ctmsvDmm2+90t1dESW4lZvvS7F8pf7q7/AL2+vTaX0qvIzIjNtZ/9laUtULqj5Ft/E2q+Ff27viPNpng/W/GLy+EdJV7fRZ7GJ4v3s/zP9qurdef9jdXtfhv4lPJ4N8R+M/F/hm58IvoJvPMtdQaCW6htYkSVyzxO6fPt3fK+37leP+B4/iPZ/tZeKvHWo/CHxJZeGdf0fTtIhuG1TR3lt3id90ssS3v+r/e/wb2+T7tfTXjDwzYeNvCeseHtTTzNP1azlsp0/vRSpsb/ANCoWkUD3Z896JrHxX+J3wVsfip4e8XNpOs6jpz6xpnhF9PtpdJkgbc9vBcO0f2nzWiKbpI50Xd0TH3vOv2lfi5a/Hf/AIJ72XjuzgFmmsXWkyy2wff5Mq6lEkse7/ZdH/KvQfg7ofxW+D/woh+FNz4P/wCEjuNJtpdP0Xxbb6hbQ6ZLB84t/tUTS/aomVdm5YopfZq4z43fs9+KPCf7Hfhv4MfDjwreeNL21azeW9hvLOzhVoruK5laTz50b96wfaE3471cZRVm+jRnO+y6po6/9u//AJFz4N/9lL0H/wBGvXaeMviVrHiP462Hwk8N6rJoVwuhS69rGtQQRS3FvB5vk28VusqvEJXbc+6VHXbF93564D9qzR/iL8UPDfwtXw18Lda1C50rxPp3iTU7W41PS4ntYrZ23W+5rra0rf7G5P8Aarc8cfDHxbY/HLwt8cPCWhS3t82itofiDwncXNvBezWjsJk8qXeYPPil/haUI3/PWlF+4lfq/wAkaXskvIseG/iR4v8AB/x+m+DnizW5Nfttb0SXV/DnitbW3gvl8p9k0FwqqIHlT76ukSr/AHkrC+DuteOtQf41+CvGXxQ1X/hKPDGoKLTX/wCz9Nia102WLz7e4WL7L5bbhvSXcrf6r5dldv4f+Her+OPjtp3xR8Q6LL4aXSdEl0vSdJvJ4prxHndWnln8hniX5URFVJX/AIzVL4g/BPXda/aE0TxZobxxeHdZ0h9G8Wo7qTLBBMs9rtT+Lf8Avom/2Jam9hxs9zgvgd8TPHHjz9ljVZNX8aasnxSi1qbQJdSbT7KKa0v/ALQkVun2f7P5XlbXidtys21n+f8Au7/j7xr8Rvh3+0Z8DPCB8XW+r+E/EpvbXUPtGkxRahcS2tk0u+WVP3fzsyttiii27fSt/S/gfrmi/tS6t4st3gj8B6paQarPaIfm/tuKJ7Xzdn91reX/AL6iWuX/AGgvDvj7Xv2kvg34g8P/AA51XxB4b8G3N/PqGpW+o6dEsourcRfuopbpGbZzu3qv+zuqm7WHB6u5euPiF8RF/bUT4dHxFp6+DrzwtLrkFtBpOy4t2FxFF80rO/mt9/5vkX979xtlaHwP+I3iqT4xfF74beJdYm8Up4QOnXmn6vc2tvDdTQXUDS+VKsCRRM6Mh+ZEXrWDq3h3x8v7c+neOYfhzq0/gu38NN4abWE1DTsmSS6WX7R5TXXm+UoH9zf/ALFHwf0Hx/pP7WHxa8Xaz8PdU0Lwt4ptrC3sdSutQ06VY/scTpvljiuGkRX3fLtVv9rbQ9NSlaV7nK2/xq+JPi79lzXfj3o/iqPTLyxgv72DwbeadBLpqwWtxKnlXDbftPn7IvvpOq7/AOCvpf4S6tr3iH4e6LrHiK6s7zUtTtYr1m0/T5LCONZUDqnlSzysrLu5+evivR7H4satHJqF7+ytF4zW/vJr+4vrH4kxWOjawzSsUuH0tv3Uny7NrSxM3yI3pX2v8LfG9z4/8IW+o32g3fhbUFdre80e+dWls51Yqybl+V1/usvBo6NmUtZKxw/ijx5rPiz40SfDDw7rUvhxtP0dNZ1rWrSGK4uolld4reC3WVXiRyUldmeJ/lVPl+fcvmnwftdb0v8Abc+Ldpq9+mq3lv4V0mODUmt1V7iPfPseVF2rvz8rbAq/J/DXVeNPh/4w+H/7SR+K/g7QZPF2l63o8Wi+INAt7m3t71fKctb3Vu07JG+NzqyvInaqfhPwX8SbL9rTxT4/m8J2UXhHWtDsrDdcaun26Awea/yxIjqzln2/6xE/22qEtF8xt/F8v8y9+zb8RPiB4o8Q/GLR/F2qafr+p+FddXTrD+z7H7BA6/Z0l+5udl3M/wDE7V5n42+N3xE+FGi+Ctf1zxul340v9a06x8SeALexs7rTdLW6l2siywRefEy/wvLcMrN610HwZ8IfFBfEnx6N/wCCdW8Av41u5dS0HWrvUNOuUtZPsi28XmrBcSssu5d/yo68fe/vcpqnwe+I+o/sn+DvA1p8OHsfEPh3WtMu9TQ6vZn+1Ht7pJbi6t3835/NIeX9+8Tc1cbczYuiPS/2rf8AktP7Nf8A2OE//pFLUXjnXPH3w7/av8Cwar8QtSb4XeLzdWttpRsLBEt9URN8Nq8/2fzfKlTzdvzb9yfeqD9pHRfiD4i+Knwc1Xw98M9W1/TfCmsPrGpXNnqWnR5jeKSLyolnuImaXDbm+6nQbmruf2sPAb/ET4CeIfIuhpGuaRGmv6TfSt/x53tr+/if/wAcK/8AAmpW1SHfqTtceK7j4ueLtTtPEuqXnhbQtMiU+GUtLPyZ9RaJpSiy/Z/P+VPJbG/70vttrhf2d/jZc/GrS9E1fQviba+INXllik8TeEtQtLeC40b5GWWG3iVYp4tsv8Vx5+5Uba1ep/DvRvEWi/CDzbxI08d6jbS6jfLu3Iuoypv2fN/AjbYl/wBhFrxrxp8EdQ+JPxK8D+KH+HkXgPx9oOrWt/qXjbT763a3vLdf+Pi3h8p/PuBKP3X+kW8XDf8AAWXVoOlzpPCfxG8dN+2V4l8Aa1rdhe+FoPCy65p9pZaZ5Dw+bd+UiSszuzsqo3zfIvz/AHa5rwn8eL/4jeNPGuhab8RIfD/xE0XULzTLb4fapaW0UE0UU37m4XzYlnklli2tvSXy13/6qrmj6B8QP+G4NV8bz/DrVoPBl14bi8NR6w+oadkPHdNL9o8pbrzfKbP9zf8A7FUfj58Etc+P3hefRPEPwytZfGayT/2D46sr21RNJCylreWWXel0j7Qm6KKKVNy/eqk7WREbu59bZ+WnfxV5RrvjfxT4F8XeDtBTwjPr3hq/iS11Dxal/BE1rdfKsW61b95Krnqyfdr1ZflpNF7JI5rxxqWt6Z4Q1u58N2EGqeILezlk0+wuJhElxPt/dI7/AMO5q+WNb+Nni/4Z+OvhNZ3vxB/4TLVvEmuW+heJ/Dv2Kzey0m4lg3usE9tErROj/dinlld0b/gdfQ/x58K+I/G3wd8Y6D4S1H+zPEupaZPbafdiVovKlZTt+dfu/wC9Xzx4o+FvjnxJ4D+AVvpHwvm8OR+B/E2nX+paG+q2fnRRRRNE7xbZWilT593zSrL/ALNTB3bTFNaWR9lL93NcX4s1DSvh54Bv5UsVks4YmWLT4V3Ndyv92FR/E0rMF/4FXVWrSyW0TTxrFLt+ZFbdtb/er5S8TfFD9oNviNf6ja/s0TeIdGsJimiyXXjfS7Ixpt2tO0X73Er5bnd8qfL3Ys5K7SFG/LY774Jfs8n4f/su6X8MLrU7zRbuXT54b280SVEltZbp3lm+zuyMq7WldVbb2FeWpbfE39jnxV4LtdQ8a33xN+D2sahBoMp1+NP7U0KWUiO3bz0/18Tuyod/3flr2fQ/HHxaufhHfeI7/wCGdpYeNhPvt/Bf9vQt+4V1Xb9sVfKaV1Duv3V5RWK81euNJ1T4x6XokHiTwpd+FNNtb6DUruw1e5tri6ee3l82FV+zSyx7fNVH3F/4Nuz5vlq9pNldLHj2k3s+vf8ABSzXo7wSeRoHw+iSwRvuq092jSv/AOy/8Bpv9pXOj/8ABTMWVqHW01j4cLLeIrfJI0V84idv9ofd/wCBV6F8RPhjq2i/HfQfjB4W0l9d1CDSJ9B1rRIp4ori9smfzYngaVkj81JV+67orK33htpvw0+Fur3nxo8UfF3xRp/9k6vqmn22i6Vo0kyTTadYRnzHErxbk82WV9zCJ2Rdi/O9JLVC2u+51f7Qml3+rfBfxhBZa/qnhy4XTLmVb3R3iW4+WJm2BpEfbu6fLhv7rLXgfwx8fah8Af2HfBfiiTW9S8XX+oaJo1po2laktqkNvdTpFFFEjwQI3lbn+bzWlban3utfU3xC0KXxN4D8Q6NasqXOo6dcWsTN93c8TKv86+af+Gd/E/xQ/Yx0X4W69p7eC/FWgadZQWF9NcR3CC+swuyZfKZ/3T7F/wBr52+X1mOjlfyG0+VWNv47eNPiF+zL4Ni+JNx4vm8baFY3VqniHQb7T7WGKK3ldYnlsngiWVNrurbZWn+Wvpi0u4r62iuYW3xSoro3qrV82+PvC/j79ov4Uv8ADjxV4Hm8I/2jLaxa9rEuoWlxaSW8cyyzfYPKlaVmfytq+bFFt83d/Btr6Ts7OKztYoIl2RRLsVf9mqXwoppaNHz18Z/2dfGXi7xpd+PfAXxd8SeCfFgs4rSHTpliutFkSN9yo9vs/ibdltzMN/8AwGvJfi1+0B4m8af8E/firqmr6eujeOtGNx4Y161tG/dR3PnRQStHu/gaKbd/wOvpdfHfjyPx1qujXPwzupNDyDpviOz1ize3kXYP+PiKR0nibd/cil/hqne/AfSPE3wr8beDtZ2yHxi11Pq1xajafNn+UOv/AFyRYlX/AK5CoUQTs0ebfH3w3YWH/BPXxLpSxD7HYeCE8iPb9xooEaL/AL5ZFry/4f8AjHUviN+1L+zZ/bhkle1+GD6+u/8AivbhEilf/vla9G1/4a/Ej4ifA6z+CGr6M+mobW10vWPGy3kD2tzYROgdreJX8/z5Yk27JYlRd7/O+35uy+JvwVu7Lxv8NfHvgrT0uNW8EpLp50hZEi+36ZLF5bwI7fIsibUZN21eq7l3Zq7rfz/QzV4pLtc4T4u6hP4f/wCCgXwLksE2Nrmh6zpt8U/5awRqsqK3+6/NfSvjCHW5vC+oL4f1C00jW2ib7Nd3tm11DE395olkTd/30K8k8KfDnXPG3x+X4t+KdIk8OppWjtomg6BdTQT3Vv5r77iedomeNXb5EVUlYbQf71eteNdQvtJ8O31zpmjXniK9WP8Ac6bYyQRyzMf7rTyRx/8AfTVM/dhFLpZfiON3K58k+DPi18UfiB+wi/xXbxqdH8X6dZalrBNnpts1rdfZp7j/AEeVZYm/d7Itv7rY/wDttW38WvjP4+8Nfsv+FvjlY+IjYXaWul6jeeF4rOBtOvYrp4FeFnlRp1b978rpKv8Au1y3wt+H3xT8J/sF6t8LdR+FmsDxg2n6lpUEMWq6U8Uv2prh0n837V91fNUNxu/uq1S/Fj4e/FLxl+wboXwv034X6u3jBbDTdMntpdU0tIYvsj27tL5v2r7r+U2zZ8395VraXL7R9tDSpZyjbzPbPjb8Vtc0j4kfC74eaHdNocvjae9E3iBYVlezit7fzdkCyK8Xnv8AwearL8jfK1cz4D8b/E3T/wBpvVfhbqPijTdc8O6Xo1tr66nf6H/xM7qKWZ4jbyy28sEETqyZVvs/zL/DWT+0Vq3j3xNonw2t9N+Eg8WTTTT3uoeDrzxBb6ZqdrLEm2GeK8iZ44liZt2+KXf88XT5qT9nvxV4x8HeK00zxV+z9qPw6tfEEohk8VXXjSLxLcXU6K3lRXUrM8+3G5U3MwX7oxWd03ddCZroj6A+LnirUPAvwy8UeItI09tW1TTNMuL21sFVm+0Sxxs6p8vqVryj4CfFBfi1Do2reEfirB8QNImlebWbW8tbWK807dbt5cSxwrE0SLLt+WVZX/6amvZ/GUmuxeFdVbw2ltL4hW3f7FHdtthaXHy+Y2G2rXz1N8CJPEX7QnhD4g6T8P8A/hW+uaLcyy6/rUN1amLXYJYHUwIsEu+X96U/e3EUT/JUxWrYnqkuxP8As/eLfGvir4ofHrwPrnjjU9WtfDV9ZWekarLZ2EV3bJPatKzfurdInbd/eib7tcBonxu+Kx/ZE+KPjCHxhZ3fiTwfrOtQrqOraPFK1xa2bsqRbIPs8SS/Kvz7W/3K9O8D+AfF/wAK/wBpD4pa3a+GZNd8N+PHsby11a1vII0sJ4LcxOl0kr+btY/daJZf9yvGb34e+Pvhn+xz+0fpnjPRbHTbS+Ou6vYTw6j580qTtK3zxKm1P7/+tb733VqpOxKu9O56X8U/GnxP8C/s/wClfGDS/FbaleaTpFrqmr+F5bG1XT7+DajXH7zyvPil2szb1k2/J/qqt658V/Hl3+0t8NPD+j+ItPh8DeMNFvNXitTpOLqBYoosBpWlfzGzKW+VYtv8W+s9dF8cfGb9nHSPho3hWbRrfWNAsrHUPFc11avp32No4xM9vEsvn+a0WdqNEiKx+/8AL82b8XLW+8H/ALYXwHt/DelHVRpnhrWol09Z0illt1W3XZEzfJ5n++yL/tLVW1sTGTlBNHaeF/H3jP4d/tKWfwx8T6/J4v0DxFo8+q6FrV9bW8F9BLbuv2i1lFtFFEy7GVlfYv8AwKsT4D6jFov7TH7VeoXL/wCj2t9o0sh/2V03dXa+H/Aeu+Pvjdp3xP8AEOiT+FLfRdIn0vSNFvJoJb3zJ3RriedoGliX5YokRUlbjfu/u1wXwT8KeOf+F6fG/UvFnw11rw54V8fvaNZ3lxqWnS+UkFr9ndZUt7p3Vmz8uzdUPVNfIFd6s5PWP2lPGvir4XWfxC8F33jVvEk0CalYeCofh1f3OkX8TfMlu90LDe0jRf8ALeK5WLd0Xb17bx18YviTb/FT4DR6bd2mg+G/HDumoeH9S0d1v7SVbN52SWV3/vfwbI2/dff+asT4N6T+0P8AAa1074VJ4G0Xx94Q08m20fx1Lr6af9ks+fKW6tdjyyOn/TL/AGRu/irU+Pnhr4iX3xe+Cmp6D4D1jxppfgi6nvNU1S31DTrb7V5tv5X7pJ7pW3/ebDbV+781Env5mq11Nb/hMPH/AIY/a0j+Hcvi0634Y17w5PrcEmoafAt3pc0dwsTJE0MUSum1/lMu9vXd/Enw8+LfiDwV8VPjN4S8Z+IbjxTovgzSrPXrXV7u1gt7zyJYpnlilEEUUTbfK+Vti1R1zS/iHeftoeH/ABtD8Mdam8G6f4fuNAm1Q6npnMktwkvnrEbrf5S7P9//AGKy9D8BeM/En7Svxeu/EHw51rS/AnjjQrfQV1RtQ05pIhBFMjyukV00u1/N+XarN9zcq1T0SBdTnPE/7R3j3UPhrpvj/wAIP431TxRJBb3yeAovh5qLaPeRSNvaBLz7B5vmiN/9es/lNs+581egeMvit8Q7f9pf4R+HbHVbXTPCnjLSb+9l0m40cre2rwW6Ptkld/nbdL9zZFs2/NurF+CsX7SHwjs9K+F+o+B9B8WaBpUQsrD4hHXltUSzTKxedZbXlklVNvyrtXgDf/FV74o+GPiC37VHwj8S6V4A1rxP4a8IWN/ZahrSalp0TTtdQxKHijlukZtrJ8+5V/2d3FIz1ex0HgXxz4s0v9pzxr8LNa8S3Gv6S/h6DxFpmo3dtaxXdh5s727wZiiSKRdy7kLpu/vb64n9j3wprmnfED403M/j3xNrkWn+N7q0ax1JbJo75vstvtmlZbXzEb7v+qaOP5V+TrW3o/h/x/8A8Nw6r43n+HOrQeDLrw5H4aj1dtQ07iSO7aX7R5S3Xm+UwP8Ac3/7FbHwl+HnjbwJ42+M1jJpPkWXijX59c0rxBDdRfZ0WW1ji2+Vv80So0Wfu7fm+9Scra2GrtNM8r+J3x1+I/wh8B2HjHxB41jh8eJqdqmq/DW1trO60+ztZ7ry1V5Yonnibyvm8159rP8Aw/wV6T+1X8/xn/Zq/wCxun/9Ipa8m1j4F/FHVv2J5Phjb+AWi8a2d9az313NrFq6a3LFepPLdRS+buZ5dm7/AEjyq9F/aM0n4ieI/iZ8HNU0D4Xavrdh4V1htX1K4t9U06LMbxSxeVGst0jNL8+5v4enzPVNJbdGXLU+rmFfP3hDxd4i+OniLxlceHfFtx4T8NeGNbfQ7cafaW1zLqN1Aq/aGnedZf3G99myLyn+Rm835uPeIZGmjR2jeJ2X7jbdy184fC3wF42/Z5+InjfS9O8MT+Lvh/4p1uXX7G+068tbeXSrif8A4+IriKeVN0W/5leLc3+xUvUSb08jyL4B/F6b4E/s1/Gzxpq9nFfarYfEDWY1s4TsSe8lukiRP9lfNf8A75r1f41eIPih8A/hvL8Tj4tbxjHpCxXHiDwvc2Frb2X2XKrObN4o/PiZfvfvZZ+ledeD/wBlfxz45+CPxo+HHjfStL8N2/ifxJf6/pGq2uofapY7iS6EsW6JU+VP3SNu83dtf7q16R4q8P8AxL+N3wZvfhj4n8HSeG9S1K2i0/WfE3262n02WHcv2iW1SKXz3dlU7Ulii+996q6WJS5dF1bY34rftGaTofxL8FaFq3jyf4a+F9e0dNXsfEIt7fyr+ff/AMer3F1FLFEvlfP/AAt86/Mv8XRfEb4w678I/hRpmp63Pb6t4g1bXV0mwuNN06W5idLi4fyJFt4N8ku23w3lr87MvFXPiJ4TunsZPDV18M7b4jfDePS7a3j0eOSza7SdHdPliuniiZRF5XzmVWUp8u7NeTQfsh+Jrf8AZpPg/Q9XXQPEOjeJn8UeD4Lmd7qLSfKuDLa2Usv8abdyt/d3/wAez51bSxbRraP8Y/G2kfG7wnp2jt488feCdfmng1VvEngW80o6E2N8UsU/2C3Vov4Nsu9v9uvqHUI7mS1lW1kjinZW8t5oyyI3qy7l3LXi3wn8XfG7xpeLYfED4daX4BtbGVXm1Wx8Qi+bUSrD/UW8afuom9ZZd23+D+77TqE8tpZzSxW0t80aMy28TJvl/wBldzKv/fTCpkvdsKO58r/Bv43fEW4+F/x/1fxBcW3jHxJ4G17UrDTbbTtPNrFcfZrWJ1RIlLt877m+87fN96uv+AfxU/4WxDo2r+EPirb/ABC0WaVrjWbe7trWK70/dA3lxJHEsTRR+bt+SVJZP+mp5rjP2c/DfxX8HW/xskufh3c+GtT8S+Ir3xJoM2ranYyW7eakSxQT/Z55Xjf5Bu+VlrWm+BMniH9oTwj8QtI+H3/Cttb0W5ll1/WYbm18vXoJYHUwIsEu6X96U/e3EUT/ACVXn3Kk76I+qd1Opnl0+gQi18x/E74hfETQv2rvhp4Lsdb0xPB/im11KWW0/s7bdwfZYEO7zmd/NbfLuX5Yvufx/wAX04a+VPjVofxAuv2rfhd4x0T4b6x4h8NeE7TUre/vbPUdMiaf7ZboqeRFPdI3yOnzb9n+zuojqwexd8XfFLX/AIS6t4U+HWu+K9a8Qa7qsF/qNz4l0fwnJeXsdnHMqxKtpZxSqJf3sa+a0XlfuvufPVD4V/HjxPo/jD4gab4qi8WeIPAeh6K+u6d4y8R+FLjQ5mCf6+1m329vG0i/eVkiT5c1t/tFfDHx/L428I/FT4X/AGO/8W+G4LmyuPDupyiKDVbKfYzxCX/lnLuiXax+XNdF4TtvHnxo8F6xafE7wfB8PrHU9PuNLfQrTWl1S4ZJV2PLLLEixL8v3VXd985pRd1di6XOPm1T40eOPhHoPxR8Ea9HN4h1KC11W38BzR2a6VcWsuG+ztcPF54n8p/9aJVTev3NtdV4u+J2teIvjhpnwk0HUW8PX39gvr+taxbRxXFxaxb/ACYYrfzVaMStJufdLEy7Ivunf8vm3wJtP2jfhDo+m/Cq98EaB4m8P6PF9i074gyeIVt4ls1bbF5ll5TytKifwfKvybd/8VdT8RPhD4p8L/Hvwx8YPBll/wAJNcW2jN4a1/Q5biOC6v7Lf5sU0EsjLGZ0l/hlZd399aYXH+GPih4v8E/tCH4ReKdWj8RW+raLLrPhzxLeW0cV0WjbZLb3UUCxROyff3RrH8v51j/AnxZ8Tviw3xf8PeI/HSabqPhzxHLo9jrHh/SIImVUiiZXSOfz02/P8yP5h+f764rsdF+H+r+MvjRZ/FjX9Bn0NtE0OXStI0OaeCW9Msr753l8qV4F4REVUlb+Pcw6Vwf7Odn8SPAfiT4y6r4h+Emv2cPiPxBLr+lRw6npMrypsjiS3f8A035Zfk38/J975+m4W40UPhn8R/if8Wv2UL/xtc+NF8O+LNFXUl+1aPp9q8N/LZvKn79J4m+VjF92Lyv9+q3xE/aA+JM3wJ+CHxD8PalpOkDxTe6La6xp8mn+cz/bHi3eVMzfu14ZdvlP9/73y0nwL8I/E3wL+yl4x8G618KtYh8T3Empm0tLfVdLkS5+3Sysu2X7V8vleb82/b/s7q4zWPAPxhvP2ZPg94Bh+Dms/wDCQeEdV0m71HdrGjpbvHYtu/dP9s6vj+5/eqY7y+Q2ezfFXxp8RPhn+0B8LNMsfFq6toHji6vNNvNL1LTofJsZYoPNWW1aJFl/gf5ZZZetXdH8c+LvCH7WUfw61PxLceKPDeueG7jXrU6ha28Vxp88VwsTRI8EUW+La/8AHvf5fvVzXx3sfiL4x+L/AMF/EmhfCfxDfaV4VvJtT1LzNS0mKVfPtTF5SK1588qbvm/h+X5XarniXQ/Htx+2h4Z8bW3w31e48IWGgXHh+51T+0NOX5p5kl89YvtXmeUu35vl38fKjVS6L1Ecpqf7R3iH4jeB9T8U+Edd8aaTqcEt4dD0nS/h9fappeopFKyxJdXH2CXzPN8r71vcRbfN/wBmtPxF8cvirPqv7Pt9HHa+DbTxxdfYtZ8L6ro8i3trOlvLLLullfds+T7vlK3H3/mqn8NPC/x8/ZnvrnwF4Y8DaR8Tfh1LqVxdaNq1x4iXS5tIgll83yrlWikeTYzv/qkb/wBlrY+P3hf4k6h8Qfgzf6R4F1PxpB4V1eXWtZ1CwvrCCNvNili8mBLi4idym/8AiCrt2fN/dVrp+YWv1OotfHPi3wd+1lpngLUvEU3iXw34l0C51e2S9tbeKbTp7eVVZImiRN0TI/8AHub/AGqseD/F3iL46+I/GVx4d8W3PhLw14Y1ttDtxp9nbXMuo3UCr9oad51l/cb32bIvKf5Gbzfm45vxbo3xA1D9snwR4wtfhrrM/hDSdHutHutXOo6Wvz3TxN5qRfavN8qLZ838X39iN/Hd+FvgLxt+zz8RPG+laZ4XuPF3w/8AFOty6/Y3mnXlrby6VPP/AMfEVxFPKm6Lf8ytFub/AGKOliI3ueTfs7/Fa4+DP7PHxm8V6lareapa/EXV4Bb28UrpLeT3UUSBEXe+3zX+4u5q6/VPjd478OfEDwVd+HH8ffELR9W1KLT9e0fUvh3f6bBp0Ev/AC+W07WUWxEYjckssvy/xcVheCf2YPiL4p+DXxi8B+KrSx8IN4i8U3viTRNY0/UjdSxXTXSS2+6JYvli3RK27zd+1vupXqHwn8VftCeILqPw/wCPvh7ovhuG1REu/GVj4hS4S/2/eNvZIm9GfH/LV127v4vu1a2sEVyppdW2a9p4w1/4y/E7xn4W8P8Aia68H6H4Plgs7vUNMtrae8u7+WPzmTNxFLEsCROn/LLc7N95NnzcX+xmupx/Ez9oZNZkhm1FfGCrLLCu1ZR9ki2vt/h3Lhtta2h+BfGfwR+PXjbX/D3hubxl4G8d3UF/dQadeWsF7pF8kXlPJsnliSWB1Ct8r71/utTv2ffAfxH8E/Fr4v6p4g8Oaba6D4o1j+1bK7i1bzbgstvFEqCLyvu/J99nX/cpdRpn0rT6434b+IvEPifwnZX/AIn8Mf8ACHa5Kz+fo39oxX32f5vl/exfK25fm/GuyqUraFBRRRTAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKZRRQAUUUUmAU3d2oorN9fRjDdjinUUU4/ogYUUUVoIKTuaKKCX0FrD8UeHrPxZ4d1XRb4yrZajay2k5hk2PskXa21v4W5ooqWCPPPBPw3+IfgeOw0ZPiJp2seFbGBbaD+0PDp/tXylUIga6jukiZuPvfZq9P02xi0uEwRk8szM7fed2+Zm/WiimtkNmhRRRR1QIKKKKn7QwrxnXPg74s8V/Eq61LWfiTfyfD2Uwyp4FtdLtoEMsezPm3nM8sbOu/Z8v93O35aKK06oT2PZW6UtFFLqNbIKKKKmWwGNceH7K81mHUJ7YzXEK4hd3Zlj/ANpU+6rfM3zferb+lFFPsAfw02iikA7qKbRRTQnsFFFFMa2Cjy6KKlgFFFFNCCnUUVEd2MWmUUVoAUUUVEgCkHLUUUALRRRQve3DzPJ/Gnwl1jVfHMPjbwn4sk8M+JIrH+zXW+sRqGmXMHneZ+9t98T7vvfPFLH9/wDirqfDmha+sNpN4o1fTtZ1KBy4Olac9ja7vmG8RPNOwba3/PSiitIpEnX0UUVmCGV5X+0L8L9d+NPwv1zwVpXiOy8Mw61BLZX15daU1+5gdNrLEq3EW1v9pt3+7RRUv9Bx3/rsbHwl8K6v4G+H+ieHde1y11+7021S0W+tdOayWWKNdibomll+baPmO/Hoq15544+AfjXxV+0J4X+Jdr480fTYvDsM9nZ6M3huWbzLedUE6Sz/AG1dz/LlXVF2/wB1qKK2+2/mKmv3a9D6ANOooqUD2QUUUUwQUUUVPUoKKKKoqwU3d1NFFRLdev6EIN2MU6iipg20vQcgooorUSCiiigYUUUUmSwpG6UUUnsC3D+GnjpRRTexXUD0paKKFsAUyiimAUUUUnsyWFFFFHRCCiiikwCgmiip7FxCiiir+0hsRulLRRRHYQUUUUwCiiikAUUUUR3JYU5elFFN7jQtFFFAwooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA//2Q==" alt="" width="1064" height="680" vspace="0" hspace="0" border="0" style="width:1064px;height:680px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></p><p>Dosing adjustment for adult and adolescent patients weighing more than 50 kg with impaired renal function:</p><table border="1" cellspacing="0" cellpadding="0" style="width:0px"><tbody><tr><td style="vertical-align:top"><p>Group</p></td><td style="vertical-align:top"><p>Creatinine clearance (ml/min/1.73m<sup>2</sup>)</p></td><td style="vertical-align:top"><p>Dose and frequency</p></td></tr><tr><td style="vertical-align:top"><p>Normal</p><p>Mild</p><p>Moderate</p><p>Severe</p><p>End-stage renal disease patients undergoing dialysis&nbsp;<sup>(1)</sup></p></td><td style="vertical-align:top"><p>&ge; 80</p><p>50-79</p><p>30-49</p><p>&lt; 30</p><p>-</p></td><td style="vertical-align:top"><p>500 to 1,500 mg twice daily</p><p>500 to 1,000 mg twice daily</p><p>250 to 750 mg twice daily</p><p>250 to 500 mg twice daily</p><p>500 to 1,000 mg once daily&nbsp;<sup>(2)</sup></p></td></tr></tbody></table><p><sup>(1)</sup>&nbsp;A 750 mg loading dose is recommended on the first day of treatment with levetiracetam.</p><p><sup>(2)</sup>&nbsp;Following dialysis, a 250 to 500 mg supplemental dose is recommended.</p><p>For children with renal impairment, levetiracetam dose needs to be adjusted based on the renal function as levetiracetam clearance is related to renal function. This recommendation is based on a study in adult renally impaired patients.</p><p><br />The CLcr in ml/min/1.73 m2 may be estimated from serum creatinine (mg/dl) determination, for young adolescents, children and infants, using the following formula (Schwartz formula):</p><p><img src="data:image/jpeg;base64,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" alt="" width="608" height="96" vspace="0" hspace="0" border="0" style="width:608px;height:96px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></p><p>ks= 0.45 in Term infants to 1 year old; ks= 0.55 in Children to less than 13 years and in adolescent female; ks= 0.7 in adolescent male</p><p>Dosing adjustment for infants, children and adolescents patients weighing less than 50 kg with impaired renal function:</p><table border="1" cellspacing="0" cellpadding="0" style="width:0px"><tbody><tr><td rowspan="2" style="vertical-align:top"><p>Group</p></td><td rowspan="2" style="vertical-align:top"><p>Creatinine clearance (ml/min/1.73m<sup>2</sup>)</p></td><td colspan="2" style="vertical-align:top"><p>Dose and frequency&nbsp;<sup>(1)</sup></p></td></tr><tr><td style="vertical-align:top"><p>Infants 1 to less than 6 months</p></td><td style="vertical-align:top"><p>Infants 6 to 23 months, children and adolescents weighing less than 50 kg</p></td></tr><tr><td style="vertical-align:top"><p>Normal</p></td><td style="vertical-align:top"><p>&ge;80</p></td><td style="vertical-align:top"><p>7 to 21 mg/kg (0.07 to 0.21 ml/kg) twice daily</p></td><td style="vertical-align:top"><p>10 to 30 mg/kg (0.10 to 0.30 ml/kg) twice daily</p></td></tr><tr><td style="vertical-align:top"><p>Mild</p></td><td style="vertical-align:top"><p>50-79</p></td><td style="vertical-align:top"><p>7 to 14 mg/kg (0.07 to 0.14 ml/kg) twice daily</p></td><td style="vertical-align:top"><p>10 to 20 mg/kg (0.10 to 0.20 ml/kg) twice daily</p></td></tr><tr><td style="vertical-align:top"><p>Moderate</p></td><td style="vertical-align:top"><p>30-49</p></td><td style="vertical-align:top"><p>3.5 to 10.5 mg/kg (0.035 to 0.105 ml/kg) twice daily</p></td><td style="vertical-align:top"><p>5 to 15 mg/kg (0.05 to 0.15 ml/kg) twice daily</p></td></tr><tr><td style="vertical-align:top"><p>Severe</p></td><td style="vertical-align:top"><p>&lt; 30</p></td><td style="vertical-align:top"><p>3.5 to 7 mg/kg (0.035 to 0.07 ml/kg) twice daily</p></td><td style="vertical-align:top"><p>5 to 10 mg/kg (0.05 to 0.10 ml/kg) twice daily</p></td></tr><tr><td style="vertical-align:top"><p>End-stage renal disease patients undergoing dialysis</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>7 to 14 mg/kg (0.07 to 0.14 ml/kg) once daily&nbsp;<sup>(2) (4)</sup></p></td><td style="vertical-align:top"><p>10 to 20 mg/kg (0.10 to 0.20 ml/kg) once daily&nbsp;<sup>(3) (5)</sup></p></td></tr></tbody></table><p><sup>(1)</sup> <strong>VITRAM</strong> oral solution should be used for doses under 250 mg, 500mg, 1000mg, for doses not multiple of 250 mg, 500mg, 1000mg when dosing recommendation is not achievable by taking multiple tablets and for patients unable to swallow tablets.</p><p><sup>(2)</sup> A 10.5 mg/kg (0.105 ml/kg) loading dose is recommended on the first day of treatment with levetiracetam.</p><p><sup>(3)</sup> A 15 mg/kg (0.15 ml/kg) loading dose is recommended on the first day of treatment with levetiracetam.</p><p><sup>(4)</sup> Following dialysis, a 3.5 to 7 mg/kg (0.035 to 0.07 ml/kg) supplemental dose is recommended.</p><p><sup>(5)</sup> Following dialysis, a 5 to 10 mg/kg (0.05 to 0.10 ml/kg) supplemental dose is recommended.</p><p><em>Hepatic impairment</em></p><p>No dose adjustment is needed in patients with mild to moderate hepatic impairment. In patients with severe hepatic impairment, the creatinine clearance may underestimate the renal insufficiency.</p><p>Therefore a 50 % reduction of the daily maintenance dose is recommended when the creatinine clearance is &lt; 60 ml/min/1.73 m2.</p><p><u>Pediatric population</u></p><p>The physician should prescribe the most appropriate pharmaceutical form, presentation and strength according to age, weight and dose.</p><p>The tablet formulation is not adapted for use in infants and children under the age of 6 years. <strong>VITRAM</strong> oral solution is the preferred formulation for use in this population. In addition, the available dose strengths of the tablets are not appropriate for initial treatment in children weighing less than 25 kg, for patients unable to swallow tablets or for the administration of doses below 250 mg, 500mg, 1000mg. In all of the above cases <strong>VITRAM</strong> oral solution should be used.</p><p><em>Monotherapy</em></p><p>The safety and efficacy of <strong>VITRAM</strong> in children and adolescents below 16 years as monotherapy treatment have not been established.</p><p>No data are available.</p><p><em>Add-on therapy for infants aged from 6 to 23 months, children (2 to 11 years) and adolescents (12 to 17 years) weighing less than 50 kg</em></p><p><strong>VITRAM</strong> oral solution is the preferred formulation for use in infants and children under the age of 6 years.</p><p>For children 6 years and above, <strong>VITRAM</strong> oral solution should be used for doses under 250 mg, 500mg, 1000mg, for doses not multiple of 250 mg, 500mg, 1000mg when dosing recommendation is not achievable by taking multiple tablets and for patients unable to swallow tablets</p><p>The lowest effective dose should be used. The starting dose for a child or adolescent of 25kg should be 250mg twice daily with a maximum dose of 750mg twice daily.</p><p>Dose in children 50 kg or greater is the same as in adults.</p><p><em>Add-on therapy for infants aged from 1 month to less than 6 months</em></p><p>The oral solution is the formulation to use in infants. Method of administration</p><p>The film-coated tablets must be taken orally, swallowed with a sufficient quantity of liquid and may be taken with or without food. The daily dose is administered in two equally divided doses.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or other pyrrolidone derivatives or to any of the excipients listed in section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Renal impairment</u></p><p>The administration of levetiracetam to patients with renal impairment may require dose adjustment. In patients with severely impaired hepatic function, assessment of renal function is recommended before dose selection (see section 4.2).</p><p><u>Acute Kidney injury</u></p><p>The use of levetiracetam has been very rarely associated with acute kidney injury, with a time to onset ranging from a few days to several months.</p><p><u>Blood cell counts</u></p><p>Rare cases of decreased blood cell counts (neutropenia, agranulocytosis, leucopenia, thrombocytopenia and pancytopenia) have been described in association with levetiracetam administration, generally at the beginning of the treatment. Complete blood cell counts are advised in patients experiencing important weakness, pyrexia, recurrent infections or coagulation disorders (section 4.8).</p><p><u>Suicide</u></p><p>Suicide, suicide attempt, suicidal ideation and behavior have been reported in patients treated with anti-epileptic agents (including levetiracetam. A meta-analysis of randomized placebo- controlled trials of anti-epileptic medicinal products has shown a small increased risk of suicidal thoughts and behavior. The mechanism of this risk is not known.</p><p>Therefore, patients should be monitored for signs of depression and/or suicidal ideation and behaviors and appropriate treatment should be considered. Patients (and caregivers of patients) should be advised to seek medical advice should signs of depression and/or suicidal ideation or behavior emerge.</p><p><u>Abnormal and aggressive behaviors</u></p><p>Levetiracetam may cause psychotic symptoms and behavioral abnormalities including irritability and aggressiveness. Patients treated with levetiracetam should be monitored for developing psychiatric signs suggesting important mood and/or personality changes. If such behaviors are noticed, treatment adaptation or gradual discontinuation should be considered. If discontinuation is considered, please refer to section 4.2.</p><p><u>Worsening of seizures</u></p><p>As with other types of antiepileptic drugs, levetiracetam may rarely exacerbate seizure frequency or severity. This paradoxical effect was mostly reported within the first month after levetiracetam initiation or increase of the dose, and was reversible upon drug discontinuation or dose decrease. Patients should be advised to consult their physician immediately in case of aggravation of epilepsy.</p><p><u>Electrocardiogram QT interval prolongation</u></p><p>Rare cases of ECG QT interval prolongation have been observed during the post-marketing surveillance. Levetiracetam should be used with caution in patients with QTc-interval prolongation, in patients concomitantly treated with drugs affecting the QTc-interval, or in patients with relevant pre-existing cardiac disease or electrolyte disturbances.</p><p><u>Pediatric population</u></p><p>The tablet formulation is not adapted for use in infants and children under the age of 6 years. Available data in children did not suggest impact on growth and puberty. However, long term effects on learning, intelligence, growth, endocrine function, puberty and childbearing potential in children remain unknown.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Antiepileptic medicinal products</u></p><p>Pre-marketing data from clinical studies conducted in adults indicate that levetiracetam did not influence the serum concentrations of existing antiepileptic medicinal products (phenytoin, carbamazepine, valproic acid, phenobarbital, lamotrigine, gabapentin and primidone) and that these antiepileptic medicinal products did not influence the pharmacokinetics of levetiracetam. As in adults, there is no evidence of clinically significant medicinal product interactions in pediatric patients receiving up to 60 mg/kg/day levetiracetam.</p><p>A retrospective assessment of pharmacokinetic interactions in children and adolescents with epilepsy (4 to 17 years) confirmed that adjunctive therapy with orally administered levetiracetam did not influence the steady-state serum concentrations of concomitantly administered carbamazepine and valproate. However, data suggested a 20 % higher levetiracetam clearance in children taking enzyme-inducing antiepileptic medicinal products. Dose adjustment is not required.</p><p><u>Probenecid</u></p><p>Probenecid (500 mg four times daily), a renal tubular secretion blocking agent, has been shown to inhibit the renal clearance of the primary metabolite, but not of levetiracetam. Nevertheless, the concentration of this metabolite remains low.</p><p><u>Methotrexate</u></p><p>Concomitant administration of levetiracetam and methotrexate has been reported to decrease methotrexate clearance, resulting in increased/prolonged blood methotrexate concentration to potentially toxic levels. Blood methotrexate and levetiracetam levels should be carefully monitored in patients treated concomitantly with the two drugs.</p><p><u>Oral contraceptives and other pharmacokinetics interactions</u></p><p>Levetiracetam 1,000 mg daily did not influence the pharmacokinetics of oral contraceptives (ethinyl- estradiol and levonorgestrel); endocrine parameters (luteinizing hormone and progesterone) were not modified. -Levetiracetam 2,000 mg daily did not influence the pharmacokinetics of digoxin and warfarin; prothrombin times were not modified. Co-administration with digoxin, oral contraceptives and warfarin did not influence the pharmacokinetics of levetiracetam.</p><p><u>Laxatives</u></p><p>There have been isolated reports of decreased levetiracetam efficacy when the osmotic laxative macrogol has been concomitantly administered with oral levetiracetam. Therefore, macrogol should not be taken orally for one hour before and for one hour after taking levetiracetam.</p><p><u>Food and alcohol</u></p><p>The extent of absorption of levetiracetam was not altered by food, but the rate of absorption was slightly reduced.</p><p>No data on the interaction of levetiracetam with alcohol are available.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Women of child-bearing potential</u></p><p>Specialist advice should be given to women who are of childbearing potential. Treatment with levetiracetam should be reviewed when a woman is planning to become pregnant. As with all antiepileptic medicines, sudden discontinuation of levetiracetam should be avoided as this may lead to breakthrough seizures that could have serious consequences for the woman and the unborn child. Monotherapy should be preferred whenever possible because therapy with multiple antiepileptic medicines AEDs could be associated with a higher risk of congenital malformations than monotherapy, depending on the associated antiepileptics.</p><p><u>Pregnancy</u></p><p>A large amount of post-marketing data on pregnant women exposed to levetiracetam monotherapy (more than 1800, among which in more than 1500 exposure occurred during the 1<sup>st</sup>&nbsp;trimester) do not suggest an increase in the risk for major congenital malformations. Only limited evidence is available on the neurodevelopment of children exposed to Keppra monotherapy in utero. However, current epidemiological studies (on about 100 children) do not suggest an increased risk of neurodevelopmental disorders or delays.</p><p>Levetiracetam can be used during pregnancy, if after careful assessment it is considered clinically needed. In such case, the lowest effective dose is recommended.</p><p>Physiological changes during pregnancy may affect levetiracetam concentration. Decrease in levetiracetam plasma concentrations has been observed during pregnancy. This decrease is more pronounced during the third trimester (up to 60% of baseline concentration before pregnancy). Appropriate clinical management of pregnant women treated with levetiracetam should be ensured.</p><p><u>Breastfeeding</u></p><p>Levetiracetam is excreted in human breast milk. Therefore, breast-feeding is not recommended.</p><p>However, if levetiracetam treatment is needed during breastfeeding, the benefit/risk of the treatment should be weighed considering the importance of breastfeeding.</p><p><u>Fertility</u></p><p>No impact on fertility was detected in animal studies (see section 5.3). No clinical data are available, potential risk for human is unknown.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Levetiracetam has minor or moderate influence on the ability to drive and use machines. Due to possible different individual sensitivity, some patients might experience somnolence or other central nervous system related symptoms, especially at the beginning of treatment or following a dose increase. Therefore, caution is recommended in those patients when performing skilled tasks, <em>e.g</em>. driving vehicles or operating machinery. Patients are advised not to drive or use machines until it is established that their ability to perform such activities is not affected.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p>The most frequently reported adverse reactions were nasopharyngitis, somnolence, headache, fatigue and dizziness. The adverse reaction profile presented below is based on the analysis of pooled placebo-controlled clinical trials with all indications studied, with a total of 3,416 patients treated</p><p>with levetiracetam. These data are supplemented with the use of levetiracetam in corresponding open-label extension studies, as well as post-marketing experience. The safety profile of levetiracetam is generally similar across age groups (adult and pediatric patients) and across the approved epilepsy indications.</p><p><u>Tabulated list of adverse reactions</u></p><p>Adverse reactions reported in clinical studies (adults, adolescents, children and infants &gt; 1 month) and from post-marketing experience are listed in the following table per System Organ Class and per frequency. Adverse reactions are presented in the order of decreasing seriousness and their frequency is defined as follows: very common (&ge;1/10); common (&ge;1/100 to &lt;1/10); uncommon (&ge;1/1,000 to &lt;1/100); rare (&ge;1/10,000 to &lt;1/1,000) and very rare (&lt;1/10,000).</p><table border="1" cellspacing="0" cellpadding="0" style="width:0px"><tbody><tr><td rowspan="2"><p>MedDRA SOC</p></td><td colspan="4" style="vertical-align:top"><p>Frequency category</p></td></tr><tr><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p><u>Common</u></p></td><td style="vertical-align:top"><p><u>Uncommon</u></p></td><td style="vertical-align:top"><p><u>Rare</u></p></td></tr><tr><td style="vertical-align:top"><p>Infections and infestations</p></td><td style="vertical-align:top"><p>Nasopharyngitis</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Infection</p></td></tr><tr><td style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Thrombocytopenia, leukopenia</p></td><td style="vertical-align:top"><p>Pancytopenia, neutropenia, agranulocytosis</p></td></tr><tr><td style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Drug reaction with eosinophilia and systemic symptoms (DRESS),</p><p>Hypersensitivity (including angioedema and anaphylaxis)</p></td></tr><tr><td style="vertical-align:top"><p>Metabolism and nutrition disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Anorexia</p></td><td style="vertical-align:top"><p>Weight decreased, weight increase</p></td><td style="vertical-align:top"><p>Hyponatraemia</p></td></tr><tr><td style="vertical-align:top"><p>Psychiatric disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Depression, hostility/ aggression, anxiety, insomnia, nervousness/irritability</p></td><td style="vertical-align:top"><p>Suicide attempt, suicidal ideation, psychotic disorder, abnormal behaviour, hallucination, anger, confusional state, panic attack, affect lability/mood swings, agitation</p></td><td style="vertical-align:top"><p>Completed suicide, personality disorder, thinking abnormal, delirium</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>Somnolence, headache</p></td><td style="vertical-align:top"><p>Convulsion, balance disorder, dizziness, lethargy, tremor</p></td><td style="vertical-align:top"><p>Amnesia, memory impairment, coordination abnormal/ataxia, paraesthesia, disturbance in attention</p></td><td style="vertical-align:top"><p>Choreoathetosis, dyskinesia, hyperkinesia, gait disturbance, encephalopathy, seizures aggravated</p></td></tr><tr><td style="vertical-align:top"><p>Eye disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Diplopia, vision blurred</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Ear and labyrinth disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Vertigo</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Cardiac disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Electrocardiogram QT prolonged</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory, thoracic and mediastinal disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Cough</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Abdominal pain, diarrhoea, dyspepsia, vomiting, nausea</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Pancreatitis</p></td></tr><tr><td style="vertical-align:top"><p>Hepatobiliary disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Liver function test abnormal</p></td><td style="vertical-align:top"><p>Hepatic failure, hepatitis</p></td></tr><tr><td style="vertical-align:top"><p>Renal and Urinary Disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Acute Kidney injury</p></td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Rash</p></td><td style="vertical-align:top"><p>Alopecia, eczema, pruritus,</p></td><td style="vertical-align:top"><p>Toxic epidermal necrolysis, Stevens-Johnson syndrome, erythema multiforme</p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal and connective tissue disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Muscular weakness, myalgia</p></td><td style="vertical-align:top"><p>Rhabdomyolysis and blood creatine phosphokinase increased*</p></td></tr><tr><td style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Asthenia/fatigue</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Injury, poisoning and procedural complications</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Injury</p></td><td style="vertical-align:top">&nbsp;</td></tr></tbody></table><p>* Prevalence is significantly higher in Japanese patients when compared to non-Japanese patients. Cases of encephalopathy have been rarely observed after levetiracetam administration. These undesirable effects generally occurred at the beginning of the treatment (few days to a few months) and were reversible after treatment discontinuation.</p><p><u>Description of selected adverse reactions</u></p><p>The risk of anorexia is higher when levetiracetam is co-administered with topiramate.</p><p>In several cases of alopecia, recovery was observed when levetiracetam was discontinued. Bone marrow suppression was identified in some of the cases of pancytopenia.</p><p><u>Pediatric population</u></p><p>In patients aged 1 month to less than 4 years, a total of 190 patients have been treated with levetiracetam in placebo-controlled and open label extension studies. Sixty of these patients were treated with levetiracetam in placebo-controlled studies. In patients aged 4-16 years, a total of 645 patients have been treated with levetiracetam in placebo-controlled and open label extension studies. 233 of these patients were treated with levetiracetam in placebo-controlled studies. In both these pediatric age ranges, these data are supplemented with the post-marketing experience of the use of levetiracetam.</p><p>In addition, 101 infants aged less than 12 months have been exposed in a post authorization safety study. No new safety concerns for levetiracetam were identified for infants less than 12 months of age with epilepsy.</p><p>The adverse reaction profile of levetiracetam is generally similar across age groups and across the approved epilepsy indications. Safety results in pediatric patients in placebo-controlled clinical studies were consistent with the safety profile of levetiracetam in adults except for behavioral and psychiatric adverse reactions which were more common in children than in adults. In children and adolescents aged 4 to 16 years, vomiting (very common, 11.2%), agitation (common, 3.4%), mood swings (common, 2.1%), affect lability (common, 1.7%), aggression (common, 8.2%), abnormal behavior (common, 5.6%), and lethargy (common, 3.9%) were reported more frequently than in other age ranges or in the overall safety profile. In infants and children aged 1 month to less than 4 years, irritability (very common, 11.7%) and coordination abnormal (common, 3.3%) were reported more frequently than in other age groups or in the overall safety profile.</p><p>A double-blind, placebo-controlled pediatric safety study with a non-inferiority design has assessed the cognitive and neuropsychological effects of levetiracetam in children 4 to 16 years of age with partial onset seizures. It was concluded that <strong>VITRAM</strong> was not different (non inferior) from placebo with regard to the change from baseline of the Leiter-R Attention and Memory, Memory Screen Composite score in the per-protocol population. Results related to behavioral and emotional functioning indicated a worsening in levetiracetam treated patients on aggressive behavior as measured in a standardized and systematic way using a validated instrument (CBCL &ndash; Achenbach Child Behavior Checklist). However subjects, who took levetiracetam in the long-term open label follow-up study, did not experience a worsening, on average, in their behavioral and emotional functioning; in particular measures of aggressive behavior were not worse than baseline.</p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after authorization of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.</p><p>&nbsp;</p><p><strong>To report any side effect(s):</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Saudi Arabia:</strong></p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp; The National Pharmacovigilance Centre (NPC)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fax: +966-11-205-7662</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SFDA Call Center: 19999</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa</p></td></tr></tbody></table><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Other GCC states:</strong></p><p>Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Symptoms</em></p><p>Somnolence, agitation, aggression, depressed level of consciousness, respiratory depression and coma were observed with <strong>VITRAM</strong> overdoses.</p><p><em>Management of overdose</em></p><p>After an acute overdose, the stomach may be emptied by gastric lavage or by induction of emesis. There is no specific antidote for levetiracetam. Treatment of an overdose will be symptomatic and may include hemodialysis. The dialyzer extraction efficiency is 60 % for levetiracetam and 74 % for the primary metabolite</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: antiepileptics, other antiepileptics, ATC code: N03AX14.</p><p>The active substance, levetiracetam, is a pyrrolidone derivative (S-enantiomer of-ethyl-2-oxo-1- pyrrolidine acetamide), chemically unrelated to existing antiepileptic active substances.</p><p><u>Mechanism of action</u></p><p>The mechanism of action of levetiracetam still remains to be fully elucidated. <em>In vitro </em>and <em>in vivo </em>experiments suggest that levetiracetam does not alter basic cell characteristics and normal neurotransmission.</p><p><em>In vitro </em>studies show that levetiracetam affects intraneuronal Ca2+ levels by partial inhibition of N- type Ca2+ currents and by reducing the release of Ca2+ from intraneuronal stores. In addition, it partially reverses the reductions in GABA- and glycine-gated currents induced by zinc and carbolines. Furthermore, levetiracetam has been shown in <em>in vitro </em>studies to bind to a specific site in rodent brain tissue. This binding site is the synaptic vesicle protein 2A, believed to be involved in vesicle fusion and neurotransmitter exocytosis. Levetiracetam and related analogs show a rank order of affinity for binding to the synaptic vesicle protein 2A which correlates with the potency of their anti-seizure protection in the mouse audiogenic model of epilepsy. This finding suggests that the interaction between levetiracetam and the synaptic vesicle protein 2A seems to contribute to the antiepileptic mechanism of action of the medicinal product.</p><p><u>Pharmacodynamic effects</u></p><p>Levetiracetam induces seizure protection in a broad range of animal models of partial and primary generalized seizures without having a pro-convulsant effect. The primary metabolite is inactive.</p><p>In man, an activity in both partial and generalized epilepsy conditions (epileptiform discharge/photoparoxysmal response) has confirmed the broad-spectrum pharmacological profile of levetiracetam.</p><p><u>Clinical efficacy and safety</u></p><p><em>Adjunctive therapy in the treatment of partial onset seizures with or without secondary generalization in adults, adolescents, children and infants from 1 month of age with epilepsy.</em></p><p>In adults, levetiracetam efficacy has been demonstrated in 3 double-blind, placebo-controlled studies at 1000 mg, 2000 mg, or 3000 mg/day, given in 2 divided doses, with a treatment duration of up to 18 weeks. In a pooled analysis, the percentage of patients who achieved 50 % or greater reduction from baseline in the partial onset seizure frequency per week at stable dose (12/14 weeks) was of 27.7 %, 31.6 % and 41.3 % for patients on 1000, 2000 or 3000 mg levetiracetam respectively and of 12.6 % for patients on placebo.</p><p><u>Pediatric population</u></p><p>In pediatric patients (4 to 16 years of age), levetiracetam efficacy was established in a double- blind, placebo-controlled study, which included 198 patients and had a treatment duration of 14 weeks. In this study, the patients received levetiracetam as a fixed dose of 60 mg/kg/day (with twice a day dosing).</p><p>&nbsp;44.6 % of the levetiracetam treated patients and 19.6 % of the patients on placebo had a 50 % or greater reduction from baseline in the partial onset seizure frequency per week. With continued long-term treatment, 11.4 % of the patients were seizure-free for at least 6 months and 7.2 % were seizure-free for at least 1 year.</p><p>In pediatric patients (1 month to less than 4 years of age), levetiracetam efficacy was established in a double-blind, placebo-controlled study, which included 116 patients and had a treatment duration of 5 days. In this study, patients were prescribed 20 mg/kg, 25 mg/kg, 40 mg/kg or 50 mg/kg daily dose of oral solution based on their age titration schedule. A dose of 20 mg/kg/day titrating to 40 mg/kg/day for infants one month to less than six months and a dose of 25 mg/kg/day titrating to 50 mg/kg/day for infants and children 6 months to less than 4 years old, was use in this study. The total daily dose was administered twice daily.</p><p>The primary measure of effectiveness was the responder rate (percent of patients with &ge; 50 % reduction from baseline in average daily partial onset seizure frequency) assessed by a blinded central reader using a 48-hour video EEG. The efficacy analysis consisted of 109 patients who had at least 24 hours of video EEG in both baseline and evaluation periods. 43.6 % of the levetiracetam treated patients and 19.6 % of the patients on placebo were considered as responders. The results are consistent across age group. With continued long-term treatment, 8.6% of the patients were seizure-free for at least 6 months and 7.8 % were seizure-free for at least 1 year.</p><p>35 infants aged less than 1 year with partial onset seizures have been exposed in placebo-control clinical studies of which only 13 were aged &lt; 6 months.</p><p><u>Monotherapy in the treatment of partial onset seizures with or without secondary generalization in patients from 16 years of age with newly diagnosed epilepsy.</u></p><p>Efficacy of levetiracetam as monotherapy was established in a double-blind, parallel group, non- inferiority comparison to carbamazepine-controlled release (CR) in 576 patients 16 years of age or older with newly or recently diagnosed epilepsy. The patients had to present with unprovoked partial seizures or with generalized tonic-clonic seizures only. The patients were randomized to carbamazepine CR 400 &ndash; 1200 mg/day or levetiracetam 1000 - 3000 mg/day, the duration of the treatment was up to 121 weeks depending on the response.</p><p>Six-month seizure freedom was achieved in 73.0 % of levetiracetam-treated patients and 72.8 % of carbamazepine-CR treated patients; the adjusted absolute difference between treatments was 0.2 % (95 % CI: -7.8 8.2). More than half of the subjects remained seizure free for 12 months (56.6 % and 58.5 % of subjects on levetiracetam and on carbamazepine CR respectively).</p><p>In a study reflecting clinical practice, the concomitant antiepileptic medication could be withdrawn in a limited number of patients who responded to levetiracetam adjunctive therapy (36 adult patients out of 69).</p><p><u>Adjunctive therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with Juvenile Myoclonic Epilepsy.</u></p><p>Levetiracetam efficacy was established in a double-blind, placebo-controlled study of 16 weeks duration, in patients 12 years of age and older suffering from idiopathic generalized epilepsy with myoclonic seizures in different syndromes. The majority of patients presented with juvenile myoclonic epilepsy.</p><p>In this study, levetiracetam, dose was 3000 mg/day given in 2 divided doses.</p><p>58.3 % of the levetiracetam treated patients and 23.3 % of the patients on placebo had at least a 50 % reduction in myoclonic seizure days per week. With continued long-term treatment, 28.6 % of the patients were free of myoclonic seizures for at least 6 months and 21.0 % were free of myoclonic seizures for at least 1 year.</p><p><u>Adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in adults and adolescents from 12 years of age with idiopathic generalized epilepsy.</u></p><p>Levetiracetam efficacy was established in a 24-week double-blind, placebo-controlled study which included adults, adolescents and a limited number of children suffering from idiopathic generalized epilepsy with primary generalized tonic-clonic (PGTC) seizures in different syndromes (juvenile myoclonic epilepsy, juvenile absence epilepsy, childhood absence epilepsy, or epilepsy with Grand Mal seizures on awakening). In this study, levetiracetam dose was 3000 mg/day for adults and adolescents or 60 mg/kg/day for children, given in 2 divided doses.</p><p>72.2 % of the levetiracetam treated patients and 45.2 % of the patients on placebo had a 50 % or greater decrease in the frequency of PGTC seizures per week. With continued long-term treatment, 47.4 % of the patients were free of tonic-clonic seizures for at least 6 months and 31.5% were free of tonic-clonic seizures for at least 1 year.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Levetiracetam is a highly soluble and permeable compound. The pharmacokinetic profile is linear with low intra- and inter-subject variability. There is no modification of the clearance after repeated administration. There is no evidence for any relevant gender, race or circadian variability. The pharmacokinetic profile is comparable in healthy volunteers and in patients with epilepsy.</p><p>Due to its complete and linear absorption, plasma levels can be predicted from the oral dose of levetiracetam expressed as mg/kg bodyweight. Therefore, there is no need for plasma level monitoring of levetiracetam.</p><p>A significant correlation between saliva and plasma concentrations has been shown in adults and children (ratio of saliva/plasma concentrations ranged from 1 to 1.7 for oral tablet formulation and after 4 hours post-dose for oral solution formulation).</p><p><em>Adults and adolescents</em></p><p>Absorption</p><p>Levetiracetam is rapidly absorbed after oral administration. Oral absolute bioavailability is close to 100 %.</p><p>Peak plasma concentrations (Cmax) are achieved at 1.3 hours after dosing. Steady-state is achieved after two days of a twice daily administration schedule.</p><p>Peak concentrations (Cmax) are typically 31 and 43 &mu;g/ml following a single 1,000 mg dose and repeated 1,000 mg twice daily dose, respectively.</p><p>The extent of absorption is dose-independent and is not altered by food.</p><p><strong>Distribution </strong></p><p>No tissue distribution data are available in humans.</p><p>Neither levetiracetam nor its primary metabolite are significantly bound to plasma proteins (&lt; 10 %).</p><p>The volume of distribution of levetiracetam is approximately 0.5 to 0.7 l/kg, a value close to the total body water volume.</p><p>Biotransformation</p><p>Levetiracetam is not extensively metabolized in humans. The major metabolic pathway (24 % of the dose) is an enzymatic hydrolysis of the acetamide group. Production of the primary metabolite, ucb L057, is not supported by liver cytochrome P450 isoforms. Hydrolysis of the acetamide group was measurable in a large number of tissues including blood cells. The metabolite ucb L057 is pharmacologically inactive.</p><p>Two minor metabolites were also identified. One was obtained by hydroxylation of the pyrrolidone ring (1.6 % of the dose) and the other one by opening of the pyrrolidone ring (0.9 % of the dose). Other unidentified components accounted only for 0.6 % of the dose.</p><p>No enantiomeric interconversion was evidenced <em>in vivo </em>for either levetiracetam or its primary metabolite.</p><p><em>In vitro</em>, levetiracetam and its primary metabolite have been shown not to inhibit the major human liver cytochrome P450 isoforms (CYP3A4, 2A6, 2C9, 2C19, 2D6, 2E1 and 1A2), glucuronyl transferase (UGT1A1 AND UGT1A6) and epoxide hydroxylase activities. In addition, levetiracetam does not affect the <em>in vitro </em>glucuronidation of valproic acid.</p><p>In human hepatocytes in culture, levetiracetam had little or no effect on CYP1A2, SULT1E1 or UGT1A1. Levetiracetam caused mild induction of CYP2B6 and CYP3A4. The in vitro data and <em>in vivo </em>interaction data on oral contraceptives, digoxin and warfarin indicate that no significant enzyme induction is expected <em>in vivo</em>. Therefore, the interaction of <strong>VITRAM</strong> with other substances, or <em>vice versa, </em>is unlikely.</p><p>Elimination</p><p>The plasma half-life in adults was 7&plusmn;1 hours and did not vary either with dose, route of administration or repeated administration. The mean total body clearance was 0.96 ml/min/kg.</p><p>The major route of excretion was via urine, accounting for a mean 95 % of the dose (approximately 93 % of the dose was excreted within 48 hours). Excretion <em>via </em>faeces accounted for only 0.3 % of the dose.</p><p>The cumulative urinary excretion of levetiracetam and its primary metabolite accounted for 66 % and 24 % of the dose, respectively during the first 48 hours</p><p>The renal clearance of levetiracetam and ucb L057 is 0.6 and 4.2 ml/min/kg respectively indicating that levetiracetam is excreted by glomerular filtration with subsequent tubular reabsorption and that the primary metabolite is also excreted by active tubular secretion in addition to glomerular filtration. Levetiracetam elimination is correlated to creatinine clearance.</p><p>Elderly</p><p>In the elderly, the half-life is increased by about 40 % (10 to 11 hours). This is related to the decrease in renal function in this population (see section 4.2).</p><p>Renal impairment</p><p>The apparent body clearance of both levetiracetam and of its primary metabolite is correlated to the creatinine clearance. It is therefore recommended to adjust the maintenance daily dose of <strong>VITRAM</strong>, based on creatinine clearance in patients with moderate and severe renal impairment (see section 4.2).</p><p>In anuric end-stage renal disease adult subjects the half-life was approximately 25 and 3.1 hours during interdialytic and intradialytic periods, respectively.</p><p>The fractional removal of levetiracetam was 51 % during a typical 4-hour dialysis session.</p><p>Hepatic impairment</p><p>In subjects with mild and moderate hepatic impairment, there was no relevant modification of the clearance of levetiracetam. In most subjects with severe hepatic impairment, the clearance of levetiracetam was reduced by more than 50 % due to a concomitant renal impairment (see section 4.2).</p><p>Pediatric population</p><p><em>Children (4 to 12 years)</em></p><p>Following single oral dose administration (20 mg/kg) to epileptic children (6 to 12 years), the half- life of levetiracetam was 6.0 hours. The apparent body weight adjusted clearance was approximately 30 % higher than in epileptic adults.</p><p>Following single oral dose administration (20 mg/kg) to epileptic children (6 to 12 years), the half- life of levetiracetam was 6.0 hours. The apparent body weight adjusted clearance was approximately 30 % higher than in epileptic adults.</p><p>Following repeated oral dose administration (20 to 60 mg/kg/day) to epileptic children (4 to 12 years), levetiracetam was rapidly absorbed. Peak plasma concentration was observed 0.5 to 1.0 hour after dosing. Linear and dose proportional increases were observed for peak plasma concentrations and area under the curve. The elimination half-life was approximately 5 hours. The apparent body clearance was 1.1 ml/min/kg.</p><p><em>Infants and children (1 month to 4 years)</em></p><p>Following single dose administration (20 mg/kg) of a 100 mg/ml oral solution to epileptic children (1 month to 4 years), levetiracetam was rapidly absorbed and peak plasma concentrations were observed approximately 1 hour after dosing. The pharmacokinetic results indicated that half-life was shorter (5.3 h) than for adults (7.2 h) and apparent clearance was faster (1.5 ml/min/kg) than for adults (0.96 ml/min/kg).</p><p>In the population pharmacokinetic analysis conducted in patients from 1 month to 16 years of age, body weight was significantly correlated to apparent clearance (clearance increased with an increase in body weight) and apparent volume of distribution. Age also had an influence on both parameters. This effect was pronounced for the younger infants, and subsided as age increased, to become negligible around 4 years of age.</p><p>In both population pharmacokinetic analyses, there was about a 20 % increase of apparent clearance of levetiracetam when it was co-administered with an enzyme-inducing antiepileptic medicinal product.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, genotoxicity and carcinogenic potential.</p><p>Adverse effects not observed in clinical studies but seen in the rat and to a lesser extent in the mouse at exposure levels similar to human exposure levels and with possible relevance for clinical use were liver changes, indicating an adaptive response such as increased weight and centrilobular hypertrophy, fatty infiltration and increased liver enzymes in plasma.</p><p>No adverse reactions on male or female fertility or reproduction performance were observed in rats at doses up to 1800 mg/kg/day (x 6 the MRHD on a mg/m2 or exposure basis) in parents and F1 generation.</p><p>Two embryo-foetal development (EFD) studies were performed in rats at 400, 1200 and 3600 mg/kg/day. At 3600 mg/kg/day, in only one of the 2 EFD studies, there was a slight decrease in foetal weight associated with a marginal increase in skeletal variations /minor anomalies. There</p><p>was no effect on embryomortality and no increased incidence of malformations. The NOAEL (No Observed Adverse Effect Level) was 3600 mg/kg/day for pregnant female rats (x 12 the MRHD on a mg/m2 basis) and 1200 mg/kg/day for fetuses.</p><p>Four embryo-foetal development studies were performed in rabbits covering doses of 200, 600, 800, 1200 and 1800 mg/kg/day. The dose level of 1800 mg/kg/day induced a marked maternal toxicity and a decrease in foetal weight associated with increased incidence of foetuses with cardiovascular/skeletal anomalies. The NOAEL was &lt;200 mg/kg/day for the dams and 200 mg/kg/day for the fetuses (equal to the MRHD on a mg/m2 basis).</p><p>A peri- and post-natal development study was performed in rats with levetiracetam doses of 70, 350 and 1800 mg/kg/day. The NOAEL was &ge; 1800 mg/kg/day for the F0 females, and for the survival, growth and development of the F1 offspring up to weaning (x 6 the MRHD on a mg/m2 basis).</p><p>Neonatal and juvenile animal studies in rats and dogs demonstrated that there were no adverse effects seen in any of the standard developmental or maturation endpoints at doses up to 1800 mg/kg/day (x 6 &ndash; 17 the MRHD on a mg/m2 basis).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Tablet core:</em></p><p>Maize Starch.</p><p>Povidone.</p><p>Talc.</p><p>Colloidal Silicon Dioxide.</p><p>Magnesium Stearate.</p><p>Purified Water.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Film-coating:</em></p><p>Opadry II 85F32004 Yellow (Polyvinyl alcohol-part. Hydrolyzed, Titan Dioxide, Macrogol/PEG3350, Talc and Iron Oxide Yellow).</p><p>Purified Water</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;&nbsp; Do not store above 30&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>VITRAM</strong> 500 mg film-coated tablets are packed into blisters consisting of 40 gsm PVDC coated 250 &mu;m PVC foil / Aluminium-foil 20 &mu;m.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                AJA Pharmaceutical Industries Company, Ltd. 
Hail Industrial City MODON, Street No 32 
PO Box 6979, Hail 55414 
Kingdom of Saudi Arabia
Tel: +966 11 268 7900

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                22 April 2021
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>